Final Programme

35 th Annual Meeting of the European Group for
Blood and Marrow Transplantation
25 th Meeting of the EBMT Nurses Group
8 th Meeting of the EBMT Data Management Group
3 rd EBMT Patient & Family Day • Saturday, 28 March 2009
Final Programme
www.congrex.ch/ebmt2009
Göteborg, Sweden,
29 March – 1 April 2009

innovation in cell processing
cessing
Sepax ® Sepax Cell Processing System
® Cell Processing
g System
The
industry
sstandard
tandard
for
the
automated automated
processing pr
o ocessing
oof
f aadult
dult
stem stem
ccells
ells
in
a
ffunctionally
unctionally
cclosed
losed
environment.
environm
e ent.
fully automated automatedd
every ev very unit processed
system
individually
iindividually di idually
regulatory
accr accreditations editations
unique uniquue
quality qquality
US FDA clearance, clearannce,
CE
mark,
Japan n
MHLW
W appr approval ovaal
> processing
oof
f cord cc
ord
bblood,
lood,
bone
marrow marr
and peripheral blood
> > 10
protocols protocols
for
TNC and MNC isolation isolat
including density
g ggradient
radient
> over
400’000 400’
000
p pprocedures
rocedures
perfomed
in stem cell
llaboratories
aboratories
aand
n nd
hhospitals
ospitals
around
tthe
h world
Biosafe
SA
- Switzerland
Biosafe
Scientific Scientific
Inc. Inc.
- - TX, T X X,
UUSA
SA
t +41 + 41
22
3365
65
227
7 27
| f +41 + 4 1 22 22
3365
65
27
37
info@biosafe.ch info@biosafe.ch | wwww.biosafe.ch
ww.
biosafe.
ch
safety
innovation innovatioon
closed
system
patented
technology

Contents
Sponsors supporting the EBMT meeting . . . . . . . . . . . . . . . . 2
Corporate Patrons supporting EBMT . . . . . . . . . . . . . . . . . . . 3
Welcome Address . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
Welcome Address 3 rd Patient & Family Day . . . . . . . . . . . . . . 7
Programme Overview
Saturday, 28 March 2009 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
Sunday, 29 March 2009 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8/9
Monday, 30 March 2009 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10–12
Tuesday, 31 March 2009 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13–15
Wednesday, 1 April 2009 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16/17
Organising Committee . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
Important Addresses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
Satellite Symposia
Saturday, 28 March 2009 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
Sunday, 29 March 2009 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24–31
Opening Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
Scientific Programme Physicians
Monday, 30 March 2009 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34–48
Tuesday, 31 March 2009 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49–65
Wednesday, 1 April 2009 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66–77
Posters Physicians
Monday, 30 March 2009 (P432 – P722) . . . . . . . . . . . . . . . . . . 78–102
Tuesday, 31 March 2009 (P723 – P1015) . . . . . . . . . . . . . . . . . 103–127
Nurses Pre-Meeting Study Day
Sunday, 29 March 2009 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128–130
Scientific Programme Nurses Group
Monday, 30 March 2009 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 131–136
Tuesday, 31 March 2009 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 137–141
Wednesday, 1 April 2009 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 142–144
Posters Nurses Group
Monday, 30 March – Wednesday, 1 April 2009 (P1110 – P1206) 145–151
Data Management Group . . . . . . . . . . . . . . . . . . . . . . . . . . . . 152–154
List of Chairs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 155
List of Speakers and Authors . . . . . . . . . . . . . . . . . . . . . . . . . 156–187
Instructions for Speakers and Authors . . . . . . . . . . . . . . . . . 188
CME Accreditation at EBMT 2009 . . . . . . . . . . . . . . . . . . . . . 189
Registration Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . 191
General Information (in alphabetical order) . . . . . . . . . . . . . . 192–194
Social Events . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 195
Daily Tours and Post-Congress Tour . . . . . . . . . . . . . . . . . . . 196
Travelling to Göteborg Convention Centre . . . . . . . . . . . . . . . 197/198
List of Exhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 199
Exhibition Floor Plan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 200/201
The Swedish Exhibition Centre . . . . . . . . . . . . . . . . . . . . . . . 202
Floor Plans of the Göteborg Convention Centre . . . . . . . . . . . 203
Göteborg City Map and List of Hotels . . . . . . . . . . . . . . . . . . 204/205
1

2
Sponsors supporting the EBMT meeting
The organisers of the EBMT 2009 express their thanks
and appreciation to all those who are generously contributing
to the success of this meeting.
Amgen (Europe) GmbH
Alexion Europe
Bristol-Myers Squibb
CaridianBCT Europe N.V.
Celgene International Sàrl
Cephalon Oncology
Chugai sanofi aventis
Fresenius Biotech GmbH
Gentium S.p.A.
Genzyme Europe B.V.
Gilead Sciences Europe Ltd.
Immunkemi F&D AB
Janssen-Cilag
Kiadis Pharma
MDS Foundation, Inc
Medac
Merck Sharp & Dohme
Merck Sharp & Dohme (Sweden) AB
Miltenyi Biotec GmbH
Mundipharma International Ltd.
Novartis Oncology
Novartis Oncology Nordic
Pfizer
Pierre Fabre Médicament
Roche
Roche AB
Schering-Plough Corporation
Therakos, Inc.
ViroPharma

Corporate Patrons supporting EBMT
Platinum Sponsor
Gold Sponsor
Silver Sponsor
Bronze Sponsor
The EBMT would like to thank its corporate patrons
for their ongoing generous support:
3

Committed
to developing and
delivering innovative therapies
Dedicated
to improving the lives
of cancer patients worldwide
Celgene International Sàrl
Route de Perreux 1
2017 Boudry
Switzerland
+41 32 729 8500
www.celgene.com
© 2009 Celgene

Welcome Address
On behalf of the EBMT, the Nordic Scientific Committee, and the Local Organising Committee,
it is our pleasure to welcome you to the 35 th Annual Meeting of the EBMT, the 25 th Meeting of
the EBMT Nurses Group, the 8 th Meeting of the EBMT Data Management Group and the
3 rd EBMT Patient & Family Day.
The Scientific Programme includes symposia, educational sessions and workshops covering
issues related to the specific problems of stem cell transplantation, the indications for
transplantation, as well as basic and translational science relevant to the field. Special
attention is dedicated to pathophysiology and clinical care of chronic GvHD. We also
re-introduce the “Controversies in SCT” as an exciting format for presentation of debatable
issues. The paediatric perspectives constitute an important part of the programme.
The EBMT Nurses Group celebrates their 25 th anniversary by bringing together nurses from many
countries to discuss the latest developments in patient care. The Nurses Group scientific
sessions present cutting-edge knowledge in the field of nursing.
The Nurses Pre-Meeting Study Day offers two separate sections to suit the needs of both
beginners and experienced participants.
The joint physicians/nurses session is a popular opportunity to share different perspectives.
The topic this year is sexuality and late effects with special reference to their impact on
quality of life; “Quality of life lessons – into the future”.
The meeting of the Data Management Group provides learning opportunities for everyone
interested in data management and statistics.
We are also very happy to organise the 3 rd EBMT Patient & Family Day. The programme
focuses on late complications and issues regarding family donors. Simultaneous sessions
outline standard treatment and new developments in haematology and transplantation.
Communication between patients’ associations is encouraged and facilitated.
Quality issues are increasingly vital in patient care. A Quality Managers’ half day meeting is
organized for the first time in Göteborg. We hope that this event will be an integrated part of
future EBMT congresses.
The EBMT aims to facilitate collaboration between everyone involved in the field of stem cell
transplantation. Accordingly, we hope that the Göteborg meeting provides an opportunity to
acquire new knowledge and foster international co-operation in a spirit of curiosity, openness
and social interaction.
Finally, although the Convention facilities are located in the city centre, and in spite of
shopping, entertainment, restaurants and 3700 hotel rooms being within 20 minutes walk,
the weather in Göteborg is notoriously unreliable. You might want to put on your warm coat
even for short walks.
Mats Brune
Congress President
Dick Stockelberg
Chair Local Organising
Committee
Per Ljungman
Scientific Chair
Elisabeth Wallhult
Local Nurse
5

6
Supporters of the 3 rd Patient&Family Day
The organisers of the 3 rd Patient & Family Day
express their great appreciation to the supporters.
Bristol-Myers Squibb AB
Celgene International Sàrl
Genzyme Europe B.V.
Immunkemi F&D AB
Janssen-Cilag
Medac
Merck Sharp & Dohme (Sweden) AB
Novartis Oncology
Novartis Oncology Nordic
Pierre Fabre Médicament
Roche AB
Congress Venue

Welcome Address 3 rd Patient&Family Day
You are welcome to the 3 rd EBMT Patient & Family Day. This event is now an established and
integral part of the annual EBMT meeting.
A positive, informed partnership between patient and doctor provides many benefits for both
parties involved, not least increased confidence and trust. This is particularly important – and
difficult - when there is a choice of treatment options. One of the mottos of this special day is
therefore “What my family and I wish we had known beforehand”.
For patients, families and friends, technical advances, new drugs and improvements in patient
care are of vital importance. Treatment success however cannot only be described as
surviving a serious disease, but also as having a good quality of life. Building on the
experience of previous years’ meetings, the 3 rd EBMT Patient & Family Day programme has
been carefully designed to bring up such issues.
In order to facilitate participation all sessions are simultaneously translated into
Swedish or English and the programme is designed to be spacious, thereby allowing
plenty of time for questions and discussion.
The morning programme addresses important questions regarding the integrity of the stem
cell donor and the problems that may occur when two family members meet the challenge of
a stem cell transplantation; one as a patient and one as a potential donor. The second
plenary session discusses the consequences of a cancer diagnosis for the patient’s body
image and the frequently overlooked problem of genital chronic Graft-versus-Host disease.
After lunch, the difficulties of presenting complex information are discussed under the
heading of “What my family and I wish we had known beforehand”. Two patients share their
experience of the information given before transplant by their doctor. Their narratives will be
commented on by two transplant physicians. Contributions from the audience are encouraged.
Later in the afternoon, simultaneous workshops outline standard treatments, with special
reference to the latest news and pioneer developments in the field of autologous and
allogeneic transplantation for leukemias, lymphomas and multiple myeloma.
One important aim of a patient organisation is to act as a pressure group and advocate the
best treatment practice on a European, national and regional level. Strong patients’
associations are beneficial for patients and also for caregivers at all stages. At this meeting,
communication between patient associations’ is encouraged and facilitated, with space made
available at the end of the scheduled programme to enable meetings between representatives
of patients’ associations. We hope that this interaction will be the starting point for a closer
cooperation between European organisations working on behalf of patients.
On behalf of the EBMT, and the organising committee, we have the pleasure to welcome you
to Göteborg, Sweden for an informative and fruitful 3 rd Patient and Family Day.
Mats Brune
Congress President 2009
Anita Waldmann
President /Myeloma Euronet
Christina Bergdahl
Chair/Swedish Blood
Cancer Association
Dietger Niederwieser
EBMT President
7

08
09
10
11
12
13
14
15
16
17
18
19
20
8
Saturday, 28 March 2009
3rd EBMT Patient & Family Day
Göteborg, Saturday, 28 March 2009 (Göteborg Convention Centre)
Room F1
Level 2
18.00–20.00
Transforming
CMV management
ViroPharma
p. 23
Physicians
Nurses
Sunday, 29 March 2009
Congress
Hall
Level 2
18.30–20.00
Opening Session
van Bekkum
Award
EBMT Lecture
Room F4
Level 2
09.00–10.30
Improving the outcomes
of matched
and mismatched
transplants by
selective allodepletion
of T-cells
Kiadis Pharma
p. 24
Room F1
Level 2
11.00–13.00 11.00–13.00
Cellular therapies: Evolution of
Therapeutic multiple myeloma
options for treatment:
stem cell planning
transplantation sustained
disease control
Miltenyi Biotec
GmbH
p. 25
13.30–15.30
New paradigms
in stem cell
mobilisation:
current challenges
& novel clinical
developments
Genzyme
Europe B.V.
09.00–10.30
New evidences
in treating
fungal infections
in allo-SCT
patients
MSD p. 24
Celgene
13.30–15.30
The way forward in
haematological
malignancies:
a forum for
practitioners
Celgene
16.00–18.00
Clinical Choices
• In imatinibresistant
CML
• Iron chelation in
SCT
p. 33
20.00
Welcome Reception at
the Göteborg Convention Centre
Data Managers
Daylight Saving Time:
p. 27
Satellite Symposia
p. 26
p. 28
Novartis
Oncology
p. 29
p. 195

Don’t forget to advance the clocks by one hour on
Sunday morning, 29 March 2009 at 2.00h
Room E3
Level 1
09.00–10.30
Defibrotide: update
of clinical studies
in hepatic venoocclusive
disease
following SCT
Gentium S.p.A.
p. 25
Gilead Sciences
16.00–17.30
p. 26
The role of ATG in
unrelated
allogeneic stem
cell transplantation
Fresenius
Biotech GmbH
p. 30
Room G3
Level 2
11.00–13.00 11.00–13.00
Treating complex Optimizing
fungal treatment for
infections: invasive fungal
when to switch, infections in the
combine or haematology
increase dose? setting
13.30–15.30
Fungal infections
in patients with
haematologic
malignancies:
diagnose or
prevent?
Schering-
Plough
p. 28
Pfizer Inc.
16.00–18.00
p. 27
Immune tolerance
therapy
for GvHD
management
THERAKOS, Inc.
p. 30
Room G4
Level 2
13.30–15.00
New developments
in haematologic
malignancies –
from bench to
beside
Mundipharma
p. 29
16.00–17.30
New approaches
in HSCT
conditioning
regimens
Pierre Fabre
p. 31
Room A7
Level 1
16.00–17.30
Management of
invasive fungal
infection:
from principle to
clinical practice
Cephalon Europe
p. 31
Sunday, 29 March 2009
Room H1
Level 1
09.00–10.00
Opening
Significance of
HLA matching
in HSCT
p. 128
20.00
Welcome Reception at the Göteborg Convention Centre
Room R2
Level 2
Nurses Pre-Meeting Study Day
10.20–12.30
The donor’s
perspective
Donor work-up,
follow-up and Rooms R2+R4
ethical issues
11.30–12.30
Workshop on Workshop on
donor issues donor issues
p. 128
p. 128
13.30–15.00 13.30–15.00
Standard Sessions Advanced Session
Infectious Evidence
complications based practice –
Debate – Making theory
protective reality
isolation
p. 129
p. 130
15.20–16.30
Infective issues
Closing
p. 129
15.20–16.30
Vaccination
strategies
Closing
p. 130
p. 195
08
09
10
11
12
13
14
15
16
17
18
19
20
9

08
09
10
11
12
13
14
15
16
17
18
19
20
10
Monday, 30 March 2009
Congress
Hall
Level 2
08.00–09.00
09.10–10.40
Presidential
Symposium
11.10–12.40
Working Party
Immunobiology
16.00–17.30
p. 37
Working Party
Acute
leukaemia
p. 46
Physicians
Room F4
Level 2
08.00–09.00
16.00–17.30
Working Party
Solid tumours
p. 47
Nurses
Room F1
Level 2
08.00–09.00
11.10–12.40
Working Party
Late effects
16.00–17.30
Working Party
Inborn errors
p. 48
Room E3
Level 1
Workshop 2 Workshop 4 Educational 2 Workshop 3
GvHD Non-HLA factors & Early complica- Cell therapy
prevention outcome of HLA tions after against
identical SCT
p. 34 p. 34 allo-SCT p. 35 malignancy p. 34
13.40–15.40
p. 36
Oral Session 1
Acute
leukaemia
p. 40
13.40–15.40
Oral Session 2
Stem cell
source
p. 41
Room G3
Level 2
11.00–12.20
Nurses Session 1
Donor issues
p. 38
p. 132
12.30–13.30
12.40–13.40 12.40–13.40 Elucidating the
Controversies in SCT 1 Controversies in SCT 2
Is SCT still first Is there a role for
treatment in allo-SCT in AML
myeloma?
p. 39
CR1?
p. 39
issues in MDS
treatment and
transplant
MDS Foundation
p. 133
13.40–15.40 13.40–15.40 13.40–15.10
Oral Session 3
Acute GvHD
Data Managers
08.00–09.00
09.00–10.30
Opening Session
A celebration of
25 years of the
EBMT-Nurses
Group p. 131
Oral Session 4
Solid tumours /
Multiple
myeloma
p. 42 p. 43
19.30 Concert in the Stenhammar Hall
Special Sessions
08.00–09.00
Workshop 5
AML in children
16.00–17.20
Nurses Session 3
Survivorship I
p. 135
17.30–19.00 Poster Sessions
p. 136
Physicians: P432 – P722 Nurses: P1110 – P1206
p. 78 –102 p. 145 –151
Room G4
Level 2
08.00–09.00
Educational 1 Educational 3
Severe aplastic Auto-SCT in
anaemia paediatric solid
p. 35 tumours p. 35
17.30–17.40
p. 39
Nurses Nat. Groups
11.00–12.20
Nurses Session 2
Symptom
management
13.40–15.40
16.00–17.20
p. 132
Oral Session 5
Experimental
stem cell
transplantation /
Stem cell
research
p. 44
Nurses Session 4
Patient
education
p. 135
17.30–18.30
Nurs. Natl. Groups
Nordic Forum
p. 136
p. 195
Satellite Symposia
Room A7
Level 1
08.00–08.50
Nurses
Educational 1
Total body
irradiation
p. 131
12.40–13.40
JACIE Session
13.40–15.40
p. 39
Oral Session 6
Early side
effects /
Late side
effects &
quality of life II
p. 45
17.30–18.30
Nurs. Natl. Groups
Germany
p. 136
Room A6
Level 1
08.00–08.50
Nurses
Educational 2
Chronic myeloid
leukaemia
p. 131
13.40–15.30
Nurses Plenary 3
Pallitive care
in paediatrics
p. 134
Room H1
Level 2
13.40–15.30
Nurses Plenary 4
GvHD – new
therapies,
nursing care &
photopheresis
p. 134
Room G2
Level 2
08.00–09.00
Workshop 1
Gene modified
stem cell therapy
p. 34
13.40–15.30
Nurses Plenary 5
Quality
management
p. 134
19.30 Concert in the Stenhammar Hall
Room A2
Level 1
13.40–15.30
Nurses Plenary 6
Compliance –
whose
responsibility?
p. 134
Room R2
Level 2
13.40–15.10
Nurses Workshop 1
Complimentary
therapies
p. 133
17.30–18.30 17.30–18.30 17.30–18.30 17.30–18.30
Nurs. Natl. Groups Nurs. Natl. Groups Nurs. Natl. Groups Nurs. Natl. Groups
UK Middle Europ. Netherlands Switzerland
p. 136
p. 136
p. 136
p. 136
p. 195
08
09
10
11
12
13
14
15
16
17
18
19
20
11
Room R4
Level 2
13.40–15.10
Nurses Workshop 2
Sexuality
p. 133
17.30–18.30
Nurs. Natl. Groups
Spain
p. 136
Room J1
Level 2
09.00–12.00
ProMISe 2
Data entry
(Beginners only)
13.00–16.00
ProMISe 2
Data retrieval
Room J2
Level 2
10.30–11.30
Inborn errors
New trends
p. 153
11.40–12.30
p. 152 p. ••
Myeloma
p. 152
Educational
Sessions
09.00–10.15
Late effects
13.15–14.45
p. 153
p. 153
MED-A form
p. 153
15.00–16.30
Aplastic
anaemia
17.00–18.00
p. 153
Data Managers
Reception
p. 153
Monday, 30 March 2009
Room R9
Level 2
09.00–12.30
ProMISe
Open Learning
Centre
13.30–16.00
p. 153
ProMISe
Open Learning
Centre
p. 153
19.30 Concert in the Stenhammar Hall
Press
Centre
Level 2
13.00–14.00
Press
Conference
p. ••
p. 195
08
09
10
11
12
13
14
15
16
17
18
19
20
12

08
09
10
11
12
13
14
15
16
17
18
19
20
Tuesday, 31 March 2009
Congress
Hall
Level 2
09.10–10.40
Plenary 1
Regenerative
medicine
p. 50
11.10–12.40
Working Party
Chronic
leukaemia
16.00–17.30
Working Party
Lymphoma
Room F4
Level 2
16.00–17.30
Working Party
Aplastic
anaemia
13 14
p. 62
11.10–12.40
Working Party
Paediatric
diseases
p. 51
p. 53
12.40–13.40 Controversies in SCT 3
Shall we go back
to BM as stem cell
source in adults
with malignancies?
p. 54
13.40–15.40 13.40–15.40
Oral Session 7
Lymphoma
p. 56
p. 63
08
09
10
11
12
13
14
15
16
17
18
19
20
Tuesday, 31 March 2009
Room F1
Level 2
11.10–12.40
Working Party
Autoimmune
diseases
p. 54
Room E3
Level 1
16.00–17.30
Working Party
Infectious
diseases
p. 64
Room G3
Level 2
08.00–09.00
08.00–09.00 08.00–09.00 08.00–09.00
Workshop 6
Relapse of AL
after allo-SCT
p. 49
Workshop 7
Targeting
cancer stem
cells p. 49
Educational 4
Myelodysplastic
syndromes
p. 49
Educational 5
Transplantation
vs enzyme
therapy p. 50
09.10–10.40
Joint Session
Physicians/Nurses
Quality of life
lessons – into
the future p. 50
Oral Session 8
Paediatric
diseases
p. 57
13.40–15.40
Oral Session 9
Infectious
complications
p. 58
13.40–15.10
Educational 7
Late
complications
after SCT
p. 55
11.00–12.20
Nurses Session 5
Paediatric
13.40–15.40
16.00–17.20
p. 138
Oral Session 10
Acute
leukaemia /
Chronic
leukaemia
p. 59
Nurses Session 9
Psychosocial
support
p. 140
Room G4
Level 2
08.00–09.00
Workshop 8
Gut GvHD
11.00–12.20
Nurses Session 6
Impact of
new therapies
p. 138
12.30–13.30
Nurses Annual
General Meeting
p. 139
14.00–15.20
Nurses Session 8
Survivorship II
16.00–17.20
p. 140
Nurses Session 10
Management
Nurses Anniversary
Reception
p. 141
Room A7
Level 1
08.00–08.50
Nurses
Educational 3
Myelodysplastic
syndromes
p. 137
11.00–12.30
Nurses Plenary
More confidence
in stem cell
mobilisation
and collection
p. 139
14.00–15.40
Nurses Session 7
Staff
education
and
development
p. 139
Room A6
Level 1
08.00–08.50
Nurses
Educational 4
EU directives
p. 137
12.40–13.40
Nature Publishing:
How to get
published
p. 54
13.40–15.40
Oral Session 11
Immunotherapy /
Experimental
GvHD
17.30–19.00 Poster Sessions
Physicians: P723 – P1007 Nurses: P1110 – P1206 Data Managers: P1008 – P1015
p. 103 –127 p. 145 –151 p. 127
p. 49
20.00 EBMT Party at Kajskjul 8
p. 60
p. 195
Room H1
Level 2
13.30–15.30
Statistical
Symposium
16.00–18.00
p. 55
CLINT
Statistical
Roundtable
Physicians
Room G2
Level 2
08.00–09.00
Educational 6
Vaccinations
13.40–15.40
p. 50
Oral Session 12
Autoimmune
diseases /
Aplastic
anaemia /
Myelodysplasia
p. 61
Nurses
Room A2
Level 2
08.00–09.30
Nurses WS 1
(repeated)
Complimentary
therapies
p. 137
Data Managers
Room J1
Level 2
09.00–12.00
ProMISe 2
Data retrieval
13.00–16.00
20.00 EBMT Party at Kajskjul 8
Tuesday, 31 March 2009
p. 154
ProMISe 2
Data entry
(Beginners only)
Room J2
Level 2
Educational
Sessions
09.00–10.15
Transplant
procedure
10.30–11.20
Special Sessions
p. 154
CML
p. 154
11.30–12.30
13.00–14.30
From study
design
to publication
Room R9
Level 2
09.00–12.30
ProMISe
Open Learing
Centre
Data collection &
working methods
p. 154 p. 154
14.45–16.15
p. 65
p. 61
17.30–19.00 Poster Sessions
Physicians: P723 – P1007 Nurses: P1110 – P1206 Data Managers: P1008 – P1015
p. 103 –127 p. 145 –151 p. 127
p. 154
Autoimmune
diseases
13.30–16.00
ProMISe
Open Learing
Centre
p. 154 p. 154
p. 154
p. 195
Satellite Symposia
08
09
10
11
12
13
14
15
16
17
18
19
20
15

08
09
10
11
12
13
14
15
16
Wednesday, 1 April 2009
Room F4
Level 2
08.00–09.00
General
Assembly
p. 66
09.00–10.30
Joint Session
WBMT
EBMT/CIBMTR
APBMT/WMDA
p. 67
10.45–12.15
Plenary 2
Immune
regeneration
and infection
p. 70
12.45–14.15
Joint Session
EBMT/
ISCT/ISEH
p. 70
Physicians
Room F1
Level 2
09.00–10.30
Educational 9
Chronic GvHD
10.45–12.15
Nuclear
Accident
Session
12.45–14.45
p. 68
p. 70
Oral Session 13
Infectious
complications /
GvHD
p. 71
Nurses
Room E3
Level 1
09.00–10.30
Workshop 9
Mesenchymal
stem cells
12.45–14.45
p. 67
Oral Session 14
Reducedintensity
transplants
p. 72
Data Managers
Room G3
Level 2
08.00–08.50
Nurses
Educational 5
AD in children
p. 142
09.00–10.40
Nurses Session 11
Standards
of care
11.00–13.00
WBMT: Worldwide Network for Blood & Marrow Transplantation
CIBMTR: Centre for International Blood and Marrow Transplant Research
APBMT: Asia Pacific Blood and Marrow Transplantation
WMDA: World Marrow Donor Association
ISEH: International Society for Hematology and Stem Cells
ISCT: International Society for Cellular Therapy
p. 143
Nurses Session 13
EBMT NG
activity
Medical update/
Awards &
Closing
p. 144
Special Sessions
Room G4
Level 2
08.00–08.50
Nurses
Educational 6
Reduced-intensity
transplant p. 142
09.00–10.20
Nurses Session 12
Multidisciplinary
collaboration
12.45–14.45
p. 143
Oral Session 15
Early side
effects /
Late effects &
quality of life I
p. 73
Closing
Room A7
Level 1
12.45–14.45
Oral Session 16
Cellular and
gene therapies
p. 74
Satellite Symposia

Room A6
Level 1
09.00–10.30
Educational 10
Allo-SCT in
lymphoma
12.45–14.45
p. 68
Oral Session 17
Inborn errors /
Haemoglobinopathy
/
Paediatric
issues
p. 75
Room H1
Level 2
09.00–10.30
Educational 8
Donor selection
in paediactric
allo-SCT p. 68
12.45–14.45
Oral Session 18
Stem cell
donor /
Regulatory
issues
p. 76
Room G2
Level 2
09.00–10.30
Workshop 10
Graft failure
12.45–14.45
p. 67
Oral Session 19
Graft vs.
Malignancy /
MRD /
Tolerance and
alloractivity
p. 77
Room H2
Level 1
Wednesday, 1 April 2009
Room J2
Level 2
36
Advance Notice / EBMT 2010
th Annual Meeting of the European Group for Blood and Marrow Transplantation
26th Meeting of the EBMT Nurses Group
9th Meeting of the EBMT Data Management Group
4th EBMT Patient & Family Day • Saturday, 20 March 2010
Vienna, Austria, 21 – 24 March 2010
www.congrex.ch/ebmt2010
10.00–11.30
Quality Mgmt
Plenary
Sessions
p. 69
11.30–13.15
Quality Mgmt
Interactive
Sessions
p. 69
Closing
08.00–09.30
Nurses
Workshop 2
(repeated)
Sexuality
11.30–13.30
p. 142
Quality Mgmt
Interactive
Sessions
p. 69
08
09
10
11
12
13
14
15
17

Committed
to developing and
delivering innovative therapies
Dedicated
to improving the lives
of cancer patients worldwide
Celgene International Sàrl
Route de Perreux 1
2017 Boudry
Switzerland
+41 32 729 8500
www.celgene.com
© 2009 Celgene

Organising Committee
Congress President
M. Brune, Göteborg
Scientific Chair
P. Ljungman, Stockholm
Chair Local Organising Committee
D. Stockelberg, Göteborg
Local Organising Committee
V. Erling, Göteborg Physician
H. Nilsson-Ehle, Göteborg Physician
L. Wennström, Göteborg Physician
E. Andersson, Göteborg Nurse
I. Andersson, Göteborg Nurse
J. Larsen, Stockholm Nurse
K. Olsson-Lundberg, Göteborg Nurse
E. Wallhult, Göteborg Nurse
C. Kristiansson, Göteborg Data Management
G. Bodö Aspström, Göteborg Secretarial
Support
Members of the Nordic Scientific
Committee
J. Abrahamsson, Göteborg
J. Arvidsson, Uppsala
M. Bengtsson, Uppsala
L. Brinch, Oslo
A. Fasth, Göteborg
T. Fioretos, Lund
G. Gahrton, Stockholm
E. Hellström-Lindberg, Stockholm
H. Hägglund, Stockholm
G. Juliusson, Lund
E. Kimby, Stockholm
G. Kvalheim, Oslo
S. Lenhoff, Lund
K. LeBlanc, Stockholm
G. Öberg, Uppsala
U. Pikhala, Helsinki
O. Ringden, Stockholm
T. Ruutu, Helsinki
H. Sengelöv, Copenhagen
A. Wahlin, Umeå
J. Winiarski, Stockholm
EBMT Board
D. Niederwieser, Leipzig President
P. Ljungman, Stockholm Secretary
J. Cornelissen, Rotterdam Treasurer
E. Aerts, Zurich President Nurses Group
F. Mc Donald, Barcelona Executive Officer
Working Party Chairpersons
V. Rocha, Paris Acute Leukaemia
J. Passweg, Geneva Aplastic Anaemia
R. Saccardi, Florence Autoimmune Diseases
T. de Witte, Nijmegen Chronic Leukaemias
A. Velardi, Perugia Immunobiology
B. Gaspar, London Inborn Errors
H. Einsele, Würzburg Infectious Diseases
A. Tichelli, Basel Late Effects
A. Sureda, Barcelona Lymphoma
C. Peters, Vienna Paediatric Diseases
M. Bregni, Milan Solid Tumours
EBMT Board Nurses Group & Nurses
Scientific Committee
E. Aerts, Zurich President
A. Mank, Amsterdam President Elect
M. Davies, Manchester Secretary
J. Blankart, Hamburg Treasurer
M. Ni Chonghaile, Scientific Committee
Dublin (chair)
E. Mazur, Katowice Scientific Committee
M.I. Rebelo, Lisbon Scientific Committee
V. Van de Crommert, Scientific Committee
Nijmegen
I. Andersson, Göteborg Local Nurse
J. Larsen, Stockholm Local Nurse
E. Wallhult, Göteborg Local Nurse
Data Management Group
C. Ruiz de Elvira, London Registry Executive
Officer
R. Brand, Leiden EBMT Statistician
M. Labopin, Paris Chair of EBMT Statistical
Subcommittee
Z. Doran, London Director, Clinical Trials
Operations
C. Kristiansson, Göteborg Local Support
19

Pall Filtration from Point-of-Entry
to Point-of-Use
Barriers against waterborne particles and
microorganisms
Advanced technology from point-of-water
entry to point-of-use
Cost competitive performance with high
flow rates, capacities and service life
No additives or influence on water
organoleptic qualities
Engineering solutions and adjuncts for
water management practices
Interested?
Please email biosvc@Pall.com or
contact your local Pall
representative.
www.pall.com/healthcarewater
Filtration. Separation. Solution.SM
© 2009 Pall Corporation.
and Pall are trademarks of Pall Corporation.
® indicates registered in the USA, and
indicates a common law trademark. GN 08.2983

Important Addresses
Address of Venue &
Secretariat during EBMT 2009
Göteborg Convention Centre
Mässans gata 20
402 26 Göteborg / Sweden
Tel. +46 31 708 82 50
Fax +46 31 708 82 52
www.gcc.se
Physicians’ Scientific Secretariat
Gunborg Bodö Aspström
Section of Haematology and Coagulation
Sahlgrenska University Hospital
413 45 Göteborg / Sweden
Tel. +46 31 3428431
Fax +46 31 417438
E-mail: EBMT2009@vgregion.se
Nurses Scientific Secretariat
Mairead Ni Chonghaile
HOPE Directorate
St. James’s Hospital
Dublin 8 / Ireland
Tel. +353 87 686 07 22
Fax +353 1 410 34 28
E-mail: bmtco-ord@stjames.ie
Data Management Group
EBMT Central Registry Office
Carmen Ruiz de Elvira
12th Floor, Tower Wing
Guy’s Hospital
Great Maze Pond
London SE1 9RT / United Kingdom
Tel. +44 207 188 8408
Fax +44 207 188 8411
E-mail: carmen.ruiz@kcl.ac.uk
Organising Secretariat
Before and after EBMT 2009
EBMT 2009
c/o Congrex Switzerland Ltd.
Association House
P.O. Box
4002 Basel / Switzerland
www.congrex.ch/ebmt2009
Congress Coordination
Tel. +41 61 686 77 11
Fax +41 61 686 77 88
E-mail: ebmt@congrex.com
Exhibition
Tel. +41 61 686 77 77
Fax +41 61 686 77 88
E-mail: exhibition.ch@congrex.com
Hotel Accommodation &
Flight Bookings
Congrex Travel Ltd.
Association House
P.O. Box
4002 Basel / Switzerland
Hotel accommodation
Tel. +41 61 690 94 11
Fax +41 61 690 94 14
E-mail: ebmt.hotels@congrex.com
Flight bookings
Tel. +41 61 560 75 60
Fax +41 61 690 92 14
E-Mail: businesstravel@congrex.com
Local Agency
SKD Euroconf AB (Congrex Group)
Mässans gata 10B
P.O. Box 5078
402 22 Göteborg / Sweden
Tel. +46 31 769 75 81
Fax +46 31 708 60 25
E-mail: EBMT2009@konferens.se
www.konferens.se
21

EUROPEAN HEMATOLOGY ASSOCIATION
14 th CONGRESS
of the
European Hematology Association
January 1, 2009:
March 1, 2009:
May 10, 2009:
Start abstract
submission and
congress registration
Deadline abstract
submission
Deadline early
registration fee
INTERNATIONALES CONGRESS CENTRUM BERLIN GERMANY JUNE 4 - 7 2009
www.ehaweb.org

Satellite Symposia Saturday, 28 March 2009
18:00– Satellite Symposium Room F1
20:00
Transforming CMV management
S1
Chairs: P. Ljungman (Stockholm, SE); F. Marty (Boston, US)
Chairs’ introduction
18:00 P. Ljungman, F. Marty (Stockholm, SE; Boston, US)
S2 The impact of CMV in SCT recipients
18:10 R. de la Cámara (Madrid, ES)
S3 Managing CMV in SCT recipients: current state of the art – case studies
18:30 V. Emery (London, UK)
S4 Managing CMV: the role of benzimidazoles
18:50 H. Einsele (Würzburg, DE)
S5 Prophylaxis for the prevention of CMV:
19:10 results from a pivotal Phase III trial in SCT recipients
M. Boeckh (Seattle, US)
19:30 Discussion
S6 Chairs’ closing remarks
19:55 P. Ljungman, F. Marty (Stockholm, SE; Boston, US)
Satellite Symposium organised by ViroPharma
23

24
Satellite Symposia Sunday, 29 March 2009
09:00– Satellite Symposium Room F4
10:30
Improving the outcomes of matched and mismatched
transplants by selective allodepletion of T-cells
S7
Chairs: A. Velardi (Perugia, IT); H. Einsele (Würzburg, DE)
The basis of selective allodepletion
09:00 J. Barrett (Bethesda, US)
S8 Results from haplo-trial in Canada with selective allodepletion
09:20 D.-C. Roy (Montreal, CA)
S9 Results from haplo-trial in Italy with selective allodepletion
09:35 A. Velardi (Perugia, IT)
S10 Results from the matched trial at NIH with selective allodepletion
09:50 S. Mielke (Würzburg, DE)
S11 Introduction of the new multicenter trial in haplo-identical transplants with
10:05 selective allodepletion
S. Mielke, D.-C. Roy (Würzburg, DE; Montreal, CA)
S12 The future of selective allodepletion and final conclusions
10:20 J. Barrett, A. Velardi (Bethesda, US; Perugia, IT)
Satellite Symposium organised by Kiadis Pharma
09:00–
10:30
Satellite Symposium
New evidences in treating fungal infections in
allo-SCT patients
Chairs: O. Cornely (Cologne, DE); J. Maertens (Leuven, BE)
Room F1
S13 Welcome and opening remarks
09:00 J. Maertens (Leuven, BE)
S14 Evidence and guidelines for the treatment of suspected fungal infections in
09:05 patients with haematological malignancies
H. Akan (Ankara, TR)
S15 Impact of baseline characteristics on outcomes in the treatment of invasive
09:25 aspergillosis in haematological and allo-SCT patients
C. Viscoli (Genoa, IT)
S16 Treating invasive fungal infections in paediatric haematological patients
09:55 J. Cornish (Bristol, UK)
10:10 Panel discussion
S17 Closing Remarks
10:25 O. Cornely (Cologne, DE)
Satellite Symposium organised by Merck Sharp & Dohme

Satellite Symposia Sunday, 29 March 2009
09:00– Satellite Symposium Room E3
10:30
Defibrotide: Update of clinical studies in hepatic venoocclusive
disease following stem cell transplantation
Chair: E. Carreras (Barcelona, ES)
S18 The pathophysiology of veno-occlusive disease
E. Holler (Regensburg, DE)
S19 Update and preliminary results from the prospective, randomized trial of
defibrotide in the prevention of hepatic veno-occlusive disease undergoing
paediatric stem cell transplantation
S. Corbacioglu (Ulm, DE)
S20 The treatment of hepatic veno-occlusive disease following SCT –
current status and future directions
P. Richardson (Boston, US)
S21 Defibrotide and VOD – other experiences in Europe
D. Niederwieser (Leipzig, DE)
Satellite Symposium organised by Gentium S. p.A.
11:00–
13:00
Satellite Symposium Room F4
S22
Cellular therapies: Therapeutic options for stem cell
transplantation
Chair: S. Scheding (Lund, SE)
Rapid and effective large-scale CD3 T cell depletion using the
CliniMACS ® System
J. Dykes (Lund, SE)
S23 HSCT from haploidentical donors in patients with high-risk acute leukaemia
F. Aversa (Perugia, IT)
S24 Adoptive T cell immunotherapy for cytomegalovirus
K.S. Peggs (London, UK)
S25 Cell-mediated killing of leukaemia and neuroblastoma using natural killer
cells after haploidentical stem cell transplantation
U. Koehl (Frankfurt, DE)
S26 Therapeutic potential of large-scale separated CD4+CD25+regulatory T cells
B. Blazar (Minneapolis, US)
Satellite Symposium organised by Miltenyi Biotec GmbH
25

26
Satellite Symposia Sunday, 29 March 2009
11:00– Satellite Symposium Room F1
13:00
Evolution of multiple myeloma treatment:
planning sustained disease control
Chairs: M. Dimopoulos (Athens, GR); P. Gimsing (Copenhagen, DK)
11:00 Welcome and introduction
S27 Stem cell transplantation in the era of novel agents: keeping options open
11:05 S. Kumar (Rochester, US)
S28 Aiming for sustained remission: the role of maintenance therapy in the
11:30 treatment of multiple myeloma
M. Attal (Toulouse, FR)
S29 Standard of care for patients with newly diagnosed multiple myeloma
11:50 who are not eligible for a transplant
P. Moreau (Nantes, FR)
S30 Long-term management of relapsed/refractory multiple myeloma with
12:15 lenalidomide plus dexamethasone
M. Dimopoulos (Athens, GR)
S31 Clinical case: practical management of long-term therapy for multiple
12:40 myeloma
G. Morgan (Sutton, UK)
12:55 Closing remarks
Satellite Symposium organised by Celgene International Sàrl
11:00 –
13:00
Satellite Symposium Room E3
S32
Treating complex fungal infections: when to switch,
combine or increase dose?
Chair: G. Maschmeyer (Potsdam, DE)
Choosing therapy following breakthrough infections with broad spectrum
azole prophylaxis in high-risk patients
R. de la Cámara (Madrid, ES)
S33 The role of combination therapy in serious fungal infections
L. Ostrosky-Zeichner (Houston, US)
S34 Is there a role for high-dose anti-fungal therapy?
F. Menichetti (Pisa, IT)
Satellite Symposium organised by Gilead Sciences Europe Ltd.

Satellite Symposia Sunday, 29 March 2009
11:00– Satellite Symposium Room G3
13:00
Optimizing treatment for invasive fungal infections in the
haematology setting
S35
Chair: M. Björkholm (Stockholm, SE)
Introduction
11:00 M. Björkholm (Stockholm, SE)
S36 Epidemiology of invasive fungal infections in the haematology setting
11:05 M. Cavling Arendrup (Copenhagen, DK)
S37 The controversy of antifungal drug monitoring
11:25 P. Donnelly (Nijmegen, NL)
S38 Pre-emptive therapy of invasive aspergillosis
11:45 R. Herbrecht (Strasbourg, FR)
S39 Managing fungal disease in haematology – updated guidelines and latest
12:15 clinical data
C. Cordonnier (Paris, FR)
12:35 Panel discussion
S40 Concluding comments
12:55 M. Björkholm (Stockholm, SE)
Satellite Symposium organised by Pfizer
13:30–
15:30
Satellite Symposium
New paradigms in stem cell mobilisation:
Room F4
S41
current challenges and novel clinical developments
Chair: N.H. Russell (Nottingham, UK)
Welcome and introduction
13:30 N.H. Russell (Nottingham, UK)
S42 The controversy: defining success and failure in stem cell collection
13:35 H.C. Schouten (Maastricht, NL)
S43 Health outcome studies in stem cell mobilisation
13:55 J.F. Apperley (London, UK)
S44 Why improvements in stem cell mobilisation are needed
14:15 N.H. Russell (Nottingham, UK)
S45 Current advances in stem cell mobilisation
14:35 A.D. Ho (Heidelberg, DE)
S46 Future directions in stem cell mobilisation
14:55 J.F. DiPersio (St. Louis, US)
15:15 Discussion and Q&A
S47 Closing remarks
15:30 N.H. Russell (Nottingham, UK)
Satellite Symposium organised by Genzyme Europe B.V.
27

28
Satellite Symposia Sunday, 29 March 2009
13:30– Satellite Symposium Room F1
15:30
The way forward in haematological malignancies:
a forum for practitioners
Chairs: P. Fenaux (Bobigny, FR); E. Hellström-Lindberg (Stockholm, SE)
13:30 Welcome and introduction
S48 The role of the stem cell transplant in myelodysplastic syndromes
13:35 G. Mufti (London, UK)
S49 Azacitidine: the first drug to prolong the survival of patients with
14:00 myelodysplastic syndromes
P. Fenaux (Bobigny, FR)
S50 Azacitidine in clinical practice
14:25 L. Silverman (New York, US)
S51 Lenalidomide in Low- and Int-1 myelodysplastic syndromes
14:45 A. Giagounidis (Duisburg, DE)
S52 Lenalidomide in non-Hodgkin lymphoma and chronic lymphocytic leukaemia
15:00 M. Czuczman (Buffalo, US)
15:25 Closing remarks
Satellite Symposium organised by Celgene International Sàrl
13:30–
15:30
Satellite Symposium
Fungal infections in patients with haematologic
malignancies: diagnose or prevent?
Chair: K. Marr (Seattle, US)
Room E3
S53 Programme overview / Opening comments
13:30 K. Marr (Seattle, US)
S54 From invasive fungal infection to invasive fungal disease:
13:35 theoretical rationale and clinical application
J. Maertens (Leuven, BE)
S55 An analysis of non-culture–based microbiological tools in today’s practice
13:55 K. Marr (Seattle, US)
S56 Therapeutic drug monitoring during antifungal prophylaxis: is it necessary?
14:20 O. Cornely (Cologne, DE)
S57 Antifungal prophylaxis in patients with HSCT/GvHD: what have we learned?
14:45 J. Maertens (Leuven, BE)
15:10 Panel discussion
15:25 Concluding remarks
Satellite Symposium organised by Schering-Plough

Satellite Symposia Sunday, 29 March 2009
13:30– Satellite Symposium Room G4
15:00
New developments in haematologic malignancies –
from bench to bedside
Chairs: J. Gribben (London, UK); E. Kimby (Stockholm, DE)
13.30 Welcome and introductions from the Chairs
S58 From in vitro data to clinical practice – new directions for Bendamustine
13:45 P. Valent (Vienna, AT)
S59 A conditioning regime with Bendamustine is a well tolerated and effective
14:10 option in lymphomas
G. Visani (Pesaro, IT)
S60 Efficacy and tolerability of Bendamustine in post-SCT and relapsed patients
14:35 in multiple myeloma
H. Einsele (Würzburg, DE)
14.55 Closing questions and remarks from the Chairs
Satellite Symposium organised by Mundipharma International Ltd.
16:00–
18:00
Satellite Symposium
Clinical choices:
• In imatinib-resistant CML
• Iron chelation in SCT
Chair: D. Niederwieser (Leipzig, DE)
Room F1
S61 Welcome & introduction
16:00 D. Niederwieser (Leipzig, DE)
S62 Resistance or suboptimal response?
16:05 Evaluating patients responding poorly
F.-X. Mahon (Bordeaux, FR)
S63 Risk-dependent choice of therapy in imatinib failure
16:20 T. Brümmendorf (Hamburg, DE)
S64 Stem cell transplantation in CML – its role today
16:40 E. Olavarria (London, UK)
S65 The role of 2nd-generation TKIs in advanced CML
17:00 K. Porkka (Helsinki, FI)
S66 Enabling patients to cope
17:20 M. Fliedner (Berne, CH)
S67 The role of iron chelation pre-and post-SCT
17:35 T. de Witte (Nijmegen, NL)
S68 Summary and conclusions
17:55 D. Niederwieser (Leipzig, DE)
Satellite Symposium organised by Novartis Oncology
29

30
Satellite Symposia Sunday, 29 March 2009
16:00– Satellite Symposium Room E3
17:30
The role of ATG in unrelated allogeneic stem cell
transplantation: current conditioning strategies in SCT
Chair: M. Brune (Göteborg, SE)
S69 Current strategies in myelo- and non-myeloablative conditioning therapies
in SCT
J. Mayer (Brno, CZ)
S70 Reduced-toxicity/reduced-intensity conditioning pre-AlloSCT with ATG
A. Nagler (Tel Hashomer, IL)
S71 Allogeneic stem cell transplantation for ALL in children and adolescents
C. Peters (Vienna, AT)
S72 Reduction of acute and chronic GvHD in allogeneic SCT from matchedunrelated
donors
J. Finke (Freiburg, DE)
Discussion
Satellite Symposium organised by Fresenius Biotech GmbH
16:00–
18:00
Satellite Symposium Room G3
S73
Immune tolerance therapy for GvHD management
Chair: A.M. Dickinson (Newcastle upon Tyne, UK)
Extracorporeal photopheresis for the treatment of refractory chronic GvHD:
clinical results and in vitro studies
A.M. Dickinson (Newcastle upon Tyne, UK)
S74 Current treatment options for paediatric GvHD
R. Handgretinger (Tübingen, DE)
S75 A new standard in extracorporeal photopheresis for chronic GvHD
P. Taylor (Rotherham, UK)
S76 GvHD and the Blood and Marrow Transplant Clinical Trials Network (BMT CTN):
what future trials should look like
P.A. Carpenter (Seattle, US)
Satellite Symposium organised by THERAKOS, Inc

Satellite Symposia Sunday, 29 March 2009
16:00– Satellite Symposium Room G4
17:30
New approaches in HSCT conditioning regimens:
raising the standards
Chair: A. Bacigalupo (Genoa, IT)
S77 IV Bu-based regimen in umbilical cord blood transplantation
G. Sanz (Valencia, ES)
S78 Which dose of IV Busulfan is the best in BuFlu regimen?
M. Mohty (Nantes, FR)
S79 New perspectives in lymphoma with IV Busulfan
N. Schmitz (Hamburg, DE)
S80 Optimizing patient outcomes in ALL
M. Gonzalez (Madrid, ES)
Satellite Symposium organised by Pierre Fabre Médicament
16:00–
17:30
Satellite Symposium
Management of invasive fungal infection:
from principle to clinical practice
Chairs: P. Corradini (Milan, IT); R. Martino (Barcelona, ES)
Room A7
S81 The evolving challenges of treating invasive fungal infections in HSCT
16:00 patients
P. Corradini (Milan, IT)
S82 Clinical evidence on Amphotericin B lipid complex in BMT patients
16:25 J.L. Ito (Duarte, US)
S83 Paediatrics antifungal formulary: which drugs, when and how much
16:50 T. Zaoutis (Philadelphia, US)
S84 Panel discussion
17:15 R. Martino (Barcelona, ES)
Satellite Symposium organised by Cephalon Europe
31

Committed
to developing and
delivering innovative therapies
Dedicated
to improving the lives
of cancer patients worldwide
Celgene International Sàrl
Route de Perreux 1
2017 Boudry
Switzerland
+41 32 729 8500
www.celgene.com
© 2009 Celgene

Opening Session Sunday, 29 March 2009
18:30– Opening Session Congress Hall
20:00
Chairs: D. Niederwieser (Leipzig, DE); M. Brune (Göteborg, SE)
85 Welcome
18:30 EBMT Congress President
M. Brune (Göteborg, SE)
Deputy Lord Mayor, Göteborg
E. Rothenberg (Göteborg, SE)
Vice-Chancellor, University of Gothenburg
P. Fredman (Göteborg, SE)
EBMT President
D. Niederwieser (Leipzig, DE)
Nurses Group President
E. Aerts (Zurich, CH)
Data Management Group Head
C. Ruiz de Elvira (London, UK)
86 Van Bekkum Award
19:05 Prophylactic transfer of Bcr/Abl, PR1 and WT1-reactive donor T-cells after
T-depleted allogeneic haematopoietic cell transplantation in patients with
chronic myeloid leukaemia
M. Bornhäuser, C. Thiede, A. Kiani, U. Platzbecker, U. Oelschlägel, J. Radke,
J. Schetelig, D. Lehmann, K. Hölig, G. Ehninger, M. Schmitz (Dresden, DE)
87 EBMT Lecture
19:25 Cell therapy in multiple myeloma – facts and visions
G. Gahrton (Stockholm, SE)
20:00 Welcome Reception
Please refer to page 195 for details.
33

34
Scientific Programme Physicians Monday, 30 March 2009
08:00– Workshop 1 Room G2
09:00
Gene modified stem cell therapy
88
Chair: P. Veys (London, UK)
The London experience
08:00 A. Thrasher (London, UK)
89 The Milano experience
08:30 A. Aiuti (Milan, IT)
08:00–
09:00
Workshop 2
GvHD prevention
Chair: L. Brinch (Oslo, NO)
Congress Hall
90 Conditioning to avoid GvHD
08:00 B. Blazar (Minneapolis, US)
91 New ways of GvHD prevention
08:30 L. Luznik (Baltimore, US)
08:00–
09:00
Workshop 3
Cell therapy against malignancy
Chair: O. Ringden (Stockholm, SE)
Room E3
92 Adoptive T-cell therapy
08:00 J.H.F. Falkenburg (Leiden, NL)
93 Adoptive NK-cell therapy
08:30 H.-G. Ljunggren (Stockholm, SE)
08:00 –
09:00
Workshop 4 Room F4
94
Non-HLA factors and the outcome of HLA identical SCT
Chair: D. Charron (Paris, FR)
Minor antigens
08:00 E. Goulmy (Leiden, NL)
95 Gene polymorphisms
08:30 E. Holler (Regensburg, DE)

Scientific Programme Physicians Monday, 30 March 2009
08:00– Educational Session 1 Room G3
09:00
Severe aplastic anaemia
96
Chair: J. Marsh (London, UK)
Indications for SCT in adults; sibling and unrelated donors
08:00 J. Passweg (Geneva, CH)
97 Paediatric bone marrow failures
08:30 C. Bonfim (Curitiba, BR)
08:00–
09:00
Educational Session 2
Early complications after allo-SCT
Chair: T. Ruutu (Helsinki, FI)
Room F1
98 Haemorrhagic cystitis
08:00 H. Hirsch (Basel, CH)
99 New respiratory viral pathogens
08:30 M. Boeckh (Seattle, US)
08:00–
09:00
Educational Session 3
Auto-SCT in paediatric solid tumours
Chair: I. Yaniv (Petach Tikva, IL)
Room G4
100 Neuroblastoma
08:00 R. Ladenstein (Vienna, AT)
101 Brain tumours
08:30 J. Finlay (Los Angeles, US)
35

36
Scientific Programme Physicians Monday, 30 March 2009
09:10– Presidential Symposium Congress Hall
10:40
Chairs: D. Niederwieser (Leipzig, DE); M. Brune (Göteborg, SE)
O102 Basic Science Award
09:10 Targeting CD83 delays GvHD onset in murine allogeneic haematopoietic
stem cell transplant recipients
B. Turner, L. Sinfield, M. Kambouris, H. Cullup, J. Wilson, A. Palkova, D. Hart,
D. Munster, A. Rice (Newcastle, UK; South Brisbane, AU)
O103 Aurora A kinase: a novel target of immunocell therapy against human
09:25 leukaemia
H. Fujiwara, T. Ochi, K. Suemori, T. Azuma, K. Kuzushima, M. Yasukawa
(Toon, Nagoya, JP)
O104 Alloreactive T-cell depleted donor lymphocyte infusions decrease
09:40 infections without causing severe GvHD after haplotype mismatched
stem cell transplantation
D.C. Roy, S. Lachance, T. Kiss, S. Cohen, L. Busque, D. Fish, G. Sauvageau,
J. Rovers, J. Roy (Montreal, CA; Amsterdam, NL)
O105 Association between HLA-matching status and reduction in relapse rate
09:55 following unrelated allogeneic haematopoietic stem cell transplantation for
myeloid and lymphoid malignancies
T. Kawase, K. Kashiwase, H. Inoko, H. Saji, S. Ogawa, S. Kato, T. Sasazuki,
Y. Kodera, Y. Morishima on behalf of The Japan Marrow Donor Program
O106 Intrabone marrow transplantation of cord blood cells is associated with
10:10 better platelet recovery and decreased acute GvHD as compared with
intravenous transplantation: an EUROCORD matched-paired analysis
F. Frassoni, M. Labopin, F. Gualandi, F.M. Sanchez-Guijo, M. Berger, M. Rovira,
M. Podestà, A.M. Raiola, G. Ubezio, R. Varaldo, D. Caballero, E. Carreras, F. Nesi,
M. Gobbi, F. Fagioli, A. Baciglaupo, N. Sacchi, I. Ionescu, E. Gluckman, V. Rocha
(Genoa, Turin, IT; Paris, FR; Salamanca, Barcelona, ES)
O107 Encouraging results of unrelated cord blood transplantation after
10:25 homogenous reduced-intensity conditioning in adults with hematological
malignancy: impact of HLA disparities on outcomes. A French multicentre
study on behalf of the SFGM-TC and Eurocord
B. Rio, A. Furst, M. Renaud, F. Legrand, R. Tabrizi, M. Uzunov, S. Lapusan, D. Blaise,
E. Deconinck, J.H. Bourhis, L. Fouillard, C. Bulabois, P. Ceballos, S. Maury,
P. Chevalier, M. Mohty, S. François, A. Huynh, M. Michallet, A. Sirvent, N. Dhedin,
N. Contentin, A. Buzyn, D. Guyotat, T. Fagot, I. Yakoub-Agha, E. Gluckman,
I. Ionescu, N. Milpied, V. Rocha on behalf of the SFGM-TC and Eurocord

Scientific Programme Physicians Monday, 30 March 2009
11:10– Working Party Immunobiology Congress Hall
12:40
Chairs: A. Velardi (Perugia, IT); A. Toubert (Paris, FR)
108 Genomics of unrelated HCT
11:10 E. Petersdorf (Seattle, US)
109 New methods to rapidly characterize minor histocompatibility antigens
11:20 J.H.F. Falkenburg (Leiden, NL)
110 Immunotherapy for infections post-transplant
11:30 H. Einsele (Würzburg, DE)
111 Adoptive cell therapy in children given allogeneic HSCT
11:40 F. Locatelli (Pavia, IT)
112 T regs from cord blood and its potential clinical application –
11:50 lessons from AlloStem
J.A. Madrigal (London, UK)
113 Immune reconstitution after cord blood transplantation supported by
12:00 third party donor cells
M. Fernandez (Barcelona, ES)
114 Current and future strategies to boost post-transplant immunity
12:10 A. Velardi (Perugia, IT)
12:20 General discussion
37

38
Scientific Programme Physicians Monday, 30 March 2009
11:10– Working Party Late effects Room F1
12:40
Chairs: A. Tichelli (Basel, CH); M. Arat (Ankara, TR)
115 Chairman’s report
A. Tichelli (Basel, CH)
116 � Randomized comparison of bone marrow and peripheral blood stem
cells for treatment of leukaemia – long-term follow-up results on survival,
GvHD and late effects
B. Friedrichs, A. Tichelli, A. Bacigalupo, N. Russell, T. Ruutu, M. Beksac, G. Socié,
N. Schmitz on behalf of the EBMT Late Effects Working Party
117 � Management of related donor care: a European survey
S. Clare, A. Mank, R. Stone, M. Davies, C. Potting, J. F. Apperley on behalf of the Research
Sub-committee of the EBMT Nurses Group and the Late Effects Working Party
118 � Secondary malignancies after stem cell transplantation – a long-term follow
up study ten years later
B. Heilmeier, N. Stowasser, G. Socie, M.T. van Lint, A. Tichelli, N. Salooja, E. Nekolla,
P. Ljungman, N. Jacobsen, M. van Weel, J. Tischer, G. Ledderose, T.M. Fliedner,
H.J. Kolb on behalf of the EBMT Late Effects Working Party
119 Stem cell donor subcommittee: presentation of the new Late Effect Working
Party EBMT subcommittee
J. Halter (Basel, CH)
120 � Survey on bronchiolitis obliterans syndrome developing after allogeneic
haematopoietic stem cell transplantation
M. Arat, A. Bekassy, J. Passweg, A. Tichelli, D. Caballero, P. Ljungman, F. Bonifazi,
A.O. Fernandez, D. Broeters, S. Guidi, J. Greil, A. Zander, G. Socié
on behalf of the EBMT Late Effect Working Party
�Abstract

Scientific Programme Physicians Monday, 30 March 2009
12:40– Controversies in SCT 1: Room F1
13:40 Is SCT still first treatment in myeloma?
Chair: C. Morris (Belfast, UK)
Auto-SCT vs. chemotherapy (what is first line?)
121 Yes
B. Barlogie (Little Rock, US)
122 No
J. Bladé (Barcelona, ES)
12:40– Controversies in SCT 2: Room E3
13:40 Is there a role for allo-SCT in AML CR1?
Chair: J.M. Rowe (Haifa, IL)
123 Yes
J.J. Cornelissen (Rotterdam, NL)
124 No
A. Burnett (Cardiff, UK)
12:40– JACIE Session 2009 Room A7
13:40
Chair: T. Ruutu (Helsinki, FI)
125 Three years of JACIE in my centre
12:40 K. Leibundgut (Berne, CH)
126 JACIE Standards, 4th edition – what you need to know!
12:55 D. Pamphilon (Bristol, UK)
127 Advanced therapy regulations
13:10 I. Slaper (Utrecht, NL)
13:25 Q&A
13:40 –
15:10
Workshop 5 Room G3
128
AML in children – indications for allogeneic SCT in
different countries
Chair: G. Dini (Genoa, IT)
Nordic countries
13:40 H. Hasle (Aarhus, DK)
129 USA
14:00 R. Aplenc (Philadelphia, US)
130 AML Relapse working group of the International BFM Study Group
14:20 G. Kaspers (Amsterdam, NL)
131 UK
14:40 B. Gibson (Glasgow, UK)
15:00 Discussion
39

40
Scientific Programme Physicians Monday, 30 March 2009
13:40– Oral Session 1 Congress Hall
15:40
Acute leukaemia
Chairs: A. Wahlin (Umea, SE); S. Giebel (Gliwice, PL)
O132 Effect of stem cell source on transplant outcomes in adults with acute
13:40 leukaemia: a comparison of unrelated bone marrow, peripheral blood and
cord blood
V. Rocha, M. Eapen, A. Scaradavou, E. Gluckman, M. Laughlin, C. Stevens,
M.M. Horowitz , J.E. Wagner on behalf of New York Blood Center, CIBMTR,
Eurocord and ALWP of EBMT
O133 IKZF1 (IKAROS) deletions represent a poor prognostic marker in BCR-ABL1
13:55 positive acute lymphoblastic leukaemia patients: a GIMEMA ALL WP report
I. Iacobucci, A. Lonetti, A. Ferrari, M. Vignetti, C.T. Storlazzi, F. Paoloni, D. Cilloni,
S. Soverini, A. Vitale, S. Chiaretti, G. Cimino, A. Astolfi, N. Testoni, C. Papayannidis,
S. Paolini, P.P. Piccaluga, L. Elia, F. Messa, C. Dell'Agnola, S. Cingarlini, G. Meloni,
G. Leone, S. Amadori, D. Russo, G. Saglio, F. Pane, M. Baccarani, R. Foà,
G. Martinelli on behalf of the GIMEMA ALL WP
O134 Alignment of chemotherapy and stem cell transplantation protocols results
14:10 in reduced transplant related mortality in children and adolescents with
acute lymphoblastic leukaemia: the BFM experience
A. Schrauder, M. Schrappe, A. v. Stackelberg, T. Klingebiel, P. Bader, W. Holter,
R. Handgretinger, W. Ebell, D. Dilloo, T. Guengoer, M. Führer, H. Kabisch,
K.-W. Sykora, G. Henze, H. Gadner, M. Zimmermann, U. Poetschger, C. Peters
(Kiel, Berlin, Frankfurt, Erlangen, Tübingen, Düsseldorf, Munich, Hamburg,
Hannover, DE; Zurich, CH; Vienna, AT)
O135 Relevance of cell dose on outcomes after unrelated bone marrow transplantation
14:25 for acute lymphoblastic leukaemia and acute myeloid leukaemia
V. Rocha, M. Eapen, S.J. Lee , J.P. Klein on behalf of CIBMTR and NMDP, Paris,
France and Milwaukee, USA
O136 Comparison of allogeneic haematopoietic cell transplantation and
14:40 chemotherapy in adult patients with non-M3 AML staying in CR1:
a retrospective nation-wide survey
S. Kurosawa, T. Yamaguchi, S. Miyawaki, N. Uchida, H. Kanamori, T. Yamashita,
K. Usuki, M. Watanabe, K. Yakushiji, S. Yano, Y. Nawa, J. Taguchi, J. Takeuchi,
Y. Nakamura, J. Tomiyama, Y. Nannya, Y. Okoshi, F. Sano, H. Shibayama, M. Hino,
Y. Moriuchi, Y. Kanda, T. Fukuda (Tokyo, Gunma, Kanagawa, Aichi, Fukuoka, Ehime,
Nagasaki, Tochigi, Ibaraki, Osaka, Saitama, JP)
O137 Unrelated allogeneic stem cell transplantation with myeloablative
14:55 conditioning in adults with acute lymphoblastic leukaemia in remission:
peripheral blood or bone marrow?
N. Basara, M. Labopin, R. Arnold, M. Eder, T. Ruutu, A. Zander, D. Beelen, H. Sengelöv
C. Faul, J. Holowiecki, V. Rocha on behalf of the Acute Leukemia Working Party
O138 PH-positive acute lymphoblastic leukaemia is characterised by recurrent copy
15:10 number anomalies in genes regulating the cell cycle and B-cell differentiation
I. Iacobucci, E. Ottaviani, A. Lonetti, A. Ferrari, A. Astolfi, CT. Storlazzi, N. Testoni,
S. Paolini, C. Papayannidis, D. Cilloni, F. Messa, S. Soverini, F. Arruga, F. Pane,
A. Vitale, M. Messina, S. Chiaretti, PP. Piccaluga, C. Dell'Agnola, S. Cingarlini, R. Foà,
M. Baccarani, G. Martinelli (Bologna, Bari, Orbassano, Turin, Naples, Rome, Verona, IT)
O139 Predictive factors for relapse in adult patients with high-risk acute lymphoblastic
15:25 leukaemia submitted to an unrelated haematopoietic progenitor transplant
C. Ferra, J. Sanz, R. Cámara, G. Sanz, A. Bermúdez, D. Valcárcel, M. Rovira,
D. Serrano, D. Caballero, I. Espigado, M. Morgades, I. Heras, C. Solano,
C. Barrenetxea, R.F. Duarte, A. Gracía-Noblejas, A. Iriondo, J.L. Díez, E. Carreras,
J. Sierra, M.A. Sanz, J.M. Ribera on behalf of GETH (Grupo Español de Trasplante
Hematopoyético), PETHEMA (Programa Español de Tratamiento en Hematología)
and the Spanish Society of Hematology

Scientific Programme Physicians Monday, 30 March 2009
13:40– Oral Session 2 Room F4
15:40
Stem cell source
Chairs: H. Sengelöv (Copenhagen, DK); M. Chandy (Vellore, IN)
O140 Double cord blood cell haematopoietic stem cell transplantation after
13:40 standard or reduced-intensity conditioning: report of the SFGM-TC Registry
H. Labussiere, Q.-H. Le, M. Robin, N. Fegueux, S. Furst, M. Mohty, E. Deconinck,
L. Fouillard, P. Fouillard, B. Rio, A. Sirvent, M. Renaud, N. Dedhin, R. Tabrizi,
S. Maury, M. Sobh, N. Raus, E. Marry, F. Garnier, M.-L. Balère, V. Rocha, D. Blaise,
M. Michallet (Lyon, Paris, Montpellier, Marseille, Nantes, Besançon, Nancy, Nice,
Tours, Bordeaux, Creteil, FR)
O141 Implementing systematic search for alternative donor in patients in need
13:55 of allogeneic transplantation: an intention-to-treat analysis of 282 patients
at a BMT unit
M.T. Lupo Stanghellini, M. Marcatti, A. Assanelli, C. Corti, C. Bonini, C. Bordignon,
J. Peccatori, M. Bernardi, F. Ciceri (Milan, IT)
O142 Less extensive chronic GvHD with PBSC and ATG for sibling transplants
14:10 without increase in TRM or relapse
F. Bonifazi, G. Bandini, E. Colaci, M. Stanzani, M. Arpinati, S. Usai, V. Giudice,
P. Tazzari, S. Rizzi, F. Ricci, M.R. Motta, M. Baccarani (Bologna, IT)
O143 Anti-HLA antibodies in unrelated cord blood transplantation
14:25 M. Takanashi, K. Fujiwara, Y. Atsuta, H. Tanaka, A. Ogawa, H. Kodo, S. Kai, H. Sato,
M. Kohsaki, H. Azuma, S. Kato, K. Nakajima (Tokyo, Nagoya, Nishinomiya, Fukuoka,
Osaka, Hokkaido, Isehara, JP)
O144 Peripheral blood stem cell mobilisation with pegfilgrastim or lenograstim
14:40 following chemotherapy in lymphoma and myeloma patients:
a randomised study
V. Pavone, A. Mele, R. De Francesco, A. Rana, S. Sibilla, G. Greco, C. Del Casale,
A. Messa, M. Morciano, M. Caputo, A. Ostuni (Tricase, IT)
O145 The "MarrowMiner", a novel, minimally invasive device for the harvest
14:55 of bone marrow: results from the MARVELOUS trial demonstrate safety,
efficacy and improved stem cell yields compared to standard marrow
harvest method
D. Kraft, M. Crocker, O. Ramella, V. Ghazarossian, A. Carrasco
(Stanford, Menlo Park, US; Guadalajara, MX)
O146 Current status of paediatric umbilical cord blood transplantation in Korea
15:10 K.H. Yoo, K.W. Sung, H.H. Koo, N.G. Chung, B. Cho, H.K. Kim, H.J. Kang, H.Y. Shin,
H.S. Ahn, H.J. Back, D.K. Han, H. Kook, T.J. Hwang, Y.J. Lim, Y.H. Lee, J.O. Ha,
H.J. Lim, J.J. Seo, S.K. Park, H.J. Jung, J.E. Park, S.Y. Kim, S.S. Park, Y.T. Lim,
E.S.Y. Yoo, K.H. Ryu, S.H. Lee, H.J. Park, B.K. Park on befalf of the Cord Blood
Transplantation Working Party of the Korean Society of Hematology
O147 HLA-mismatched unrelated donors as alternative graft source for allogeneic
15:25 stem cell transplantation after ATG-containing conditioning regimen
N. Kröger, T. Zabelina, T. Binder, F. Ayuk, U. Bacher, G. Amtsfeld, H. Lellek,
J. Schrum, R. Erttmann, T. Eiermann, A.R. Zander (Hamburg, DE)
41

42
Scientific Programme Physicians Monday, 30 March 2009
13:40– Oral Session 3 Room F1
15:40
Acute graft-versus-host disease
Chairs: A. Urbano-Ispizua (Sevilla, ES); D. Blaise (Marseille, FR)
O148 Prospective evaluation of proteomic screening with an aGvHD-specific
13:40 proteomic pattern in more than 350 patients
E.M. Weissinger, E. Holler, M. Schleuning, G. Beutel, H. Greinix, A.M. Dickinson,
J. Ferrara, A. Krons, J. Kontsendorn, N. Hahn, H.J. Kolb, J. Metzger, A. Ganser
(Hannover, Regensburg, Wiesbaden, Munich, DE; Vienna, AT; Newcastle, UK;
Ann Abor, US)
O149 Proteomic patterns and graft-versus-host disease after allogeneic
13:55 haematopoietic stem cell transplantation
P. Chiusolo, S. Bellesi, C. Fanali, S. Giammarco, S. Sica, R. Inzitari, F. Iavarone,
G. Leone, M. Castagnola (Rome, IT)
O150 DAAM2 polymorphism is closely related to the clinical outcomes of
14:10 allogeneic haematopoietic stem cell transplantation
H.G. Yi, I. Kim, J.H. Lim, M.H. Lee, S.S. Yoon, C.S. Kim, B.K. Kim, S. Park
(Incheon, Seoul, KR)
O151 Pre-emptive therapy based on aGvHD-specific proteomic patterns:
14:25 a single-centre experience
E.M. Weissinger, J. Metzger, E. Schiffer, B. Hertenstein, H. Diedrich, G. Beutel,
J. Kontsendorn, N. Hahn, H. Mischak, A. Ganser (Hannover, Bremen, DE)
O152 INF-G levels before SCT are strongly correlated to acute GvHD
14:40 M. Uzunel, S. Kearsley, S. Nava, S. Ruhm, M. Remberger, H. Karlsson (Stockholm, SE)
O153 Correlation between plasma interleukin-7 and interleukin-15 levels and
14:55 acute graft-versus-host disease and relapse in patients undergoing
myeloablative allgeneic stem cell transplantation
S. Thiant, I. Yakoub-Agha, L. Terriou, J.P. Jouet, J.P. Dessaint, M. Labalette (Lille, FR)
O154 Noninvasive assessment of intestinal graft-versus-host disease activity by
15:10 molecular imaging with 18F-fluorodeoxyglucose positron emission tomography
M. Stelljes, S. Hermann, G. Köhler, G. Silling, W.E. Berdel, O. Schober, M. Schäfers,
J. Kienast (Münster, DE)
O155 Diagnosis and grading of intestinal acute graft-versus-host disease
15:25 following allogeneic stem cell transplantation by colonoscopy
W. Kreisel, M. Dahlberg, J. Harder, A. Schmitt-Graeff, J. Finke (Freiburg, DE)

Scientific Programme Physicians Monday, 30 March 2009
13:40– Oral Session 4 Room E3
15:40
Solid tumours / Multiple myeloma
Chairs: G. Gahrton (Stockholm, SE); C. Morris (Belfast, UK)
O156 High-dose chemotherapy with autologous stem-cell support versus
13:40 standard-dose chemotherapy: meta-analysis of individual patient data from
6 randomised metastatic breast cancer trials
T. Demirer, N. Ueno, M. Johnson, M. Bregni, D.A. Berry on behalf of the
EBMT-MDACC Meta-analysis group
O157 Post-transplant immunotherapy with donor-lymphocyte infusion and
13:55 novel agents to upgrade partial into complete and molecular remission in
allografted patients with multiple myeloma
N. Kröger, A. Badbaran , M. Lioznov, S. Schwarz, S. Zeschke, Y. Hildebrandt,
F. Ayuk, D. Atanackovic, G. Schiling, T. Zabelina, U. Bacher, E. Klyuchnikov,
A. Shimoni, A. Nagler, P. Corradini, B. Fehse, A.R. Zander (Hamburg, DE;
Tel Hashomer, IL; Milan, IT)
O158 Long-term follow-up of a comparison of non-myeloablative allografting with
14:10 autografting for newly diagnosed myeloma
B. Bruno, R. Sorasio, F. Patriarca, N. Mordini, B. Allione, F. Carnevale-Schianca,
L. Giaccone, I. Resta, M. Festuccia, M. Rotta, P. Omedè, A. Evangelista, M. Aglietta,
A. Levis, A. Gallamini, R. Fanin, A. Palumbo, R. Storb, G. Ciccone, M. Boccadoro
(Turin, Udine, Cuneo, Alessandria, Candiolo, IT; Seattle, US)
O159 Bortezomib induction prior to reduced-intensity autologous transplantation
14:25 followed by lenalidomide consolidation/maintenance in elderly untreated
myeloma patients
A. Palumbo, F. Gay, P. Falco, A. Falcone, T. Guglielmelli, C. Cangialosi, N. Pescosta,
L. De Rosa, M. Rizzo, M. Gilestro , F. Cavallo, A. Larocca, V. Magarotto, V. Montefusco,
C. Crippa, M. Boccadoro (Turin, San Giovanni Rotondo, Orbassano, Palermo,
Bolzano, Rome, Milan, Brescia, IT)
O160 Allogeneic stem cell transplantation for multiple myeloma with a T-cell depleted
14:40 reduced-intensity conditioning regimen using both unrelated and related donors
P.A. von dem Borne, C.W.J. Starrenburg, W.A.F. Marijt, C.J.M. Halkes,
J.H.F. Falkenburg, R. Willemze (Leiden, NL)
O161 Impact of genetic abnormalities after allogeneic stem cell transplantation in
14:55 multiple myeloma: report of the Société Française de Greffe de Moelle et de
Thérapie Cellulaire (SFGM-TC)
D. Roos Weil, P. Moreau, H. Avet-Loiseau, M. Kuentz, N. Milpied, G. Socié, S. Furst,
A. Huynh, S. Vigouroux, S. Le Gouill, A. Thiebault, A. Buzyn, J.-Y. Cahn, N. Maillard,
I. Yakoub-Agha, J. Soulier, N. Raus, J.-P. Fermand, B. Rio, J.L. Golmard, M. Attal,
D. Blaise, M. Michallet, N. Dhedin (Paris, Nantes, Créteil, Bordeaux, Marseille,
Toulouse, Grenoble, Poitiers, Lille, Lyon, FR)
O162 High-dose therapy/autologous stem cell transplantation increases complete
15:10 remission rate in multiple myeloma irrespective of the induction regimen
used: TD (Thalidomide/dexamethasone), VTD (bortezomib/thalidomide/
dexamethasone) or VBMCP/VBAD plus bortezom
L. Rosiñol, M.T. Cibeira, J. Martínez, M.V. Mateos, M.J. Terol, J. de la Rubia,
L. Palomera, F. de Arriba, A. Oriol, A. Alegre, J. Besalduch, R. de Paz, J. García-Laraña,
J. Díaz-Mediavilla, A. Sureda, J.J. Lahuerta, J. San Miguel, J. Bladé (Barcelona,
Madrid, Salamanca, Valencia, Zaragoza, Murcia, Palma de Mallorca, ES)
O163 Autologous stem cell transplantation in elderly patients with multiple
15:25 myeloma: age per se does not affect outcome
J. El-Cheikh, C. Chabannon, A.M. Stoppa, R. Bouabdallah, D. Coso,
J.M. Schiano de Collela, P. Ladaique, D. Blaise (Marseille, FR)
43

44
Scientific Programme Physicians Monday, 30 March 2009
13:40– Oral Session 5 Room G4
15:40
Experimental stem cell transplantation /
Stem cell research
Chairs: T. Fioretos (Lund, SE); W. Linkesch (Graz, AT)
O164 MSCs-DCs interaction: a cell-cell contact mechanism inducing tolerance
13:40 A. Aldinucci, T. Biagioli, L. Pieri, P. Romagnoli, B. Mazzanti, R. Saccardi,
L. Massacesi, C. Ballerini (Florence, IT)
O165 Vascular regeneration by adult blood-derived endothelial colony-forming
13:55 cells expanded under animal serum-free conditions
A. Reinisch, N. A. Hofmann, A. Obenauf, K. Kashofer, E. Rohde, K. Schallmoser,
D. Thaler, M. Fruehwirth, K. Flicker, W. Linkesch, M. Speicher, D. Strunk (Graz, AT)
O166 Human umbilical cord blood collagen-adherent, nestin-positive
14:10 neurological progenitors mediate neuroprotection in an oxidative
stress-induced ischaemic model
H. Arien-Zakay, S. Lecht, H. Galski, P. Lazarovici, A. Nagler (Tel Hashomer,
Jerusalem, IL)
O167 The impact of CD4+Foxp3+ regulatory T-cells on immunity to murine
14:25 cytomegalovirus after bone marrow transplantation depends on the source
of T-cell regeneration
M. Bruinsma, E.J. Wils, B. Lowenberg, J.J. Cornelissen, E. Braakman (Rotterdam, NL)
O168 Inhibition of vasculogenesis ameliorates GvHD and tumours after allo-BMT
14:40 O. Penack, E. Henke, D. Suh, C. King, O. Smith, I.-K. Na, A. Holland, A. Ghosh,
S. Lu, R. Jenq, C. Liu, G. Murphy, T. Lu, D. Scheinberg, D.C. Gao, V. Mittal,
R. Benezra, M. Van den Brink (New York, Gainsville, Boston, US)
O169 Keratinocyte growth factor improves allogeneic bone marrow engraftment
14:55 through a CD4+Foxp3+ regulatory T-cell-dependent mechanism
M. Bruinsma, P.L. van Soest, P.J.M. Leenen, B. Lowenberg, J.J. Cornelissen,
E. Braakman (Rotterdam, NL)
O170 Peripheral expansion of CD31+ cells contributes to the reconstitution of
15:10 the naive T-cell compartment after allogeneic stem cell transplantation
S. Ringhoffer, M. Rojewski, A. Wochnik, M. Wiesneth, H. Döhner, D. Bunjes,
M. Ringhoffer (Ulm, DE)
O171 Rapamycin-based GvHD prophylaxis after T-cell replete unmanipulated
15:25 haploidentical peripheral stem cell transplantation for advanced leukaemias:
preliminary results of the TrRaMM study
J. Peccatori, D. Clerici, A. Forcina, C. Messina, M.T. Lupo Stanghellini, M. Noviello,
V. Valtolina, G. Giorgiani, R. Crocchiolo, M. Marcatti, S. Mastaglio, A. Assanelli,
E. Guggiari, A. Crotta, S. Gattillo, S. Rossini, C. Corti, M. Bernardi, F. Locatelli,
C. Bonini, F. Ciceri (Milan, Pavia, IT)

Scientific Programme Physicians Monday, 30 March 2009
13:40– Oral Session 6 Room A7
15:40
Early side effects / Late effects and quality of life II
Chairs: E. Carreras (Barcelona, ES); T. Masszi (Budapest, HU)
O172 Iron depletion pattern in patients with iron overload after allogeneic
13:40 haematopoietic cell transplantation treated by phlebotomy
A.-K. Eisfeld, R. Burkhardt, D. Teupser, S. Schroeder, R. Krahl, E. Edel,
D. Niederwieser, H.K. Al-Ali (Leipzig, DE)
O173 A therapeutic platelet transfusion strategy without routine prophylactic
13:55 transfusion is feasible and safe and reduces platelet transfusion numbers
signifcantly: final analysis of a randomised study after high-dose
chemotherapy and PBSCT
H. Wandt, K. Schäfer-Eckart, K. Wendelin, M. Rottmann, M. Thalheimer,
M.S. Schubert, R. Conradi, R. Schwerdtfeger, L. Leimer, M. Kaufmann, A.F. Klenner,
G. Dölken, M. Schaich, G. Ehninger (Nuremberg, Heidelberg, Wiesbaden, Stuttgart,
Greifswald, Dresden, DE)
O174 Favourable outcome for haematopoietic transplant recipients requiring
14:10 intensive therapy unit admission: a 10-year single-centre experience
A. Holroyd, W. Townsend, P. Naik, S. Mackinnon, D. Howell, A. Goldstone,
D. Linch, K. Peggs, K. Thomson, M. Singer, E. Morris (London, Essex, UK)
O175 Validation of comorbidity indexes in reduced-intensity conditioning
14:25 allogeneic stem cell transplantation. The haematopoietic cell transplantation
comorbidity index is the best predictor of NRM and survival
P. Barba, J.L. Piñana, D. Valcarcel, A. Amorós, R. Martino, A. Sureda, J. Briones,
J. Delgado, M. Granell, S. Brunet, R. Sunol, J. Sierra (Barcelona, ES)
O176 Bone complications following allogeneic haematopoietic stem cell
14:40 transplantation: a single-centre prospective study
A.D. Petropoulou, R. Porcher, A.-L. Herr, A. Devergie, P. Orcel, G. Socié,
M. Robin (Paris, FR)
O177 The long-term effect of pubertal development on bone mineral density in
14:55 patients who underwent HSCT during childhood
G. Fichera, A. Gaiero, A. Rovelli, M. Faraci, M.T. van-Lint, F. Fioredda,
M. Migliavacca, G. Dini, C. Uderzo, A. Cohen (Savona, Monza, Genoa, IT)
O178 Feasability of extracorporeal photopheresis in managing patients with
15:10 bronchiolitis obliterans following allogeneic stem cell transplantation:
a single-centre experience
J. McCarty, A. Toor, H. Chung, S. Roseff, R. Edwards, J. Lamberta, J. Anderson,
K. Candler, A. Rome (Richmond, US)
O179 Cultural and family influence in decision making in Arab society among
15:25 patients undergoing high-dose chemotherapy and autologous stem cell
transplant. Cultural Adapted FACT-BMT Study
S. Akhtar, A. Al-Zahrani, E. Abdalla, E. Colcol, H. Soudy, I. Maghfoor (Riyadh, SA)
45

46
Scientific Programme Physicians Monday, 30 March 2009
16:00– Working Party Acute leukaemia Congress Hall
17:30
Chairs: V. Rocha (Paris, FR); J. Esteve (Barcelona, ES)
180 Report of the ALWP
16:00 V. Rocha (Paris, FR)
16:05 Studies of subcommittees
181 � Management of relapse after allogeneic HSCT for AML using reducedintensity
conditioning (RIC) – a common study by the ALWP subcommittees
on immunotherapy and RIC
C. Schmid, M. Mohty, A. Nagler, M. Labopin, E. Polge, B. Samey, V. Rocha
on behalf of the the ALWP subcommittees on immunotherapy and RIC
182 � Management of relapse after allogeneic HCT in acute lymphoblastic
leukaemia: the EBMT experience
A. Spyridonidis, C. Schmid, M. Labopin, L. Volin, A. Bacigalupo, H. Sengelöv,
N. Milpied, M. Falda, I. Yakoub-Agha, E. Polge, B. Samey, V. Rocha on behalf of
the Immunotherapy Subcommittee of ALWP
183 � Association between the haematopoietic cell transplantation-specific
comorbidity index and non-relapse mortality after reduced-intensity
conditioning allogeneic stem cell transplantation for AML in first complete
remission
M. Mohty, M. Labopin, J.J. Cornelissen, R. Tabrizi , N. Theorin , J.A. Perez Simon,
E. Polge, A. Nagler, V. Rocha on behalf of the ALWP of EBMT
184 � Comparison of outcomes after allogeneic HSCT for adult patients with AML
in remission using in the conditioning regimen either I.V. Busulfex (BU) plus
Cyclophosphamide (Cy) or TBI plus Cy: an- ALWP-EBMT survey
A. Nagler, M. Labopin, A. Simoni, L. Volin, D. Bunjes, A. Huynh, A. Buzyn,
A. Rambaldi, V. Rocha on behalf of the ALWP-EBMT
185 � Association of human development index with rates and outcomes of HSCT
for patients with acute myeloid leukaemia
S. Giebel, M. Labopin, G. Ehninger, D. Beelen, D. Blaise, R. Blasczyk, A. Bacigalupo,
T. Czerw, V. Rocha on behalf on Acute Leukaemia Working Party of the EBMT
186 � Role of molecular markers in AML for guiding transplant indications
J. Esteve on behalf of the Molecular Markers Subcommittee – ALWP
187 � Aprospective study on the feasibility of related and unrelated donor search
17:00 and haematopoietic cell transplantation for adults with acute leukaemia at
31 European transplant centres
V. Rocha, M. Arat, V. Koza, N.C. Gorin, A. Ferrant, K. Schäfer Eckart, F. Ebeling,
G. Milone, P. De Fabritiis, L. Verdonck, A. Bosi, J. Esteve, B. Allione, J. Maertens,
A. Olivieri, C. Pilatrino, A.-L. Herr, F. Pinto, C. Arrais, S. Nabhan, G. Socié, G. Dini,
E. Gluckman, E. Polge, M. Labopin on behalf of the Acute Leukaemia Working
Party of EBMT
188 Impact of HLA matching in unrelated HSCT for patients with acute
17:10 leukaemia
E. Petersdorf (Seattle, US)
�Abstract

Scientific Programme Physicians Monday, 30 March 2009
16:00– Working Party Solid tumours Room F4
17:30
Chairs: M. Bregni (Milan, IT); J.-O. Bay (Clermont-Ferrand, FR)
189 Introduction
M. Bregni (Milan, IT)
190 Retrospective trial summary
J.-O. Bay (Clermont-Ferrand, FR)
191 Metanalysis in breast cancer
D.A. Berry (Houston, US)
192 Comment
P. Pedrazzoli (Milan, IT)
193 Allografting in breast cancer
D. Blaise (Marseille, FR)
194 Comment
F. Peccatori (Milan, IT)
195 Allografting in renal cancer
M. Bregni (Milan, IT)
196 Conclusions
M. Bregni (Milan, IT)
47

48
Scientific Programme Physicians Monday, 30 March 2009
16:00– Working Party Inborn errors Room F1
17:30
Chairs: B. Gaspar (London, UK); F. Porta (Brescia, IT)
197 � Long-term outcome of MPS I patients treated with HSCT
16:00 J.J. Boelens, M. Aldenhoven, T. de Koning, A. O’Meara, P. Veys,
M. Cavazzana-Calvo, A. Rovelli, J. E. Wraith, R. Wynn on behalf of the
EBMT Working Party Inborn Errors
198 � Survey of presentation, management and outcome of children with X-linked
16:15 lymphoproliferative disorder
C. Booth, K. Gilmour, A. Gennery, P. Heath, P. Arkwright, A. Plebani, A. Soresina,
A. Finocchi, C. Pignata, T. Broccoletti, G. Notheis, M. Albert, I. Meyls, K. Kalwak,
S. Pasic, B. Gaspar on behalf of the EBMT Working Party Inborn Errors
199 � Outcome of haematopoeitic stem cell transplantation for radiosensitive
16:30 DNA double strand breakage repair defects
A. Gennery on behalf of the EBMT Working Party Inborn Errors
200 Outcome of HSCT for ADA deficiency – results of a retrospective
16:45 multi-centre study in Europe and USA
B. Gaspar on behalf of the EBMT Working Party Inborn Errors
201 � Haematopoietic stem cell transplantation in children with Griscelli
17:00 syndrome: a single-centre experience
A. Al-Ahmary, A. Al-Ghonaium, M. Ayas, H. Al-Mousa, A. Al-Jefry, B. Al-Saud,
A. Al-Seraihy, S. Al-Muhsen, M. Al-Mahr, H. Al-Dhekri, H. El-Solh (Riyadh, SA)
202 � Long-term survival and immune constitution after haematopoietic stem cell
17:15 transplantation in severe combined immune deficiency in Saudi Arabia
S. Al-Muhsen, M. Ayas , N. Alkhamees , H. Shaheen , A. Alghonaium, B. Al-Saud,
H. Al-Mousa, H. Aldhekry , R. Arnaout , A. Al-Jefry, A. Alseraihy, A. Alboug, A. Al-Hersi,
A. Al-Ahmary, H. El-Solh (Riyadh, SA)
17:30 – Physicians Poster Presentation (P432 – P722)
19:00
Please refer to pages 78 –102 for details
�Abstract

Scientific Programme Physicians Tuesday, 31 March 2009
08:00– Workshop 6 Room F4
09:00
Relapse of acute leukaemia after allo-SCT
203
Chair: A. Nagler (Tel Hashomer, IL)
Monitoring for relapse
08:00 P. Bader (Frankfurt, DE)
204 Management of relapse
08:30 H.-J. Kolb (Munich, DE)
08:00–
09:00
Workshop 7
Targeting cancer stem cells
Chair: G. Kvalheim (Oslo, NO)
Room F1
205 Leukaemias
08:00 D. Bonnet (London, UK)
206 Solid tumours
08:30 R. Bjerkvig (Bergen, NO)
08:00–
09:00
Workshop 8
Gut GvHD
Chair: A.R. Zander (Hamburg, DE)
Room G4
207 Mucous membrane immunology
08:00 A. Kantele (Helsinki, FI)
208 Diagnosis and management of gut GvHD
08:30 G. McDonald (Seattle, US)
08:00 –
09:00
Educational Session 4
Myelodysplastic syndromes
Chair: C. Schmid (Augsburg, DE)
Room E3
209 SCT as a part of the treatment algorithm for MDS
08:00 E. Hellström-Lindberg (Stockholm, SE)
210 How to perform SCT in MDS
08:30 N. Kröger (Hamburg, DE)
49

50
Scientific Programme Physicians Tuesday, 31 March 2009
08:00– Educational Session 5 Room G3
09:00
Transplantation vs enzyme therapy of inherited
metabolic storage disorders
211
Chair: A. Fasth (Göteborg, SE)
SCT
08:00 P. Hoogerbrugge (Nijmegen, NL)
212 Enzyme therapy
08:30 J.E. Wraith (Manchester, UK)
08:00–
09:00
Educational Session 6
Vaccinations
Chair: D. Engelhard (Jerusalem, IL)
Room G2
213 Bacterial infections
08:00 C. Cordonnier (Créteil, FR)
214 Viral infections
08:30 P. Ljungman (Stockholm, SE)
09:10–
10:40
Plenary Session 1
Regenerative medicine
Chair: K. Le Blanc (Stockholm, SE)
Congress Hall
215 Organ repair using fetal tissue
09:10 Y. Reisner (Rehovot, IL)
216 Neural and adipose stem cells
09:40 K. Spalding (Stockholm, SE)
217 Osteogenic precursor cells
10:10 P. Bianco (Rome, IT)
09:10 –
10:40
Joint Session Physicians / Nurses
Quality of life lessons – into the future
Chairs: M. Brune (Göteborg, SE); E. Aerts (Zurich, CH)
Room F4
218 Quality of life studies – the nuts and bolts
09:10 A. Kiss (Basel, CH)
219 The impact of genital GvHD on life
09:40 E. Smith-Knutsson (Trollhättan, SE)
220 The impact of long-term follow-up on survivorship
10:10 D. Greenfield (Sheffield, UK)

Scientific Programme Physicians Tuesday, 31 March 2009
11:10– Working Party Chronic leukaemias Congress Hall
12:40
Chairs: T. de Witte (Nijmegen, NL); L. Garderet (Paris, FR)
221 � Bortezomib (Velcade®)-Thalidomide-Dexamethasone (VTD) vs
Thalidomide-Dexamethasone to treat multiple myeloma (MM)
patients progressing or relapsing after autologous transplantation:
the MMVAR trial, a study from the myeloma subcommittee of the
Chronic Leukaemia Working Party
L. Garderet, S. Iacobelli, P. Moreau, F. Onida, C. Koenecke, T. Pabst, C. Doyen,
C. Crawley, R. Hajek, W. Linkesch, J.L. Harousseau, M. Michallet, Z. Doran,
T. de Witte, D. Niederwieser, G. Gahrton, C. Morris on behalf of the Chronic
Leukemia Working Party of the EBMT
222 � Dose-reduced conditioning followed by allogeneic stem cell transplantation
in patients with myelofibrosis. Results from a multicenter prospective trial
of the chronic leukemia working party of the european group for blood and
marrow transplantation (EBMT)
N. Kröger, E. Holler, G. Kobbe, M. Bornhäuser, R. Schwerdtfeger, A. Nagler,
W.A. Bethge, M. Stelljes, L. Uharek, H. Wandt, M. van Os, A. Barrois, A. Burchert,
P. Corradini, J. Schubert, M. Kaufmann, P. Dreger, G. Wulf, H. Einsele, M. Gramatzki,
T. Zabelina, U. Bacher, A. Zander, F. Fortmann, M. Heinzelmann, M. Kvasnicka,
J. Thiele, D. Niederwieser, T. de Witte on behalf of the Chronic Leukemia
Working Party
223 � Autologous stem cell transplantation (ASCT) vs ASCT followed by
reduced-intensity conditioning (RIC) allogeneic SCT with identical sibling
donor in previously untreated multiple myeloma (MM):
a prospective controlled trial by the EBMT
B. Björkstrand, S. Iacobelli, U. Hegenbart, A. Gruber, H. Greinix, L. Volin, F. Narni,
P. Musto, M. Beksac, A. Bosi, G. Milone, P. Corradini, H. Goldschmidt, T. de Witte,
C. Morris, D. Niederwieser, G. Gahrton for the EBMT CLWP Multiple Myeloma
Subcommitee
224 � The DMSO survey – first analysis
C. Morris, M. Scholten, A. van Biezen, T. de Witte, T. Ruutu on behalf of the Chronic
Leukemia Working Party of the EBMT
225 � Observational audit on T-PLL transplants based on EBMT/ERIC
recommendations for allogeneic and autologous stem cell transplantation
in T prolymphocytic leukaemia
W. Wiktor-Jedrzejczak, C. Dearden, A. van Biezen, R. Foà, M. Hallek, M. Herling,
G. Hopfinger, E. Kimby, M. Michallet, D. Milligan, J. Schetelig, L. Volin, T. de Witte,
D. Catovsky, P. Dreger on behalf of the Chronic Leukemia Working Party of the
European Group for Blood and Marrow Transplantation (EBMT), and the European
Research Initiative on Chronic Lymphocytic Leukemia (ERIC)
226 � Effect of prior therapy with Nilotinib or Dasatinib on the outcome after
allogeneic stem cell transplantation for patients with chronic myeloid
leukaemia
M. Schleuning, E. Olavarria, M. Scholten, A. van Biezen, M. Michallet, A. Nagler,
A. Hochhaus, A. Grigg, R. Silver, P. Schuld, D. Niederwieser, T. de Witte
on behalf of the CML Sub-committee of the Chronic Leukemia Working Party
�Abstract
51

52
Scientific Programme Physicians Tuesday, 31 March 2009
Working Party Chronic leukaemias (continued) Congress Hall
227 � Autologous transplantation for rare myelomas: an EBMT retrospective
analysis
C. Morris, M. Drake, J. Apperley, S. Iacobelli, D. Niederwieser, A. van Biezen,
B. Bjorkstrand, G. Gahrton on behalf of the subcommittee of the Chronic
Leukaemia Working Party of the EBMT
228 � The effect of transfusions and iron toxicity on non-relapse mortality in
patients with untreated adult MDS treated with myeloablative alloSCT:
a retrospective study of the MDS subcommittee of the Chronic Leukaemia
Working Party of the EBMT
L. Spinnewijn, L. Strobbe, A. van Biezen, R. Brand, J. Finke, U. Platzbecker,
T. Ruutu, D. Beelen, R. Schwerdtfeger, Y. Fløisand, R. Martino, H.K. Al-Ali,
A. Atienza, K. Steinerova, N. Kröger, T. de Witte on behalf of the Chronic Leukemia
Working Party of the EBMT
229 � Autologous and allogeneic stem cell transplantation for Richter’s
transformation: a retrospective analysis from the Chronic Leukaemia
Working Party and Lymphoma Working Party of the EBMT
K. Cwynarski, A. van Biezen, R. Brand, M. Scholten, B. Metzner, J.L. Harousseau,
V. Koza, K. Remes, F. Ciceri, A. Nagler, T. de Witte, A. Sureda, P. Dreger
on behalf of the Chronic Leukaemia Working Party
230 Joint ALWP/CLWP study on RIC vs MAC in MDS/AML, retrospective study
R. Martino, A. van Biezen, E. Polge, R. Willemze, J. Maertens, L. Volin,
C. de Souza, J. Schetelig, J. Finke, N. Kröger, V. Rocha, T. de Witte
on behalf of the ALWP and CLWP
231 Second tx/DLI after relapse in MDS, retrospective study
C. Schmid (Augsburg, DE)
�Abstract

Scientific Programme Physicians Tuesday, 31 March 2009
11:10– Working Party Paediatric diseases Room F4
12:40
Chairs: C. Peters (Vienna, AT); R. Ladenstein (Vienna, AT)
232 � Survey on transplantations from a 8 out of 10 matched allogeneic donor
11:10 (in haematological malignancies)
A. Balduzzi, P. Sedlacek (Monza, IT; Prague, CZ)
233 � Sibling donor complications of haematopoietic progenitor cell collection in
11:20 children: 2008 report of EBMT Paediatric Diseases Working Party
J. Styczynski, N. Elarouci, C. Peters, G. Dini on behalf of the Pediatric Diseases
Working Party
234 Survey on allogeneic stem cell transplantation in adolescents
11:30 G. Dini, N. Elarouci, I. Yaniv, C. Peters on behalf of the Pediatric Diseases Working
Party
235 � Survey on the use of monoclonal antibodies in the treatment of resistant
11:40 acute GvHD in children
M. Miano et al, an EBMT-PDWP Proposal
236 � Relapse after allogeneic transplantation for childhood acute lymphoblastic
11:50 leukaemia in complete remission
A. Balduzzi, V. Rocha, M. Eapen on behalf of the EBMT Paediatric Working Party,
the EBMT Acute Leukaemia Working Party and the CIBMTR
237 � Transplantation for adolescents and young adults with neuroblastoma
12:00 I. Yaniv (Petach Tikva, IL)
238 Review and approach on current indications for allogeneic SCT in solid
12:10 tumours
R. Ladenstein (Vienna, AT)
239 � The prospective study on the incidence and outcome of VOD with the
12:20 prophylactic use of defibrotide in paediatric stem cell transplantation has
completed enrolment: update on the VOD-DF Study
S. Corbacioglu on behalf of EBMT PDWP and PCTO
12:30 General discussion
�Abstract
53

54
Scientific Programme Physicians Tuesday, 31 March 2009
11:10– Working Party Autoimmune diseases Room F1
12:40
Chairs: R. Saccardi (Florence, IT); D. Farge (Paris, FR)
240 Overview
11:10 R. Saccardi (Florence, IT)
241 � Transplantation for autoimmune diseases in North and South America:
11:24 update on reported data from the CIBMTR
M.C. Pasquini (Milwaukee, US)
242 � Present status of hematopoietic stem cell transplantation in multiple
11:38 sclerosis
G.L. Mancardi, R. Saccardi (Genoa, Florence, IT)
243 � The ASTIS trial
11:52 J. van Laar, D. Farge, A. Tyndall on behalf of the ASTIS investigators
244 � Autologous stem cell transplantation for severe systemic lupus
12:06 Erythematosus: the EBMT approved ASTIL TRIAL
D. Farge, J. van Laar, D. Jayne, A. Voskuyl, R. Cervera, A. Doria, F. Hiepe,
D. Boumpas, U. Walker, R. Saccardi
on behalf of the Autoimmune Diseases Working Party
245 � Autologous stem cell transplantation for Crohn's disease trial:
12:20 early report of toxicity and efficacy
C.J. Hawkey, E. Ricart, L. Chalkley, S. Danese, M. Allez, F. Onida, J.-F. Colombel,
M. Clarke, M. Simpson (Nottingham, UK; Barcelona, ES; Milan, IT; Lille, FR)
246 Concluding remarks
12:34 R. Saccardi (Florence, IT)
12:40 –
13:40
Controversies in SCT 3 Room F4
247
Shall we go back to bone marrow as stem cell source in
adult patients with malignancies?
Chair: A. Bacigalupo (Genoa, IT)
Yes
M. Mohty (Nantes, FR)
248 No
S. Couban (Halifax, CA)
12:40 – How to get published Room A6
13:40
Chair: J. Goldman (London, UK)
How to get your paper published?
Professor John Goldman (Bone Marrow Transplantation, Editor-in-Chief) will explain
how authors need to prepare their manuscripts for submission to a peer reviewed
journal. The process that a paper undergoes from submission to publication at
Nature Publishing Group's "Bone Marrow Transplantation" will be explained.
�Abstract

Scientific Programme Physicians Tuesday, 31 March 2009
13:30– Statistical Symposium Room H1
15:30
Chair: R. Brand (Leiden, NL)
249 Primary endpoint
M. Labopin (Paris, FR)
250 Summarizing differences in cumulative incidence functions
M.J. Zhang (Milwaukee, US)
251 A competing risks analysis of infection after peripheral blood stem-cell
transplantation
J. Beyersmann (Freiburg, DE)
13:40–
15:10
Educational Session 7
Late complications after SCT
Chair: A. Rovo (Basel, CH)
Room E3
252 Metabolic syndrome in children
13:40 M. Taskinen (Helsinki, FI)
253 Vascular complications
14:10 A. Tichelli (Basel, CH)
254 Secondary tumours
14:40 J. Deeg (Seattle, US)
55

56
Scientific Programme Physicians Tuesday, 31 March 2009
13:40– Oral Session 7 Congress Hall
15:40
Lymphoma
Chairs: G. Juliusson (Lund, SE); N. Milpied (Pessac, FR)
O255 Allogeneic stem cell transplantation as salvage therapy in patients with
13:40 diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous
stem cell transplantation. An analysis of the EBMT Registry
R. van Kampen, C. Canals, H. Schouten, A. Nagler, K. Thomson, K. Ward,
J.-P. Vernant, A. Buzyn, J. Maertens, J.J. Luan, A. Uyttebroeck, S. Maury,
N. Milpied, J.P. Jouet, G. Ossenkoppele, A. Sureda for the Lymphoma Working Party
of the EBMT
O256 Allotransplant after autologous haematopoietic stem cell transplantation
13:55 relapse in aggressive lymphoma patients: update af a retrospective
GITMO study
L. Rigacci, A. Bosi, B. Puccini, P. Corradini, L. Castagna, N. Cascavilla, G. Milone,
A. Bacigalupo, R. Scimè, G. Specchia, A. Rambaldi, P. Leoni, F. Ciceri, A. Levis,
S. Guidi, B. Bruno, R. Oneto, R. Fanin on behalf of GITMO
O257 Allogeneic stem cell transplantation in high-risk relapse of aggressive
14:10 lymphoma. Results of a prospective phase II study
B. Glass, J. Hasenkamp, A. Görlitz, P. Dreger, J. Schubert, G. Wulf, M. Nickelsen,
L. Trümper, N. Schmitz on behalf of the DSHNHL
O258 Early allogeneic stem cell transplantation for peripheral T-cell lymphoma
14:25 results in a lower relapse rate and a higher non-relapse mortality than
high-dose therapy followed by autologous transplantation.
Results of a retrospective EBMT analysis
M. Nickelsen, C. Canals, C. Kyriakou, N. Schmitz, M. Engelhardt, T. Relander,
W. Linkesch, V. Koza, G. Meloni, D. Caballero, A. Lopez-Guillermo, K. Indrac,
H. Wandt, N. Theorin, B. Glass, A. Buzyn, G. Wulf, E. Conde, G. Socie, A. Sureda
on behalf of the Lymphoma working party of EBMT
O259 HLA-identical allogeneic stem cell transplantation for patients with primary
14:40 cutaneous T-cell lymphoma: a retrospective analysis of the Lymphoma
Working Party of the European Blood and Marrow Transplantation Group
R.F. Duarte, C. Canals, F. Onida, E. Olavarría, W. Arcese, A. Ferrant, F. Narni,
G. Lambertenghi Deliliers, A. Bacigalupo, D. Bunjes, J.M. Rowe, N. Schmitz,
A. Sureda (Barcelona, ES; Milan, Rome, Modena, Genoa, IT; London, UK;
Brussels, BE; Ulm, Hamburg, DE; Haifa, IL)
O260 Comparison between autologous and allogeneic stem cell transplantation
14:55 in patients with relapsing follicular lymphoma: use of the Propensity Score
to reduce recruitment bias in observational studies
D. Sibon, F.S. de Fontbrune, M. Resche-Rigon, P. Brice, J. Briere, M. Robin,
S. Chevret, R.P. de Latour, C. Gisselbrecht, C. Thieblemont, G. Socié (Paris, FR)
O261 Effectiveness of autologous bone marrow transplantation in relapsed or
15:10 resistant HIV-related lymphomas: a monocentre Italian experience at a
national cancer centre
M. Michieli, R. Manuele, M. Rupolo, P. Bulian, M. Mazzucato, L. Abbruzzese,
F.M. Rossi, S. Zanussi, R. Tedeschi, E. Zanet, M. Spina, E. Vaccher, A. Steffan,
V. Gattei, L. De Marco, P. De Paoli, U. Tirelli (Aviano, IT)
O262 Patients with classical Hodgkin’s disease and monoclonal B-cells
15:25 detected in autologous PBSC grafts have decreased overall survival after
transplantation
S. Takach, L. Yang, J. Ho, E. Sabri, L. Martin, M. Halpenny, H. Atkins, M. Sabloff,
S. McDiarmid, L. Huebsch, I. Bence-Bruckler, A. Giulivi, D. Allan (Ottawa, CA)

Scientific Programme Physicians Tuesday, 31 March 2009
13:40– Oral Session 8 Room F4
15:40
Paediatric diseases
Chairs: U. Pihkala (Helsinki, FI); P. Sedlacek (Prague, CZ)
O263 Predictive value of MRD monitoring after allogeneic SCT in relapsed
13:40 childhood acute lymphoblastic leukaemia: analysis of the ALL-REZ BFM
Group
P. Bader, H. Kreyenberg, G. Henze, C. Eckert, M. Reising, A. Willasch,
R. Panzer-Gruemeyer , A. Barth, A. Borckhardt, C. Peters, R. Handgretinger,
W. Holter, A. Schrauder, A. Schulz, B. Strahm, C. Roessig, T. Klingebiel,
A. v. Stackelberg (Frankfurt, Berlin, Düsseldorf, Tübingen, Erlangen, Kiel, Ulm,
Freiburg, Münster, DE; Vienna, AT)
O264 Second allogeneic stem cell transplantation in children with acute
13:55 leukaemia and myelodysplastic syndromes – A retrospective analysis of
behalf of the German Registry for Pediatric Stem Cell Transplantation (PRST)
J. Soerensen, A. Borckhardt, C. Peters, H. Kabisch, M. Führer, A. Schulz,
C. Niemeyer, KW. Sykora, K. Ehlert, J. Beck, T. Klingebiel, P. Bader
(Frankfurt, Düsseldorf, Hamburg, Munich, Ulm, Freiburg, Hannover, Münster,
Jena, DE; Vienna, AT)
O265 Haematopoietic stem cell transplantation for advanced primary
14:10 myelodysplastic syndromes in children: influence of chromosomal
aberrations on outcome
B. Strahm, F. Locatelli, J. Beck, E. Bersträßer, M. Bierings, A. Chybicka, W. Ebell,
M. Schmugge, P. Sedlacek, J. Starý, S. Matthes-Martin, M. van Heuvel-Eibrink,
D. Wojcik, M. Zecca, G. Göhring, B. Schlegelberger, C. Niemeyer
(Freiburg, Jena, Berlin, Hannover, DE; Pavia, IT; Zurich, CH; Utrecht,
Rotterdam, NL; Wroclaw, PL; Prague, CZ; Vienna, AT)
O266 Adoptive transfer of Hexon-specific T-cells as a treatment of adenovirus
14:25 reactivation following allogeneic stem cell transplantation
K. Opherk, W.A. Bethge, F. Schuster, M. Scheible, P. Bader, M.H. Albert, M. Sauer,
G. Stuhler, S. Matthes-Martin, R. Handgretinger, P. Lang, T. Feuchtinger
(Tübingen, Düsseldorf, Frankfurt, Munich, Hannover, Würzburg, DE; Vienna, AT)
O267 Haplo-identical stem cell transplantation in children with relapsed
14:40 neuroblastoma
P. Lang, J. Toporskj, R. Handgretinger, I. Müller, T. Klingebiel, W. Schwinger,
U. Koehl, H. Teltschik, M.H. Albert, P. Bader (Tübingen, Frankfurt, Munich, DE;
Lund, SE; Graz, AT)
O268 Allogeneic disparities in the dendritic cell surface molecule immunoglobulin-
14:55 like transcript 5 induce antibody responses in stem cell transplanted patients
K. Pfistershammer, P. Steinberger, W. Pickl, H. Greinix, A. Lawitschka (Vienna, AT)
O269 Potential role of indoleamine 2,3-dioxygease in induction of allo-antigen
15:10 specific tolerance
B. Juergens, E. Veith, L. Krempl, A. Heitger (Vienna, AT)
O270 Haplo-identical stem cell transplantation with CD3/CD19 depleted stem
15:25 cells: analysis of activity and recovery of co-transfused NK cells
P. Lang, H. Teltschik, M. Pfeiffer, I. Müller, T. Feuchtinger, M. Schumm, M. Ebinger,
R. Handgretinger (Tübingen, DE)
57

58
Scientific Programme Physicians Tuesday, 31 March 2009
13:40– Oral Session 9 Room F1
15:40
Infectious complications
Chairs: A. Ullmann (Mainz, DE); P. Donnelly (Nijmengen, NL)
O271 Dasatinib differentialy modulates key effector functions of moncyte-derived
13:40 dendritic cells
C. Köchel, C. Dix, H. Einsele, R. Seggewiss (Würzburg, DE)
O272 Mutant TIRAP gene polymorphism is associated with outcomes in HLA
13:55 genoidentical bone marrow transplants recipients with leukaemia
V. Rocha, R. Porcher, N. Kabbara, R. Peffault de Latour, M. Robin,
W. Andadre de Oliveira, C.A. Rodrigues, H. Bittencourt, M. Tavela, A. Devergie,
P. Ribaud, E. Gluckman, M. Zago, G. Socié (Paris, FR)
O273 Herpes viruses reactivation in patients after allogeneic haematopoietic
14:10 stem cell transplantation and polymorphism within the stromal cell-derived
factor-1 (SDF-1/CXCL12) gene
E. Jaskula, A. Gieryng, K. Bogunia-Kubik, A. Tarnowska, M. Mordak-Domagala,
A. Lange (Wroclaw, PL)
O274 Generation of donor polyomavirus BK-specific T-cell lines to be employed for
14:25 BKV-related haemorrhagic cystitis after allogeneic HSCT
S. Basso, M. Cioni, A. Gurrado, R. Maccario, S. Telli, D. Pagliara, V. Spartà,
F. Locatelli, P. Comoli (Pavia, IT)
O275 Differences in reconstitution of T-cell immunity to cytomegalovirus,
14:40 Epstein-Barr virus and Varicella zoster virus
F. Khan, S. Sy, S. Liu, F. Zhou, Y. Liu, A. Ugarte-Torres , J. Russell, J. Storek
(Calgary, CA)
O276 Normalised EBV quantity in patients after allogeneic haematopoietic stem
14:55 cell transplantation – Benign reactivation, localised and generalised EBV
lymphoproliferative disease
P. Hubacek, A. Hrdlickova, E. Mejstrikova, V. Valkova, E. Kabickova, L. Capkova,
P. Keslova, R. Formankova, M. Markova, P. Cetkovsky, P. Sedlacek (Prague, CZ)
O277 Significant reduction in the diagnosis of possible and probable invasive
15:10 fungal infection by applying the revised EORTC definitions of invasive fungal
disease
D.A. Tsitsikas, A. Morin, B. Murtagh, G. Athorn, T. Suaris, S. Ellis, S. Vinnicombe,
M. Wilks, S. Doffman, S. Agrawal (London, UK)
O278 HHV6 reactivation is an important risk factor for poor outcomes in
15:25 myeloablative, but not in non-myeloablative treated allogeneic HSCT patients
A.P.J. de Pagter, E. Meijer, L. Keukens, M. Schutten, J.J. Cornelissen, D. van Baarle,
E. Fries, R. Schuurman, E.A.M. Sanders, J.J. Boelens (Utrecht, Rotterdam, NL)

Scientific Programme Physicians Tuesday, 31 March 2009
13:40– Oral Session 10 Room G3
15:40
Acute leukaemia / Chronic leukaemia
Chairs: E. Kimby (Stockholm, SE); E. Olavarria (London, UK)
O279 Unrelated donor peripheral blood progenitor cells compared to bone marrow
13:40 in children and adolescents with acute leukaemia
O. Ringden, M. Eapen, F. Locatelli, R. Champlin, H. Frangoul, M. Remberger, A. Gee,
M. Laughlin, V. Rocha on behalf of The European Group for Blood and Marrow
Transplantation and the Center for International Blood and Marrow Transplant
Research
O280 Prognostic risk assessment based on combined cytogenetics and molecular
13:55 screening for optimal choice of post-remission therapy in patients with
acute myeloid leukaemia
M. Torrebadell, M. Camos, M. Pratcorona, M. Rozman, M. Rovira, C. Martínez,
F. Fernández-Avilés, A. Carrió, D. Costa, E. Montserrat, E. Carreras, J. Esteve
(Barcelona, ES)
O281 Allogeneic stem cell transplantation for Philadelphia-positive acute
14:10 lymphoblastic leukaemia in recent years: a retrospective EBMT analysis of
patients transplanted in first remission
O.G. Ottmann, M. Labopin, T. Ruutu, G. Socie, A. Bekassy, A. Rambaldi, B. Samey,
J. Esteve, V. Rocha on behalf of the EBMT Acute Leukemia Working Party
O282 Upfront versus minimal-residual disease triggered imatinib after allogeneic
14:25 stem cell transplantation for pH+ acute lymphoblastic leukaemia:
interim analysis of a randomised phase III GMALL study
B. Wassmann, H. Pfeifer, M. Bornhäuser, W.A. Bethge, J. Dengler, M. Stadler,
D. Beelen, N. Basara, R. Schwerdtfeger, K. Schäfer-Eckhart, L. Uharek, M. Stelljes,
D. Hoelzer, O.G. Ottmann on behalf of the GMALL study group
O283 Influence of myeloablative conditioning regimens on outcomes after single
14:40 unrelated cord blood transplantation for adults with leukaemia:
an analysis on behalf of Eurocord-EBMT-Netcord
S. Nabhan, V. Rocha, M. Labopin, W. Arcese, A. Sirvent, I. Ionescu, R. Bizzetto,
K. Boudjedir, W. Chaves, A.-L. Herr, E. Gluckman, G. Sanz (Paris, Nice, FR;
Rome, IT; Valencia, ES)
O284 Allogeneic myeloablative haematopoietic stem cell transplantation for
14:55 chronic myeloid leukaemia in the imatinib era
J. Pavlu, H. Auner, R. Szydlo, E. Olavarria, C. Giles, M. Klammer, A. Kew,
D. Milojkovic, I. Gabriel, K. Rezvani, F. Dazzi, D. Marin, J. Goldman, J. Apperley
(London, Bristol, UK; Halifax, CA)
O285 Preconditioning with alemtuzumab is a safe strategy before allogeneic
15:10 stem cell transplantation in patients with chronic lymphocytic leukaemia:
results of a large prospective phase II study
J. Schetelig, M. Bornhäuser, C. Thiede, A. Kiani, U. Platzbecker, U. Oelschlägel,
M. Hänel, G. Geissler, R. Schwerdtfeger, K. Kolbe, M. Kaufmann, M. Zeis,
K. Schäfer-Eckart, W. Siegert, G. Ehninger on behalf of the Cooperative German
Transplant Study Group
O286 Standard and reduced-intensity allogeneic haematopoietic stem cell
15:25 transplantation
M. Michallet, Q.-H. Le, P. Dreger, M. Sobh, D. Niederwieser, V. Koza, T. Ruutu,
N. Russell, L. Verdonck, D. Milligan, N. Dedhin, T. Kozak, M. Boogaerts, J. Finke,
N. Tedone, A. Van Bietzen, R. Brand, T. de Witte on behalf of the CLWP
59

60
Scientific Programme Physicians Tuesday, 31 March 2009
13:40– Oral Session 11 Room A6
15:40
Immunotherapy/ Experimental graft-versus-host disease
Chairs: R. Handgretinger (Tübingen, DE); A.M. Dickinson (Newcastle, UK)
O287 Cellular immune modulation by mesenchymal stems cells or regulatory
13:40 T-cells inhibits alloantigen mediated graft-versus-host reaction but also
impairs graft-versus-tumour reactions targeting tumour specific antigens
M. Stelljes, S. Harmata, V. Schlösser, C. Opitz, W.E. Berdel, J. Kienast (Münster, DE)
O288 NOD2 deficiency in experimental GvHD
13:55 O. Penack, O. Smith, X. Liu, A. Cunningham, U. Rao, N. Jim, I.-K. Na, A. Holland,
A. Ghosh, S. Lu, R. Jenq, C. Ubeda, K. Brandl, E. Pamer, M. Van den Brink
(New York, US)
O289 N-acetyl-L-cysteine promotes T-cell mediated immunity in allogeneic
14:10 settings in vivo and in vitro
H. Karlsson, S. Nava, M. Remberger, Z. Hassan, M. Hassan, O. Ringdén
(Stockholm, SE)
O290 Low incidence of graft-versus-host disease in unmanipulated, G-CSF
14:25 primed bone marrow transplantation from haplo-identical related donor
for haematological malignancies
S. Santarone, E. Di Bartolomeo, P. Bavaro, M. Montanari, P. Leoni, G. De Angelis,
R. Cerretti, W. Arcese, P. Di Bartolomeo (Pescara, Ancona, Rome, IT)
O291 Interleukin-21 promotes the generation of highly cytolytic acute myeloid
14:40 leukaemia-reactive CD8 T-cell clones from the naïve and central memory
compartment of HLA-matched healthy donors
E. Distler, M. Frey, E. Schnürer, E.M. Wagner, C. Huber, W. Herr (Mainz, DE)
O292 The absolute number as well as the activation kinetics of regulatory
14:55 T-cells determines the successful generation of primary anti-tumour and
pathogen-specific immune responses from the naïve donor T-cell repertoire
I. Jedema, J. Pots, M. van de Meent, R. Willemze, J.H.F. Falkenburg (Leiden, NL)
O293 In vitro generation of autologous EBV LMP2-specific cytotoxic T-lymphocytes
15:10 for the treatment of nasopharyngeal carcinoma
S. Basso, P. Pedrazzoli, A. Gurrado, M. Cioni, S. Secondino, R. Schiavo, M. Zecca,
G. Giorgiani, R. Maccario, S. Siena, S. Siena, F. Locatelli, P. Comoli (Pavia, Milan, IT)
O294 Rapid and robust expansion of antigen-specific T-cells with an early effector
15:25 phenotype
M. Wölfl, K. Merker, M. Eyrich, P.G. Schlegel (Würzburg, DE)

Scientific Programme Physicians Tuesday, 31 March 2009
13:40– Oral Session 12 Room G2
15:40
Autoimmune diseases / Aplastic anaemia / Myelodysplasia
Chairs: G. Öberg (Uppsala, SE); C. Guglielmi (Rome, IT)
O295 High incidence of improvement after autotologous HSCT in relapsing-
13:40 remitting phase of multiple sclerosis
R. Saccardi, M. Di Gioia, A. Bosi, I. Donnini, P. Maggi, M. Sormani, F. Gualandi,
P. Di Bartolomeo, G. La Nasa, A. Donelli, F. Lanza, F. Papineschi, G.L. Mancardi
(Florence, Genoa, Pescara, Gagliari, Modena, Ferrara, Pisa, IT)
O296 Autologous non-myeloablative HSCT for refractory Crohn's disease:
13:55 persistent 80% disease remission over 5 years after stem cell transplant
R.K. Burt, J. Bucha, F. Milanetti, A. Testori, R. Craig (Chicago, US)
O297 Autologous haematopoietic stem cell transplantation as a treatment
14:10 modality for multiple sclerosis: a 9-year experience of Russian-American
cooperation
Y.L. Shevchenko, A.A. Novik, A.N. Kuznetsov, B. Afanasyev, I.A. Lisukov,
O.A. Rykavicin, A.A. Myasnikov, T.I. Ionova, V.Y. Melnichenko, D.A. Fedorenko,
K.A. Kurbatova, R.A. Ivanov, N.E. Osipova, A.D. Kulagin, S.V. Shamanski,
R.V. Kruglina, A.V. Kartashov, G. Gorodokin (Moscow, St. Petersburg, Novosibirsk,
Petrozavodsk, RU; New Jersey, US)
O298 Survey of outcomes of unrelated cord blood transplant in patients with
14:25 severe acquired aplastic anaemia and paroxysmal nocturnal haemoglobinuria.
A study by EUROCORD and the Aplastic Anaemia Working party of the EBMT
A. Ruggeri, R. Peffault de Latour, G. Michel, V. Gandemer, G. Sanz, I. Ionescu,
D. Purtill, K. Boudjedir, S. Nabhan, E. Gluckman, G. Socié, J. Passweg, V. Rocha
(Paris, Marseille, Rennes, FR; Valencia, ES; Geneva, CH)
O299 Proposal for the response criteria of immunosuppressive therapy in children
14:40 with aplastic anaemia
A. Yoshimi, S. Kojima, A. Ohara, M. Führer, C. Niemeyer (Freiburg, Munich, DE;
Nagoya, Tokyo, JP)
O300 Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic
14:55 haematopoietic stem cell transplantation for myelodysplastic syndromes:
final results of an international prospective phase II trial
T. Ruutu, D. Beelen, J. Finke, J. Holowiecki, L. Uharek, J. Kienast, K. Larsson,
A.R. Zander, M. Gramatzki, H. Einsele, L. Volin, R. Trenschel, M. Schnitzler,
S. Giebel, I.W. Blau, M. Stelljes, R. Repp, G. Stuhler, M. Freund, J. Casper
(Helsinki, FI; Essen, Freiburg, Berlin, Münster, Hamburg, Kiel, Würzburg,
Rostock, DE;Katowice, PL; Stockholm, SE)
O301 Unrelated cord blood transplantation in adults with MDS or secondary acute
15:10 myeloblastic leukaemia: a survey on behalf of Eurocord and CLWP of EBMT
M. Robin, G. Sanz, I. Ionescu, B. Rio, A. Sirvent, M. Renaud, E. Carreras, N. Milpied,
E. Gluckman, N. Kröger, V. Rocha on behalf of Eurocord and the CLWP of EBMT
O302 Myelodysplastic syndromes in adolescents: characteristics and clinical
15:25 outcome
M. Zecca, P. Noellke, E. Bergsträßer, B. de Moerloose, H. Hasle, S. Matthes-Martin,
L. Sainati, J. Starý, B. Strahm, M. van den Heuvel-Eibrink, D. Wójcik, C. Niemeyer,
F. Locatelli on behalf of EWOG-MDS
61

62
Scientific Programme Physicians Tuesday, 31 March 2009
16:00– Working Party Lymphoma Congress Hall
17:30
Chairs: A. Sureda (Barcelona, ES); H. Schouten (Maastricht, NL)
303 Introduction and conclusions from previous meetings
A. Sureda (Barcelona, ES)
304 Lymphoma database / achievements of the LWP in 2008
A. Sureda (Barcelona, ES)
305 Education in the LWP. Next educational course
A. Sureda, S. Robinson (Barcelona, ES; Bristol, UK)
Ongoing retrospective analysis
306 Stem cell transplantation for Richter’s syndrome.
A joint analysis between the CLL subcommittee of the CLWP/LWP
K. Cwynarski (London, UK)
307 Cord blood transplantation versus matched unrelated donor allogeneic
transplant in patients with lymphoid malignacies.
A joint analysis between LWP/CLL subcommittee of the CLWP/Eurocord
C. Arrais (Sao Paulo, BR)
308 Reduced-intensity allogeneic stem cell transplantation for Mantle cell
lymphoma
S. Robinson (Bristol, UK)
309 Autologous stem cell transplantation versus reduced-intensity allogeneic
transplant in patients with follicular lymphoma
S. Robinson (Bristol, UK)
New retrospective analysis
310 Autologous stem cell transplantation in lymphomatoid granulomatosis
K. Siegloch (Hamburg, DE)
311 Stem cell mobilization strategies for lymphomas.
A prospective observational audit
H. Schouten (Maastricht, NL)
Prospective clinical trials
312 Randomised study of rituximab (mabthera) in patients with relapsed
follicular lymphoma prior to high dose therapy as in vivo purging and
to maintain remission following high dose therapy (Lym1 Trial)
R. Pettengel (London, UK)
313 Reduced-intensity allogeneic stem cell transplantation for cutaneous
T-cell lymphoma
R.F. Duarte (Barcelona, ES)

Scientific Programme Physicians Tuesday, 31 March 2009
16:00– Working Party Aplastic anaemia Room F4
17:30
Chairs: J. Passweg (Geneva, CH); A. Locasciulli (Rome, IT)
314 Chairman Report
16:00 J. Passweg (Geneva, CH)
315 � Should irradiated blood products be given routinely to all patients with
16:05 aplastic anaemia undergoing immunosuppressive therapy with
antithymocyte globulin (ATG)? A survey from the EBMT Severe Aplastic
Anaemia Working Party
J. Marsh, G. Socié, A. Tichelli, H. Schrezenmeier, B. Hochsmann, A. Risitano,
M. Führer, A. Bekassy, E.T. Korthof, A. Locasciulli, P. Ljungman, A. Bacigalupo,
B. Camitta, N.S. Young, J. Passweg on behalf of the EBMT Severe Aplastic
Anaemia Working Party
316 � Stem cell transplantation for paroxysmal nocturnal haemoglobinuria:
16:10 an on going joint study of the AAWP EBMT Group and the French Society
of Haematology
R. Peffault de Latour, H. Schrezenmeier, J.-Y. Mary, A. Bacigalupo, C. de Souza,
R. Willemze, A. Tichelli, J. Passweg, G. Socie on behalf of the Aplastic Anemia
Working Party of European Blood and Marrow Transplant Group and the French
Society of Hematology
317 � Does using a new donor for second haematopoietic stem cell transplantation
16:25 for patients with Fanconi anaemia influence the outcome?
A survey from the EBMT Severe Aplastic Anaemia Working Party
E.T. Korthof, M. Ridder, R. Oneto, A. Bacigalupo, A. Locasciulli, J. Marsh, A. Tichelli,
J. Hows, J. Rischewsky, J. Passweg, G. Socié, C. Dufour on behalf of the EBMT
Severe Aplastic Anaemia Working Party
318 � Pregnancy after allogeneic haematopoietic stem cell transplantation in
16:40 Fanconi anaemia patients: multi-institution case series of female fertility
recovery
S. Nabhan, M. Bitencourt, M. Duval, M. Abecasis, C. Dufour, K. Boudjedir,
V. Rocha, G. Socié, J. Passweg, K. Goi, J. Sanders, R. Pasquini, E. Gluckman
on behalf of the EBMT Severe Aplastic Anaemia Working Party
319 � Unrelated donor search for severe aplastic anaemia:
16:55 preliminary results of a donor versus no donor comparison
S. Maury, M. Balère, S. Pollichieni, R. Oneto, A. Bacigalupo, J. Passweg
on behalf of the EBMT Severe Aplastic Anaemia Working Party
320 Total treatment algorithm
17:10 J. Passweg, A. Tichelli, C. Dufour, H. Schrezenmeier, A. Moicean, A. Risitano,
P. Ljungman, S. Maury, M. Aljurf, A. Locasciulli, A. Bacigalupo, V. Mialou,
A. Bekassy, E.T. Korthof, M. Führer, F. Ciceri, R. Peffault de Latour, J. Marsh,
G. Socié on behalf of the EBMT Severe Aplastic Anaemia Working Party
17:20 Discussion: the place of unrelated donor transplantation in SAA
�Abstract
63

64
Scientific Programme Physicians Tuesday, 31 March 2009
16:00– Working Party Infectious diseases Room E3
17:30
Chairs: H. Einsele (Würzburg, DE); R. Martino (Barcelona, ES)
321 � Prophylaxis against cytomegalovirus with oral maribavir in allogeneic stem
cell transplant recipients: results of a phase 3 randomized, double-blind,
placebo-controlled trial
F. Marty, M. Boeckh, P. Ljungman, S. Villano on behalf of the Maribavir Study
1263-300 Clinical Study Group
322 � Human metapneumovirus in immunocompromised patients with
hAematological malignancies: awareness with caution and respect!
L.F.R. Span, N.M. van Dijk, C.F.M. Linssen, W.N.K.A. van Mook on behalf of the
EBMT Infectious Diseases Working Party
323 � Immune response to the 23-valent polysaccharide pneumococcal vaccine
(PPV23) after the 7-valent conjugate vaccine (PCV7) in allogeneic stem cell
transplant (SCT) recipients: results of the EBMT IDWP01 trial
C. Cordonnier, M. Labopin, V. Chesnel, P. Ribaud, R. De La Camara, R. Martino,
A. Ullmann, T. Parkkali, A. Locasciulli, K. Yakouben, K. Pauksens, D. Niederwieser,
J. Apperley, E. Bonnet, H. Einsele, P. Ljungman on behalf of the EBMT Infectious
Diseases Working Party and Wyeth-Lederle
324 � The opsonophagocytic activity (OPA) of the sera collected one month after
3 doses of the anti-pneumococcal conjugate 7-valent vaccine (PCV7, Prevnar)
strongly correlates with the specific antibody titers after allogeneic HSCT:
results of the EBMT IDWP01
C. Cordonnier, M. Labopin, K. Jansen, M. Pride, V. Chesnel, E. Bonnet, H. Einsele,
P. Ljungman on behalf of the EBMT Infectious Diseases Working Party and
Wyeth-Pharma
325 � Standard operating procedures for prevention of infection in haematopoietic
stem cell transplant units: a survey of the Infectious Diseases Working Party
of the EBMT
Y. Hicheri, H. Einsele, R. Martino, C. Cordonnier on behalf of the Infectious Diseases
Working Party of the EBMT
326 Palifermin studies
S. McCann (Dublin, IE)
327 European Aspergillus PCR Initiative (EAPCRI)
P. Donnelly (Nijmegen, NL)
328 � Voriconazole for secondary prophylaxis of invasive fungal infection in
allogeneic stem cell transplant recipients: results of the Vosifi Study
C. Cordonnier, H. Einsele, M. Rovira, J. Maertens, E. Olavarria, C. Faucher,
O.A. Cornely, R. De La Camara, C.-P. Heussel, M. Pineau, P. Ljungman
on behalf of the VOSIFI Study Group and the Infectious Diseases Working
Party of the European Bone and Marrow Transplantation Group
329 Cidofovir treatment for BK virus-related haemorrhagic cystitis
S. Cesaro (Padua, IT)
330 HHV-6 Diagnostic Pitfalls
P. Hubacek, K. Ward (Prague, CZ; London, UK)
331 Prognostic factors associated with outcome of invasive aspergillosis in patients
with acute leukaemia and recipients of a haematopoietic cell transplantation:
proposal for retrospective study from the EBMT-IDWP and the EORTC-ISG
R. Martino (Barcelona, ES)
332 Status of Valganciclovir trial
H. Einsele (Würzburg, DE)
�Abstract

Scientific Programme Physicians Tuesday, 31 March 2009
16:00– CLINT Statistical Roundtable Room H1
18:00
Analysis of HCT centre specific outcomes
Chair: R. Szydlo (London, UK)
333 Conclusions and perspectives of Work Package 5 of the CLINT project
A. Latouche, T.S. Scheike (Paris, FR; Copenhagen, DK)
This session is organised by M. Labopin and A. Latouche as part of the EU
project “Facilitating International Prospective Clinical Trials in Stem Cell
Transplantation” (CLINT) funded by the EC Sixth Framework Programme.
17:30– Physicians Poster Presentation (P723 – P1007)
19:00
Please refer to pages 103 –127 for details
65

66
Scientific Programme Physicians Wednesday, 1 April 2009
08:00– General Assembly Room F4
09:00
Chair: D. Niederwieser (Leipzig, DE)
Agenda:
President's report
D. Niederwieser (Leipzig, DE)
Secretary's report
P. Ljungman (Stockholm, SE)
Treasurer's report
J.J. Cornelissen (Rotterdam, NL)
Registry report
C. Ruiz de Elvira (London, UK)
Clinical Trials report
Z. Doran (London, UK)
2009 Elections results
D. Niederwieser (Leipzig, DE)
Award of Nature Publishing: Poster prizes
J. Goldman (London, UK)
EBMT 2010 meeting in Vienna, Austria
W. Linkesch (Graz, AT)

Scientific Programme Physicians Wednesday, 1 April 2009
09:00– Joint Session WBMT Room F4
10:30 (EBMT, CIBMTR, APBMT, WMDA)
Chairs: D. Niederwieser (Leipzig, DE); M. Horowitz (Milwaukee, US);
Y. Kodera (Nagoya, JP); M. Oudshoorn (Leiden, NL)
368 Overview of unrelated adult and cord blood donation:
the WMDA annual survey
M. Oudshoorn (Leiden, NL)
369 Unrelated donor outcomes and plans for assessing related donor outcomes:
a report from the NMDP/CIBMTR
D.L. Confer (Minneapolis, US)
370 Related donor outcomes from the Japanese registry:
the importance of pre-registration
Y. Kodera (Nagoya, JP)
371 Proposal for an EBMT supported donor outcome registry
A. Gratwohl (Basel, CH)
09:00–
10:30
Workshop 9
Mesenchymal stem cells
Chair: F. Locatelli (Pavia, IT)
Room E3
338 Mesenchymal stem cells: state of the art
09:00 W. Fibbe (Leiden, NL)
339 MSC/MAPc to enhance cardiac function
09:30 J. Tolar (Minneapolis, US)
340 Mesenchymal stem cells in radiation injuries
10:00 A. Chapel (Paris, FR)
09:00 –
10:30
Workshop 10
Graft failure
Chair: N. Russell (Nottingham, UK)
Room G2
341 Mechanisms
09:00 J. Mattsson (Stockholm, SE)
342 Risk factors and prevention
09:30 O. Ringdén (Stockholm, SE)
343 Management
10:00 A. Bacigalupo (Genoa, IT)
67

68
Scientific Programme Physicians Wednesday, 1 April 2009
09:00– Educational Session 8 Room H1
10:30
Donor selection in paediatric allo-SCT
344
Chair: T. Klingebiel (Frankfurt, DE)
Haplo
09:00 R. Handgretinger (Tübingen, DE)
345 Mis-match SCT
09:30 J. Cornish (Bristol, UK)
346 Cord blood
10:00 V. Rocha (Paris, FR)
09:00–
10:30
Educational Session 9
Chronic GvHD
Chair: A. Gratwohl (Basel, CH)
Room F1
347 Pathophysiology of chronic GvHD
09:00 W. Shlomchik (New Haven, US)
348 Chronic pulmonary GvHD
09:30 K.R. Cooke (Ann Arbor, US)
349 How do I treat chronic GvHD?
10:00 2nd and 3rd line therapies
G. Socié (Paris, FR)
09:00–
10:30
Educational Session 10
Allo-SCT in lymphoma
Chair: H. Hägglund (Stockholm, SE)
Room A6
350 Morbus Hodgkin
09:00 A. Sureda (Barcelona, ES)
351 Indolent lymphomas
09:30 S. Mackinnon (London, UK)
352 CLL
10:00 P. Dreger (Heidelberg, DE)

Scientific Programme Physicians Wednesday, 1 April 2009
10:00– EBMT Quality Management Meeting Room H2
13:45
Chair: J.F. Apperley (London, UK)
353 Welcome and Introduction
10:00 J.F. Apperley (London, UK)
354 Lecture 1
10:15 The requirements of a quality manager:
experience, roles, responsibilities and training
A. Piquet-Gauthier (Lyon, FR)
355 Lecture 2
10:45 Validation – when, what and how do we validate?
S. Shouls (London, UK)
11:15 Coffee
Room H2 Room J2
356 Document control 357 Quality indicators
11:30 B. Wauben (Maastricht, NL) 11:30 N. Som (Bristol, UK)
K. Patel (London, UK) P.E. Donot (Lyon, FR)
358 Errors, accidents & adverse events 359 Changing the culture
12:00 K. Patel (London, UK) 12:00 P.E. Donot (Lyon, FR)
N. Som (Bristol, UK) P. Huynh (Brussels, BE)
360 Quality indicators 361 Document control
12:30 N. Som (Bristol, UK) 12:30 B. Wauben (Maastricht, NL)
P.E. Donot (Lyon, FR) K. Patel (London, UK)
362 Changing the culture 363 Errors, accidents & adverse events
13:00 P.E. Donot (Lyon, FR) 13:00 K. Patel (London, UK)
P. Huynh (Brussels, BE) N. Som (Bristol, UK)
364 Meeting close
13:30 J.F. Apperley (London, UK)
69

70
Scientific Programme Physicians Wednesday, 1 April 2009
10:45– Plenary Session 2 Room F4
12:15
Immune regeneration and infection
365
Chair: P. Ljungman (Stockholm, SE)
Innate and adaptive immunity to fungal infections:
10:45 a new view of an old paradigm
L. Romani (Perugia, IT)
366 Immune deficiencies after stem cell transplantation
11:15 K.L. Weinberg (Stanford, US)
367 Thymic function after SCT
11:45 G. Holländer (Basel, CH)
10:45– Education session for the Committee on Room F1
12:15 Nuclear Accidents
Chair: R. Powles (London, UK)
334 US/European consensus on medical management of radiation accidents
10:45 B. Sirohi (Cambridge, UK)
335 Biological dosimetry
11:05 D. Lloyd (Oxfordshire, UK)
336 TBI and multi-organ failure: extrapolation from treating patients with
11:25 acute leukaemia
R. Powles (London, UK)
337 Primate work relating to a sub lethal/lethal total body irradiation model
11:45 T. Mac Vittie (Baltimore, US)
12:05 Discussion
12:45 – Joint Session EBMT/ISCT/ISEH Room F4
14:15
Chairs: A. Velardi (Perugia, IT); F. Lanza (Ferrara, IT), W.E. Fibbe (Leiden, NL)
372 IDO and T-cell regulation in immunity to infections and transplantation
12:45 tolerance
F. Fallarino (Perugia, IT)
373 Tolerance induction for haploidentical haematopoietic transplantation
13:07 Y. Reisner (Rehovot, IL)
374 Immune regulatory role of mesenchymal stem cells in the prevention/
13:29 treatment of GvHD
K. Le Blanc (Stockholm, SE)
375 Long-term control of HIV by CCR5 Delta32/Delta32 stem cell transplantation
13:52 E. Thiel (Berlin, DE)

Scientific Programme Physicians Wednesday, 1 April 2009
12:45– Oral Session 13 Room F1
14:45
Infectious complications / Graft-versus-host disease
Chairs: J. Abrahamsson (Göteborg, SE); K. Ward (London, UK)
O376 Genomic Instability after allogeneic HCT is frequent in oral and rare in nasal
12:45 mucosal cells: effect of chronic GvHD?
F. Khan, S. Sy, P. Louie, D. Stewart, J. Russell, J. Storek (Calgary, CA)
O377 IgG antibodies against human cytomegalovirus late protein UL94 in the
13:00 pathogenesis of scleroderma-like skin lesions in chronic graft-versus-host
disease
R. Pastano, C. Dell'Agnola, C. Bason, F. Gigli, C. Rabascio, A. Puccetti, G. Cetto,
F. Peccatori, G. Martinelli, C. Lunardi (Milan, Verona, Genoa, IT)
O378 Rituximab significantly reduces the incidence of acute graft-versus-host
13:15 disease and attenuates the unspecific cellular immune system
M. Christopeit, V. Schütte, S. Theurich, T. Weber, W. Grothe, G. Behre (Halle, DE)
O379 Recovery of specific CMV CD8+ T-lymphocytes and T-reg after allogenic
13:30 peripheral stem cell transplantation: a single-centre experience
D. Pastore, M. Delia, A. Mestice, P. Carluccio, F. Gaudio, A. Russo Rossi,
A.M. Giordano, A. Ricco, A.M. Mazzone, M. Leo, V. Liso, G. Specchia (Bari, IT)
O380 Acute graft-versus-host disease and cord blood source are risk factors for
13:45 Clostridium difficile infection after allogeneic stem cell transplantation
L. Willems, R. Peffault de Latour, R. Porcher, M. Lafaurie, I. Cazin, M. Robin,
V. Rocha, A. Devergie, G. Socié, P. Ribaud (Paris, FR)
O381 Allogeneic haematopoietic stem cell transplantation and norovirus
14:00 gastroenteritis: a previously unrecognised cause of morbidity
C. Roddie, J. Paul, R. Benjamin, C. Gallimore, J. Xerry, J.J. Gray, K. Peggs,
E. Morris, K.J. Thomson, K.N. Ward (London, UK)
O382 Respiratory symptom surveillance to optimise the detection of community
14:15 respiratory virus in haematopoietic stem cell transplant recipients:
preliminary results
A.C. dos Santos, L. Perilio, R.M. Zerbinati, M.O. Souza, V. Colturato, M.P. de Souza,
M. Mauad, C.M. Machado (Jaú, São Paulo, BR)
O383 Hepatitis B after allogeneic transplantation: reverse seroconversion and its
14:30 association with inmmunosuppressive therapy for liver graft-versus-host
disease
M. Bastos Oreiro, A. Lopez de la Guia, M. Canales Albendea, R. De Paz Arias,
M. Martín Salces, R. Arrieta Gallastegui, F. Hernandez Navarro (Madrid, ES)
71

72
Scientific Programme Physicians Wednesday, 1 April 2009
12:45– Oral Session 14 Room E3
14:45
Reduced-intensity transplants
Chairs: J. Sierra (Barcelona, ES); H. Sengelöv (Copenhagen, DK)
O384 Allogeneic stem cell transplantation following a reduced-intensity
12:45 conditioning regimen in relapsed lymphomas: 5-year follow-up of the phase
II study of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)
P. Corradini, A. Dodero, L. Farina, R. Fanin, F. Patriarca, R. Miceli, P. Matteucci,
F. Ciceri, R. Scime', F. Narni, E. Pogliani, A. Locasciulli, C. Carniti, A. Bacigalupo,
A. Rambaldi, F. Bonifazi, A. Olivieri, M. Brune, A. Gianni, C. Tarella
(Milan, Udine, Palermo, Modena, Rome, Genoa, Bergamo, Bologna, Potenza,
Turin, IT; Göteborg, SE)
O385 Prospective randomised study comparing non-myeloablative (Flu-TBI)
13:00 and reduced intensity (FLU-BU-ATG) conditioning for haematological
malignancies: a multicentre ITAC study
D. Blaise, R. Tabrizzi, M. Michallet, J.-O. Bay, C. Faucher, S. Furst, M. Mohty,
N. Milpied, J. El Cheikh, A. Boyer Chammard, A.G Le Corroller, J.M Boher
(Marseille, Bordeaux, Lyon, Clermont-Ferrand, Nantes, FR)
O386 Unrelated donors, no prior chemotherapy and low CD3 content of the
13:15 graft increase the rate of graft failure after stem cell transplantation with
reduced-intensity conditioning
G.-N. Franke, S. Leiblein, E. Hennig, D. Niederwieser, T. Lange (Leipzig, DE)
O387 Co-transplantation of mesenchymal stem cells might mitigate acute GvHD
13:30 without abrogating graft-versus-tumour alloreactivity after allogeneic
transplantation with non-myeloablative conditioning
F. Baron, E. Willems, C. Lechanteur, E. Baudoux, P. Frère, J. F. Vanbellinghen,
F. Bruck, A. Gothot, K. Hafraoui, G. Fillet, Y. Beguin (Liege, BE)
O388 Impact of cytogenetics risk on outcome after reduced-intensity conditioning
13:45 allogeneic stem cell transplantation from an HLA-identical sibling for
patients with acute myeloid leukaemia in first complete remission
M. Mohty, M. Labopin, N. Milpied, J.J. Cornelissen, D. Blaise, E. Petersen,
N. Theorin, H. Goker, G. Socié, V. Rocha on behalf of the Acute Leukemia
Working Party of EBMT
O389 Haplo-identical allogeneic haematopoietic cell transplantation in adults
14:00 using reduced-intensity conditioning and CD3/CD19-depleted grafts
B. Federmann, M. Bornhäuser, L. Kordelas, D. Beelen, G. Stuhler, R. Schwerdtfeger,
M. Stelljes, C. Faul, W. Vogel, R. Handgretinger, L. Kanz, W.A. Bethge
(Tübingen, Dresden, Essen, Würzburg, Wiesbaden, Münster, DE)
O390 Up-front allogeneic stem cell transplantation as part of induction or salvage
14:15 therapy in primary high-risk and relapsed acute myeloid leukaemia
F. Stölzel, J. Schetelig, U. Platzbecker, C. Thiede, T. Illmer, M. Schaich, M. Füssel,
C. Theuser, M. Hänel, R. Mahlberg, G. Ehninger, M. Bornhäuser
(Dresden, Chemnitz, Trier, DE)
O391 Non-myeloablative allogeneic stem cell transplantation in mantle cell
14:30 lymphoma
S. Le Gouill, N. Kröger, N. Dhedin, A. Nagler, K. Bouabdallah, I. Yakoub-Agha,
C.-E. Bulabois, A. Buzyn, B. Rio, M.-P. Moles, A. Shimoni, T. Guillaume, N. Milpied,
C. Leux, J.L. Harousseau, M. Mohty (Nantes, Paris, Bordeaux, Lille, Grenoble,
Angers, FR; Hamburg, DE; Tel Hashomer, IL)

Scientific Programme Physicians Wednesday, 1 April 2009
12:45– Oral Session 15 Room G4
14:45
Early side effects / Late effects and quality of life I
Chairs: J. Arvidson (Uppsala, SE); J. Weis (Freiburg, DE)
O392 The influence of killer immunoglobulin-like receptor genes in identical
12:45 HLA-matched sibling adult haemopoietic stem cell transplantation
J.A. Davidson, M. Waller, G. Lucas, J.A.L. Yin, E. Liakopoulou, K.V. Poulton
(Manchester, UK)
O393 The influence of donor killer immunoglobulin-like receptors and recipient
13:00 HLA ligand matching in identical HLA-matched sibling adult haemopoietic
stem cell transplantation
J.A. Davidson, G. Lucas, J.A.L. Yin, E. Liakopoulou, K.V. Poulton (Manchester, UK)
O394 “Late altered immunity” – A distinct entity in long-term survivors after
13:15 allogeneic HSCT?
A. Rovó, T. Daikeler, J. Halter, I. Heijnen, D. Heim, C. Arber, A. Tyndall, A. Gratwohl,
A. Tichelli (Basel, CH)
O395 Late altered organ function in long-term survivors after allogeneic HSCT:
13:30 a paired comparison with their identical sibling donor
A. Rovó, T. Daikeler, J. Halter, D. Heim, J. Studt, M. Medinger, C. Arber, M. Stern,
D. Tsakiris, A. Tyndall, A. Gratwohl, A. Tichelli (Basel, CH)
O396 The impact of early CD4+ lymphocyte recovery in the outcome of
13:45 patients who undergo allogeneic bone marrow or peripheral blood stem
cell transplantation
R. Fedele, C. Garreffa, M. Martino, G. Messina, D. Princi, A. Dattola, G. Console,
G Irrera, E. Massara, T. Moscato, E. Spiniello, R. Monteleone, M. Cuzzola,
P. Iacopino (Reggio Calabria, IT)
O397 Long-term immune deficiency after allogeneic stem cell transplantation
14:00 following a myeloablative conditioning regimen
E. Corre, M. Carmagnat, M. Busson, R. Peffault de Latour, M. Robin, P. Ribaud,
A. Toubert, C. Rabian, G. Socié (Paris, FR)
O398 Engraftment syndrome after autologous haematopoietic stem cell
14:15 transplantation: modified clinical criteria and C-reactive protein levels
allow an accurate diagnosis
E. Carreras, F. Fernández-Avilés, L. Silva, C. Fernández-de-Larrea, C. Martínez,
L. Rosiñol, P. Marín, M. Rovira (Barcelona, ES)
O399 Hyperleptinaemia in long-term transplant survivors with metabolic
14:30 syndrome
C. Annaloro, L. Airaghi, S. Forti, P. Usardi, A. Orsatti, F. Onida, A. Della Volpe,
G. Lambertenghi Deliliers (Milan, IT)
73

74
Scientific Programme Physicians Wednesday, 1 April 2009
12:45– Oral Session 16 Room A7
14:45
Cellular and Gene therapies
Chairs: K. Malmberg (Stockholm, SE); M. Cavazzana-Calvo (Paris, FR)
O400 Phase I-II trial of adoptive immunotherapy with haploidentical KIR
12:45 ligand-mismatched natural killer cells in high-risk acute myeloblastic
leukaemia patients
A. D'Addio, A. Curti, L. Ruggeri, E. Urbani, A. Bontadini, F. Fruet, V. Giudice, E. Dan,
M.R. Motta, S. Rizzi, S. Paolini, G. Martinelli, A. Velardi, M. Baccarani, R.M. Lemoli
(Bologna, Perugia, IT)
O401 WT1-TCR gene transfer into haematopoietic stem cells:
13:00 a tumour immunotherapy model
C. Pospori, M. Cesco-Gaspere, S. Xue, C. Voisine, M. Perro, A. Holler, G. Wright,
H. Stauss, E. Morris (London, UK)
O402 Targeting allo-reactivity to leukaemia
13:15 I. Abrahamsen, E. Stronen, S. Wälchli, J. Johansen, G. Gaudernack, G. Tjønnfjord,
S. Kumari, F. Lund-Johansen, J. Olweus (Oslo, NO)
O403 Generation of leukaemia antigen-specific donor lymphocyte infusions
13:30 powered by streptamer-based selection
X. Wang, A. Schmitt, L. Germeroth, M. Freund, M. Schmitt (Rostock, Göttingen, DE)
O404 Identification of four new HLA class II restricted minor histocompatibility
13:45 antigens as haematopoietic targets in anti-tumour immunity
A.N. Stumpf, E.D. van der Meijden, C.A.M. van Bergen, R. Willemze,
J.H.F. Falkenburg, M. Griffioen (Leiden, NL)
O405 Generation of EBV CTL resistant to calcineurin inhibitors for treatment of
14:00 post transplant lymphoproliferative disease
J. Brewin, K. Straathof, H. Karlsson, C. Mancao, S. Samarasinghe, B. Savoldo,
G. Dotti, M. Pule, P. Amrolia (London, UK)
O406 CD8-depleted DLI convert mixed to full donor T-cell chimerism and
14:15 replenishes the CD52-positive T-cell pool after alemtuzumab-based T-cell
depleted allo-transplantation
R.G. Meyer, E.M. Wagner, A.F. Lay, T. Schmitt, J. Hemmerling, U.F. Hartwig,
D. Wehler, K. Bender, C. Huber, W. Herr (Mainz, DE)
O407 TLR9 but not NOD2/CARD15 gene polymorphism influenced outcome in
14:30 AML-patients transplanted from HLA-identical sibling donors
A.H. Elmaagacli, M. Koldehoff, D. Beelen (Essen, DE)

Scientific Programme Physicians Wednesday, 1 April 2009
12:45– Oral Session 17 Room A6
14:45
Inborn errors / Haemoglobinopathy / Paediatric issues
Chairs: J. Winiarski (Stockholm, SE); D. Baronciani (Cagliari, IT)
O408 Successful busulfan-based reduced-intensity conditioning in high-risk
12:45 paediatric and adult chronic granulomatous disease – The Swiss experience
T. Güngör, J. Halter, G. Stüssi, F. Scherer, U. Schanz, R. Seger (Zurich, Basel, CH)
O409 HSCT in infantile osteopetrosis: retrospective analysis and future
13:00 management
A. Schulz, D. Moshous, W. Friedrich, A. Villa (Ulm, DE; Paris, FR; Segrate/Milan, IT)
O410 Stem cell transplantation in Diamond-Blackfan anaemia:
13:15 a retrospective analysis
J.J. Meerpohl, B. Strahm, M. Kartal, M. Bernardo, P. Lang, S. Matthes-Martin,
A. Schulz, M. Schmugge, A. Fischer, F. Locatelli, C. Niemeyer
(Freiburg, Tübingen, Ulm, DE; Pavia, IT; Vienna, AT; Zurich, CH)
O411 Comparison of outcomes of mismatched related stem cell and unrelated
13:30 cord blood transplants in children with severe T-cell deficiencies
J. Fernandes, V. Rocha, P. Landais, B. Neven, A. Gennery, P. Veys, W. Friedrich,
D. Wall, C. Díaz de Heredia, A. Cant, M. Labopin, B. Gaspar, A. Fischer,
E. Gluckman, M. Cavazzana-Calvo on behalf of Eurocord and the Inborn Errors
Working Party of the EBMT
O412 Unrelated cord blood transplantation in Wiskott Aldrich syndrome:
13:45 a single-centre experience in 18 patients
C. Bonfim, A. Koliski, R.T. Gomes, J. Morando, S. Fortier, M. Bitencourt, D. Setubal,
L. Medeiros, M. Oliveira, E. Nunes, J. Ruiz, R. Pasquini, J. Zanis-Neto (Curitiba, BR)
O413 Outcome in patients with severe combined immunodeficiency diagnosed at
14:00 birth in comparison with proband siblings: the case for neonatal screening
L. Brown, J. Xu-Bayford, G. Davies, P. Veys, A. Gennery, M. Slatter, B. Gaspar
(London, Newcastle, UK)
O414 Treosulfan-based conditioning regimen for allogeneic haematopoietic stem
14:15 cell transplantation in patients with thalassaemia major: an update
M. Bernardo, M. Zecca, E. Piras, A. Vacca, G. Giorgiani, G. Caocci, P. Comoli,
A. Mastronuzzi, A. Bertaina, G. La Nasa, F. Locatelli (Pavia, Cagliari, IT)
O415 A novel antibody-based minimal-intensity conditioning regimen for children
14:30 with severe organ toxicity or DNA repair disorders
K.C. Straathof, K. Rao, M. Eyrich, G. Hale, P. Bird, E. Berrie, L. Brown, P.G. Schlegel,
N. Goulden, B. Gaspar, A. Gennery, P. Landais, G. Davies, M.K. Brenner, P.A. Veys,
P. Amrolia (London, Oxford, Newcastle, UK; Würzburg, DE; Paris, FR; Houston, US)
75

76
Scientific Programme Physicians Wednesday, 1 April 2009
12:45– Oral Session 18 Room H1
14:45
Stem cell donor / Regulatory issues
Chairs: M. Bengtsson (Uppsala, SE); V. Koza (Pilsen, CZ)
O416 Significant differences in outcome following unrelated donor HCT can be
12:45 better predicted using an algorithm incorporating both allele and epitope
level matching for HLA-DPB1
B.E. Shaw, K. Fleischhauer, E. Zino, M. Malkki, S. Spellman, Y. Morishima, T. Gooley,
E. Petersdorf on behalf of the International Histocompatibility Working Group in
Hematopoietic Cell Transplantation
O417 HLA-DPB1 mismatching results in the generation of a full repertoire of
13:00 HLA-DPB1 specific CD4+ T-cell responses showing immunogenicity of all
HLA-DP alleles
C.E Rutten, S.A.P van Luxemburg-Heijs, E.D van der Meijden, M. Griffioen,
R. Willemze, J.H.F. Falkenburg (Leiden, NL)
O418 Preregistration and five-year follow-up system for bone marrow and
13:15 peripheral blood stem cell family donors – The interim report
Y. Kodera, S. Kim, K. Nagafuji, M. Hino, K. Miyamura, R. Suzuki
on behalf of the Japan Society for Hematopoietic Cell Transplantation
O419 Association of CXCL12, VCAM1 and CD34 gene polymorphisms with
13:30 peripheral blood progenitor cell mobilisation in healthy donors
B. Martin-Antonio, M. Carmona, P. Trujillo, I. Espigado, J. Alcántara, A. Freire,
A. Urbano-Ispizua (Sevilla, ES)
O420 A caspase8 promoter polymorphism is associated with increased TRM and
13:45 reduced survival following T-cell depleted unrelated donor transplantation
using alemtuzumab
S. Krishnamurthy, B.E. Shaw, J. Byrne, C. Seedhouse, N. Mayor, J.A Madrigal,
N. Russell (Nottingham, London, UK)
O421 Plerixafor plus G-CSF can successfully mobilise CD34+ cells from patients
14:00 with lymphoid malignancies who have previously failed chemotherapy
and/or cytokine mobilisation: compassionate use experience in Spain
R.F. Duarte, P. Marín, M. Ortiz, C. Morante, J. Delgado, J.J. Mateos-Mazón,
J. Gayoso (Barcelona, Málaga, Oviedo, Baracaldo, Madrid, ES)
O422 Autologous cord blood storage: a counselling survey report
14:15 P. Saracco, L. Fazio, A. Dragonetti, G. Rabacchi, M. Pagliarino (Turin, IT)
O423 Gender discrimination in haematopoietic stem cell transplantation:
14:30 is it real?
U. Rozovski, L. Gepstein, U. Abadi, S. Tavor, O. Gur, O. Ben-Tal, S. Trestman,
F. Aviv, I. Kirgner, R. Eshel, E. Rom, O. Kagan, E. Naparstek (Tel Aviv, IL)

Scientific Programme Physicians Wednesday, 1 April 2009
12:45– Oral Session 19 Room G2
14:45
Graft versus malignancy / MRD / Tolerance and alloreactivity
Chairs: S. Lenhoff (Lund, EC); A. Bosi (Florence, IT)
O424 5-azacitidine treatment for imminent relapse in patients with high-risk
12:45 myelodysplastic syndromes or acute myeloid leukaemia after allogeneic
peripheral blood stem cell transplantation
U. Platzbecker, J. Radke, A. Kiani, M. von Bonin, B. Mohr, U. Oelschlägel,
G. Ehninger, M. Bornhäuser, C. Thiede (Dresden, DE)
O425 Post-transplant monitoring of haematopoietic chimerism in childhood ALL:
13:00 competitive STR-PCR versus real-time sequence polymorphism (SP)-PCR
A. Willasch, B.S. Reincke, H. Kreyenberg, G. Schneider, G. Weber, E. Rettinger,
R. Handgretinger, B. Kremens, D. Dilloo, B. Strahm, J. Beck, T. Klingebiel, P. Bader
(Frankfurt, Tübingen, Essen, Düsseldorf, Freiburg, Jena, DE)
O426 Pretransplantation administration of anti-thymocyte globulin as part of the
13:15 conditioning induces T regulatory cells – Clinical implications
A. Nagler, R. Yerushalmi, E. Refaeli, L. Eskar Sebban, N. Rozenblum, R. Or,
M. Shapira, I. Resnick, A. Shimoni, D. Naor (Tel Hashomer, Jerusalem, IL)
O427 Naturally acquired tolerance and sensitisation to minor histocompatibility
13:30 antigens in healthy family members
A.G.S. van Halteren, E. Jankowska-Gan, A. Joosten, E. Blokland, J. Pool, A. Brand,
W.J. Burlingham, E. Goulmy (Leiden, NL; Madison, US)
O428 Conventional dendritic cells are the critical donor APC presenting alloantigen
13:45 after BMT
K. Markey, T. Banovic, R. Kuns, N. Raffelt, S. Olver, A. Don, Y. Wilson, A. Pettit,
J. Bromberg, G. Hill, K. MacDonald (Brisbane, AU; New York, US)
O429 Recipient lymphocyte infusion in miHC-incompatible murine bone marrow
14:00 chimeras: antileukaemic effect despite preservation of transplantation
tolerance
L. De Somer, B. Sprangers, O. Rutgeerts, C. Lenaerts, M. Waer, A.D. Billiau (Leuven, BE)
O430 CTLA-4-blockade-induced antileukaemic response and autoimmunity
14:15 after allogeneic bone marrow transplantation: study of regulatory T-cell
frequency and function
L. De Somer, S. Fevery, D.M. Bullens, P. Vandenberghe, O. Rutgeerts, C. Lenaerts,
L. Boon, A. Kasran, M. Waer, A.D. Billiau (Leuven, BE; Utrecht, NL)
O431 Birth order of donor and recipient after HLA-identical sibling transplants:
14:30 an analysis of haematopoietic stem cell transplants for aplastic anaemia
and of living donor kidney transplants for kidney failure
A. Gratwohl, B. Döhler, M. Stern, C. Bucher, J. Passweg, G. Opelz on behalf of the
SAA Working Party of the EBMT and the Collaborative Transplant Study
14:45 – Closing Session Room G4
15:00
Chairs: M. Brune (Göteborg, SE); P. Ljungman (Stockholm, SE);
D. Niederwieser (Leipzig, DE); E. Aerts (Zurich, CH);
C. Ruiz de Elvira (London, UK)
77

78
Posters Physicians Monday, 30 March 2009
17:30– Acute leukaemia
19:00
P432 Leukaemia-free survival of AML patients conditioned with FBM or other RIC
protocols prior to allogeneic stem cell transplantation
R. Marks, M. Labopin, H. Bertz, T. de Witte, V. Rocha, J. Finke on behalf of the Acute and
Chronic Leukemia Working Parties
P433 A survey on the outcomes following allogeneic haematopoietic stem cell
transplantation for adult patients with acute lymphoblastic leukaemia in first
relapse: a retrospective study on behalf of the ALWP from the EBMT
S. Santarone, M. Labopin, P. Di Bartolomeo, R. Arnold, J. Finke, H.J. Kolb, C. Cordonnier,
M. Baccarani, A. Fassas, M. Michallet, G. Ehninger, B. Samey, V. Rocha on behalf of the
ALWP EBMT
P434 Fludarabine and PK-targeted intravenous busulfan before allografting for adult
acute lymphoid leukaemia
S. Santarone, M. Alsina, E. Ayala, T. Field, M. Kharfan-Dabaja, L. Ochoa, L. Perez,
J. Perkins, J. Raychaudhuri, D. Sullivan, H. Fernandez, C. Anasetti (Tampa, US)
P435 T-cell depleted unrelated donor stem cell transplants appear to be of value for
adult Philadelphia chromosome negative ALL patients and should be evaluated
prospectively in new large group studies
B. Patel, K. Kirkland, R. Pearce, R. Szydlo, R. Clark, C. Craddock, E. Liakopoulou,
A. Fielding, S. Mackinnon, E. Olavarria, M. Potter, N. Russell, G. Cook, B.E. Shaw,
A. Goldstone, D. Marks on behalf of the British Society of Blood and Marrow
Transplantation
P436 High-resolution genome-wide analysis of copy number abnormalities in adult
acute myeloid leukaemia using single nucleotide polymorphism arrays identified
poor risk pts candidate to allo-BMT
I. Iacobucci, E. Ottaviani, F. Salmi, A. Astolfi, N. Testoni, S. Luatti, C. Papayannidis,
P. Giannoulia, P. Paolini, P.P. Piccaluga, D. Cilloni, F. Messa, F. Arruga, C. Dell'Agnola,
S. Cingarlini, D. Russo, M. Baccarani, G. Martinelli (Bologna, Orbassano, Turin, Verona,
Brescia, IT)
P437 Sequential conditioning in high-risk leukaemia: a single-centre experience in
116 patients
G. Kobbe, M. Kondakci, A. Czibere, I. Bruns, S. Balleisen, R. Fenk, L. Distelmeier, T. Graef,
U. Germing, R. Haas (Düsseldorf, DE)
P438 Cytomegalovirus induces apoptosis in acute myeloid leukaemia and thereby
reduces markedly the risk for relapse after transplant
A.H. Elmaagacli, M. Koldehoff, T. Gromke, B. Opalka, I. Hilgendorf, R.S Ross,
R. Trenschel, S. Bauer, L. Kordelas, H. Ottinger, D. Beelen (Essen, Rostock, DE)
P439 Expression of different isoforms of the B-cell mutator activation-induced cytidine
deaminase in BCR-ABL1-positive acute lymphoblastic leukaemia patients
identified poor risk group pts candidate to an allo-BMT
A. Lonetti, I. Iacobucci, A. Ferrari, M. Messina, D. Cilloni, S. Soverini, S. Chiaretti,
E. Ottaviani, N. Testoni, C. Papayannidis, F. Messa, F. Salmi, A. Vitale, F. Arruga, F. Pane,
P.P. Piccaluga, C. Dell'Agnola, S. Cingarlini, A. Gnani, S. Paolini, G. Saglio, M. Baccarani,
R. Foà, G. Martinelli (Bologna, Rome, Orbassano, Naples, Verona, IT)
P440 Successful myeloablative transplantation in high-risk acute myeloid leukaemia
using unrelated donors with alemtuzumab for T-cell depletion
K. Thomson, P. Kottaridis, E. Morris, R. Chakraverty, K. Peggs, S. Mackinnon (London, UK)
P441 Clofarabine ± fludarabine with IV busulfan as reduced-toxicity conditioning
therapy for allogeneic stem cell transplantation (Allo-SCT) in advanced myeloid
leukaemia/MDS
B. Andersson, M. de Lima, L. Worth, P. Thall, U. Popat, R. Jones, E. Shpall, C. Hosing,
T. Madden, R. Kazerooni, P. McAdams, A. Alousi, P. Kebriaei, R. Champlin (Houston, US)

Posters Physicians Monday, 30 March 2009
17:30– Acute leukaemia (continued)
19:00
P442 Allogeneic transplantation in adult AML 1st CR: better results with unrelated
donors compared to HLA matched sibling transplants
F. Bonifazi, G. Bandini, E. Colaci, M. Arpinati, M. Stanzani, S. Usai, A. Bontadini, A. Curti,
S. Paolini, S. Rizzi, M.R. Motta, V. Giudice, M. Baccarani (Bologna, IT)
P443 The outcome of adult patients affected by acute myeloid leukaemia relapsing
after allogeneic transplant: a single-centre experience
I. Cutini, S. Guidi, C. Nozzoli, B. Bartolozzi, F. Mannelli, G. Gianfaldoni, S. Bencini, A. Bosi
(Florence, IT)
P444 A single-centre experience with allogeneic haematopoietic stem cell
transplantation for acute lymphoblastic leukaemia: analysis of factors leading to
improved outcome
P. Kaczmarek, M. Potter, M. Ethell, J. Treleaven, F. Davies, C. Dearden, G. Morgan,
B.E. Shaw (Sutton, UK)
P445 GvHD prophylaxis using low-dose cyclosporine is safe and reduces the risk of
relapse and death in leukaemic recipients of HLA-identical sibling transplants
R. Olsson, M. Remberger, J. Mattsson, Z. Hassan, O. Ringdén (Sweden, SE)
P446 HD-Mel phase II study in first relapse of AML: high rate of extramedullary
manifestation in subsequent relapses after sequential auto-/allograft
H. Martin, R. Schwerdtfeger, B. Wassmann, S. Mousset, H. Pfeifer, H. Serve, G. Bug
(Frankfurt, Wiesbaden, DE)
P447 Outcome of secondary AML following BCR-ABL negative myeloproliferative
disorders
S. Ayari, P. Chevallier, T. Guillaume, R. Garant, V. Dubruille, T. Gastinne, S. Le Gouill,
N. Blin, B. Mahe, J.L. Harousseau, M. Mohty, P. Moreau, J. Delaunay (Nantes, FR)
P448 Prognostic factors in relapsed acute myeloid leukaemia patients receiving an
allogeneic haematopoetic stem cell transplantation as salvage therapy:
a retrospective analysis on behalf of the Northern Italy Leukemia Group
(NILG) experience
I.M. Cavattoni, E. Morello, E. Oldani, T. Intermesoli, E. Audisio, C. Minotto, E. Terruzzi,
E. Borlenghi, G. Rossi, E. Pogliani, F. Marmont, A. Rambaldi, R. Bassan, S. Cortelazzo
(Bolzano, Bergamo, Turin, Noale, Monza, Brescia, IT)
P449 Busulfan and melphalan as conditioning regimen for autologous stem cell
transplantation in acute myelogenous leukaemia patients in first complete
remission: a Gruppo Italiano Trapianto di Midollo Osseo (GITMO) retrospective
study
R.M. Lemoli, A. D'Addio, G. Marotta, V. Mettivier, E. Zuffa, M. Montanari, A. de Vivo,
A. Bonini, P. Galieni, A.M. Carella, S. Guidi, M. Michieli, A. Olivieri, A. Bosi
(Bologna, Siena, Naples, Ravenna, Ancona, Reggio Emilia, Ascoli Piceno,
San Giovanni Rotondo, Florence, Aviano, Potenza, IT)
P450 Impact of molecular markers on long-term outcome after allogeneic
haematopoietic stem cell transplantation for acute myeloid leukaemia patients
M. Michallet, M. Sobh, X. Thomas, C. Charlot, F. Barraco, G. Cannas, F.E. Nicolini,
E. Nicolas-Virelizier, C. Plesa, Y. Chelghoum, J. Troncy, J.-P. Magaud, I. Tigaud,
S. Hayette (Lyon, FR)
P451 Allogeneic stem cell transplantation after sequential therapy using high-dose
melphalan and myeloablative conditioning in patients with refractory acute
myeloid leukaemia
N.K. Steckel, R. Trenschel, L. Kordelas, T. Gromke, H. Ottinger, M. Koldehoff,
A.H. Elmaagacli, C. Schulte, D. Beelen (Essen, DE)
79

80
Posters Physicians Monday, 30 March 2009
17:30– Acute leukaemia (continued)
19:00
P452 Allogeneic HSCT after prior treatment combining chemotherapy and gemtuzumab
ozogamicin: a series of 44 cases
P. Chevallier, T. Prebet, C. Faucher, P. Turlure, M. Hunault-Berger, S. Vigouroux,
T. Guillaume, F. Mechinaud, J. Delaunay, J.L. Harousseau, N. Ifrah, P. Moreau, D. Blaise,
N. Vey, N. Milpied, M. Mohty (Nantes, Marseille, Limoges, Angers, Bordeaux, FR)
P453 Comparison of busulphan (16 mg/kg) + fluda versus standard BU-CY in
allogeneic transplantation of adult patients affected with leukaemia: advantages
of bus+fluda are evident also using oral route for busulphan administration
G. Milone, S. Leotta, E. Mauro, S. Coppoletta, M. Poidomani, E. Marturano, A. Spadaro,
S. Mercurio, A. Strano, M.G. Camuglia, G. Avola, A. Di Marco (Catania, IT)
P454 Phase I-II induction intensified regimens including fludarabine or mylotarg for
acute myeloid leukaemia patients: comparison by response and follow-up
C. Papayannidis, A. Candoni, S. Paolini, E. Ottaviani, I. Iacobucci, M. Rondoni,
M. Malagola, P.P. Piccaluga, D. Cilloni, R. Fanin, G. Visani, M. Baccarani, D. Russo,
G. Martinelli (Bologna, Udine, Siena, Brescia, Orbassano, Turin, Pesaro, IT)
P455 Myeloablative allogeneic stem cell transplantation in adults with acute
lymphoblastic leukaemia 1985 – 2005. A single-centre study
Y. Fløisand, L. Brinch, I. Dybedal, T. Gedde-Dahl, D. Heldal, P. Holme, T. Egeland,
G. Tjønnfjord (Oslo, NO)
P456 PET-CT scan for diagnosis of extramedullary relapse of AML after allogenic stem
cell transplantation
T. Stuebig, D. Judith, B. Sauter, F. Gruenwald, R. Taube, M. Schleuning, H. Baurmann,
R. Schwerdtfeger (Wiesbaden, Frankfurt, DE)
P457 Isolated extra-medullary relapse of acute leukaemia after allogeneic stem cell
transplantation. Different kinetics and better prognosis than systemic relapse
A. Shimoni, A. Rand, I. Hardan, N. Shem-Tov, R. Yerushalmi, A. Nagler (Tel-Hashomer, IL)
P458 Favourable outcome of allogeneic stem cell transplantation for patients with
intermediate-risk AML in 1.CR – A single-centre experience from 2003–2008
M. Karas, K. Steinerová, P. Jindra, D. Lysák, S. Vokurka, T. Svoboda, L. Mohammad,
V. Koza (Pilsen, CZ)
P459 Gemtuzumab ozogamicin, fludarabine, ara-C and cyclosporineA (MFAC) regimen
as induction therapy in relapsed or refractory CD33+ acute myeloid leukaemia
prior to allogeneic haematopoetic stem cell transplantation:
a single-centre experience
M. von Bonin, U. Oelschlägel, B. Mohr, U. Platzbecker, C. Thiede, M. Bornhäuser,
G. Ehninger, T. Illmer (Dresden, DE)
P460 Allogeneic stem cell transplantation for secondary acute myeloid leukaemia:
7-year experience of a single centre
Y. Koh, B.S. Kim, S.M. Bang, I. Kim, D.S. Lee, S.S. Yoon, J.S. Lee, K.S. Han, S. Park,
B.K. Kim (Seoul, Seongnam, KR)
P461 Unrelated and related HSCT in elderly AML patients: is young matched unrelated donor
comparable or superior to older sibling donor? An analysis of 76 allografted patients
aged above 50 years from the Czech Acute Leukaemia Clinical Register (ALERT)
P. Jindra, J. Muzik, K. Indrak, V. Koza, M. Karas, K. Chroust, F. Al Sabty, E. Demeckova,
P. Cetkovsky, A. Jungova, P. Zak (Pilsen, Brno, Olomouc, Prague, Hradec Kralove, CZ;
Bratislava, SK)
P462 A novel resistant FIP1L1-PDGFRa mutation in acute myeloid leukaemia,
resistance to imatinib mesylate and allogeneic haemopoietic stem cell
transplantation
Y. Sorour, C. Dalley, J. Snowden, N.C.P. Cross, J.T. Reilly (Sheffield, Southampton, UK)

Posters Physicians Monday, 30 March 2009
17:30– Acute leukaemia (continued)
19:00
P463 Reasons why acute leukaemia patients with established indication for stem
cell transplantation do not finally undergo the procedure and its clinical
consequences
F.J. Márquez-Malaver, I. Espigado, J. Falantes, M. Carmona, I. Montero, J. González,
M.L. Martino, V. De la Osa García, Á. Urbano-Ispizua (Sevilla, ES)
P464 Continuous infusion idarubicin and intravenous busulphan as conditioning
regimen to autologous stem cell transplantation for patients with acute myeloid
leukaemia
F. Ferrara, P. Musto, S. Palmieri, C. Copia, M. Pedata, T. Izzo, C. Criscuolo
(Rionero in Vulture, Naples, IT)
P465 Effect of HLA disparity on the outcome of allogeneic unrelated transplants in AML
F. Bonifazi, G. Bandini, E. Colaci, M. Stanzani, M. Arpinati, S. Usai, A. Bontadini, A. Curti,
S. Paolini, S. Rizzi, M.R. Motta, M. Baccarani (Bologna, IT)
P466 Allogeneic blood stem cell transplants for AML using the Bu4Cy2 regimen in AML:
long term experience
L. Brinch, Y. Fløisand, G. Tjønnfjord, T. Gedde-Dahl, D. Heldal, P. Holme, T. Egeland
(Oslo, NO)
P467 Gemtuzumab ozogamicin prior to conditioning regimen before allogeneic
haematopoietic stem cell transplantation may lead to acceptable outcome in
high-risk acute myeloid leukaemia patients
M. Markova, V. Valkova, A. Vitek, H. Klamova, D. Pohlreich, P. Cetkovsky (Prague, CZ)
P468 Sustained complete molecular response and low treatment related mortality after
allogeneic haematopoietic stem cell transplantation for Philadelphia-positive
acute lymphoblastic leukaemia patients previously treated with tyrosine kinase
inhibitors
H. de Lavallade, T. Prebet, J. El Cheikh, C. Faucher, N. Vey, A. Charbonnier,
C. Chabannon, D. Blaise, S. Furst (Marseille, FR)
P469 17-year-old boy with secondary acute leukaemia presents with Ewing's
sarcoma/PNET following allogenic-SCT
L. Grkovic, P. Roncevic, R. Serventi-Seiwerth, M. Nola, D. Batinic, K. Gjadrov Kuvezdic,
R. Lasan Trcic, D. Ozretic, B. Labar (Zagreb, HR)
P470 Allogeneic haematopoietic stem cell transplantation in AML t(8;21) in first
complete remission gives superior relapse free survival over repetitive high-dose
cytosine arabinoside in certain populations
S. Ahmed, F. Al-Qurashi, N. Chaudhri, M. Aljurf, H. Al-Zahrani, F. Al-Sharif, S. Mohamed,
A.J.M. Saleh, M. Bakr, A. Nassar, S. Zaidi, K. Enazi, M. Patel, W. Rasheed, K. Ibrahim,
R. Al-Nounou, E. Elghazaly, F. Al-Mohareb (Riyadh, SA; Muscat, OM)
P471 High-performance liquid chromatographic assay of busulfan in plasma samples –
Self-modification
T. Burycz, L. Usnarska-Zubkiewicz, A. Wiela-Hojenska (Wroclaw, PL)
P472 Paediatric high-risk AML: excellent early disease-free-survival using a
fludarabine-based myeloablative preparative regimen
P.-L. Tan, A. Yeoh, T.-C. Quah (Singapore, SG)
P473 Mobilisation of autologous PBSCT in patients with AML in first complete
remission: choosing the optimal mobilising regimen
A. Pivkova, S. Genadieva Stavrik, Z. Stojanoski, L. Cevreska, B. Georgievski (Skopje, MK)
P474 Extramedullary relapse in cases of acute myeloid leukaemia after allogeneic
stem cell transplantation
L. Perez-Bercoff, B. Gustafsson, O. Ringden, P. Ljungman (Stockholm, SE)
81

82
Posters Physicians Monday, 30 March 2009
17:30– Acute leukaemia (continued)
19:00
P475 Prognostic significance of residual disease in bone marrow before allogenic
transplantation in acute myeloid leukaemia
M.L. Amigo, A. Fernandez, E. López, M. Osma, E. Pérez, C. Castilla, I. Heras, J. Nieto,
F. Ortuño, V. Vicente (Murcia, ES)
P476 Gemtuzumab-ozogamicin as maintenance therapy after autologous stem cell
transplantation in elderly patients with acute myeloid leukaemia
A.M. Carella, M. Greco, E. Merla, N. Cascavilla (San Giovanni Rotondo, IT)
P477 Transplant procedures in comparison to conventional therapy in the treatment of
acute myeloid leukaemia: long-term follow-up
M. Elez, D. Stamatovic, L. Tukic, O. Tarabar, B. Balint, B. Todoric Zivanovic, O. Tasic,
V. Skuletic, M. Malesevic, S. Marjanovic (Belgrade, RS)
P478 First complete remission versus other than first complete remission in acute
myelogenous leukaemia with allogeneic haematopoietic stem cell transplantation
K. Alimoghaddam, F. Khatami, A. Jalali, M. Jahani, M. Iravani, S. Mousavi, B. Bahar,
A. Masnavi, E. Eini, A. Ghavamzadeh (Tehran, IR)
P479 Dasatinib in the treatment of extramedullary relapse in BCR/ABL+ AML patients
after allogeneic transplantation
R. Scimè, S. Tringali, A. Cavallaro, A. Indovina (Palermo, IT)
P480 Two types of conditioning for HSCT in paediatric acute lymphoblastic leukaemia
N. Minakovskaya, N. Kirsanova, O. Aleinikova (Minsk, BY)
P481 Allogeneic transplantation from alternative donors is feasible in elderly patients
with poor prognosis acute myeloid leukaemia or myelodysplastic syndrome:
a single-centre experience
M. Tassara, M. Bernardi, J. Peccatori, A. Crotta, M.T. Lupo Stanghellini, C. Messina,
C. Corti, A. Assanelli, D. Clerici, S. Mastaglio, S. Malato, F. Ciceri (Milan, IT)
17:30 – Stem cell source
19:00
P482 Results of two phase III, multicentre, randomised, placebo-controlled trials of
plerixafor + G-CSF versus G-CSF + placebo for mobilisation and engraftment of
non-Hodgkin’s lymphoma and multiple myeloma patients undergoing autologous
transplantation
J.F. DiPersio, I.N. Micallef, A.P. Nademanee, P.J. Stiff, E.A. Stadtmauer, R.T. Maziarz,
B.J. Bolwell, J. Angell, G. Bridger, G. Calandra (Saint Louis, Rochester, Duarte, Maywood,
Philadelphia, Portland, Cleveland, Cambridge, US)
P483 Expansion potential of adipose tissue-derived mesenchymal stem cells:
role of the addition of human platelet lysate
C. Almici, R. Verardi, A. Neva, G. Piovani, A. Bianchetti, G. Santoro, D. Russo, S. Barlati,
M. Marini (Brescia, IT)
P484 Unrelated cord blood transplantation after myeloablative conditioning for adult
patients with myelodysplastic syndrome
J. Ooi, S. Takahashi, N. Tsukada, S. Kato, A. Sato, F. Monma, A. Tojo, S. Asano (Tokyo, JP)
P485 Efficacy of plerixafor plus G-CSF compared to G-CSF plus placebo for
mobilisation of CD34+ haematopoietic progenitor cells in patients older than
60 years with non-Hodgkin's lymphoma or multiple myeloma
I.N. Micallef, J.F. DiPersio, A.P. Nademanee, P.J. Stiff, E.A. Stadtmauer, R.T. Maziarz,
B.J. Bolwell, J. Angell, G. Bridger, G. Calandra (Rochester, Saint Louis, Duarte, Maywood,
Philadelphia, Portland, Cleveland, Cambridge, US)

Posters Physicians Monday, 30 March 2009
17:30– Stem cell source (continued)
19:00
P486 Prospective analysis for antigen-specific cellular immune reconstitution after
cord blood transplantation: immune response to CMV is not affected by HLA
disparity
S. Takahashi, M. Ishige, N. Watanabe, T. Yamaguchi, J. Ooi, N. Tsukada, S. Kato, A. Sato,
F. Monma, R. Yamazaki, A. Fujita, N. Toki, H. Tanaka, T. Uehara, K. Fujimaki, K. Oshima,
Y. Aisa, K. Motohashi, R. Hyo, Y. Najima, H. Kanamori, Y. Nannya, R. Sakai, S. Takada,
T. Kobayashi, T. Hoshino, K. Matsumoto, K. Hideyuki, J. Kato, A. Yokota, N. Nakamura,
M. Tanaka, T. Mori, H. Sakamaki, S. Okamoto on behalf of Kanto Study Group for Cell
Therapy (KSGCT)
P487 HHV6 infection is a hallmark of cord blood transplant in adults and may
participate to delayed engraftment: a comparison with matched unrelated donors
as stem cell source
P. Chevallier, T. Guillaume, L. Planche, I. Hebia-Fellah, C. Bressolette-Bodin, F. Rialland,
M. Coste-Burel, S. Ayari, J. Delaunay, V. Horvais, M. Mohty, P. Moreau, J.L. Harousseau,
B. Imbert-Marcille (Nantes, FR)
P488 A novel P-glycoprotein (Pgp) -dependent ex-vivo approach for expansion
of human umbilical cord blood CD133+ cells significantly enriches the
CD34+/CD38- fraction
H. Galski, I. Bar, A. Nagler (Tel Hashomer, IL)
P489 Clinical expansion of cord blood derived T-cells for use as donor lymphocyte
infusion after cord blood transplantation
M. Okas, J. Gertow, O. Ringdén, J. Mattsson, M. Uhlin (Stockholm, SE)
P490 Immediate plasma removal and cryopreservation in HAS/DMSO corrects reduced
CD34+ cell viability in cryopreserved cell harvests from patients with systemic
amyloidosis
R. Krishna, V. Day, J. Snowden, D. Pawson, C. Birchall, K. El-Ghariani, G. Cook,
A. Lubenko (Sheffield, Leeds, UK)
P491 Incidence of early infections after double cord blood transplantation preceded by
a non-myeloablative conditioning regimen in adult patients
J.A.E. Somers, E. Meijer, K. Sintnicolaas, M. Oudshoorn, E. Braakman, A. Brand,
J.J. Cornelissen (Leiden, Rotterdam, NL)
P492 The use of HLA-specific monoclonal antibodies to determine graft kinetics in
patients after double cord blood transplantation
J.A.E. Somers, Y. van Hensbergen, A. Mulder, J.J. Cornelissen, A. Brand
(Leiden, Rotterdam, NL)
P493 Effect of plerixafor plus G-CSF among patients who failed to collect sufficient
haematopoietic stem cells after mobilisation attempt with chemotherapy plus
cytokines
P.J. Shaughnessy, P.A. McSweeney, S. Solomon, J. McCarty, F. van Rhee, E.D. Jacobsen,
G. Calandra, D. Huebner (San Antonio, Denver, Atlanta, Richmond, Little Rock, Boston,
Cambridge, US)
P494 Quantification of mesenchymal stem cells in grafts adds to the benefits of
haematopoietic stem cell and T-cell analysis in prediction of the duration of
aplasia but not probability of acute graft-versus-host disease: preliminary results
K. Dalva, T. Özçelik, M. Tol, E. Ayyildiz, H. Ersoy, M. Ertem, A. Ikinciogullari, O. Ilhan,
M. Beksac (Ankara, TR)
P495 Quality controls of cord blood units according to JACIE standards are highly
predictive in unrelated cord blood transplant
A. Picardi, A. Spagnoli, M. Caniglia, R. Pinto, T. Dentamaro, I. Mangione, L. Cudillo,
L. Cupelli, F. Zinno, A. Bruno, G. Del Proposto, G. Kloger, L. Lecchi, W. Arcese
(Rome, Milan, IT; Düsseldorf, DE)
83

84
Posters Physicians Monday, 30 March 2009
17:30– Stem cell source (continued)
19:00
P496 Similar engraftment kinetics of cord blood transplantations of double units in
adults, versus single units in children
G. Goldstein, R. Elhasid, B. Bielorai, A. Toren, R. Yerushalmi, A. Shimoni, A. Nagler
(Ramat Gan, Haifa, IL)
P497 Cord blood stem cells enumerated using 7-AAD modified ISHAGE guidelines may
contain significant numbers of non-viable (apoptotic) cells
R.C Duggleby, S. Querol, R. Horton, S. Gomez, J.A Madrigal (London, Nottingham, UK)
P498 Evaluation of umbilical cord blood unit processing efficiency in routine laboratory
conditions
V. Kindler, C. Troeger, G. Nicoloso de Faveri, A. Gratwohl, A. Tichelli, J. Passweg,
S. Meyer-Monard (Geneva, Basel, Berne, CH)
P499 Reduced dose of lenograstim is as efficacious as standard dose for peripheral
blood stem cell mobilisation and transplantation: a randomized study in patients
undergoing autologous peripheral stem cell transplantation
M. Ozturk, F. Arpaci , S. Ataergin , A. Ozet, T. Cetin, O. Kuzhan, B. Ozturk, S. Komurcu,
S. Kilic, T. Guler, B. Budakoglu (Ankara, TR)
P500 Microbial contamination: 10-year survey at a cord blood bank, Pavia
P. Bergamaschi, R. Daturi, A. Marchesi, B. Romano, V. Genovese, T. Quaglini, M. Rossi,
C. Del Fante, G. Viarengo, E. Giacobone, C. Perotti, L. Salvaneschi (Pavia, Voghera, IT)
P501 Microbial contamination of peripheral blood stem cell products for autologous
transplantation
P. Bergamaschi, C. Parisi, R. Daturi, E. Giacobone, A. Marchesi, B. Romano, V. Genovese,
C. Del Fante, G. Viarengo, C. Perotti, L. Salvaneschi (Pavia, IT)
P502 Efficacy, complication rates, and cost-effectiveness of chemotherapy plus
granulocyte-colony-stimulating factor conditioned mobilisation of peripheral
blood haematopoietic stem cells in over 150 patients with haematological
malignancies
I. Gabriel, J. Sharon-Richman, E. Olavarria, A. Rahemtulla , E. Kanfer, D. Marin,
D. Milojkovic, K. Rezvani, D. MacDonald, R. Szydlo, J. Apperley (London, UK)
P503 Efficiency of high-dose etoposide phosphate and G-CSF for primary and secondary
stem cell mobilisation – A single-centre retrospective analysis of 66 patients
K. Jost, M. Leithäuser, C. Grosse-Thie, I. Hilgendorf, C. Kahl, G. Kundt, M. Freund,
C. Junghanss (Rostock, DE)
P504 Plerixafor is highly effective in the mobilisation of PBSC for autologous
transplantation from patients failing to mobilise by conventional means:
the initial Scottish experience in three transplant centres
W.C. Gordon, P.R.E. Johnson, P.H. Roddie, P.C.A. Shepherd, F.M. Scott, J.M. Davies,
L.M. Manson, D. Culligan, Y.-L. Chee, A.N. Parker, I.G. McQuaker, A. Clark, R.L. Soutar,
K.W. Douglas (Glasgow, Edinburgh, Aberdeen, UK)
P505 Immune reconstitution is significantly impaired following double umbilical cord
blood transplantation in adult patients
A. Manaka, C. Balotis, M. Vagia, S. Vasiliou, Z. Poulopoulou, M. Papageorgiou, E. Bika,
M. Karatza, M. Garofalaki, I. Kakkas, C. Papasteriades, J. Apostolidis, N. Harhalakis,
I. Baltadakis, D. Karakasis, E. Nikiforakis (Athens, GR)
P506 Transplanted CD34+ cell dose is associated with long-term platelet count
recovery following autologous haematopoietic stem cell transplant in patients
with non-Hodgkin’s lymphoma and multiple myeloma
P.J. Stiff, I.N. Micallef, A.P. Nademanee, E.A. Stadtmauer, R.T. Maziarz, B.J. Bolwell,
G. Calandra, G. Bridger, J.F. DiPersio (Maywood, Rochester, Duarte, Philadelphia,
Portland, Cleveland, Cambridge, Saint Louis, US)

Posters Physicians Monday, 30 March 2009
17:30– Stem cell source (continued)
19:00
P507 Rescue from failed growth factor and/or chemotherapy haematopoietic stem cell
mobilisation with G-CSF and plerixafor: a single-centre experience
C.J. Fowler, A. Dunn, B. Hayes-Lattin, K. Hansen, L. Hansen, K. Lanier, V. Nelson,
T. Kovacsovics, J. Leis, G. Calandra, R.T. Maziarz (Portland, Cambridge, US)
P508 High-dose G-CSF is safe and effective for mobilisation of haemopoietic cells
for autologous stem cell transplantation with clinical utility in the majority of
sub-optimal mobilisers
A. Alfred, S. Mahmood, D.A. Jones, D. Hess, J.G. Wright, J. Snowden, A. Mijovic
(Sheffield, London, UK)
P509 Stable mixed donor-donor chimerism after double cord blood transplantation
J. Gertow, S. Berglund, M. Okas, O. Ringdén, M. Uhlin, J. Mattsson (Stockholm, SE)
P510 Mobilisation of peripheral blood stem cells in patients with malignant lymphomas
with pegfilgrastim following chemotherapy
S. Alekseev, M. Estrina, E. Kochina, E. Babenko, M. Popova, N. Mikhaylova,
L. Zubarovskaya, B. Afanasyev (St. Petersburg, RU)
P511 Monitoring of HPC-CB production process: implementation of an internal quality
control
A. Pontari, D. Marcuccio, G. Pucci, I. Bova, A. Dattola, C. Garreffa, E. Spiniello, D. Princi,
R. Monteleone, G. Gallo, P. Scaramozzino, P. Iacopino (Reggio Calabria, IT)
17:30– Graft-versus-host disease – preclinical and animal models
19:00
P512 Interferon gamma is required for MSC-mediated immunosuppression in a murine
model of GvHD
M. Kambouris, B. Turner, L. Sinfield, H. Cullup, D. Hart, K. Atkinson, A. Rice
(South Brisbane, AU; Newcastle-Upon-Tyne, UK)
P513 CD83 antibody prevents GvHD and does not impair GvL induction
H. Cullup, J. Wilson, R. Lourie, Y. Shen, A. Palkova, K. Radford, A.M. Dickinson, A. Rice,
D. Hart, D. Munster (South Brisbane, AU; Newcastle-Upon-Tyne, UK)
P514 Th17/Treg ratio in human gastro-intestinal graft-versus-host disease
G. Socié, P. Ratajczak, C. Leboeuf, A. Desveaux, R. Peffault de Latour, M. Robin,
P. Bertheau, A. Janin (Paris, FR)
P515 Donor T-lymphocytes deficient for NF-KB inducing kinase do not cause
graft-versus-host disease
M. Ramírez, L. Casanova, C. Sánchez-Valdepeñas, I. Colmenero, M. González-Vicent,
M.A. Díaz, L. Madero, M. Fresno (Madrid, ES)
P516 Donor HSP70-hom gene polymorphism as a risk factor of chronic GvHD
A. Kuzyk, K. Bogunia-Kubik, G. Jackson, A.M. Dickinson (Newcastle upon Tyne, UK;
Wroclaw, PL)
P517 Differential reactivity of rabbit anti T-lymphocyte globulin with peripheral blood
mononuclear cell compartments in patients' sera 21 days post allogeneic
haematopoetic stem cell transplantation
C. Ziegler, J. Finke, C. Grüllich (Freiburg, Heidelberg, DE)
P518 Serum catalase to predict graft-versus-host disease after allogeneic stem cell
transplantation
B. Kircher, P. Schumacher, J. Clausen, J. Auberger, D. Nachbaur (Innsbruck, AT)
P519 Human iNKT compartment homeostasis after haematopoietic stem cell allograft
A. Rossignol, A. Yip-Fa, C. Giraud, M. Charron, N. Maillard, A. Chauvineau, A. Barra,
A. Herbelin, J.M. Gombert, F. Guilhot (Poitiers, Paris, FR)
85

86
Posters Physicians Monday, 30 March 2009
17:30– Graft-versus-host disease – preclinical and animal models
19:00 (continued)
P520 Dysregulation of human plasmacytoid dendritic cells in chronic graft-versus-host
disease
A. Rossignol, A. Yip-Fa, C. Giraud, S. Noel, N. Maillard, A. Chauvineau, A. Barra,
F. Guilhot, J.M. Gombert (Poitiers, FR)
P521 Immunomodulation induced by extracorporeal photochemotherapy:
impact of cryoconservation
E. Merlin, R. Veyrat-Masson, P. Halle, M. Berger, F. Deméocq, J. Chassagne, J. Kanold
(Clermont-Ferrand, FR)
P522 Genetic similarity of chromosome 6 between patients receiving haematopoietic
stem cell transplantation and HLA-matched sibling donors
H. Turpeinen, L. Volin, L. Nikkinen, P. Ojala, A. Palotie, J. Saarela, J. Partanen
(Helsinki, FI; Cambridge, UK)
17:30– Graft-versus-host disease – clinical
19:00
P523 A comparison of 2 initiation timing of cyclosporine used as a single drug for GvHD
prevention
M. Shapira, L. Dray, M. Aker, B. Gesundheit, S. Samuel, R. Or, I. Resnick (Jerusalem, IL)
P524 Comparison between an artificial neural network and logistic regression in
predicting acute graft-versus-host disease following unrelated haematopoietic
stem cell transplantation
G. Caocci, R. Baccoli, A. Vacca, E. Piras, R. Littera, C. Giardini, F. Locatelli, C. Carcassi,
G. La Nasa (Cagliari, Pesaro, Pavia, IT)
P525 Correlation of interleukin-23 receptor gene polymorphism with reduced incidence
of acute GvHD
M. Wermke, S. Maiwald, R. Schmelz, C. Thiede, G. Ehninger, M. Bornhäuser,
R. Wassmuth (Dresden, DE)
P526 Patients with chronic graft-versus-host disease responding to extracorporeal
photopheresis significantly decrease immature/transitional B-cell numbers
during therapy
Z. Kuzmina, R Weigl, R. Knobler, N. Worel, H. Greinix, W. Pickl (Vienna, AT)
P527 Increased proportions of TH17+ cells in patients post HSCT heralds overt aGvHD
D. Dlubek, E. Jaskula, M. Sedzimirska, J. Lange, A. Lange (Wroclaw, PL)
P528 Once-weekly liposomal amphotericin B for prophylaxis of invasive fungal
infection after graft-versus-host disease in allogeneic haematopoietic stem cell
transplantation: a comparative retrospective monocentre study
J. El-Cheikh, L. Wang, B. Esterni, C. Faucher, S. Furst, P. Berger, D. Blaise (Marseille, FR)
P529 mTOR inhibitors for treatment of sclerodermatous chronic graft-versus-host
disease following allogeneic stem cell transplantation
Z. Jedlickova, I. Burlakova, A. Cook, H. Baurmann, R. Schwerdtfeger, M. Schleuning
(Wiesbaden, DE)
P530 Impairment of endothelial protein C pathway in tissues involved by acute and
chronic graft-versus-host disease
F. Toraldo, A. Bucalossi, M. Tozzi, C. Miracco, V. Mormouras, M.T. Pirrotta, E. Cosci,
S. Machetti, F. Lauria, G. Marotta (Siena, IT)
P531 Role of the HLA-G 14-base pair deletion-insertion polymorphism in the
development of severe acute GvHD following unrelated haematopoietic stem cell
transplantation in beta-thalassaemia patients
R. Littera, E. Piras, F. Alba, S. Lai, A. Vacca, L. Cappai, G. Caocci, C. Giardini, F. Locatelli,
C. Carcassi, G. La Nasa (Cagliari, Pesaro, Pavia, IT)

Posters Physicians Monday, 30 March 2009
17:30– Graft-versus-host disease – clinical (continued)
19:00
P532 Recipient CTLA-4 genotype is a prognostic factor for acute GvHD in
haematopoietic stem cell transplantation for thalassaemia
S. Orrù, A. Vacca, N. Orrù, G. Caocci, L. Martorana, E. Piras, R. Littera, A. Ledda,
C. Giardini, M. Bernardo, F. Locatelli, C. Carcassi, G. La Nasa (Cagliari, Pesaro, Pavia, IT)
P533 The frequencies of T helper 1, T helper 2 in CD4+ T-cells and plasma
interleukin-10 are good biomarkers of graft-versus-host disease
S.-P. Yeh, Y.-M. Liao, C.-F. Chiu, W.-J. Lo, C.-L. Lin (Taichung, TW)
P534 Low-dose alemtuzumab as GvHD-prophylaxis in matched and mismatched
allogeneic sibling and unrelated donor transplantation
H. Bertz, A. Zerweck, D. Räpple, R. Waesch, R. Marks, J. Finke (Freiburg, DE)
P535 Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for
cutaneous acute graft-versus-host disease
N. Dhédin, A. Ghadiri, M. Uzunov, S. Nguyen, J.P. Vernant, P. Debré, C. Combadière (Paris, FR)
P536 Assessment of liver damage with transient hepatic elastography (FibroScan) in
patients with chronic graft-versus-host disease
C. Skert, A. Peli, K. Prestini, L. Biasi, C. Filì, M. Malagola, C. Bergonzi, M. Mendeni,
A. Roccaro, M. Puoti, D. Russo (Brescia, IT)
P537 Serotherapy in paediatric allogeneic stem cell transplantation:
comparison of ATG and Campath-1H as part of conditioning
C.M. Jol-van der Zijde, A.M. Jansen-Hoogendijk, M. Egeler, A.C. Lankester,
R.G.M. Bredius, M.J.D. van Tol (Leiden, NL)
P538 Kinetics of active and total thymoglobulin in paediatric stem cell transplantation
C.M. Jol-van der Zijde, A.M. Jansen-Hoogendijk, S. Raaijmakers, M. Egeler,
A.C. Lankester, R.G.M. Bredius, M.J.D. van Tol (Leiden, NL)
P539 Prevalence of genital graft-versus-host disease after allogeneic stem cell
transplantation
E. Smith Knutsson, A.K. Broman, Y. Björk, D. Hallberg, L. Helström, O. Nilsson,
K. Sundfeldt, M. Styrenius, M. Brune (Trollhättan, Göteborg, Stockholm, SE)
P540 Antithymocyte globulins as part of the myeloablative conditioning regimen can
reduce the risk of severe graft-versus-host disease after allogeneic stem cell
transplantation from matched-unrelated donors
M. Mohty, M.-L. Balère, G. Socié, N. Milpied, N. Ifrah, M. Kuentz, J.L. Harousseau,
J.P. Vernant, M. Michallet, A. Buzyn, J.-Y. Cahn, J.H. Bourhis, D. Blaise, C. Raffoux,
H. Esperou, I. Yakoub-Agha for the Societé Francaise de Greffe de Moelle et de Therapie
Cellulaire (SFGM-TC)
P541 Chronic GvHD of the lung significantly impairs quality of life and the activity
profile – Results of a prospective German multicentre validation trial
D. Wolff, P. Herzberg, P. Heussner, F. Mumm, I. Hilgendorf, S. von Harsdorf, A. Gerbitz,
H. Greinix, G. Hildebrandt, C. Junghanss, E. Holler (Regensburg, Leipzig, Munich,
Rostock, Ulm, Berlin, DE; Vienna, AT)
P542 GvHD associated impairment of physical functioning, depression, and anxiety.
Results from a prospective trial on physical and psychological functioning in
patients before and after allogeneic haematopoietic stem cell transplantation
M. Viehweg, P. Herzberg, H. Andree, I. Hilgendorf, M. Leithäuser, C. Junghanss,
J. Casper, M. Freund, D. Wolff (Rostock, Leipzig, Regensburg, DE)
P543 Prophylaxis with mycophenolate mofetil and cyclosporine can decrease the
incidence of severe acute GvHD following reduced-intensity conditioning
allogeneic stem cell transplantation from matched unrelated donors
E. Brissot, P. Chevallier, T. Guillaume, J. Delaunay, S. Ayari, V. Dubruille, S. Le Gouill,
B. Mahe, T. Gastinne, N. Blin, B. Saulquin, P. Moreau, J.L. Harousseau, M. Mohty (Nantes, FR)
87

88
Posters Physicians Monday, 30 March 2009
17:30– Graft-versus-host disease – clinical (continued)
19:00
P544 Killer immunoglobulin-like receptor (KIR) 2DS3 gene and survival outcome in
identical HLA-matched sibling adult haematopoietic stem cell transplantation
J.A. Davidson, G. Lucas, J.A.L. Yin, E. Liakopoulou, K.V. Poulton (Manchester, UK)
P545 Vascular endothelial growth factor gene polymorphisms may predict the risk
of acute graft-versus-host disease following allogeneic transplantation:
preventive effect of VEGF on acute GvHD
D.H. Kim, N.Y. Lee, M.H. Lee, S.K. Sohn, J.H. Jang, K. Kim, S.J. Kim, W.S. Kim,
C.W. Jung (Seoul, Daegu, KR)
P546 The successful treatment of steroid-refractory liver graft-versus-host disease
with pulse cyclophosphamide: excellent long-term results
M. Krejci, J. Mayer, Y. Brychtova, M. Doubek, Z. Racil, Z. Koristek, M. Navratil,
M. Tomiska, J. Vorlicek (Brno, CZ)
P547 A phase II clinical trial using extracorporeal photophoresis for chronic GvHD:
evidence for immune switching
U. Holtick, X.N. Wang, S.R. Marshall, M. von Bergwelt-Baildon, C. Scheid, A.M. Dickinson
(Cologne, DE; Newcastle upon Tyne, UK)
P548 Extracorporeal photopheresis for the treatment of steroid-resistant acute
graft-versus-host disease
S. Fritsch, J. Tischer, G. Ledderose, B. Maier, R. Reibke, A. Rank, H.J. Kolb (Munich, DE)
P549 Extracorporeal photopheresis in the management of steroid-refractory chronic
graft-versus-host disease after allogeneic stem cell transplantation
P. Kaloyannidis, A. Papalexandri, I. Sakellari, E. Yannaki, I. Batsis, D. Mallouri,
A. Barbouti, M. Ganidou, A. Fassas, A. Anagnostopoulos (Thessaloniki, GR)
P550 Initial liver involvement in acute graft-versus-host disease predicts severe acute
GvHD and high non-relapse mortality
M. Robin, R. Porcher, R. de Castro, G. Fisher, R. Peffault de Latour, P. Ribaud, V. Rocha,
A. Devergie, J.-Y. Mary, G. Socié (Paris, FR)
P551 Biomarkers associated with occurrence and severity of graft-versus-host disease
S. Ahmed, O. Donze, E. Holler, X.N. Wang, A.M. Dickinson (Newcastle, UK; Epalinges, CH;
Regensburg, DE)
P552 Alemtuzumab as treatment of steroid-refractory acute graft-versus-host disease:
results of a phase II study
C. Martínez, C. Solano, C. Ferrá, A. Sampol, D. Valcárcel, J.A. Pérez-Simón on behalf of
the Spanish Group for Stem Cell Transplantation
P553 Polymorphisms of MTHFR and clinical outcomes in allogeneic stem cell
transplantation
P. Chiusolo, S. Bellesi, S. Giammarco, S. Marietti, D. De Ritis, E Metafuni, S. DeMattteis,
G. Leone, S. Sica (Rome, IT)
P554 Kruppel-like factor 13 polymorphisms and clinical outcomes after allogeneic
haematopoietic stem cell transplantation
K.H. Lim, S.H. Park, E. Park, J.A. Song, I. Kim, S.S. Yoon, B.K. Kim, S. Park (Seoul, KR)
P555 Human mesenchymal stromal cells expanded with human platelet lysate are safe
and effective for the treatment of steroid-refractory graft-versus-host disease
M. Introna, C. Capelli, C. Micò, A. Algarotti, A. Grassi, A. Salvadè, G. Gaipa, D. Belotti,
P. Perseghin, G. D'Amico, A. Rovelli, A. Balduzzi, J. Golay, J. Golay, A. Biondi, A. Rambaldi,
E. Biagi (Bergamo, Monza, IT)
P556 Chronic GvHD is associated with a deficiency of CD27+IgD+IgM+ B cells
I. Hilgendorf, B. Mueller-Hilke, C. Junghanss, M. Leithäuser, M. Freund, D. Wolff
(Rostock, Regensburg, DE)

Posters Physicians Monday, 30 March 2009
17:30– Graft-versus-host disease – clinical (continued)
19:00
P557 A single nucleotide polymorphism in the intelectin 1 gene (ITLN1) is associated
with acute intestinal graft-versus-host disease
H. Hauser, O. Zach, O. Krieger, H. Kasparu, J. Koenig, A. Weltermann, D. Lutz (Linz, AT)
P558 Bone marrow and intestinal but not peripheral blood eosinophilia predicts
graft-versus-host disease after haematopoetic cell transplantation with
reduced-intensity conditioning
P. Roesch, G.-N. Franke, T. Lange, T. Aigner, D. Niederwieser, N. Basara (Leipzig, DE)
P559 The impact of cytokine genetic polymorphisms in acute graft-versus-host disease
in HLA-matched sibling bone marrow transplants in the Sardinian population
M.G. Orofino, M. Congia, M.A. Sanna, D. Macis, M. Badiali, M.C. Addari, A. Piroddi,
F. Rizzo, F. Cossu, I. Ronch, F. Argiolu (Cagliari, IT)
P560 Retrospective evaluation between ATG-genzyme – ATG-fresenius in allogeneic
HSCT setting; impact on GVHD, infections, relapse and survival
D. Baronciani, C. Depau, M. Pettinau, F. Zaccheddu, F. Pilo, D. Derudas, A. Lai,
E. Angelucci (Cagliari, IT)
P561 Cytokine expression and genotype can affect outcomes after haematopoietic
stem cell transplantation
B.E. Turner, J.L. Harrold, J. Norden, E.A. Douglas, A.M. Dickinson (Newcastle upon Tyne, UK)
P562 Methylation in the promoter region and expression of FOX-P3 correlate with
GVHD, relapse and survival after HLA-identical sibling allogeneic SCT
C. Manzano, P. Balsalobre, D. Serrano, G. Rodríguez-Macías, J. Gayoso,
A. Gómez-Pineda, J.L. Díez-Martín, I. Buño (Madrid, ES)
P563 Ultrasonographic features of acute gastrointestinal graft-versus-host disease
after allogeneic stem cell transplantation
G. Carnevale Maffè, R. Ciccocioppo, K. Markopoulos, S. Tirella, C. Alvisi, O. Luinetti,
A. Colombo, F. Ripamonti, E.P. Alessandrino, G. Corazza (Pavia, IT)
P564 Eye graft-versus-host disease in patients with allogeneic haematopoitic stem
cell transplantation
A. Mikhaylova, Y. Astahov, B. Afanasyev (St. Petersburg, RU)
P565 Rituximab is an effective treatment for refractory chronic graft-versus-host
disease but is associated with high incidence of infections
I. Batsis, A. Karpouza, I. Sakellari, E. Yannaki, P. Kaloyannidis, D. Mallouri, C. Smias,
A. Fassas, A. Anagnostopoulos (Thessaloniki, GR)
P566 Impact of cyclosporine A concentration on the incidence of severe acute
graft-versus-host disease after allogeneic stem cell transplantation
F. Mallard, E. Brissot, P. Chevallier, T. Guillaume, J. Delaunay, S. Ayari, V. Dubruille,
S. Le Gouill, B. Mahe, T. Gastinne, N. Blin, B. Saulquin, P. Moreau, J.L. Harousseau,
M. Mohty (Nantes, FR)
P567 Intracellular markers of eosinophils and mast cells in patients with chronic
graft-versus-host disease associated with high-grade eosinophilia
L. Komarova, N. Mikhaylova, B. Afanasyev (St. Petersburg, RU)
P568 Effects of graft-versus-host-disease and immunosuppressive treatment on
immune response to vaccination after bone marrow transplantation
S. Einarsdottir, P.O. Andersson, P. Horal, B. Kaijser, M. Brune (Göteborg, SE)
P569 Limited efficacy of low-dose imatinib in pulmonary chronic graft-versus-host
disease
M. Stadler, H. Diedrich, H. Kamal, R. Ahlborn, S. Buchholz, A. Ganser, M. Eder (Hannover, DE)
P570 Efficacy and tolerability of long-term inolimomab treatment for acute
graft-versus-host disease
L. Kammoun, M. Uzunov, S. Nguyen, N. Dhedin, L. Sutton, J.P. Vernant (Paris, FR)
89

90
Posters Physicians Monday, 30 March 2009
17:30– Graft-versus-host disease – clinical (continued)
19:00
P571 Effective therapy of steroid-refractory acute GvHD with CD52 antibody alemtuzumab
M. Gramatzki, N. Schub, A. Günther, C. Ehlert, A. Schrauder, R. Repp (Kiel, DE)
P572 Rituximab for chronic graft-versus-host disease
G. Nair, U. Schanz, G. Stüssi (Zurich, CH)
P573 Thymoglobulin prophylaxis of chronic GvHD after full matched peripheral blood SCT
Y. Zalyalov, B. Ganapiev, A. Zinchenko, L. Galenko, V. Kostorov, B. Afanasyev
(St. Petersburg, RU)
P574 Eight-colour flow cytometry to establish the frequency of multiple T-lymphocyte
subsets early after allogeneic haematopoietic stem cell transplantation in
paediatrics
C. Winzler, E. Calore, M. Giordan, M. Gazzola, R. Destro, G. Tridello, M. Pillon, S. Cesaro,
G. Basso, C. Messina (Padua, IT)
P575 Assessment of bioequivalence of a generic cyclosporine (Equoral) by a
prospective randomised controlled trial in allogeneic stem cell transplant (ASCT)
recipients
T. Ben Othman, N. Ben Fredj, A. Klouz, A. Abdelkefi, S. Ladeb, L. Torjeman, A. Lakhal,
M. Lakhal (Tunis, TN)
P576 Addition of anti-thymocyte globulin could reduce the GvHD and not increase
mortality in unrelated stem cell transplantation
T.-D. Tan (Taipei, TW)
P577 Alemtuzumab 20 mg only in vivo confers efficient GvHD prophylaxis in sibling and
matched unrelated HCT
A. Spyridonidis, M. Karakantza, A. Symeonidis, E. Triantafyllou, E. Tzouvara, A. Kourakli,
M. Tiniakou, N. Zoumbos (Patras, GR)
P578 Prognostic significance of elevated interleukin-13 levels in patients prior to
haematopoietic stem cell transplantation
J.L. Harrold, E.A. Leitch, G. Jackson, A.M. Dickinson (Newcastle upon Tyne, UK)
P579 Allogeneic haematopoietic stem cell transplantation from the third party donor in
a recipient of allogeneic kidney graft
E. Snarski, T. Torosian, M. Rokicka, M. Paluszewska, A. Tomaszewska, A. Gronkowska,
E. Urbanowska, M. Król, L. Koperski, W. Wiktor-Jedrzejczak (Warsaw, PL)
P580 A pilot study of intra-arterial infusion of a relatively small number of
mesenchymal stem cells for treatment of steroid-refractory acute
graft-versus-host disease
F. Nakamura, H. Ohgushi, H. Machida, A. Fukunaga, H. Hirata, N. Arima (Osaka, Hyogo, JP)
P581 Survival benefit and lower relapse rate in patients experiencing graft-versus-host
disease after allogeneic retransplantation with dose-reduced conditioning
S. Eder, N. Worel, A. Schulenburg, W. Rabitsch, A. Rosenmayr, G. Fischer, M. Mitterbauer,
P. Kalhs, C. Zielinski, H. Greinix (Vienna, AT)
P582 A new approach for the diagnosis of chronic graft-versus-host disease
scleroderma-like: preliminary data and clinical implications
E. Massara, M. Cuzzola, M. Martino, R. Monteleone, R. Fedele, C. Rigolino, E. Spiniello,
F. Gatto, T. Moscato, P. Iacopino (Reggio Calabria, IT)
P583 Analysis of incidence, risk factors, clinical presentation and impact on outcome of
chronic GvHD after reduced-intensity conditioning. A single-centre experience
G. Grillo, P. Marenco, E. Zucchetti, P. Brasca, V. Mancini, G. Bertani, M. Turrini, C. Gabutti,
E. Morra (Milan, IT)
P584 Response of extensive sclerodermatous chronic graft-versus-host disease to an
mTOR inhibitor-based treatment
G. Bug, H. Pfeifer, S. Mousset, J. Schwaeble, H. Serve, H. Martin (Frankfurt, DE)

Posters Physicians Monday, 30 March 2009
17:30– Multiple myeloma
19:00
P585 Lenalidomide therapy increases the frequency of activated T- and NK-cells in
patients with relapsed multiple myeloma following allogeneic stem cells
transplantation
M. Lioznov, P. Freiberger, Y. Hildebrandt, U. Bacher, A.R. Zander, N. Kröger (Hamburg, DE)
P586 Thalidomide + dexamethasone as maintenance after single autologous stem
cell transplantation improves progression-free survival in advanced multiple
myeloma. A prospective Brazilian randomised trial
A. Maiolino, V. Hungria, G. Oliveira-Duarte, D. Mercante, E.C.M. Miranda, A. Quero,
A. Miguel Peres, P. Tanaka, L. Oliveira, R. Magalhães, E. Rego, M. Nucci, I. Lorand-Metze,
C. Lima, I. Zalcberg, E. Braggio, C. de Souza (Rio de Janeiro, São Paulo, Campinas,
Ribeirão Preto, BR)
P587 Application of the propensity score matching method to the estimation of survival
benefit of non-myeloablative allogeneic transplantation in patients with multiple
myeloma relapsing after a first autologous transplantation
L. Karlin, B. Arnulf, S. Chevret, M. Robin, R. Peffault de Latour, M. Malphettes,
N. Kabbara, B. Asli, L. Ades, V. Rocha, J.-P. Fermand, G. Socié (Paris, FR)
P588 Outcomes in patients with multiple myeloma following autologous stem cell
transplantation using intravenous busulfan and melphalan:
a matched comparison to a double autologous transplant strategy
conditioned with melphalan and CBV
M. Blanes, J. de la Rubia, J.J. Lahuerta, J.D. González, P. Ribas, C. Solano, A. Alegre,
M.A. Sanz (Valencia, Madrid, Las Palmas, ES)
P589 Effect of plerixafor plus G-CSF on tumour cell mobilisation in patients with
multiple myeloma
S. Fruehauf, J. Topaly, S. Muller, M. Moos, H. Goldschmidt, A.D. Ho, G. Calandra
(Heidelberg, DE; Cambridge, US)
P590 Outpatient stem cell transplantation for multiple myeloma
A. Ghavamzadeh, K. Alimoghaddam, A. Karimi, A. Manookian, M Asadi, R. Maheri,
A.R. Shamshiri (Tehran, IR)
P591 Detrimental effect of platelet contamination on the quality of stem cells products
collected to autograft patients with multiple myeloma
A. Leon, L. Garderet, C. Soler, H. Rouard, N.C. Gorin , P. Bierling (Paris, FR)
P592 Is there a curative potential of autologous stem cell transplantation in multiple
myeloma? Long-term results from a single-centre series
M. Rovira, L. Rosiñol, F. Fernández-Avilés, C. Martínez, E. Giné, J. Esteve, M.T. Cibeira,
P. Marín, E. Carreras, J. Bladé (Barcelona, ES)
P593 Autologous peripheral blood stem cell transplantation in 5 patients affected by
POEMS syndrome
L. Laurenti, S. De Matteis, P. Chiusolo, N. Piccirillo, F. Sorà, M. Tarnani, S. Bellesi,
C. Giannotta, E. Nobile Orazio, G. Leone, S. Sica (Rome, Rozzano Milan, IT)
P594 Bortezomib and lenalidomide for multiple myeloma patients relapsed after
allogeneic stem cell transplantation
P. Corradini, V. Montefusco, B. Bruno, E. Merla, R. Sorasio, A. Olivieri, A. Falcone,
L. Giaccone, L. Farina, F. Spina, A. Dodero, R. Milani, A.M. Carella, N. Cascavilla
(Milan, Turin, San Giovanni Rotondo, Potenza, IT)
P595 Ethnicity and autologous stem cell transplantation in myeloma
H. Auner, C. Giles, J. Pavlu, E. Olavarria, D. Macdonald, E. Kanfer, J. Apperley,
A. Rahemtulla (London, UK)
P596 Vinorelbine and pegfilgrastim for mobilization of peripheral blood progenitor cells
in patients with multiple myeloma: a predictive and cost-effective procedure
M.J. Bargetzi, T. Pabst, A. Schoenenberger, J. Burger, P. Fernandez, P. Moosmann,
A.R. Huber, M. Wernli, M. Heizmann (Aarau, Berne, CH)
91

92
Posters Physicians Monday, 30 March 2009
17:30– Multiple myeloma (continued)
19:00
P597 Genetic prognostic factors and the outcome of autologous stem cell transplantation
in plasma cell disorders
M. Dávid, S. Kosztolányi, Á. Szomor, D. Alpár, B. Kajtár, Á. Nagy, G. Kovács, R. Csalódi,
J. Hermesz, J. Tábori, C. Szalontay, H. Losonczy, L. Pajor (Pécs, HU)
P598 CD66A expression on plasma cells from multiple myeloma patients
C.H. Lee, B. Guinn, S. Brooks, D. Richardson, K. Orchard (Southampton, UK)
P599 Regional differences in haematopoietic stem cell activity in South East England:
a multi-centre investigation of inequalities in utilisation and inequity of access to
treatment for multiple myeloma
H. Owiti, J.F. Apperley (London, UK)
P600 Plerixafor plus G-CSF is effective without significant toxicity in PBSC mobilisation
from myeloma patients with dialysis-dependent renal failure who have failed to
mobilise by conventional means: an initial series of three patients
K.W. Douglas, P.J. Hayden, M.E. O'Dwyer, A. Rahemtulla (Glasgow, London, UK; Galway, IE)
P601 Severe renal impairment is not a major limit for autologous stem cell
transplantation in patients with multiple myeloma or amyloidosis
V. Fiaccadori, F. Ripamonti, A. Colombo, P. Bernasconi, D. Caldera, M. Merli, C. Elena,
G. Pica, E.P. Alessandrino (Pavia, IT)
P602 Short-course pretransplant velcade, thalidomide and dexamethasone regimen
induces high complete response rate without compromising CD34+ cell
collection in untreated multiple myeloma patients: preliminary results of a
single-centre experience
E. Pennese, M. Dargenio, M.R. De Paolis, P. Forese, R. Matera, G. Pugliese,
G. Reddiconto, A. Valacca, C. Vergine, N. Di Renzo (Lecce, IT)
P603 11 years of single-centre experience with stem cell transplantation for multiple
myeloma
J. Radocha, V. Maisnar, P. Zak, A. Zavrelova, M. Cermanova, M. Kmonicek, L. Jebavy,
J. Maly (Hradec Kralove, CZ)
P604 Autologous haematopoietic progenitor cell transplantation followed by a reducedintensity
conditioning and allotransplantation in de novo multiple myeloma
patients: an update
M. Martino, G. Console, E. Spiniello, D. Marcuccio, G. Messina, G. Irrera, R. Fedele,
E. Massara, I. Bova, T. Moscato, M. Cuzzola, P. Iacopino (Reggio Calabria, IT)
P605 Impact of low-dose thalidomide as maintenance therapy in advanced multiple
myeloma patients following high-dose therapy
A. Andreini, F. Randon, C. Tecchio, G. Quaresmini, F. Frattini, R. Di Bella, M. Sorio,
S. Ledro, C. Perbellini, D. de Sabata, F. Benedetti (Verona, IT)
P606 Impact of pretransplantation, mobilisation and graft variables on transplant
outcome after autologous haematopoietic stem cell transplantation for patients
with multiple myeloma
M. Michallet, M. Sobh, Q.-H. Le, F. Barraco, C. Dumontet, Y. Chelghoum, E. Nicolas-
Virelizier, X. Thomas, A. Praire, C. Plesa, G. Cannas, F.E. Nicolini, J. Troncy (Lyon, FR)
P607 Lenalidomide as salvage therapy after allogeneic transplant for primary plasma
cell leukaemia: a case report
I. Attolico, M. Cimminiello, G. Discepoli, R.A. Cifarelli, M. Pizzuti, N. Filardi,
M. Poggiaspalla, D. Vertone, A. Olivieri (Potenza, Ancona, Metaponto, IT)
P608 Tolosa-Hunt-like syndrome in a myeloma patient receiving palifermin shortly
after high-dose melphalan therapy
S. Mueller, H. Steffen, F. Wendel, M. Kreissl, R. Seggewiss, H. Einsele, S. Knop (Würzburg, DE)
P609 Autologous peripheral blood stem cell transplantation in patient in advanced
stage of POEMS syndrome
M. Cioch, J. Manko, A. Dmoszynska (Lublin, PL)

Posters Physicians Monday, 30 March 2009
17:30– Solid tumours
19:00
P610 High-dose chemotherapy with autologous haematopoietic stem cell transplantation
for metastatic breast cancer in Italy: evaluation of data from the GITMO registry
1990–2005
M. Martino, S. Secondino, A. Zambelli, R. Schiavo, M. Aieta, A. Ballestrero, C. Zamagni,
M. Musso, A. Capaldi, G. Azzarello, B. Bruno, P. Pedrazzoli on behalf of Gruppo Italiano
per il Trapianto di Midollo, di Cellule Staminali Emopoietiche e di Terapia Cellulare
(GITMO) – Sezione Tumori Solidi
P611 Reduced-intensity conditioning allogeneic stem cell transplantation for high-risk
neuroblastoma: French experience
C. Paillard, P. Lutz, A. Tchirkov, N. Cojean, A. David, E. Dore, F. Isfan, E. Merlin,
A. Marabelle, R. Rousseau, F. Deméocq, J. Kanold (Clermont-Ferrand, Strasbourg,
Lyon, FR)
P612 Increased frequency and responsiveness of PSA-specific T cells after allogeneic
stem cell transplantation for prostate cancer
J. Mattsson, M. Okas, J. Gertow, M. Uhlin (Stockholm, SE)
P613 Ewing's sarcoma at relapse: sequential high-dose cyclophosphamide, etoposide,
mitoxantrone+melphalan followed by autologous peripheral blood stem cell
rescue in a cohort of paediatric patients
R. Luksch, M Podda, L. Gandola, S. Mapelli, P. Daolio, F. Ravagnani, M. Casanova,
G. Cefalo, M. Massimino, D. Polastri, A. Ferrari, F. Spreafico, M. Terenziani, C. Meazza,
P. Coluccia, V. Bedini, L. Piva, F. Fossati-Bellani (Milan, IT)
P614 Treosulfan plus melphalan as megachemotherapy for autologous haematopoietic
stem cell transplantation in children and young adults with high-risk or relapsed
neuroblastoma and Ewing/PNET
M. Choma, K. Drabko, A. Zaucha- Prazmo, B. Wojcik, M. Leda, J. Wachowiak,
J. Kowalczyk (Lublin, Poznan, PL)
P615 Salvage high-dose chemotherapy and autologous peripheral blood stem cell
transplantation in patients with relapsed or refractory germ cell tumours:
a Turkish oncology group study
F. Arpaci, M. Ozturk, E. Ozdemir, A. Ozet, S. Ataergin, S. Dagdas, O. Kuzhan, S. Kilic,
B. Ozturk, S. Komurcu, G. Ozet (Ankara, TR)
17:30 – Experimental stem cell transplantation
19:00
P616 Evaluation of alloimmune responses in humanised NOD/SCID/IL2Rg^null mice
following human CD34+ stem cell transplantation
U.F. Hartwig, M. Nonn, S.A. Khan, A. Brunk, J. Hemmerling, R.G. Meyer, M.C. Andre,
R. Handgretinger, C. Huber, W. Herr (Mainz, Tübingen, DE)
P617 Pharmacokinetics of ATG-fresenius S in patients undergoing allogeneic stem cell
transplantation: implications for adoptive immunotherapy
S. Mastaglio, J. Peccatori, M. Bernardi, D. Clerici, A. Crotta, C. Messina, A. Assanelli,
C. Corti, M.T. Lupo Stanghellini, M. Marcatti, C. Bonini, F. Ciceri (Milan, IT)
P618 Bimodal immunomodulatory effect of multipotent adult progenitor cells on
alloreactive T-cell responses
A. Luyckx, L. De Somer, O. Rutgeerts, F. Ulloa-Montoya, M. Geeraerts, C. Lenaerts,
M. Waer, C. Verfaillie, A.D. Billiau (Leuven, BE)
P619 Horizontal gene transfer through apoptotic bodies confers a novel mechanism of
epithelial chimerism after allogeneic HCT
M. Waterhouse, M. Themeli, A. Spyridonidis, J. Finke (Freiburg, DE; Patras, GR)
93

94
Posters Physicians Monday, 30 March 2009
17:30– Experimental stem cell transplantation (continued)
19:00
P620 Radiation dose, recipient gender and cell dose as risk factors for graft survival in
a canine non-myeloablative HSCT model
S. Lange, A. Knueppel, D. Killian, G. Knuebel, A. Sekora, G. Kundt, M. Freund,
C. Junghanss (Rostock, DE)
P621 CD34-selected stem cell boost for poor graft function after allogeneic stem cell
transplantation for myelofibrosis
E. Klyuchnikov, M. Lioznov, U. Bacher, A.R. Zander, N. Kröger (Hamburg, DE)
P622 Stem cell transplantation in autosomal recessive hyper-IgE-syndrome
U. Benninghoff, S. Gatz, C. Schütz, M. Hönig, F. Speth, K. Schwarz, A. Schulz, W. Friedrich
(Ulm, DE)
P623 Toll-like receptor 2 is responsible for enhanced engraftment of G-CSF-mobilised
peripheral blood stem cells
Y.D. Joo, H.J. Won, S.M. Lee, J.H. Park, S.K. Park, I. Choi, S.K. Seo, H.M. Ryoo
(Busan, Ulsan, Daegu, KR)
P624 Phenotypic and functional characterisation of canine regulatory T-cells in the
allogeneic setting
A. Knueppel, S. Lange, A. Sekora, D. Killian, M. Freund, C. Junghanss (Rostock, DE)
17:30– Stem cell research
19:00
P625 Human embryonic stem cell ex vivo differentiation system is a new tool for
investigation of early yolk sac haematopoiesis
G.W. Basak, S. Yasukawa, B. Minev, E. Carrier (Warsaw, PL; La Jolla, US)
P626 Novel system for development of ectopic bone marrow: identification and
isolation of the haematopoietic stem cell niche initiating cell population
C. Chan, D. Kraft, C. Chen, C. Luppen, J. Kim, I. Weissman (Stanford, US)
P627 Expression, regulation and potential function of NFAT transcription factors in
human mesenchymal stem cells
S. Quick, F. Hauck, K. Mueller, I. Habermann, M. Bornhäuser, M. Suttorp, G. Ehninger,
A. Kiani (Dresden, DE)
P628 Immunomodulatory properties of umbilical cord blood-derived mesenchymal
stromal cells expanded in the presence of platelet lysate: potential for clinical
application
M. Bernardo, M. Avanzini, C. Perotti, A. Cometa, N. Zaffaroni, F. Novara, A. Moretta,
R. Maccario, W. Fibbe, F. Locatelli (Pavia, Milan, IT; Leiden, NL)
P629 No evidence of the JAK2V617F mutation in mesenchymal stromal cells in
mutated patients with primary myelofibrosis
S. Asenova, F. Ayuk, A. Badbaran, A.R. Zander, U. Larsen, S. Hannemann, N. Kröger,
C. Lange, U. Bacher (Hamburg, DE)
P630 Global comparative transcriptome analysis of human cord blood stem cells and
adult stem cells: differential stemness state
M. Cuzzola, G. Pucci, A. Pontari, D. Marcuccio, I. Bova, C. Rigolino, M.C. Cannatà,
A. Meliadò, I. Callea, T. Del Vecchio, O. Iacopino, P. Scaramozzino, R. Surace, E. Spiniello,
C. Garreffa, A. Dattola, P. Iacopino (Reggio Calabria, IT)
P631 Complement compatibility of human mesenchymal stem cells during clinical
infusion into whole blood for treatment of graft-versus-host disease
G. Moll, I. Rasmusson, G. Elgue, B. Sundberg, K. Nilsson Ekdahl, K. Le Blanc, B. Nilsson
(Stockholm, Uppsala, SE)

Posters Physicians Monday, 30 March 2009
17:30– Stem cell research (continued)
19:00
P632 Comparison of bone marrow buffy coat-, bone marrow fat- and adipose
tissue-derived mesenchymal stromal cells
B. Mazzanti, S. Dal Pozzo, S. Benvenuti, I. Cellai, G. Gerlini, S. Urbani, C. Ballerini,
M. Santosuosso, A. Bosi, R. Saccardi (Florence, IT)
P633 PB CD34+ cells are better predictors than HPC of the success of PBPC harvest
I.L. Barbosa, C. Carvalho, F. Campilho, S.M. Lopes, S. Roncon, A.P. Gonçalo, T. Sousa,
C. Mendes, R.B. Ferreira, C.P. Vaz, A. Campos, A. Carvalhais (Porto, PT)
P634 Immunophenotype of human bone marrow MSCs on early and late passages
during ex vivo expansion
E. Osipova, T. Astrelina, B. Purbueva, A. Ystiugov, E. Skorobogatova, Z. Dishleva,
S. Roumiantsev, M. Yakovleva, O. Mayorova (Moscow, RU)
P635 Mesenchymal stem cell response to chemotherapeutic damage
J. May, J. Xu, R. Morse, N. Avent, C. Cox, S. Wexler, C. Donaldson (Bristol, Bath, UK)
P636 Viability of CD34+ cells in cryopreserved cord blood
Y.W. Eom, S.H. Jeong, J.H. Choi, S.Y. Kang, H.W. Lee, H.C. Kim, J.S. Park (Suwon, KR)
17:30– Early side effects / Late effects and quality of life
19:00
P637 Genetic polymorphism of cytochrome P450 1B1 (C432G) is associated with an
increased treatment-related mortality and lower overall survival in patients
undergoing allogeneic haematopoietic stem cell transplantation
M. Koldehoff, L. Kordelas, U. Graeven, D. Beelen, A.H. Elmaagacli
(Essen, Mönchengladbach, DE)
P638 Uptake and outcome of artificial reproductive techniques following SCT for
leukaemia: a single-centre experience
N. Farah, H. Auner, E. Kanfer, A. Rahemtulla, D. Marin, J. Apperley, N. Salooja
(London, UK)
P639 Hepatic veno-occlusive disease in children after haematopoietic stem cell
transplantation: incidence, risk factors, and outcome
S.H. Lee, Y.J. Kwon, H.J. Park, B.K. Park, J.A. Park, H.J. Im, J.J. Seo, K.H. Yoo,
K.W. Sung, H.H. Koo, H.J. Kang, H.Y. Shin, H.S. Ahn, K.S. Lee, T.J. Hwang
(Goyang, Seoul, Daegu, Hwasun, KR)
P640 Clinical significance of autoantibody expression and autoimmune disease-like
manifestations in allogeneic stem cell transplantation recipients
J.H. Moon, J.S. Gyung, S.J. Lee, J.G. Kim, Y.S. Chae, S.N. Kim, J.S. Suh, K.S. Lee,
S.K. Sohn (Daegu, KR)
P641 Safe dosing of once-daily intravenous busulphan by pharmacokinetic test-dose
analysis in adult allogeneic haematopoietic stem cell transplant patients
S.B. Kangarloo, F. Naveed, N.J. Bahlis, C. Brown, M.A. Chaudhry, A. Daly, P. Duggan,
M. Geddes, M.L. Savoie, D. Stewart, J. Storek, D. Quinlan, M. Yang, N. Zacarias,
J. Russell (Calgary, CA)
P642 The incidence and morbi-mortality of veno-occlusive syndrome after allogeneic
HSCT have decreased in the last decade. A single-centre experience
M. Diaz-Beya, L. Rosiñol, M. Rovira, C. Martínez, F. Fernández-Avilés, E. Carreras
(Barcelona, ES)
P643 Cognitive development, self physical function and satisfaction profile in long-term
survivors of paediatric HSCT
M. Faraci, M. Miano, M.G. Calevo, G. Hanau, F. Fioredda, G. Dini, E. Lanino, M. Canepa
(Genoa, IT)
95

96
Posters Physicians Monday, 30 March 2009
17:30– Early side effects / Late effects and quality of life (continued)
19:00
P644 Late mortality in children and adolescents undergoing haematopoietic stem cell
transplantation: impact on life expectancy of 507 patients
S. Fortier, J. Morando, F. Piazera, J. Ruiz, L. Medeiros, M. Oliveira, E. Nunes, D. Setúbal,
V. Funke, M. Bittencourt, R. Pasquini, C. Medeiros, J. Zanis Neto, C. Bonfim
on behalf of the Bone Marrow Transplantation Service of the Clinical Hospital –
Federal University of Paraná
P645 Late-onset neutropenia in 53 patients treated with radioimmunotherapy and
autologous stem cell transplantation for non-Hodgkin's lymphoma
V. Pavone, A. Rana, A. Mele, C. Del Casale, A. Messa, G. Greco, S. Sibilla,
R. De Francesco, V. Frusciante, A. Varraso, B. Botto, U. Vitolo, G. Milone, S. Leotta,
P. Iacopino, G. Console, A. Olivieri, M. Cimminiello, V. Mettivier, L. Pezzullo, D. Baronciani,
E. Angelucci, M. Musso, N. Cascavilla, A. Guarini, S. Capalbo, G. Loseto, G. Quarta,
F. Gaudio, G. Specchia, V. Liso, A. Ostuni (Tricase, San Giovanni Rotondo, Turin, Catania,
Reggio Calabria, Potenza, Naples, Cagliari, Palermo, Bari, Foggia, Brindisi, IT)
P646 EBV-driven post-transplant lymphoproliferative disorder following allogeneic
stem cell transplant: A review of one centre's experience
J. Laird, A.N. Parker, G. MacQuaker, A. Clark, C. Aitken (Glasgow, UK)
P647 Major ABO-incompatibility, reduced-intensity conditioning regimens, and patient
age are associated with prolonged red cell transfusion dependency after
allogeneic haematopoietic stem cell transplantation
D. Dahl, C. Koenecke, H. Heuft, E. Dammann, M. Stadler, S. Buchholz, J. Krauter, M. Eder,
K. Sykora, C. Klein, A. Hahn, A. Ganser, M. Sauer (Hannover, DE)
P648 Long-term outcome of patients with human herpesvirus-6 encephalitis after
allogeneic stem cell transplantation
R. Sakai, H. Kanamori, K. Motohashi, W. Yamamoto, S. Matsuura, A. Fujita, R. Oshima,
H. Kuwabara, A. Maruta, Y. Ishigatsubo, S. Fujisawa (Yokohama, JP)
P649 Donor-derived alveolar macrophages are the effecter cells in cryptogenic
organizing pneumonia after SCT
M. Ito, M. Fujino, D. Kajiura, A. Kominami, T. Yokoyama, F. Nomura, K. Miyamura (Nagoya, JP)
P650 The significance of the specific comorbitity index (HCT-CI) in predicting
non-relapse mortality following allogeneic stem cell transplantation with
myeloablative regimens
P. Kaloyannidis, D. Mallouri, C. Apostolou, I. Sakellari, E. Yannaki, C. Smias, I. Batsis,
S. Tsimperis, R. Saloum, A. Anagnostopoulos, A. Fassas (Thessaloniki, GR)
P651 Late-onset non-infectious pulmonary complications after allogeneic stem cell
transplantation: results of a treatment strategy with multi-disciplinary
cooperation
M. Brunori, G. Biscione, I. Mininni, F. Oriolo, G.F. Torelli, W. Barberi, B. Lucarelli, V. Valle,
E. Iannella, F. Natalino, F. Pasqua, A. Perrone, R. Foà, A.P. Iori (Rome, IT)
P652 Platelet transfusion refractoriness in paediatric patients following allogeneic
haematopoietic stem cell transplantation
T. Ileri, M. Ertem, E. Unal Ince, A. Sayili, Z. Uysal, N. Solaz (Ankara, TR)
P653 High burden of late effects after haematopoietic stem cell transplantation in
childhood. A single-centre study
D. Bresters, I.C.M. van Gils, W.J.W. Kollen, L.M. Ball, W. Oostdijk, J.G. van der Bom,
M. Egeler (Leiden, NL)
P654 High incidence of secondary malignancies after allogeneic haematopoietic stem
cell transplantation
S. Neuburger, P. Hemmati, G. Massenkeil, T. Terwey, T. Kim, P. le Coutre, B. Dörken,
R. Arnold (Berlin, Gütersloh, DE)

Posters Physicians Monday, 30 March 2009
17:30– Early side effects / Late effects and quality of life (continued)
19:00
P655 Prognostic factors and outcomes of patients admitted to the ICU after
haematopoietic stem cell transplant
C. Martínez, A. Carrillo, E. López, E. Pérez, J. Sánchez-Blanco, J. Nieto, C. Castilla,
I. Heras, V. Vicente (Murcia, ES)
P656 Long-term follow-up of nutritional status after haematopoietic stem cell
transplantation in infants
D.J. Campos, A. Koerich, R. Jung, A.M. Ordoñez, S. Fortier, J. Zanis Neto, C. Bonfim
(Curitiba, BR)
P657 The use of intravenous busulfan combined with cyclophosphamide reduces early
hepatic toxicity and non-relapse mortality following allogeneic haematopoietic
stem cell transplantation compared to oral busulfan-containing regimen
H.J. Jun, K.H. Kim, M.H. Chang, S.Y. Yi, S.J. Kim, J.H. Jang, K. Kim, W.S. Kim, D.H. Kim,
S.J. Kim, W.S. Kim, C.W. Jung (Seoul, KR)
P658 Usefulness of a simplified scoring system to predict early non-relapse mortality
after stem cell transplantation
P. Balsalobre, C. Muñoz, D. Serrano, J. Gayoso, G. Rodríguez-Macías, I. Buño,
Y. Martinez, A. Gomez-Pineda, J.L. Diez-Martin (Madrid, ES)
P659 Incidence and clinical presentation of disreactive immune reconstitution after
stem cell transplantation in PID: the experience of a children's hospital, Brescia
F. Porta, R. Schumacher, L. Notarangelo, C. Forino, D. Demartiis, V. Bennato, V. Grassi,
L. Lorenzi, F. Bolda, A. Bosi, S. Berta, R. Baffelli, E. Mazzolari, A. Lanfranchi (Brescia, IT)
P660 Impact on engraftment, transfusional requirements and outcomes of AB0
incompatibility in allogeneic stem cell transplant
E. López, J. Nieto, S. Palacios, A. Vaccaro, M.L. Lozano, V. Roldán, N. Navarro,
C. Castilla-Llorente, I. Heras, V. Vicente (Murcia, ES)
P661 Prevention of treatment-related ovarian failure by gonadotropin-releasing
hormone analogue is ineffective in young women with relapsed/refractory
Hodgkin's lymphoma treated with peripheral blood stem cells autografting
S. Falorio, S. Santarone, F. Fioritoni, F. Angrilli (Pescara, IT)
P662 Autologous stem cell transplantation in >70-year-old patients:
one hospital experience
J. Nuñez, C. Montes, A. Bermúdez, L. Yañez, A. Iriondo, A. Insunza (Santander, ES)
P663 Adverse impact of iron overload on transplant outcome
G. Sucak, Z.A. Yegin, Z. Özkurt, Z. Aki, M. Yagci (Ankara, TR)
P664 Prognostic impact of serum ferritin concentration on survival following reducedintensity
conditioned allogeneic haemopoietic stem cell transplantation
R. Oakes, N. Sood, R. Pearce, G. Cook, M. Gilleece (Leeds, London, UK)
P665 Activation of haemostasis after transfusion of cryopreserved haematopoietic
stem cells containing dimethyl-sulfoxide
J.-D. Studt, S. Meyer-Monard, C. Arber, M. Stern, D. Heim, G. Marbet, A. Gratwohl,
D.A. Tsakiris (Basel, CH)
P666 Retrospective comparison of oral and intravenous busulphan based
myeloablative conditioning regimens in allogeneic stem cell transplantation
K. Liapis, F. Panitsas, F. Michelis, M. Vagia, K. Manaka, V. Delistrati, I. Baltadakis,
D. Karakasis, J. Apostolidis, N. Harhalakis, E. Nikiforakis (Athens, GR)
P667 Differences in endocrine sequelae after non-myeloablative and full-intensity
conditioning in patients who underwent haematopoietic stem cell transplantation
in childhood or adolescence
L. Papusha, D. Balashov, A. Tulpakov, Y. Skvortsova, E. Skorobogatova, A. Maschan
(Moscow, RU)
97

98
Posters Physicians Monday, 30 March 2009
17:30– Early side effects / Late effects and quality of life (continued)
19:00
P668 Melphalan dose per kilogram of body weight has significant influence on oral
mucositis after allogeneic stem cell transplantation with FLU/MEL conditioning
regimen
S. Vokurka, K. Steinerova, M. Karas, V. Koza (Pilsen, CZ)
P669 Acute and chronic renal insufficiency after allogeneic haematopoietic stem cell
transplantation in children
T. Ileri, M. Ertem, Z.B. Ozcakar, E. Unal Ince, Z. Uysal, M. Ekim, F. Yalcinkaya (Ankara, TR)
P670 Translation and validation of the Functional Assessment of Cancer Therapy-Bone
Marrow Transplant (FACT-BMT) Version 4 quality of life instrument into Arabic
among lymphoma patients who underwent high-dose chemotherapy and
autologous stem cell transplant
A. Al-Zahrani, H. Soudy, E. Colcol, E. Abdalla, I. Maghfoor, S. Akhtar (Riyadh, SA)
P671 Transplant conditioning toxicity: a comparison of 3 myeloablative protocols
M. Shapira, R. Or, M. Aker, L. Dray, B. Gesundheit, S. Samuel, I. Resnick (Jerusalem, IL)
P672 Nitrogen balance in patients undergoing autologous haematopoietic stem cell
transplantation
A.A. Novik, V.N. Matyshevskaya, V.Y. Melnichenko, D.A. Fedorenko, T.I. Ionova,
S.I. Trifonov, K.F. Kim, T.S. Sysoeva, G. Gorodokin (New Jersey, US; Moscow, RU)
P673 Resolution of pure red cell aplasia after reduced-intensity allogenic stem cell
transplantation with major ABO mismatch during therapy with lenalidomide
F. Pilo, D. Derudas, D. Baronciani, C. Depau, R. Murru, E. Angelucci (Cagliari, IT)
P674 Comparison of acute renal failure in unmanipulated and CD34+ cell-selected
myeloablative allogeneic stem cell transplantation: a single-centre experience
F. Fernández-Avilés, L. Quintana, P. Abrisqueta, M. Rovira, C. Martínez, L. Rosiñol,
E. Carreras, J. Campistol, E. Montserrat (Barcelona, ES)
P675 Safety and pharmacokinetics of intravenous versus oral busulfan used in
pretransplantation myeloablative conditioning therapy
M.L. Battista, F. Patriarca, M. Medeot, A. Sperotto, M. Cerno, A. Geromin, F. Florio,
R. Fanin (Udine, IT)
P676 Increased risk for transplant-related toxicity and mortality in patients with iron
overload
L. Gil, A. Lojko-Dankowska, A. Nowicki, A. Czyz, D. Dytfeld, M. Komarnicki (Poznan, PL)
P677 Immune reconstitution more than one year after allogeneic haematopoietic
stem cell transplantation
S. Narayan, J. Adams, G.S. Lucas, J. Burthem, E. Tholouli, H. Lenehan, J.A.L. Yin
(Manchester, UK)
P678 Busulfex (i.v. BU) and CY regimen before SCT: a phase II pharmacokinetics
combined study
S.-W. Kim, S.I. Mori, R. Tanosaki, T. Fukuda, M. Kami, H. Sakamaki, T. Yamashita,
Y. Kodera, S. Terakura, S. Taniguchi, S. Miyakoshi, N. Usui, S. Yano, Y. Kawano,
Y. Nagatoshi, M. Harada, Y. Morishima, S. Okamoto, A.M. Saito, Y. Ohashi, R. Ueda,
Y. Takaue (Tokyo, Aichi, Nagoya, Kagoshima, Fukuoka, Omuta, JP)
P679 Motor disability as early complication of haematopoietic stem cells
transplantation
A. Tendas, P. Niscola, S. Delogu, T. Dentamaro, L. Cupelli, A. Siniscalchi, L. Scaramucci,
M. Giovannini, M. Ales, G. Natale, R. Cinque, A.P. Perrotti, P. De Fabritiis (Rome, IT)
P680 Quality of life in adult survivors of blood and marrow transplantation correlates
strongly with physical and psychological late effects of treatment:
a mixed methods approach
L. Fredrick, R. Beeken, N. Taylor, C. Eiser, J. Wright, J. Snowden, C. Dalley (Sheffield, UK)

Posters Physicians Monday, 30 March 2009
17:30– Early side effects / Late effects and quality of life (continued)
19:00
P681 Pilot study on prophylactic use of zoledronic acid to prevent bone loss in
allogeneic recipients
S.K. Sohn, Y.S. Chae, J.G. Kim, J.H. Moon, S.N. Kim, S.J. Lee, J.S. Suh, K.S. Lee
(Daegu, KR)
P682 The impact of bone marrow fibrosis in the outcome of haematopoietic stem cell
transplantation
G. Sucak, E. Suyani, Z. Aki, N. Akyürek, Z. Özkurt, S. Altindal, A. Yegin (Ankara, TR)
17:30– Inborn errors
19:00
P683 Assessment of reduced-intensity conditioning regimens for haematopoietic stem
cell transplantation in primary immunodeficiency
H. Robinson, M. Slatter, D. Barge, N. Bown, A. Jackson, H. Harvey, T. Flood, A. Cant,
M. Abinun, A. Gennery (Newcastle upon Tyne, UK)
P684 Haematopoietic stem cell transplantation for STAT3 deficiency
A. Gennery, M. Slatter, D. Barge, C. Woellner, B. Grimbacher, S. Jolles, H. Harvey,
T. Flood, A. Cant, M. Abinun (Newcastle upon Tyne, London, Cardiff, UK)
P685 Stem cell transplantation for Nijmegen breakage syndrome – Experience in
6 patients
M.H. Albert, A. Gennery, J. Greil, C.M. Cale, K. Kalwak, I. Kondratenko, G. Notheis,
M. Fuhrer, B.H. Belohradsky (Munich, Heidelberg, DE; Newcastle, London, UK;
Wroclaw, PL; Moscow, RU)
P686 Haematopoietic stem cell transplantation in Griscelli syndrome type 2:
a single-centre report of 10 patients
J. Pachlopnik Schmid, D. Moshous, M. Cavazzana-Calvo, S. Blanche, G. de Saint Basile,
A. Fischer (Paris, FR)
P687 Neonatal pancytopenia and severe hepatic failure revealing an intrauterine
twin-to-twin haematopoetic stem cell transfer
D. Moshous, I. Radford Weiss, S. Caillat-Zucman, N. Brousse, M.-D. Dumont, C. Picard,
O. Ackermann, M. Fabre, F. Méchinaud, A. Fischer (Paris, FR)
P688 Bone marrow transplantation in adult cerebral X-linked adrenoleukodystrophy:
an update
J.-S. Kühl, W. Köhler, O. Bandmann, S. Buchholz, P. Hemmati, J. Snowden, P. Sokolowski,
M. Stadler, T. Terwey, R. Arnold (Berlin, Wermsdorf, Hannover, DE; Sheffield, UK)
P689 How to condition patients with Omenn syndrome or atypical SCID with gamma
delta T-cell predominance? Single-centre experience on 10 patients
K. Kalwak, E. Gorczynska, M. Ussowicz, J. Owoc-Lempach, A. Dyla, D. Pazdzior,
J. Musial, M. Skarznska, D. Wójcik, J. Porwolik, M. Van der Burg, K. Schwarz, A. Chybicka
(Wroclaw, PL; Bergen, NO; Rotterdam, NL; Ulm, DE)
P690 Targeting to an optimal AUC of intravenous busulfan prevents graft failure in
transplantation in children with non-malignant diseases
I.H. Bartelink, R.G.M. Bredius, S.V. Belitser, M. Bierings, C.A.J. Knibbe, M. Egeler,
A.C. Lankester, A.C.G. Egberts, J. Zwaveling, J.J. Boelens (Utrecht, Leiden, NL)
P691 Allogeneic stem cell transplantation in Farber’s disease with bone involvement:
long-lasting and substantial improvement
A. Jarisch, J. Soerensen, L. Porto, M. Kieslich, T. Klingebiel, P. Bader (Frankfurt, DE)
P692 Haematopoietic stem cell transplantation in children with bone marrow failure:
a single-centre experience
A. Kupesiz, G. Tezcan Karasu, V. Uygun, P. Kurt, Z. Ozturk, M. Kazik, V. Hazar, A. Yesilipek
(Antalya, TR)
99

100
Posters Physicians Monday, 30 March 2009
17:30– Inborn errors (continued)
19:00
P693 Successful allogeneic peripheral blood stem cell transplantation from an
HLA-identical sibling in a patient with mitochondrial neurogastrointestinal
encephalomyelopathy
K.S. Hill, D. Richardson, S. Hammans, M. Stroud, D. Fine, V. Walker, J. Newman,
N. McKeag, C. Hurlock, K. Orchard (Southampton, UK)
P694 Malignancy as a presentation of common gamma chain deficient severe
combined immunodeficiency
M. Slatter, K. Windebank, B. Angus, A. Barborie, A. Perry, T. Lester, G. Norbury, M. Abinun,
T. Flood, A. Cant, A. Gennery (Newcastle upon Tyne, London, UK)
P695 Haematopoietic stem cell transplantation for DNA-DSB repair defects using a
modified Fanconi anaemia conditioning regimen
M. Slatter, D. Barge, P. Jeggo, H. Harvey, T. Flood, A. Cant, M. Abinun, A. Gennery
(Newcastle upon Tyne, Brighton, UK)
P696 Haematopoietic stem cell transplantation for cerebral X-linked
adrenoleucodystrophy in adult
E. Paubelle, F. Suarez, D. Ghez, N. Maillard, M. Rubio, R. Delarue, I. Hirsch, B. Varet,
C. Bellesmes, P. Aubourg, A. Buzyn (Paris, FR)
P697 Successful treatment of Griscelli syndrome with unrelated cord blood
transplantation
M. Kazýk, G. Karasu, V. Uygun, A. Kupesiz, V. Hazar, A. Yesilipek (Antalya, TR)
P698 Graft failure in major histocompatibility complex class II deficiency
C. Forino, D. De Martiis, R. Marzollo, S. Cavagnini, A. Lanfranchi, E. Mazzolari,
R.M. Lemoli, L.D. Notarangelo, F. Porta (Brescia, Bologna, IT; Boston, US)
17:30– Cellular and gene therapies
19:00
P699 JAK2-V617F-triggered pre-emptive and salvage adoptive immunotherapy with
donor-lymphocyte infusion in patients with myelofibrosis following allogeneic
stem cell transplantation
H. Alchalby, E. Klyuchnikov, A. Badbaran, Y. Hildebrandt, F. Ayuk, U. Bacher, O. Bock,
M. Kvasnicka, B. Fehse, A. Zander, N. Kröger (Hamburg, Hannover, Cologne, DE)
P700 Evidence for genomic stability of bone marrow-derived MSCS after large-scale
expansion in a humanised system
K. Schallmoser, E. Rohde, A. Reinisch, A. Obenauf, C. Bartmann, G. Lanzer, W. Linkesch,
D. Strunk (Graz, AT)
P701 KIR/KIR-L mismatched NK cells reconstitution after allogeneic SCT needs T-cell
depletion and contributes to GvL effect
J. Hasenkamp, A. Borgerding, G. Wulf, W. Jung, L. Trümper, B. Glass (Göttingen,
Hamburg, DE)
P702 Phase I-II clinical trial on the use of bone marrow mononuclear cells in the
treatment of amyotrophic lateral sclerosis. Nine-month follow-up
M. Blanquer, F. Iniesta, F.J. Ruiz, J. Meca, J. Gómez Espuch, R. Villaverde, J. M. García
Santos, S. Torres del Rio, C. Funes, V. Izura, P. de Mingo Casado, A. Sánchez Salinas,
V. Sáez, R. Carles, C. Antúnez, L. Vivancos Moreau, J. Hernández Palazón, P. Bleda,
M. J. Majado, M. A. Pérez Espejo, S. Martínez, J. M. Moraleda (Murcia, ES)
P703 SCT recipients have specific tolerance to MSC but not to the MSC donor
M. Sundin, J. Barrett, O. Ringdén, M. Uzunel, H. Lönnies, Å. Dackland, B. Christensson,
K. Le Blanc (Stockholm, SE; Bethesda, US)

Posters Physicians Monday, 30 March 2009
17:30– Cellular and gene therapies (continued)
19:00
P704 Contribution of endothelial and mesenchymal niche cells to haematopoietic
progenitor expansion in a humanised system
M. Fruehwirth, D. Thaler, A. Reinisch, K. Schallmoser, E. Rohde, N. A. Hofmann,
W. Linkesch, D. Strunk (Graz, AT)
P705 The incidence of first mobilisation failure with chemotherapy and G-CSF in
594 patients with lymphoproliferative disease: potential for intervention with
Plerixafor
M.J. Watts, D. Linch (London, UK)
P706 Outcomes of the patients with myelodysplastic syndrome, acute myeloid
leukaemia with multilineage dysplasia and treatment-related acute myeloid
leukaemia after allogeneic stem cell transplantation. A single-centre experience
K. Steinerova, V. Koza, P. Jindra, D. Lysak, M. Karas, T. Svoboda (Pilsen, CZ)
P707 Imatinib mesylate in the treatment of sclerodermatous chronic graft-versus-host
disease
I. Yakoub-Agha, L. Magro, B. Catteau, V. Coiteux, L. Terriou, J.P. Jouet (Lille, FR)
P708 Two distinct populations of enriched non-mobilised peripheral blood mononuclear
cells with different functional capacities
N. Bloom, T. Kniazhansky, A. Treves, A. Nagler (Ramat-Gan, IL)
P709 Expansion of human mesenchymal stem cells seeded in biological scaffods
E. Michalopoulos, C. Saliagopoulou, T. Chatzistamatiou, A. Thiakos, A.C. Papassavas,
C. Stavropoulos-Giokas (Athens, GR)
P710 Three-year clinical follow-up of 5 patients treated with suicide gene modified
donor lymphocyte infusion therapy in Japan
S. Kaneko, Y. Okoshi, M. Otsu, N. Nemoto, K. Suzukawa, Y. Hasegawa, H. Kojima,
T. Fukushima, R. Sumazaki, M. Onodera, Y. Harada, H. Sakamaki, M. Tsuchida, S. Kato,
C. Bonini, C. Bordignon, T. Nagasawa, S. Chiba, H. Nakauchi on behalf of the Tsukuba
TK-DLI Gene Tharapy Group
P711 Older age does not influence allogeneic peripheral blood stem cell mobilisation in
a population of mainly Caucasian donors
H. de Lavallade, P. Ladaique, C. Lemarie, S. Furst, C. Faucher, D. Blaise, C. Chabannon,
B. Calmels (Marseille, FR)
P712 Use of amniotic membrane as a reparative wound dressing in patients with
post-traumatic wounds. Preliminary results
C. García de Insausti, G. Castellanos, M. Blanquer, M. J. Majado, P. Bleda, F. Iniesta,
F. J. Rodríguez Lozano, F. J. Nicolás, J. M. Moraleda (Murcia, ES)
P713 Autologous stem cell transplantation for acute myeloid leukaemia:
a 12-year, single-centre follow-up study
M.J. Garcia-Rodriguez, R. Arrieta, M.A. Canales, F. Hernandez-Navarro (Madrid, ES)
P714 A new scaffold for bone tissue engineering based in mesenchynal stem cells and
glass-ceramics
L. Meseguer Olmo, C. García de Insausti, A. Bernabeu Esclapez, F. J. Rodríguez Lozano,
M. Vallet Regi, M. Blanquer, J. M. Moraleda, M. Clavel (Murcia, ES)
P715 Impact of mesenchymal stem cell transfusion on thrombotic microangiopathy
post haematopoietic stem cell transplantation
M. Ansari, V. Kindler, C. Delcò, V. Salah, Y. Chalandon, F. Gumy-Pause, A. Rougemont,
S. Moll, P. Parvex, H. Chehade, D. Strunk, J. Passweg, H. Ozsahin (Geneva, CH; Graz, AT)
P716 Cyclosporin monitoring at 2 hours from oral intake leads to less toxicity and
better compliance in patients undergoing haematopoietic stem cell
transplantation and immunosuppressive treatment for severe aplastic anaemia
B. Montante, M.B. Pinazzi, A. Severino, A. Proia, I. Majolino, A. Locasciulli (Rome, IT)
101

102
Posters Physicians Monday, 30 March 2009
17:30– Cellular and gene therapies (continued)
19:00
P717 Rapid immunological reconstitution after infusion of allogeneic, cytokine induced
killer cells: a case report in a patient with Sezary syndrome
C. Micò, A. Grassi, G. Borleri, A. Algarotti, C. Capelli, M. Introna, A. Rambaldi (Bergamo, IT)
P718 Clinical scale serum-free expansion of human mesenchymal stromal cells:
validation of a "two-steps" protocol under GMP conditions
C. Capelli, V. Barbui, O. Pedrini, E. Gotti, G. Borleri, A. Rambaldi, J. Golay, M. Introna
(Bergamo, IT)
P719 Comparison between BEAM and lomustine, Ara-C, etoposide and melphalan as
conditioning regimen before stem cell transplantation. A single-centre experience
G. Grillo, P. Marenco, G. Bertani, E. Zucchetti, M. Turrini, P. Brasca, C. Gabutti, E. Morra
(Milan, IT)
P720 Clinical impact of bronchoalveolar lavage in stem cell transplanted patients with
pneumonia
U. Forslöw (Stockholm, SE)
17:30– Graft engineering
19:00
P721 A computational intelligent method for diagnosis of acute graft-versus-host
disease based on gene expression data
M. Cuzzola, C. Rigolino, R. Fedele, E. Massara, M. Martino, G. Irrera, G. Messina,
G. Console, D. Princi, M. Fiaschè, A. Meliadò, F.C. Morabito, P. Iacopino
(Reggio Calabria, IT)
P722 Evaluation of a tubing system with an incorporated DMSO-resistant sterile filter
for cryopreservation of cellular products outside of cleanroom facilities
A. Humpe, S. Schubert, A. Ketels, M. Gramatzki (Kiel, DE)

Posters Physicians Tuesday, 31 March 2009
17:30– Minimal residual disease
19:00
P723 Relevance of minimal residual disease and chimerism for the detection of relapse
after haematopoietic stem cell transplantation
B. Gruhn, J. Sanft, N. Pfaffendorf, I. Wolff, F. Zintl, J. Beck (Jena, DE)
P724 Kinetics of CD3+ T-cell engraftment correlates with development of acute GvHD
and relapse in patients treated with reduced-intensity conditioning allogeneic
stem cell transplantation
E. Toffoletti, F. Patriarca, A. Chiarvesio, A. Michelutti, A. Sperotto, M. Cavallin,
M.L. Battista, F. Zaja, R. Fanin (Udine, IT)
P725 The predictive value of [18f]fdg -pet/ct after autologous stem cell transplantation
F. Sorà, N. Piccirillo, P. Chiusolo, L. Laurenti, M. Lavalle, I. Innocenti, G. Ausoni,
S. De Matteis, V. Rufini, G. Leone, S. Sica (Rome, IT)
P726 In multiple myeloma, stringent CR utilising in situ nucleic acid hybridisation
provides a cheap, robust alternative for patient stratification post autograft
K. Lund, G. Marron, A.N. Parker, I.G. McQuaker, R. Jackson, D. Moffat, A. Clark
(Glasgow, UK; Adelaide, AU)
P727 Early intervention at the stage of molecular relapse after allogeneic
haematopoietic stem cell transplantation
M. Krejci, J. Mayer, M. Doubek, D. Dvorakova, O. Horky (Brno, CZ)
P728 Clinical value of flow cytometric immunophenotyping analyses for minimal
residual disease detection in stem-cell products in patients with follicular and
mantle cell lymphoma: comparison to IgH-polymerase chain reaction
H. Kato, K. Yamamoto, Y. Oki, D. Chihara, S. Ine, H. Taji, M. Seto, Y. Kagami, Y. Morishima
(Nagoya, JP)
P729 The time to complete donor haematopoietic chimerism may predict the outcome
of allogeneic stem cell transplantation
C. Vadikolia, I. Sakellari, D. Mallouri, I. Batsis, A. Bitzioni, B. Tahinopoulou, E. Stalika,
I. Zorbas, A. Anagnostopoulos, A. Fassas (Thessaloniki, GR)
P730 Quantitative analysis of chimerism by real-time polymerase chain reaction of
insertion/deletion polymorphism is a useful predictor of relapse after allogeneic
stem cell transplantation for acute leukaemia
N. Jacque, N. Dhedin, M. Uzunov, S. Nguyen Quoc, J. Lazarovici, L. Sutton, J.P. Vernant,
D. Bories (Paris, FR)
P731 Clinical management of patients in mixed chimerism after myeloablative
allogeneic stem cell transplantation from an HLA-identical sibling donor
M. Kwon, I. Buño, P. Balsalobre, D. Serrano, G. Rodriguez-Macias, J. Gayoso, A. Pineda,
J.L. Diez Martín (Madrid, ES)
17:30 – Graft versus malignancy
19:00
P732 NK-cell education after allogeneic haematopoietic stem cell transplantation in
humans
P. Haas, P. Loiseau, R. Tamouza, J.-M. Cayuela, G. Henry, C. Falk, D. Charron, G. Socié,
A. Toubert, N. Dulphy (Paris, FR; Heidelberg, DE)
P733 Limited chronic GvHD significantly improves outcome after allogeneic
haematopoietic stem cell transplantation in advanced haematological diseases
C. Kahl, D. Wolff, A. Nogai, G. Kundt, J. Hahn, E. Holler, L. Uharek, C. Junghanss,
M. Leithäuser, E. Thiel, M. Freund (Rostock, Regensburg, Berlin, DE)
103

104
Posters Physicians Tuesday, 31 March 2009
17:30– Graft versus malignancy (continued)
19:00
P734 Improved overall survival in patients recovering with high gamma/delta T-cells
after allogeneic haematopoietic stem cell transplantation
L. Kordelas, M. Junge, T. Gromke, N. Steckel, R. Trenschel, H. Ottinger, A.H. Elmaagacli,
D. Beelen (Essen, DE)
P735 Reconstitution of KIR-expressing natural killer cells and survival after haploidentical
stem cell transplantation for acute myeloblastic leukaemia
M. Stern, L. Ruggeri, C. de Angelis, A. Mancusi, A. Velardi (Perugia, IT)
P736 The effect of alefacept given for steroid refractory/dependent graft-versus-host
disease on relapse rate
M. Shapira, L. Dray, I. Resnick, M. Aker, P. Stepansky, B. Gesundheit, R. Or (Jerusalem, IL)
P737 Escalated lymphodepletion followed by donor lymphocyte infusion can induce a
potent graft-versus-tumour response
T. Guillaume, P. Chevallier, S. Ayari, J. Delaunay, F. Mechinaud, P. Moreau,
J.L. Harousseau, M. Mohty (Nantes, FR)
P738 Effective induction of graft versus malignancy effect after unrelated allogeneic HCT
using donor lymphocyte infusions derived from frozen aliquots of the original graft
J. Hasskarl, A. Zerweck, J. Isernhagen, H. Bertz, J. Finke (Freiburg, DE)
P739 Killer-cell-immunoglobulin-like receptor/HLA mismatches improve survival after
stem cell transplantation of patients with acute myeloid leukaemia
R. Richter, G. Bug, S. Mousset, E. Seifried, H. Serve, C. Seidl, H. Martin (Frankfurt, DE)
P740 Molecular evidence for graft-versus-leukaemia effects in T-prolymphocytic
leukaemia after non-myeloablative allogeneic stem cell transplantation
M. Rieger, M. Brüggemann, S. Dietrich, U. Hegenbart, M. Hensel, M. Moos, A.D. Ho,
M. Kneba, P. Dreger (Heidelberg, Kiel, Mannheim, DE)
P741 The impact of NOD2/CARD15 SNP 5 on the outcome of unrelated donor
haematopoietic stem cell transplantation for acute lymphoblastic leukaemia
N. Mayor, B.E. Shaw, L. Cooke, S. Marsh, J.A. Madrigal (London, UK)
17:30 – Non-haematopoietic tissue repair
19:00
P742 Pro-atherogenic risk of cellular therapy for vascular regeneration?
E. Rohde, T. Pfeifer, K. Schallmoser, A. Reinisch, N. A. Hofmann, E. Froehlich,
G. Rechberger, G. Lanzer, D. Kratky, D. Strunk (Graz, AT)
P743 Recombinant human granulocyte colony-stimulating factor administration for
treatment of amyotrophic lateral sclerosis: a double blind randomised study
B. Nefussy, I. Artamonov, V. Deutsch, E. Naparstek, V. Drory, A. Nagler
(Tel Aviv, Tel Hashomer, IL)
P744 EPO and MIP-1 alpha are associated with increased levels of vascular progenitors
in autologous haematopoietic stem cell grafts
L. Labonte, C. Li, L. Yang, A. Gillingham, M. Halpenny, A. Giulivi, D. Allan (Ottawa, CA)
P745 Adipocyte tissue-derived stem cells to treat severe cutaneous radiation
syndrome: preliminary study in a rat model
D. Agay, P. Garrigou, F. Forcheron, N. Grenier, L. Touvard, Y. Chancerelle, V. Meineke,
F. Hérodin, M. Drouet (La Tronche, FR; Munich, DE)
P746 Refining GMP-manufactured density gradient media for optimised mesenchymal
stromal/stem cell isolation and expansion
G. Grisendi, C. Annerén , L. Cafarelli, E. Veronesi, R. Sternieri, G.L. Cervo, S. Luminari,
A. Frassoldati, M. Maur, G. Palazzi, P. Paolucci, P. Conte, M. Dominici
(Modena, IT; Uppsala, SE)

Posters Physicians Tuesday, 31 March 2009
17:30– Lymphoma
19:00
P747 Analysis of peripheral blood stem cells mobilisation in patients with
non-Hodgkin's lymphoma treated with the DHAP regimen plus filgrastim
or pegfilgrastim
F. Gaudio, A.M. Giordano, T. Perrone, D. Pastore, M. Delia, C. De Risi, A. Spina, V. Liso,
G. Specchia (Bari, IT)
P748 The absolute lymphocyte count on day 15 after autologous peripheral blood
haematopoietic stem cell transplantation is associated with the clinical outcomes
in non-Hodgkin's lymphoma patients
T. Moscato, M. Martino, G. Messina, G. Irrera, G. Console, D. Marcuccio, A. Dattola,
R. Fedele, E. Massara, M. Cuzzola, I. Bova, E. Spiniello, P. Iacopino (Reggio Calabria, IT)
P749 Long-term outcome of high-dose chemotherapy with autologous haemopoietic
progenitor cells transplant in high-risk lymphoma
T. Moscato, M. Martino, G. Console, R. Fedele, G. Irrera, E. Massara, G. Messina,
C. Stelitano, S. Molica, M. Brugiatelli, A. Peta, C. Musolino, A. Abbadessa, P. Iacopino
(Reggio Calabria, Catanzaro, Messina, Caserta, IT)
P750 Modified BEAM schedule (lomustine instead carmustine) in the conditioning of
ABMT for lymphoid malignancies
P. Perfetti, C. Scollo, E. Terruzzi, M. Parma, E. Pogliani, P. Pioltelli (Monza, IT)
P751 High-dose chemotherapy and autologous stem cell transplant for relapsed
or refractory Hodgkin’s lymphoma in 58 adolescent patients.
Evaluation of prognostic factors and their impact on survival
S. Akhtar, A. El Weshi, M. Rahal, M. Abdelsalam, H. Al Husseini, I. Maghfoor
(Riyadh, Dammam, SA; Octeville, FR)
P752 Tandem auto-SCT and reduced-intensity conditioning allo-SCT for relapsed or
transformed aggressive B cell non-Hodgkin's lymphoma
A. Clavert, E. Brissot, V. Dubruille, B. Mahe, T. Gastinne, N. Blin, P. Chevallier,
T. Guillaume, J. Delaunay, S. Ayari, B. Saulquin, A. Moreau, J.L. Harousseau,
P. Moreau, S. Le Gouill, M. Mohty (Nantes, FR)
P753 Long-term results of fludarabine/melphalan as reduced-intensity conditioning
regimen in mantle cell lymphoma: age matters
J. Gayoso, R. Martino, P. Balsalobre, I. Heras, J.L. Piñana, D. Serrano, J. De la Serna,
J.F. Tomas, A. Fernandez de Sevilla, A. Sureda, J.L. Diez-Martin, D. Caballero
(Madrid, Barcelona, Murcia, Salamanca, ES)
P754 High-dose sequential chemotherapy with autologous stem cell transplant in
relapsed or refractory Hodgkin's lymphoma: long-term results and late toxicity.
A single center experience
C. Tecchio, F. Randon, G. Quaresmini, F. Frattini, A. Andreini, R. Di Bella, M. Sorio,
F. Benedetti (Verona, IT)
P755 Comparison of toxicity of BEAM vs. LACE regimen in patients of lymphoma
N. Kumar, A. Joshi, M. Shah, S. Kannan, S. Gupta, R. Nair, N. Khattry (Mumbai, IN)
P756 Clinical outcomes of high-dose chemotherapy using mitoxantrone, etoposide,
cytarabine, and melphalan (NEAM) followed by autologous stem cell
transplantation in chemosensitive relapsed or primary refractory aggressive
non-Hodgkin's lymphoma patients
J.W. Kim, B.S. Kim, S.M. Bang, J.S. Kim, S.T. Lee, I. Kim, S.S. Yoon, J.S. Lee, K.S. Han,
S. Park, B.K. Kim (Seoul, KR)
P757 Salvage chemotherapy with alternating MINE-ESHAP regimen for relapsed
or refractory Hodgkin's lymphoma previous to autologous stem cell trasplant:
a single-centre experience
C. Fernández de Larrea, C Martínez, A López-Guillermo, M. Rovira, F. Fernández-Avilés,
E. Montserrat, E. Carreras (Barcelona, ES)
105

106
Posters Physicians Tuesday, 31 March 2009
17:30– Lymphoma (continued)
19:00
P758 Outcome of 132 autologous stem cell transplantations in relapsed or refractory
Hodgkin’s lymphoma
Z. Csukly, A. Barta, A. Batai, V. Goda, L. Gopcsa, L. Lengyel, P. Remenyi, M. Reti, A. Sipos,
E. Torbagyi, A. Tremmel, T. Masszi (Budapest, HU)
P759 Long-term outcome of autologous haematopoietic stem cell transplantation
following a uniform conditioning regimen in patients with Hodgkin's lymphoma –
A single-centre experience
A. Czyz, A. Lojko, L. Gil, D. Drozdowska, D. Dytfeld, A. Nowicki, M. Kozlowska,
K. Sawinski, M. Komarnicki (Poznan, PL)
P760 (R-)DHAP vs. (R-)IEV as salvage treatment for relapsed or refractory B-cell NHL:
comparison of response rates, stem cell mobilisation and toxicity
B. Dengler, A. Müller, U. Keller, C. Peschel, J. Duyster, H. Menzel (Munich, Erlangen, DE)
P761 Single or double autologous stem cell transplantation for transformed aggressive
B-cell non-Hodgkin’s lymphoma
A. Clavert, V. Roland, S. Le Gouill, V. Dubruille, B. Mahe, T. Gastinne, N. Blin, P. Chevallier,
T. Guillaume, J. Delaunay, S. Ayari, A. Devys, G. Flandrois, B. Saulquin, A. Moreau,
P. Moreau, J.L. Harousseau, M. Mohty (Nantes, FR)
P762 Intermediate VP-16 (1gr/m²) plus G-CSF (10mcg/kg) or cyclophosphamide
(3gr/m²) plus G-CSF (10mcg/kg) for progenitor cell mobilisation in lymphoma
patients
A. Pivkova, S. Genadieva Stavrik, Z. Stojanoski, L. Cevreska, O. Karanfilski, V. Milenkov,
B. Georgievski (Skopje, MK)
P763 Pretransplantation positron emission tomography as predictive factor in
malignant lymphomas
L. Nassi, S. Bassi, M. Negri, L. Travaini, E. Cocorocchio, F. Gigli, A. Vanazzi, L. Preda,
P.R. Rafaniello, L. Orlando, D. Laszlo, G. Martinelli (Milan, IT)
P764 Autologous stem cell transplantation improve outcome in non-Hodgkin's
lymphoma: results of a computer science analysis
M. Pelosini, F. Baronti, S. Galimberti, F. Caracciolo, E. Benedetti, F. Papineschi, A. Starita,
M. Petrini (Pisa, IT)
P765 The role of post-transplantation 18F-fluoro-deoxyglucose positron emission
tomography in T-cell non-Hodgkin's lymphoma patients
B.S. Sohn, S. Kim, D.H. Lee, S.W. Kim, I.K. Hong, J.S. Ryu, J. Huh, J.S. Lee, C. Suh
(Seoul, KR)
P766 Rituximab plus donor lymphocyte infusion to prevent or treat relapse for B-cell
malignancies after allogeneic haematopoietic stem cell transplantation
I.M. Cavattoni, H. Schieder, T. Zabelina, U. Bacher, F. Ayuk, C. Wolschke, A. Zander,
N. Kröger (Hamburg, DE)
P767 TEAM (thiotepa, etoposide, cytarabine, melphalan) as conditioning regimen for
lymphoma treatment with autologous haematopoietic stem cell transplantation
A.M. Carella, G. Palumbo, M. Greco, E. Merla, M. Dell'Olio, P. Scalzulli, S Capalbo,
G Pisapia, P. Mazza, F. Ferrara, A. Guarini, A. Iacobazzi, P. Musto, N. Cascavilla
(San Giovanni Rotondo, Foggia, Taranto, Naples, Bari, Rionero in Vulture, IT)
P768 Vinorelbine and gemcitabine as a salvage regimen prior to stem cell
transplantation in refractory or relapse Hodgkin’s disease
Z. Aki, G. Sucak, A. Yegin, Z. Özkurt, M. Yagci (Ankara, TR)
P769 GEMOX is an effective and low-toxicity salvage protocol for refractory and
relapsed advanced Hodgkin’s lymphoma
L. Facchini, B. Sanchez-Gonzalez, D. Valcarcel, A. Salar, A. Ferrari, J. Delgado, J. Briones,
J. Sierra, A. Sureda (Barcelona, ES)

Posters Physicians Tuesday, 31 March 2009
17:30– Lymphoma (continued)
19:00
P770 Low toxicity after chemoimmuno-conditioning in mantle cell lymphoma
M. Binder, R. Ziebermayr, M. Girschikofsky, H. Kasparu, J. Koenig, O. Krieger,
A. Weltermann, D. Lutz (Linz, AT)
P771 Haematopoietic stem cell transplantation in mantle cell lymphoma patients
between 2001 and 2008 – A single-centre experience
A. Barta, Á. Bátai, Z. Csukly, V. Goda, L. Gopcsa, B. Kapas, L. Lengyel, N. Lovas, S. Lueff,
Z. Matrai, G. MIkala, S. Nahajevszky, M. Peto, A. Sipos, E. Torbagyi, R. Rasonyi, M. Reti,
A. Tremmel, P. Remenyi, T. Masszi (Budapest, HU)
P772 Successful outcome of patients with relapsed/refractory Hodgkin's lymphoma
treated with high dose therapy at a national adult bone marrow transplant unit,
Dublin
C. Bacon, P. Daly, D. O Mahony, P. Browne, E. Conneally, C. Flynn, N. Chadwick,
N. Gardiner, E. Higgins, S. O Briain, R. Mc Dermott, S. McCann, E. Vandenberghe
(Dublin, IE)
P773 Haematopoietic stem cell transplantation in T-cell neoplasms:
the Budapest experience
L. Gopcsa, A. Barta, A. Batai, Z. Csukly, V. Goda, B. Kapas, L. Lengyel, N. Lovas, S. Lueff,
Z. Matrai, G. Mikala, S. Nahajevszky, M. Peto, R. Rasonyi, M. Reti, A. Sipos, A. Tremmel,
E. Torbagyi, P. Remenyi, T. Masszi (Budapest, HU)
P774 Correlation of lymphocyte recovery and progression- free survival after
autologous stem cell transplantation in patients with Hodgkin's lymphoma
H. Mocikova, B. Vackova, R. Pytlik, P. Obrtlikova, P. Kobylka, M. Trneny (Prague, CZ)
P775 Reduced-intensity allogeneic haematopoietic stem cell transplantation for
lymphomas
F. Bonifazi, E. Colaci, G. Bandini, M. Arpinati, M. Stanzani, S. Usai, P. Tazzari, A. Bontadini,
F. Ricci, E. Dan, S. Taioli, M.P. Fina, C. Pellegrini, P. Zinzani, M. Baccarani (Bologna, IT)
P776 The effect of rituximab in first line therapy to results of autologus haematopoietic
stem cell transplantation in relapsed non-Hodgkin's lymphoma patients
S. Civriz Bozdag, P. Topcuoglu, S. Bakanay, M. Arat, O. Ilhan, M. Beksac, A. Uysal,
O. Arslan, T. Demirer, G. Gurman, N. Konuk, M. Ozcan (Ankara, TR)
17:30 – Paediatric issues
19:00
P777 NOD2/CARD15 mutations have no impact on the clinical outcome of paediatric
patients after allo-SCT – A retrospective multicentre study
H. Kreyenberg, A. Jarisch, C. Niemeyer, B. Strahm, B. Kremens, J. Beck, A. Schrauder,
S. Burdach, M. Führer, C. Roessig, H. Kabisch, E. Holler, T. Klingebiel, P. Bader
(Frankfurt, Freiburg, Essen, Jena, Kiel, Munich, Münster, Hamburg, Regensburg, DE)
P778 Reconstitution of NK receptors after haploidentical transplantation with
CD3/CD19 depleted grafts in children: fast recovery of CD16 positive NK cells
enables early ADCC activity
M. Pfeiffer, T. Feuchtinger, H. Teltschik, I. Müller, R. Handgretinger, P. Lang (Tübingen, DE)
P779 Risk factors, BK virus association, and outcome of haemorrhagic cystitis in
children after haematopoietic stem cell transplantation
B. Gruhn, L. Maier, R. Egerer, F. Zintl, J. Beck (Jena, DE)
P780 Differences in immune reconstitution in children receiving either bone marrow or
cord blood stem cell transplantation
A.P.J. de Pagter, L. Keukens, S. Belitzer, E. Baeten, A.P. de Gouw, A. Bloem, J.J. Boelens
(Utrecht, NL)
107

108
Posters Physicians Tuesday, 31 March 2009
17:30– Paediatric issues (continued)
19:00
P781 High percentage of perforin-expressing T-cells is associated with herpesvirus
reactivations clearance early after haematopoietic stem cell transplantation in
children
A.P.J. de Pagter, J.J. Boelens, R. Jacobi, E.A.M. Sanders, R. Schuurman, D. van Baarle
(Utrecht, NL)
P782 Adenovirus DNA positivity in nasopharyngeal fluid preceding haematopoietic
stem cell transplantation: a very strong predictor for adenovirus reactivation in
paediatric patients
A.P.J. de Pagter, L. Haveman, R. Schuurman, M. Bierings, J.J. Boelens (Utrecht, NL)
P783 A prognostic score at diagnosis for Ewing tumour patients with metastatic
disease at extra-pulmonary sites
R. Ladenstein, U. Pötschger, J. Whelan, O. Oberlin, M. Paulussen, M.C. Delay, I. Lewis,
H. van den Berg, H. Jürgens (Vienna, AT; London, Leicester, UK; Villejuif, FR; Basel, CH;
Amsterdam, NL; Münster, DE)
P784 Rituximab is effective in refractory autoimmune hemolytic anaemia following
allogeneic haematopoietic stem cell transplantation
R. Formankova, P. Sedlacek, P. Keslova, E. Mejstrikova, M. Pisacka, E. Linhartova,
H. Zizkova, J. Stary (Prague, CZ)
P785 Reduced-intensity conditioning regimen and allogeneic stem cell transplantation
from related or unrelated HLA-identical donor in high-risk neuroblastoma
A. Prete, R. Rondelli, E. Lanino, C. Favre, M. Rabusin, F. Locatelli, A. Pession, F. Fagioli
on behalf of the AIEOP-BMT Group
P786 Feasibility of intensive care for paediatric patients in HSCT setting
P. Stepensky, I. Yatsiv, J. Baron, M. Aker, M. Weintraub, S. Revel-Vilk, M. Shapira,
R. Or, I. Resnick (Jerusalem, IL)
P787 Management of Epstein-Barr virus infection after haematopoietic stem cell
transplantation in 80 paediatric allogeneic recipients
M. Faraci, I. Caviglia, G. Morreale, E. Lanino, D. Cuzzubbo, S. Giardino, E. Di Marco,
C. Cirillo, F. Scuderi, G. Dini, P. Terranova, E. Castagnola (Genoa, IT)
P788 Targeting to optimal busulfan exposure is associated with a low relapse rate and
high acute-GvHD 2-4 rates in MDS and JMML patients
I.H. Bartelink, R.G.M. Bredius, M. Bierings, C.A.J. Knibbe, M. Egeler, A.C. Lankester,
A.C.G Egberts, J. Zwaveling, J.J. Boelens (Utrecht, Leiden, NL)
P789 Results of a phase II study on the use of peg-filgrastim for the collection of
autologous peripheral CD34+ stem cells in paediatric patients
S. Cesaro, G. A. Zanazzo, G. Tridello , S. Frenos, A. Bellan, S. Dallorso
(Padua, Trieste, Florence, Genoa, IT)
P790 Outcome of second transplant for relapsed haematological paediatric
malignancies
M. Andres, J. Fernández-Navarro, F. Bautista, L. Moreno, A. Verdeguer (Valencia, ES)
P791 Comparing efficacy and toxicity of conditioning regimen of treosulfan +
cyclophosphomide versus busulfan + cyclophosphomide in children with
haematological malignancies after allogeneic haematopoietic stem cell
transplantation
N. Stancheva , E. Semenova, Y. Vasilieva, N. Zubarovskaya , V. Vavilov, O. Goloschapov,
I. Mushchitskaya , L. Zubarovskaya , B. Afanasyev (St. Petersburg, RU)
P792 Osteochondroma after HSCT in childhood. An Italian study on behalf of the
AIEOP-HSCT Group
M. Faraci, F. Bagnasco, P. Corti, C. Messina, F. Fagioli, M. Podda, A. Prete, D. Caselli,
L. Edoardo, G. Dini, R. Rondelli, R. Haupt on behalf of the AIEOP-HSCT group

Posters Physicians Tuesday, 31 March 2009
17:30– Paediatric issues (continued)
19:00
P793 Incidence of thyroid dysfunction after busulphan-based conditioning regimens for
haematopoietic stem cell transplantation
R. Masetti, F. Baronio, K. Kleinschmidt, S. Bonetti, A. Pasini, R. Rondelli, A. Prete,
A. Cicognani, A. Pession (Bologna, IT)
P794 Inflammatory BCG adenitis associated with immune reconstitution following
allogeneic haematopoietic stem cell transplant in infancy
E. Searle, H. Patel, F.J. Vilar, G. Batra, R.F. Wynn (Manchester, UK)
P795 Clofarabine versus fludarabine for haploidentical stem cell transplantation in
paediatric patients with refractory leukaemias
H.-M. Teltschik, I. Müller, M. Pfeiffer, T. Feuchtinger, M. Schumm, R. Handgretinger,
P. Lang (Tübingen, DE)
P796 Effective immunotherapy of donor-derived AML after unrelated stem cell
transplantation
I. von Luettichau, C.V. Denne, P. Bader, S. Schnittger, I. Furlan, B. Strahm, C. Peters,
A. Wawer, H.J. Kolb, S. Burdach (Munich, Frankfurt, Freiburg, DE; Vienna, AT)
P797 Allogeneic haematopoietic stem cell transplantation for secondary
haematological malignancy in children and adolescents – Results of the Polish
Paediatric Group for HSCT
J. Wachowiak, G. Grund, W. Gabor, A. Chybicka, E. Gorczynska, J. Owoc-Lempach,
J. Kowalczyk, K. Drabko, M. Choma (Poznan, Wroclaw, Lublin, PL)
P798 Allogeneic stem cell transplantation in children with non-Hodgkin's lymphoma –
Polish experience
B. Wojcik, M. Choma, K. Drabko, A. Zaucha-Prazmo, J. Kowalczyk, E. Gorczynska,
J. Owoc-Lempach, K. Kalwak, M. Leda, J. Wachowiak, J. Gozdzik (Lublin, Wroclaw,
Poznan, Cracow, PL)
P799 Loss of chimerism following allogenic haematopoietic progenitor cell
transplantation in children: a silent alarm
F.J. Bautista Sirvent, L. Moreno Martin Retortillo, A. Verdeguer Miralles, M. Andres
Moreno, J.M. Fernandez Navarro, V. Castel (Valencia, ES)
P800 Haematopoietic progenitor cell transplantation for infants:
our institutional experience
F.J. Bautista Sirvent, L. Moreno Martin Retortillo, A. Verdeguer Miralles,
M. Andres Moreno, J.M. Fernandez Navarro, V. Castel (Valencia, ES)
P801 High-dose chemotherapy in patients with high-risk Ewing's sarcoma of pelvis.
A single-centre experience
I. Dolgopolov, V. Boyarshinov, R. Pimenov, N. Subbotina, I. Visotchin, S. Siegel,
G. Mentkevich (Moscow, RU; Los Angeles, US)
P802 Allogeneic transplantation using adjusted blood busulfan levels results in a very
low incidence of veno-occlusive disease, irrespective of the presence of the
glutathione S-transferase M1 null genotype
R. Elhasid, E. Efrati, A. Khalil, J. Stein, I. Zaidman, M. Ben Arush, J.M. Rowe, N. Krivoy
(Haifa, Petach-Tikva, IL)
P803 Divergent GvHD in identical twins receiving bone marrow from a single donor for
halting metachromatic leukodystrophy
J. Schrum, A. Bley, H. Kabisch, A. Zander (Hamburg, DE)
P804 Prospective, multicentre, open trial in high-risk paediatrics using a reduced
intensity with intravenous busulfan and fludarabine
C. Paillard, P. Lutz, G. Leverger, G. Michel, P. Bordigoni, M. Poirée, D. Plantaz, J.P. Vannier,
P. Halle, F. Deméocq, J. Kanold (Clermont-Ferrand, Strasbourg, Paris, Marseille, Nancy,
Nice, Grenoble, Rouen, FR)
109

110
Posters Physicians Tuesday, 31 March 2009
17:30– Paediatric issues (continued)
19:00
P805 Immune reconstitution and immunisation in paediatric allogeneic bone marrow
transplant recipients
H. Olkinuora, S. Siitonen, E. von Willebrand, U. Pihkala-Saarinen, J. Kantele, O. Vainio,
H. Käyhty, R.-M. Ölander, M. Roivainen, I. Davidkin, K. Vettenranta (Helsinki, Turku, Oulu, FI)
P806 CB transplant in a haemophilic child
D. Caselli, V. Tintori, F. Bambi, S. Frenos, M. Veltroni, M. Morfini, S. Guidi, M. Aricò (Florence, IT)
P807 Cord blood transplantation at King Hussein Cancer Center: an evolving experience
in a newly developed programme
A. Hussein, A. Al-Zabin, S. Musleh, R. Rihani, F. Abdul-Rahman, H. Al-Ta'ani,
M. Sarhan (Amman, JO)
P808 Improved outcomes of paediatric allogeneic haemopoietic stem cell
transplantation following implementation of standardised transplant procedures
in preparation for JACIE accreditation
Y. Sorour, J. Williams, S. Rush, S. Barrott, A. Vora (Sheffield, UK)
P809 Outcome of high-dose chemotherapy and autologous haematopoietic stem cell
transplantation in children with high-risk primary central nervous system tumour
S.Y. Kwon, S.C. Won, H.S. Kim, C.J. Lyu (Seoul, KR)
P810 Severe haemorrhagic cystitis in children undergoing haematopoietic stem cell
transplantation
A.A. Hamidieh, M. Jalili, A. Ghavamzadeh, M. Jahani, K. Alimoghaddam,
A. Khodabandeh, B. Bahar, A. Mousavi, M. Iravani (Tehran, IR)
P811 Estimation of glomerular filtration rates in paediatric patients undergoing stem
cell transplantation: the role of cistatine plasma levels
R. Mar, J. Fernández-Navarro, M. Sanahuja, J. Lucas, M. Matoses, M. Andres,
A. Verdeguer (Valencia, ES)
P812 Malnutrition and use of nutritional support in infants submitted to haematopoietic
stem cell transplantation
R. Jung, A.M. Ordoñez, D.J. Campos, A. Koerich, S. Fortier, J. Zanis Neto, C. Bonfim
(Curitiba, BR)
P813 Early multiple viral infections may predict chronic GvHD among paediatric stem
H. Olkinuora, M. Taskinen, U. Pihkala-Saarinen, K. Vettenranta (Helsinki, FI)
P814 Allogeneic HSCT in children and adolescents with relapsed or refractory
Hodgkin's lymphoma
I. Badell, M. Torrent, M. Gonzalez-Vicent, C. Diaz de Heredia, A. Martinez,
J.M. Perez-Hurtado on behalf of GETMON
P815 The effectiveness of tacrolimus and minidose methotrexate for prevention of
acute graft-versus-host disease after an allogeneic stem cell transplantation in
children: a single-centre experience in Korea
S.S. Park, S.E. Jun, Y.T. Lim (Pusan, KR)
17:30 – Haemoglobinopathy
19:00
P816 Optimal thalassaemia-free survival and minimal regimen-related toxicity in
50 consecutive high-risk beta thalassaemia paediatric patients using
myeloablative therapy with intravenous busulphan
R. Chiesa, B. Cappelli, R. Crocchiolo, E. Biral, A. Noè, I. Frugnoli, T. Roccia, C. Evangelio,
M. Fossati, F. Ciceri, M.G. Roncarolo, S. Marktel (Milan, IT)
P817 Purified T-depleted peripheral blood and bone marrow CD34 transplantation from
haplo identical mother to child with thalassaemia
P. Sodani (Rome, IT)

Posters Physicians Tuesday, 31 March 2009
17:30– Haemoglobinopathy (continued)
19:00
P818 Haematopoietic stem cell transplantation from related donors in severe beta
thalassaemia
A. Ghavamzadeh, A.A. Hamidieh, M. Jahani, K. Alimoghaddam, A. Mousavi, M. Iravani,
B. Bahar, A. Khodabandeh, M. Jalili (Tehran, IR)
P819 Donor’s NK cells may influence the engraftment in paediatrics patients after
T-cell depleted haploidentical stem cell transplant for thalassaemia
A. Isgro, M. Marziali, P. Sodani, J. Gaziev, P. Polchi, G. De Angelis, K. Paciaroni, C. Alfieri,
M.D. Simone, D. Fraboni, G. Lucarelli (Rome, IT)
P820 Co-transplantation of HLA-identical related donors mesenchymal stromal cells
and haematopoietic stem cells in class III thalassaemia major patients
A. Ghavamzadeh, K. Alimoghaddam, A.A. Hamidieh, A. Karimi, N. Valizadeh, M. Bashtar,
A.R. Shamshiri (Tehran, IR)
P821 Donor lymphocyte infusions after allogeneic bone marrow transplantation for
thalassaemia: a single-centre experience
G. Karasu, V. Uygun, M. Kazik, A. Kupesiz, P. Kurt, Z. Öztürk, V. Hazar, A. Yesilipek
(Antalya, TR)
P822 Cyclosporine neurotoxicity in beta-thalassaemic children undergoing
myeloablative BMT
A. Noè, S. Marktel, R. Chiesa, C. Evangelio, I. Frugnoli, M. Fossati, E. Biral, S. Napolitano,
F. Ferrua, A. Biffi, T. Roccia, M.G. Roncarolo, F. Ciceri, B. Cappelli (Milan, IT)
P823 Stem cell transplantation in sickle cell anaemia
G. De Angelis, C. Gallucci, K. Paciaroni, C. Alfieri, A. Isgro, M. Marziali, A. Roveda,
M. Simone, A. Montuoro, P. Sodani, P. Polchi, T. Wakama, J. Gaziev, G. Lucarelli
(Rome, IT; Abuja, NG)
P824 Immunological evaluation after haematopoietic stem cell transplantation for
beta-thalassaemia
M. Marziali, A. Isgro, J. Gaziev, D. Fraboni, P. Sodani, K. Paciaroni, C. Gallucci,
A. Montuoro, P. Polchi, A. Roveda, G. Lucarelli (Rome, IT)
17:30 – Infectious complications
19:00
P825 Impairment of anti-leukaemia and anti-tumour CD8+ cytotoxic T-lymphocyte
function by antifungal agents in vitro
E. Distler, H.H. Chapin, E. Koch, C. Lass-Flörl, A. Ullmann, C. Huber, W. Herr
(Mainz, DE; Innsbruck, AT)
P826 Genetic polymorphisms in the genes encoding human Toll-like receptor 1–10
C. Enevold, I. Christensen, B. Kornblit, K. Bendtzen, C. Heilmann, N. Jacobsen, K. Müller
(Copenhagen, DK)
P827 Prospective evaluation of Candida mannan and mannan antibody to diagnose
candidiasis in febrile neutropenic patients
M. Ellis, B. Al-Ramadi, R. Bernsen, J. Kristensen, H. Alizadeh, U. Hedstrom (Al Ain, AE)
P828 Neglected tropical diseases in haematopoietic stem cell transplantation:
a single-centre experience in Brazil
T.C. Martins, I. Colturato, M. S. Leite, A.J. Simione, V. Colturato, M.P. de Souza,
M. Mauad, W. Azevedo, C.M. Machado (Jaú, São Paulo, BR)
P829 Each herpesvirus elicits a unique T-cell response in chronically infected healthy
individuals
F. Khan, S. Sy, S. Liu, F. Zhou, Y. Liu, A. Ugarte-Torres, J. Storek (Calgary, CA)
111

112
Posters Physicians Tuesday, 31 March 2009
17:30– Infectious complications (continued)
19:00
P830 The impact of Dectin-1 polymorphism Tyr238Stop on the occurrence of Candida
colonisation and disease of haematopoietic stem cell transplantation recipients
W.J.F.M. van der Velden, T.S. Plantinga, B. Ferwerda, P. Donnelly, M.G. Netea,
N.M.A. Blijlevens (Nijmegen, NL)
P831 The natural history and control of cytomegalovirus infection following allogeneic
stem cell transplantation
G. Garnett, M. Boeckh, H. Einsele, V. Emery (London, UK; Seattle, US; Würzburg, DE)
P832 Lower respiratory tract respiratory virus infections increase the risk of invasive
aspergillosis following a reduced-intensity allogeneic haematopoietic stem cell
transplantation
R. Martino, R. Parody, J.L. Piñana, D. Valcarcel, A. Sureda, S. Brunet, J. Briones,
J. Delgado, F. Sanchez, N. Rabella, J. Sierra (Barcelona, ES)
P833 Outbreak of waterborne Pseudomonas aeruginosa infections in a reverse
isolation haematology unit
A.F. Widmer, R. Frei, M. Stern, D. Heim, C. Arber, M. Battegay, U. Flückiger, A. Gratwohl
(Basel, CH)
P834 Children with acute leukaemia have an increased risk for Varicella zoster
reactivation after allogeneic stem cell transplantation: a possible role for
fludarabine
A.C. Lankester, C.M. Jol-van der Zijde, P. Hissinkmuller, A.C.T.M. Vossen, L.M. Ball
(Leiden, NL)
P835 Different CMV and EBV reactivation among alternative donor transplants
depending on the type of stem cell source: a single-centre analysis
M. Mikulska, A. Ibatici, A. Dominietto, A.M. Raiola, V. Pinto, M. Soracco, F. Gualandi,
V. Del Bono, T. Lamparelli, M.T. Van Lint, C. Viscoli, A. Bacigalupo, F. Frassoni (Genoa, IT)
P836 Reappraisal of bacterial prophylaxis in allogeneic marrow or peripheral blood
stem cell transplantations after myeloablative conditionings
J. Kanda, T. Ichinohe, T. Saito, K. Yamashita, T. Kondo, T. Ishikawa, S. Ichiyama,
T. Uchiyama (Kyoto, JP)
P837 Functional immune reconstitution after high-dose chemotherapy parallels control
of endogenous viral reactivation: the torquetenovirus model
D. Focosi, F. Maggi, M. Albani, J. Rocchi, V. Ricci, S. Gragnani, M. Ghimenti,
F. Papineschi, M. Bendinelli, M. Pistello, L. Ceccherini-Nelli, M. Petrini (Pisa, IT)
P838 Risk of hepatitis B development and efficacy of prophylaxes with lamivudine after
allogeneic stem cell transplantation
L. Giaccone, I. Resta, A. Marengo, R. Sorasio, F. Fiore, M. Rizzetto, M. Boccadoro,
A. Marzano, B. Bruno (Turin, IT)
P839 Posaconazole and cyclosporine drug interaction in allogeneic HSCT:
dose adjustment, interaction kinetics and safety profile
I. Sánchez-Ortega, T. Caballero, C. Montes, B. Patiño, J. Villa, M. Arnan, L. Yáñez,
A. Iriondo, L. Vázquez, R.F. Duarte (Barcelona, Salamanca, Santander, ES)
P840 Tetramer-screening to predict the risk of recurrent CMV-reactivation after HSCT:
a 2-year screening and follow-up phase
S. Borchers, S. Luther, N. Hahn, J. Kontsendorn, M. Stadler, H. Diedrich, A. Ganser,
E.M. Weissinger (Hannover, DE)
P841 Respiratory syncytial virus infection in recipients of allogeneic stem cell
transplantation: retrospective study of the incidence, clinical features and
outcome
G. Avetisyan, J. Mattsson, P. Ljungman (Stockholm, SE)

Posters Physicians Tuesday, 31 March 2009
17:30– Infectious complications (continued)
19:00
P842 CMV infection and disease after allogeneic stem cell transplantation with
reduced-intensity conditioning
G. Avetisyan, H. Hägglund, Z. Hassan, K. LeBlanc, J. Mattsson, O. Ringdén, J. Winiarski,
P. Ljungman (Stockholm, SE)
P843 RSV infection after allogeneic haematopoietic stem cell transplantation from a
single centre
F. Piazera, S. Fortier, J. Morando, C. Bonfim, M. Bitencourt, V. Funke, D. Setubal, J. Ruiz,
C. Arns, R. Silva, R. Pasquini, C. Medeiros, J. Zanis (Curitiba, BR)
P844 Voriconazole plasma levels monitoring in allogeneic haematopoietic stem cell
transplant recipients
J. Winterová, Z. Rácil, L. Malášková, I. Kocmanová, B. Weinbergerová, J. Mayer (Brno, CZ)
P845 Prevalence of multiresistant pathogens in surveillance and clinical isolates from
patients undergoing haematopoietic stem cell transplantation in Hungary:
a single-centre experience
C. Kassa, J. Sinkó, K. Kállay, A. Kertész, M. Konkoly-Thege, G. Kriván (Budapest, HU)
P846 Incidence of Clostridium difficile infection in patients undergoing allogeneic stem
cell transplantation – A single-centre analysis
G. Beutel, S. Buchholz, J. Krauter, E. Dammann, H. Diedrich, M. Stadler, P. Kirschner,
A. Ganser, M. Eder (Hannover, DE)
P847 Multiple co-pathogens are associated with increased morbidity and mortality in
parainfluenza virus 3 infection
A. Hodson, M. Kasliwal, A Retter, K. Cuthill, M. Streetly, M. Kazmi, E. MacMahon, K. Raj
(London, UK)
P848 Refractory late onset haemorrhagic cystitis following fludarabine and
alemtuzumab conditioned allogeneic haematopoietic stem cell transplant
A. Hodson, M. Streetly, P. Fields, K. Raj, E. MacMahon, M. Kazmi (London, UK)
P849 Immune response of human polymorphonuclear neutrophils to Aspergillus
fumigatus
J. Loeffler, M. Mezger, I. Wozniok, H. Einsele (Würzburg, DE)
P850 The rate of cytomegalovirus infection and disease in correlation with the type
of haematopoietic stem cell transplantation in the era of pre-emptive antiviral
therapy
B. Gesundheit, R. Or, E. Budowski, M. Shapira, I. Resnick, S. Samuel, L. Dray, O. Kaplan,
D. Wolf (Jerusalem, IL)
P851 Neutropenic enterocolitis: usefulness of ultrasound sonography.
Single-centre experience
E. Benedetti, F. Simonetti, F. Caracciolo, F. Papineschi, E. Orsitto, M. Tonerini, B. Bruno,
M. Pelosini, D. Focosi, M. Petrini (Pisa, Turin, IT)
P852 Outcome of allogeneic haematopoietic stem cell transplantations in patients with
secondary antifungal prophylaxis due to proven or suspected prior fungal
infection
S. Rohde, M. Leithäuser, G. Kundt, M. Haversath, D. Wolff, I. Hilgendorf, H. Andree,
J. Casper, C. Kahl, M. Freund, C. Junghanss (Rostock, DE)
P853 Cytomegalovirus pre-emptive strategy guided by Ag pp65 or quantitative PCR
after reduced-intensity conditioning allogeneic stem cell transplantation:
a single-centre experience
J.L. Piñana, R. Martino, N. Rabella, P. Barba, N. Margall, M. Roig, D. Valcarcel, J. Sierra
(Barcelona, ES)
113

114
Posters Physicians Tuesday, 31 March 2009
17:30– Infectious complications (continued)
19:00
P854 Adoptive transfer of cytomegalovirus-specific CD8+ T-cells powered by
streptamer technology leads to enduring virus clearance in patients after
allogeneic stem cell transplantation
A. Schmitt, T. Tonn, D. Busch, G. Grigoleit, H. Einsele, M. Odenthal, L. Germeroth,
M. Ringhoffer, S. Ringhoffer, M. Wiesneth, D. Michel, T. Mertens, M. Rojewski,
M. Marx, S. von Harsdorf, H. Döhner, E. Seifried, D. Bunjes, M. Schmitt
(Rostock, Frankfurt, Munich, Würzburg, Göttingen, Ulm, DE)
P855 NOD2/CARD15 polymorphism evaluation in autologous stem cell transplantation
S. Giammarco, S. Bellesi, P. Chiusolo, S. Marietti, D. De Ritis, L. De Padua, E. Metafuni,
G. Leone, S. Sica (Rome, IT)
P856 Prospective study of oral valganciclovir for pre-emptive therapy of
cytomegalovirus after allogeneic stem cell transplantation
R. de la Camara, L. Vazquez, J. Lopez, C. Solano, D. Serrano, A. Garcia Noblejas,
J.M. Ribera Santasusana, C. Ferra (Madrid, Salamanca, Valencia, Barcelona, ES)
P857 Towards standardisation of Epstein-Barr viral load quantification:
comparison of four different ways of measurement in peripheral blood of
paediatric patients after allogeneic haematopoietic stem cell transplantation
S. Volke, B. Gruhn, W. Woesmann, E. Landmann, J. Beck, A. Reiter, H. Wagner
(Giessen, Jena, DE)
P858 Use of saliva in the detection of HCMV DNA in allogeneic stem cell transplantation
and its comparison with viral load in blood by real-time PCR
J. Correa-Silva, O. Bruna-Romero, R. Resende, L. Miranda, F. Oliveira, F. Costa, S. Xavier,
S. Figueiredo-Neves, R. Gomez, H. Bittencourt (Belo Horizonte, BR)
P859 EBV and HHV-6 reactivation associate with mental disturbances in alloHSCT
patients
A. Burniak, E. Jaskula, S. Madej, A. Lange (Wroclaw, PL)
P860 Reactivations of CMV, HHV6 and EBV differ with respect to the risk factors and
the clinical outcome in patients post haematopoietic stem cell transplantation
E. Jaskula, D. Dlubek, A. Tarnowska, D. Duda, A. Lange (Wroclaw, PL)
P861 Levofloxacin prophylaxis after high-dose chemotherapy and autologous
peripheral stem cell support: does it work? A single-centre experience
A. Anastasia, L. Castagna, S. Bramanti, B. Sarina, R. Mazza, E. Todisco, L. Giordano,
A. Santoro (Rozzano, IT)
P862 Impact of prior invasive pulmonary aspergillosis on outcome in patients receiving
reduced-intensity conditioning allogeneic haematopoietic stem cell
transplantation
J. El-Cheikh, L. Wang, C. Faucher, S. Furst, B. Esterni, P. Berger, D. Blaise (Marseille, FR)
P863 Use of “high flow” totally implantable central venous access ports for
myeloablative conditioning followed by allogeneic stem cell transplantation:
a prospective study
A. Abdelkefi, O. Ben Gaied, S. Laabidi, H. Allouche, S. Ladeb, N. Ajmi, M. Maamar,
L. Torjman, A. Lakhal, A. Mezlini, M. Elloumi, N. Ben Romdhane, T. Ben Othman
(Tunis, Sfax, TN)
P864 Graft-versus-host disease and fungal infections are the main outcome predictors
after allogeneic stem cell transplantation using reduced-intensity conditioning
regimens
F. Patriarca, M.l. Battista, A. Sperotto, M. Medeot, A. Geromin, M. Cerno, E. Toffoletti,
S. Buttignol, C. Savignano, C. Rinaldi, V. Miotti, R. Fanin (Udine, IT)

Posters Physicians Tuesday, 31 March 2009
17:30– Infectious complications (continued)
19:00
P865 Early recovery of immunoglobulin levels at 3 months after allogeneic peripheral
blood stem cell transplantation can predict favourable transplantation outcomes
J.H. Moon, S.J. Lee, J.G. Kim, Y.S. Chae, S.N. Kim, J.S. Suh, K.S. Lee, S.K. Sohn
(Daegu, KR)
P866 Infectious complications after cord blood transplant: impact on mortality and
analysis of risk factors for bacterial, fungal and viral infections
C. Girmenia, L. Malandruccolo, A.P. Iori, W. Barberi, G.F. Torelli, V. Valle, E. Iannella,
B. Lucarelli, M. Screnci, G. Gentile, A. Micozzi, R. Foà (Rome, IT)
P867 Serum vascular endothelial growth factor in adult haematological patients with
neutropenic fever: a prospective comparison with C-reactive protein
E. Jantunen, S. Hämäläinen, I. Matinlauri, T. Kuittinen, I. Koivula, A. Juutilainen
(Kuopio, Turku, Helsinki, FI)
P868 Risk of bacterial contamination at autologous peripheral blood stem cell
collection and infusion
A. Yilmaz, E. Ayyildiz, M. Bay, A. Azap, G. Gürman, Ö. Arslan, O. Ilhan, M. Arat (Ankara, TR)
P869 Monitoring strategy of adenovirus infections in allogeneic stem cell transplant
patients
H. Omar, G. Avetisyan, P. Ljungman (Huddinge, SE)
P870 No difference in the risk of invasive fungal infections after HLA identical sibling or
unrelated donor transplantation receiving low-dose ATG-F in the preparative
regimen before transplant. Results from a single centre
F. Bonifazi, G. Bandini, S. Usai, E. Colaci, M. Stanzani, M. Arpinati, N. Vianelli, M.R. Motta,
S. Rizzi, M. Baccarani (Bologna, IT)
P871 Cytomegalovirus-specific immune reconstitution monitored by ELISPOT assay in
allogeneic haematopoietic stem cell transplantation
C. Nozzoli, L. De Risi, S. Guidi, A. Orsi, B. Bartolozzi, A. Gozzini, L. Lombardini,
R. Saccardi, A. Bosi (Florence, IT)
P872 Treatment of respiratory syncytial virus infection with nebulised ribavirin and the
humanised monoclonal antibody palivizumab in eight haemopoietic stem cell
transplant recipients
D.A. Tsitsikas, H. Oakervee, J. Cavenagh, S. Agrawal, J. Gribben, F. Mattes (London, UK)
P873 Long-term low-dose valacyclovir against Varicella-zoster virus reactivation after
allogeneic haematopoietic stem cell transplantation
K. Oshima, T. Takahashi, T. Mori, T. Matsuyama, K. Usuki, Y. Asano-Mori, F. Nakahara,
S. Okamoto, M. Kurokawa, Y. Kanda (Saitama, Tokyo, Tochigi, JP)
P874 Low-dose amphotericin B lipid complex or liposomal amphotericin B prophylaxis
of invasive fungal infections in children following stem cell transplantation for
haemoglobinopathies
J. Gaziev, C. Alfieri, M. Marziali, A. Isgro, P. Sodani, P. Polchi, M.D. Simone, C. Gallucci,
K. Paciaroni, A. Roveda, G. De Angelis, A. Montuoro, G. Lucarelli (Rome, IT)
P875 Secondary prophylaxis and pre-emptive antifungal therapy are effective in
allogeneic transplanted patients nursed in highly protective environment
P. Marenco, G. Grillo, G. Bertani, C. Gabutti, V. Mancini, M. Turrini, A. Brizio, E. Morra
(Milan, IT)
P876 The role of prophylactic antimicrobials during autologous stem cell
transplantation: a single-centre experience
B.S. Sohn, D.H. Yoon, S. Kim, D.H. Lee, S.W. Kim, J. Huh, J.S. Lee, C. Suh
(Seoul, KR)
115

116
Posters Physicians Tuesday, 31 March 2009
17:30– Infectious complications (continued)
19:00
P877 Rota- and calicivirus infections following allogeneic haematopoetic stem cell
transplantation
K. Kállay, J. Sinkó, G. Benyó, Á. Tóth, V. Goda, G. Kriván (Budapest, HU)
P878 Preliminary monocentric survey on the prevalence of HBV seropositivity in HSCT
recipients
P. Usardi, C. Annaloro, M. Viganò, P. Lampertico, F. Onida, E. Tagliaferri, A. Della Volpe,
G. Lambertenghi Deliliers (Milan, IT)
P879 Catheter-related infections in tunnelled central venous devices in haematologic
malignancies and haematopoietic stem cell transplantation patients.
A single-centre experience
E. Carrillo Cruz, J. Falantes González, J. González Campos, M. Ruiz Seixas, A. Urbano
Ispizua, I. Espigado Tocino (Sevilla, ES)
P880 High efficacy and low toxicity of short-course oral valganciclovir given as
one-week BID treatment and one-week QD maintenance as pre-emptive
therapy for post-HSCT CMV infection
A.J.M. Saleh, F. Al-Mohareb, F. Al-Rabiah, N. Chaudhri, F. Al-Sharif, H. Al-Zahrani,
S. Mohamed, K. Al-Anazi, M. Patel, W. Rasheed, A. Elghazaly, M. Bakr, S. Ahmed,
A. Nassar, F. Hussain, Z. Nurgat, H. Al-Abdely, M. Aljurf (Riyadh, SA)
P881 Peripherally inserted central venous catethers in the management of autologous
haematopoietic stem cell transplantation
S. Bellesi, G. De Pascale, P. Chiusolo, G. Scoppettuolo, M. Pittiruti, F. Sorà, L. Laurenti,
G. Leone, S. Sica (Rome, IT)
P882 Frequency and mains causes of the febrile episodes during myeloablative
chemotherapy neutropenia induced after bone marrow transplant
A. Talbi, R. Ahmed Nacer, M. Benakli, R. Belhadj, F. Mehdid, M. Baazizi, N. Rahmoune,
K. Saidani, D. Ait Ouali, S. Madene, S. Abderrahmani, R.M. Hamladji (Algiers, DZ)
P883 Cytomegalovirus DNAemia and treatment following allogeneic stem cell
transplantation with focus on long-term outcome
J. Lindahl (Göteborg, SE)
P884 Emergence of uncommon infection in bone marrow transplantation:
the modern Trojan horse?
T. Zuckerman, N. Benyamini, N. Haddad, R. Fineman, I. Avivi, E. Sabo, J.M. Rowe, I. Oren
(Haifa, IL)
P885 Invasive fungal infection in patients after allogeneic haematopoietic stem cell
transplantation. A single-centre experience
N. Zubarovskaya , Y. Vasilieva, E. Semenova, N. Stancheva , E. Morozova, N. Klimko,
A. Chukhlovin , B. Afanasyev (St. Petersburg, RU)
P886 The utility of screening swabs in allogeneic haematopoeitic stem cell transplant
recipients: a retrospective evaluation
S. Ager, N. Young, H. Inns, G. Cook, M. Gilleece, S. Liebersbach, G. Shenton, T. Collyns
(Leeds, UK)
P887 Posaconazole has superior clinical efficacy and cost-effectiveness to
itraconazole for antifungal prophylaxis in allogeneic stem cell transplant
recipients: a single-centre experience
R.F. Duarte, B. Patiño, C. Muñoz, M. Arnan, T. Peralta, C. Gudiol, I. Sánchez-Ortega,
R. Parody, A. Clopés, J.L. López-Belmonte, F.J. Sabater, A. Fernández de Sevilla
(Barcelona, Madrid, ES)
P888 Is serological or PCR positivity of Toxoplasma gondii in donor or recipient the
reason for haematopoietic stem cell transplantation delay?
L. Krol, M. Matulova, P. Hubacek, P. Keslova, R. Formankova, P. Sedlacek (Prague, CZ)

Posters Physicians Tuesday, 31 March 2009
17:30– Infectious complications (continued)
19:00
P889 Ciprofloxacine as an antibacterial prophylaxis for patients undergoing
high-dose chemotherapy and autologous stem cell transplantation –
A single-centre experience
A. Wolska, A. Wierzbowska, A. Szmigielska-Kaplon, A. Pluta, T. Robak (Lodz, PL)
P890 Use of ciprofloxacin to prevent bacterial infection in patients receiving high-dose
chemotherapy and autologous stem cell transplantation for multiple myeloma,
AML, and lymphoma/solid tumours
E. Bauernschmitt, T. Szislo, C. Peschel, H. Menzel (Munich, DE)
17:30– Chronic leukaemias
19:00
P891 In vivo T-cell depletion in allogeneic haematopoietic cell transplantation for
chronic lymphocytic leukaemia: a retrospective EBMT analysis
J. Schetelig, D. Milligan, D. Niederwieser, L. Volin, J. Maertens, N. Russell, A. Gratwohl,
M. Bornhäuser, M. van Gelder, A. van Biezen, R. Brand, T. de Witte, P. Dreger
on behalf of the Chronic Leukemia Working Party
P892 CD34+ from high Sokal risk chronic myeloid leukaemia patients expresses gene
profile significantly different from CD34+ obtained from low and intermediate
Sokal risk pts: a subgroup of CML pts candidate to upfront search for BMT donor?
C. Terragna, S. Durante, A. Astolfi, F. Palandri, F. Castagnetti, G. Rosti, N. Testoni,
S. Luatti, A. Poerio, I. Iacobucci, R.M. Lemoli, S. Soverini, D. Russo, M. Malagola,
M. Baccarani, G. Martinelli (Bologna, Brescia, IT)
P893 Apoptosis induction by treosulfan is superior to busulfan in risk-defined human
CLL cells
V. Ristovska, N. Wagner, M. Herling, T. Herold, M. Hallek, G. Fingerle-Rowson
(Cologne, Munich, DE)
P894 Allogeneic haematopoietic stem cell transplantation as a curative therapy in
primary and secondary myelofibrosis
S. Lissandre, J.-O. Bay, J.-Y. Cahn, V. Cacheux, A. Cabrespine, J. Cornillon,
B. Cassinat, R. Peffault de Latour, G. Socié, M. Robin (Paris, Clermont-Ferrand, Grenoble,
Saint-Etienne, FR)
P895 Outcome of allogeneic stem cell transplantation in patients with chronic myeloid
leukaemia treated with second generation tyrosine kinases inhibitors after
imatinib failure
F. Palandri, M. Breccia, A.P. Iori, F. Bonifazi, R. Latagliata, E. Colaci, G.F. Torelli,
F. Castagnetti, V. Valle, S. Usai, G. Martinelli, C. Dell'Agnola, S. Cingarlini, G. Rosti,
M. Baccarani, G. Alimena (Bologna, Rome, Verona, IT)
P896 Cancer-testis antigen expression and immunogenicity in chronic myeloid
leukaemia
T. Luetkens, F. Uhlich, T. Stasche, R. Akblukak, Y. Hildebrandt, S. Kobold, K. Bartels,
T. Brümmendorf, P. Schafhausen, N. Kröger, C. Bokemeyer, D. Atanackovic (Hamburg, DE)
P897 Second allogeneic stem cell transplantation for osteomyelofibrosis relapsed after
initial allogeneic stem cell transplantation
E. Klyuchnikov, F. Ayuk, U. Bacher, A. Zander, N. Kröger (Hamburg, DE)
P898 Innovative phase I-II study of concomitant and consecutive treatment with
dasatinib and MK-0457 in refractory Ph+ CML and ALL patients candidates for
allogeneic bone marrow transplantation of savage
C. Papayannidis, I. Iacobucci, S. Soverini, S. Paolini, S. Santucci, F. De Rosa, D. Cilloni,
F. Messa, F. Pane, V. Meneghini, P. Giannoulia, E. Ottaviani, N. Testoni, B. Lama,
M. Pantaleo, M. Baccarani, G. Martinelli (Bologna, Orbassano, Turin, Naples, Verona, IT)
117

118
Posters Physicians Tuesday, 31 March 2009
17:30– Immunotherapy
19:00
P899 Generation of WT1 peptide-specific T-cells out of healthy volunteer donors for
adoptive immunotherapy after allogeneic stem cell transplantation
G. Weber, J. Karbach, S. Kuci, H. Kreyenberg, A. Willasch, T. Klingebiel, W. Wels, E. Jäger,
P. Bader (Frankfurt, DE)
P900 Human alloreactive CD4+ T-cells as potent effector cells and sole mediators of
anti-tumour responses in a NOD/Scid mouse model for human acute leukaemia
S. Stevanovic, M. Griffioen, B.A. Nijmeijer, M.L.J. Van Schie, R. Willemze,
J.H.F Falkenburg (Leiden, NL)
P901 The composition and quality of leukaemia-derived dendritic cells,T-cells and the
cellular microenvironment is predictive for the antileukaemic T-cell cytotoxic
reactions of DC-primed T-cells and the response to therapy
H. Schmetzer, A. Liepert, C. Grabrucker, D. Fischbacher, M. Merle, M. Freudenreich,
F. Schuster, S. Reuther, A. Kremser, J. Loibl, R. Reibke, C. Schmid, T. Kroell, H.J. Kolb
(Munich, Augsburg, DE)
P902 The use of steroids but not T-cell recovery disturbs reconstitution of NK cell
receptor repertoire after alloHSCT
S. Giebel, J. Dziaczkowska, T. Czerw, J. Wojnar, M. Krawczyk-Kulis, I. Nowak,
A. Holowiecka-Goral, A. Segatti, S. Kyrcz-Krzemien, J. Holowiecki, P. Kusnierczyk
(Gliwice, Katowice, Wroclaw, PL; Pavia, IT)
P903 Chemotherapy before donor lymphocyte infusion enhances lymphocyte activation
and induces clinical responses
G.F. Torelli, R. Maggio, W. Barberi, N. Peragine, M.S. De Propris, A.P. Iori, V. Valle,
E. Iannella, F. Natalino, E. Arleo, A. Guarini, R. Foà (Rome, IT)
P904 Clinical grade generation of human anti-adenovirus-cytotoxic T-cells for adoptive
immunotherapy
L. Aissi-Rothe, V. Decot, C. Mathieu, A. Kennel, V. Venard, H. Jeulin, A. Salmon,
L. Clement, P. Bordigoni, J.F. Stoltz, D. Bensoussan (Vandoeuvre Les Nancy, FR)
P905 CXCL8 and CCL2 secretion by dendritic cells generated from AML-blasts (DCleu)
as well as IFN-g or IL-6 release in mixed lymphocyte cultures from T-cells after
DC-priming are predictive for antileukaemic T-cell reactions
D. Fischbacher, M. Merle, A. Liepert, C. Grabrucker, A. Kremser, J. Loibl, C. Schmid,
T. Kroell, H.J. Kolb, H.M. Schmetzer (Munich, Augsburg, DE)
P906 Immune response of human propagated gd-T-cells to neuroblastoma recommend
the Vd1 subset for gd-T-cell based immunotherapy
K. Schilbach, K. Frommer, S. Meier, R. Handgretinger, M. Eyrich (Tübingen, DE)
P907 Priming and expansion of HLA-B*0702/CMV_pp65 restricted CTL for adoptive
immunotherapy by use of artifical antigen presenting complexes is essentially
influenced by differential triggering of co-stimulatory pathways
M. Kapp, K. Fick, S. Jackob, M. Oelke, R. Thiele, E. Baumeister, S.M. Tan, H. Wajant,
J.P. Schneck, A. Opitz, H. Einsele, G. Grigoleit (Würzburg, DE; Baltimore, US)
P908 Assessment of signalling events in antigen-specific T-cells by combining
phosphoepitope specific flow cytometry and MHC-multimer staining
R. Thiele, M. Kapp, E. Baumeister, K. Fick, G. Stuhler, A. Opitz, H. Einsele, G. Grigoleit
(Würzburg, DE)
P909 Escalating doses of donor lymphocytes to rescue from rejection following bone
marrow transplantation for thalassaemia
I. Frugnoli, B. Cappelli, R. Chiesa, A. Noè, E. Biral, S. Gattillo, T. Roccia, C. Evangelio,
M. Fossati, S. Napolitano, A. Giardelli, C. Soliman, F. Ciceri, M.G. Roncarolo, S. Marktel
(Milan, IT)

Posters Physicians Tuesday, 31 March 2009
17:30– Immunotherapy (continued)
19:00
P910 Influence of bone marrow-derived human mesenchymal stem cells on the in vitro
induction of anti-tumour T-cell responses
D. Montagna, F. Locatelli, E. Montini, M. Avanzini, L. Caliogna, I. Turin, A. Moretta,
A. Mastronuzzi, V. Spartà, I. Possenti, M. Bernardo, R. Maccario (Pavia, IT)
P911 Pre-treating human NK cells with dasatinib increases cytotoxicity against
resistant Daudi but not sensitive K562 or Jurkat cells –
An example for differential immunomodulation
N. Hassold, K. Seystahl, C. Dix, J. Wischhusen, H. Einsele, R. Seggewiss (Würzburg, DE)
P912 Treatment of threatening rejection after umbilical cord blood transplantation with
ex vivo expanded CB derived T-cells
M. Uhlin, M. Okas, J. Gertow, J. Mattsson (Huddinge, SE)
P913 Developing a murine model to study B cells as APC in vivo
T. Liebig, A. Shimabukuro-Vornhagen, N. Klein-Gonzalez, E. Kondo, C. Wickenhauser,
M. von Bergwelt-Baildon (Cologne, DE)
P914 Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic
T EMRA lymphocytes
A. Pievani, M. Franceschetti, G. Borleri, L. Vago, K. Fleischhauer, J. Golay, M. Introna
(Bergamo, Milan, IT)
P915 Generation of cytokine-induced killer cells for adoptive immunotherapy
E. Rettinger, S. Kuci, G. Weber, B. Voss, S. Kloess, A. Willasch, H. Kreyenberg, U. Koehl,
P. Bader, T. Klingebiel (Frankfurt, DE)
17:30– Aplastic anaemia
19:00
P916 Bone marrow transplantation for children and adolescents with severe aplastic
anaemia: analysis of 75 pts heavily transfused patients treated with busulfan +
cyclophosphamide
C. Bonfim, S. Fortier, M. Bitencourt, L. Medeiros, J. Ruiz, M. Oliveira, A. Koliski,
D. Setubal, V. Funke, E. Nunes, J. Morando, C. Medeiros, R. Pasquini, J. Zanis-Neto
(Curitiba, BR)
P917 Results of haematopoietic stem cell transplantation in children with severe
aplastic anaemia in Hungary (1992–2008)
G. Krivan, K. Kállay, G. Vértesi, G. Benyó, G. Márton, R. Simon, Á. Tóth, K. Nagy
(Budapest, Miskolc, HU)
P918 Fludarabine, cyclophosphamide with or without low dose TBI for alternative donor
transplants in acquired aplastic anaemia: a report from the EBMT-SAA Working Party
A. Bacigalupo, F. Locatelli, E. Lanino, J. Marsh, G. Socié, S. Maury, A. Ibatici, A. Prete,
A. Locasciulli, S. Cesaro, J. Passweg (Genoa, Pavia, Bologna, Rome, Padua, IT;
London, UK; Paris, Créteil, FR; Geneva, CH)
P919 Allogeneic haematopoietic stem cell transplantation with cyclophosphamide and
alemtuzumab for severe aplastic anaemia
F. Lodi, M. Laercio, G. Fischer, C. Rodrigues, A. Macedo, S. Magalhães, R. Lamego,
L. Fogliatto, J. Oliveira, H. Bittencourt (Belo Horizonte, Sao Paulo, Porto Alegre, BR)
P920 A pilot study of anti-interleukin-2 receptor antibody daclizumab combined with
cyclosporine as salvage immunosuppressive therapy for refractory or relapsed
aplastic anaemia
A. Kulagin, I. Lisukov, I. Kruchkova, V. Sergeevicheva, A. Gilevich, S. Sizikova,
O. Korolkova, V. Kozhevnikov, V. Kozlov (Novosibirsk, RU)
P921 More than five years survival of aplastic anaemia patients receiving
non-transplant treatment
A. Moicean, A.M. Popp, M. Brinza, C. Calugaroiu, T. Puscariu on behalf of the Romanian
Working Group for Aplastic Anemia
119

120
Posters Physicians Tuesday, 31 March 2009
17:30– Autoimmune diseases
19:00
P922 Autologous stem cell transplantation for refractory systemic lupus erythematosus:
clinical effects and immune reconstitution
I. Lisukov, V. Sergeevicheva, S. Sizikova, A. Kulagin, I. Kruchkova, A. Gilevich, A. Sizikov,
L. Konenkova, E. Chernykh, E. Kurganova, V. Kozhevnikov, N. Pronkina, E. Blinova,
V. Borisov, T. Sentyakova, A. Demin, V. Kozlov (Novosibirsk, RU)
P923 Development of antinuclear antibodies with new specificities in systemic
lupus erythematosus after autologous haematopoietic stem cell transplantation
suggests de novo development of disease rather than lupus reactivation
T. Alexander, A. Thiel, O. Rosen, G. Massenkeil, G. Burmester, H. Radtke, R. Arnold,
F. Hiepe (Berlin, DE)
P924 Induction of immune tolerance to gluten in coeliac disease after allogeneic
haematopoietic stem cell transplantation for thalassaemia major
M. Bernardo, R. Ciccocioppo, G. Giorgiani, A. Cometa, M. Valli, A. Mastronuzzi,
R. Maccario, G. Corazza, F. Locatelli (Pavia, IT)
P925 Reversal of neurologic disability after non-myeloablative autologous
haematopoietic stem cell transplantation for relapsing-remitting multiple
sclerosis
R.K. Burt, J. Bucha, F. Milanetti, A. Testori (Chicago, US)
P926 Incidence of cytomegalus virus infection in autoimmune diseases after
autologous stem cell transplantation
F. Pieroni, A.B.P.L. Stracieri, M.C. Rodrigues, D.A. Moraes, G.M.N. Barros, B.P. Simões,
J.C. Voltarelli (Ribeirão Preto, BR)
P927 Autologous haematopoietic stem cell transplantation for refractory Crohn's
disease: updating the Milan experience without CD34+ cell selection
F. Onida, A. Cassinotti, C. Annaloro, A. Della Volpe, P. Usardi, B. Motta, S. Ardizzone,
E. Tagliaferri, G. Bianchi Porro, G. Lambertenghi Deliliers (Milan, IT)
P928 Haematopoietic stem cell transplantation for severe autoimmune diseases.
A single-centre 12-year experience
F. Gualandi, B. Bruno, S. Bregante, A. Dominietto, M.T. van Lint, L. Grassia, A. Uccelli,
E. Capello, G.L. Mancardi, A. Bacigalupo, A.M. Marmont (Genoa, IT)
P929 Thiotepa-cyclophosphamide high-dose immunosuppressive therapy with
autologous haematopoietic stem cell transplantation in aggressive forms of
multiple sclerosis: results in 9 patients
R. Greco, L. Moiola, T. Roccia, M. Radaelli, J. Peccatori, C. Bonini, C. Corti, M. Bernardi,
M.T. Lupo Stanghellini, G. Comi, F. Ciceri (Milan, IT)
P930 Factor VIII haemophilia acquired as secondary autoimmune disease after
haematopoietic stem cell transplantation (ASCT) for refractory systemic lupus
erythematosus (SLE) dissolves with relapse of SLE – A case report
T. Alexander, S. Schneider, S. Ziemer, U. Schneider, H. Radtke, G. Burmester, A. Thiel,
R. Arnold, F. Hiepe (Berlin, DE)
P931 A two step approach to autologous peripheral blood stem cell transplantation for
refractory chronic inflammatory bowel diseases – The Freiburg Pilot Study
W. Kreisel, K. Potthoff, H. Bertz, P. Hasselblatt, T. Baumert, C. Arnold, J. Finke
(Freiburg, DE)
P932 Autologous stem cell transplant for severe refractory Crohn's disease:
The UK experience
M. Kazmi, A. Ansari, J. Sanderson, G. Jackson, A. Lobo, N. Thompson, J. Snowden
(London, Newcastle, Sheffield, UK)

Posters Physicians Tuesday, 31 March 2009
17:30– Myelodysplasia
19:00
P933 Prognostic impact of pretransplantation transfusion-dependency and serum
ferritin level in patients with myelodysplastic syndrome undergoing allogeneic
stem cell transplantation: a study from the Gruppo Italiano Trapianto di Midollo
Osseo (GITMO)
E.P. Alessandrino, M. G. Della Porta, A. Bacigalupo, M. T. Van Lint, M. Falda, E. Angelucci,
F. Onida, M. Bernardi, A.P. Iori, A. Rambaldi, R. Cerretti, P. Marenco, P. Pioltelli,
L. Malcovati, C. Pascutto, R. Oneto, R. Fanin, A. Bosi on behalf of Gruppo Italiano
Trapianto di Midollo Osseo (GITMO)
P934 Allo SCT in therapy-related MDS arising from solid tumour or malignant
lymphoma treatment without additional adverse prognostic factors of the HCT-CI
Index leads to comparable results as in primary MDS
R. Trenschel, N. Steckel, L. Kordelas, T. Gromke, A.H. Elmaagacli, C. Schulte, D. Beelen
(Essen, DE)
P935 Chimerism analysis as a predictor of relapse of myelodysplastic syndrome after
allogeneic stem cell transplantation
M. Tobiasson, R. Olsson, M. Remberger, E. Hellström-Lindberg, J. Mattsson
(Eskilstuna, Stockholm, SE)
P936 Update on immunosuppressive therapy for children with refractory cytopenia
A.M.J. Peters, A. Yoshimi, I. Baumann, B. Strahm, I. Furlan, E. Bergsträßer, A. Fischer,
F. Locatelli, M. M. van den Heuvel-Eibrink, M. Führer, C. Niemeyer (Freiburg, Bayreuth,
Munich, DE; Zurich, CH; Pavia, IT; Rotterdam, NL)
P937 Allogeneic haematopoietic cell transplantation for myelodysplastic syndrome:
prognostic significance of pretransplant IPSS score and co-morbidity
J.H. Lee, J.H. Lee, S. Lim, D.Y. Kim, S.H. Kim, Y.S. Lee, Y.A. Kang, S.I. Kang, S.G. Ryu,
M.J. Jeon, M. Seol, E.J. Seo, H.S. Chi, C.J. Park, S. Jang, S.C. Yun, K.H. Lee (Seoul, KR)
P938 Allogeneic haematopoietic stem cell transplantation for acute myeloblastic
leukaemia or myelodysplastic syndrome in patients older than 50 years
M. Robin, R. Porcher, L. Adès, E. Raffoux, R. Peffault de Latour, A. Petropoulou,
N. Boissel, P. Ribaud, A. Devergie, V. Rocha, P. Fenaux, H. Dombret, G. Socié
(Paris, Bobigny, FR)
P939 The effect of transfusions and iron toxicity on non-relapse mortality in patients
with untreated adult MDS treated with myeloablative alloSCT: a retrospective
study of the MDS subcommittee of the Chronic Leukaemia Working Party of the
EBMT
L. Spinnewijn, A. van Biezen, R. Brand, J. Finke, U. Platzbecker, T. Ruutu, D. Beelen,
R. Schwerdtfeger, Y. Floisand, R. Martino, D. Niederwieser, A. Atienza, K. Steinerova,
N. Kröger, T. de Witte on behalf of the MDS subcommittee of the Chronic Leukaemia
Working Party of the EBMT
P940 Allogeneic haematopoietic stem cell transplantation as front line therapy for
patients with “de novo” or secondary myelodysplastic syndrome:
a single-centre experience
M. Sorio, R. Di Bella, A. Andreini, C. Tecchio, F. Frattini, G. Quaresmini, F. Randon,
G. Ruggeri, A. Al-Kafaff, S. Ledro, D. de Sabata, F. Benedetti (Verona, IT)
121

122
Posters Physicians Tuesday, 31 March 2009
17:30– Reduced-intensity transplants
19:00
P941 Role of co-morbidity score, age and disease status at transplant in predicting
survival and non-relapse mortality in patients with MDS and leukaemia
undergoing reduced-intensity conditioning transplantation
S.W. Bokhari, L. Watson, E. Das-Gupta, J. Byrne, N. Russell (Nottingham, UK)
P942 C-reactive protein predicts outcome after reduced conditioning allogeneic stem
cell transplantation
M. Remberger, J. Mattsson (Stockholm, SE)
P943 A comparison of campath and thymoglobulin as part of conditioning before
allogeneic HSCT
M. Remberger, A.-C. Norlin (Stockholm, SE)
P944 Factors affecting thymopoiesis after non-myeloablative conditioning
E. Castermans, M. Hannon, R. Cheynier, E. Willems, A. Gothot, V. Geenen, Y. Beguin,
F. Baron (Liege, BE; Paris, FR)
P945 Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reducedintensity
conditioning regimen for allogeneic haematopoietic cell transplantation
in patients with advanced indolent non-Hodgkin's lymphoma
W.A. Bethge, T. Lange, S. von Harsdorf, M. Bornhäuser, B. Federmann, M. Stadler,
L. Uharek, S. Knop, G. Wulf, H. Dittmann, C. Faul, W. Vogel, L. Kanz, D. Bunjes
(Tübingen, Leipzig, Ulm, Dresden, Hannover, Berlin, Würzburg, Göttingen, DE)
P946 Dose-escalated radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as
part of a reduced-intensity conditioning regimen for allogeneic haematopoietic
cell transplantation in patients with advanced aggressive non-Hodgkin's
lymphoma
W.A. Bethge, S. von Harsdorf, M. Bornhäuser, D. Beelen, M. Stelljes, R. Schwerdtfeger,
L. Uharek, B. Federmann, C. Faul, W. Vogel, H. Dittmann, L. Kanz, D. Bunjes
(Tübingen, Ulm, Dresden, Essen, Münster, Wiesbaden, Berlin, DE)
P947 Conditioning regimens prior to allogeneic stem cell transplantation in acute
leukaemia: the role of dose intensity
A. Shimoni, A. Rand, I. Hardan, N. Shem-Tov, R. Yerushalmi, A. Nagler (Tel-Hashomer, IL)
P948 Cytoreduction with clofarabine/Ara-C combined with reduced-intensity
conditioning and allogeneic stem cell transplantation in patients with high-risk,
relapsed, or refractory acute leukaemia
S. Buchholz, J. Krauter, E. Dammann, G. Beutel, M. Stadler, M. Eder, A. Ganser (Hannover, DE)
P949 Reduced-intensity conditioning umbilical cord blood transplantation in adults:
age, disease status and infectious complications are important risk factors for
outcome
S. Fürst, C. Faucher, J. El Cheikh, J. Boher, P. Ladaique, C. Lemarié, N. Vey, A. Stoppa,
R. Bouabdallah, H. de Lavallade, M. Mohty, C. Chabannon, D. Blaise (Marseille, FR)
P950 Long-term clinical and molecular outcomes following RIC-allogeneic HSCT from
HLA-identical sibling in patients with advanced mycosis fungoides and Sézary
syndrome
F. Onida, E. Berti, G. Saporiti, L. Corti, C. Annaloro, E. Tagliaferri, A. Della Volpe, P. Vezzoli,
P. Usardi, G. Lambertenghi Deliliers (Milan, IT)
P951 Double reduced-intensity allogeneic haematopoietic stem cell transplantation
J.-O. Bay, A. Cabrespine-Faugeras, C. Faucher, R. Tabrizi, P. Bordigoni, K. Bilger,
J.P Jouet, M. Renaud, V. Mialou, M. Robin, M. Kuentz, P. Chevallier, N. Dhédin,
A. Huynh, F. Garban, F. Witz, A. Buzyn, T. De Revel, C. Galambrun, E. Deconnick,
N. Contentin, S. Francois, D. Blaise, M. Michallet on behalf of the Société Française de
Greffe de Moelle et de Thérapie Cellulaire, SFGMTC

Posters Physicians Tuesday, 31 March 2009
17:30– Reduced-intensity transplants (continued)
19:00
P952 Immune reconstitution after haplo-identical haematopoietic cell transplantation:
impact of reduced-intensity conditioning and CD3/CD19 depleted grafts
B. Federmann, M. Haegele, C. Faul, W. Vogel, L. Kanz, W.A. Bethge (Tübingen, DE)
P953 Acute graft-versus-host disease prophylaxis after reduced-intensity conditioning
in allogeneic peripheral blood stem cell transplantation from HLA-identical sibling
donors. Comparison of CsA and MMFvs CsA and MTX
J.L. Piñana, D. Valcarcel, F. Fernandez-Avilés, R. Martino, M. Rovira, P. Barba, A. Sureda,
E. Carreras, J. Sierra (Barcelona, ES)
P954 Regulatory T-cells and chronic GvHD after non-myeloablative conditioning
S. Humblet-Baron, E. Castermans, J.F. Vanbellinghen, M. Hannon, N. Jacobs, E. Willems,
S. Ormenese, Y. Beguin, F. Baron (Liege, BE)
P955 Pretransplant characteristics could predict full donor chimerism on day +90 and
day +180 and outcomes in reduced-intensity alemtuzumab conditioning
allogeneic transplantation can be influenced by chimeric status
E. Nikolousis, S. Tauro, C. Brookes, S. Paneesha, I. Novitzky Basso, P. Mahendra,
M. Cook, F. Clark, D. Macmullan, M. Griffiths, R. Lovell, S. Chaganti, S. Chaganti,
D. Milligan, S. Robinson, C. Craddock (Birmingham, Dundee, Bristol, UK)
P956 Effect of donor and recipient ABO group on overall survival post allogeneic
HSC transplant: is minor-side ABO incompatibility still associated with adverse
outcome in reduced-intensity conditioning allograft despite the use of
alemtuzumab in conditioning?
E.K. Nicholson, A. Clark, I.G. McQuaker, A.N. Parker, K.W. Douglas (Glasgow, UK)
P957 Allogeneic HSCT with reduced intensity versus myeloablative conditioning
regimens in paediatric acute lymphoblastic leukaemia
E. Semenova, N. Stancheva , I. Kazantsev, Y. Vasilieva, V. Kostorov, S. Shiryaev,
B. Afanasyev, L. Zubarovskaya (St. Petersburg, RU)
P958 Outcome of sequential regimen of chemotherapy and reduced-intensity
conditioning in patients with advanced haematological malignancies
M. Krejci, J. Mayer, Y. Brychtova, M. Doubek, Z. Racil, Z. Koristek, M. Navratil,
M. Tomiska, J. Vorlicek (Brno, CZ)
P959 Improved outcome following reduced-intensity conditioning for second allogeneic
stem cell transplantation
D. Nachbaur, J. Auberger, J. Clausen, B. Lindner (Innsbruck, AT)
P960 Reduced-intensity HLA-haplo-identical stem cell transplantation with post
transplantation cyclophosphamide in patients with advanced haematological
malignancies
D. Nachbaur, J. Auberger, R. Muehlmann, B. Kircher, J. Clausen (Innsbruck, AT)
P961 Clinical course and outcome of 20 patients with two or more allogeneic
haematopoetic stem cell transplantations
C. Grosse-Thie, K. Borchert, K. Jost, I. Hilgendorf, H. Andree, M. Leithauser, C. Kahl,
M. Freund, C. Junghanss (Rostock, DE)
P962 Reduced-intensity conditioning with fludarabine/cyclophosphamide has
remarkably high activity in relapsed or refractory lymphoid malignancies
F.S. Dijkstra, O. Visser, S. Zweegman, P.C. Huijgens, J.J.W.M. Janssen (Amsterdam, NL)
P963 Long-term follow-up after non-myeloablative allogeneic related transplant with
melfalan and fludarabine in patients with aggressive T-cell lymphoma.
Results from three prospective trials. The GELTAMO experience
D. Caballero, J. Gayoso, R. Arranz, A. Sampol, J. Perez-Oteiza, R. Martino, J. Tomas,
I. Heras, C. Solano, J.L. Diez, L. Vazquez, J. San Miguel on behalf of the GEL/TAMO group
123

124
Posters Physicians Tuesday, 31 March 2009
17:30– Reduced-intensity transplants (continued)
19:00
P964 Long-term follow-up after non-myeloablative allogeneic related transplant
with melfalan and fludarabine in patients with aggressive B-cell lymphoma:
results of three consecutive multicentre trials from the GEL/TAMO Group
D. Caballero, R. Martino, M.L. Vasquez, J.L. Piñana, I. Heras, C. Ferra, J.F. Tomas,
R. Arranz, J. Perez-Oteiza, J. Briones, J. San Miguel on behalf of the GEL/TAMO group
P965 Reduced-intensity transplant for MDS/AML – A single-centre experience and
retrospective analysis
S. McLean, M. Ni Chonghaile, E. Lawlor, C. Flynn, E. Vandenberghe, P. Browne,
E. Conneally (Dublin, IE)
P966 Non-myeloablative stem cell transplantation (NST) conditioning protocol without
anti-thymocytic globulin
M. Shapira, L. Drey, I. Resnick, P. Tsirigotis, B. Gesundheit, R. Or (Jerusalem, IL)
P967 Results of reduced-intensity conditioning stem cell transplantation with
intensified fludarabine-based regimen for advanced lymphoid malignancies
J. Falantes, M. Rodríguez, F.J. Márquez, M. Carmona, E. Ríos, A. Marín, M. Martino,
I. Montero, J. González, R. Parody, A. Urbano-Ispizua, I. Espigado (Seville, ES)
P968 Reduced-toxicity conditioning with busulfan and fludarabine and allogeneic stem
cell transplant: chimerism evaluation and global outcome of 26 consecutive
patients
A. Algarotti, C. Micò, A. Salvi, C. Zanotti, A. Grassi, A. Rambaldi (Bergamo, IT)
P969 Long-term results of reduced intensity compared to myeloablative conditioning
before stem cell transplantation
Y. Brychtova, M. Doubek, M. Krejcí, M. Navrátil, O. Horký, T. Jurcek, J. Mayer (Brno, CZ)
P970 Effect of supplementary CD56+ lymphocyte infusion in HLA-matched nonmyeloablative
stem cell transplantation
S.J. Kim, H.W. Lee, J.S. Kim, J.W. Cheong, Y.H. Min (Seoul, KR)
17:30– Stem cell donor
19:00
P971 Military induction centres as stem cell donor registration sites:
effects on donor recruitment
J. Stein, A. Peles-Bortz, N. Shriki, A. Sinai, B. Zisser, I. Yaniv (Petach Tikva, IL)
P972 Natalizumab treatment modulates phenotypic profile and expression of adhesion
molecules in bone marrow and peripheral blood CD34+ cells of patients with
multiple sclerosis
U. Oelschlägel, T. Ziemsen, C. Garten, M. Markgraf, G. Ehninger, M. Bornhäuser
(Dresden, DE)
P973 Could donor selection according the KIR repertoire be feasible?
Analysis of KIR genes diversity of the HLA haplotype A1B8DR3 (AH 8.1):
Study on Czech National Marrow Donors Registry donors
P. Jindra, P. Venigova, V. Koza, J. Navratilova, K. Steinerova, H. Pittrova (Pilsen, CZ)
P974 Results of a prospective, monocentric study on the search of an unrelated donor
for patients with high-risk acute lymphoblastic leukaemia
A.P. Iori, V. Valle, A. Piciocchi, G.F. Torelli, G. Meloni, A.M. Testi, W. Barberi, A. Vitale,
L. Malandruccolo, E. Iannella, B. Lucarelli, E. Arleo, M.P. Perrone, L. Laurenti, M. Screnci,
R. Ricci, W. Arcese, R. Foà (Rome, IT)
P975 Retrospective study of safety of peripheral blood stem cell donation by family
members
J. Wiersum-Osselton, A.M. van Walraven, W. Fibbe, A. Brand (The Hague, Leiden, NL)
P976 Distribution of killer cell immunoglobulin-like receptor genes in East China and
Taiwanese populations
H. Huang, G. Wu, X. Lai, Y. Tan, Y. Luo, F. Zhu (Hangzhou, CN)
P977 Clinical outcome of haematopoietic stem cell transplant from AB0-blood group
incompatible donors
C. Elena, F. Ripamonti, P. Bernasconi, D. Caldera, A. Colombo, P. Isernia, M. Merli,
V. Fiaccadori, G. Pica, C. Pascutto, M. Lazzarino, E.P. Alessandrino (Pavia, IT)

Posters Physicians Tuesday, 31 March 2009
17:30– Stem cell donor (continued)
19:00
P978 Factors predicting allogeneic peripheral blood stem cell mobilisation after G-CSF
treatment in healthy donors
E. Brissot, P. Chevallier, T. Guillaume, J. Delaunay, S. Ayari, V. Dubruille, S. Le Gouill,
B. Mahe, T. Gastinne, N. Blin, B. Saulquin, G. Flandrois, A. Devys, A. Cesbron, V. Stocco,
P. Moreau, J.L. Harousseau, M. Mohty (Nantes, FR)
P979 Allele frequencies at HLA class I and class II loci in Iranian placental blood
samples
A. Ghashghaie, K. Alimoghaddam, M. Ostadali, H. Ghaffari, L. Khansari, M. Sadraee,
E. Mir Rasekhian, I. Mohyedin, F. Raoofi, Z. Noori, H. Eshaghi, H. Yaghmaian,
A. Ghavamzadeh (Tehran, IR)
P980 Mobilisation and harvest of peripheral blood stem cells for allogeneic stem cell
transplantation from 69 healthy donors less than 18 years old
M. Benakli, R. Ahmed Nacer, R. Belhadj, F. Mehdid, N. Rahmoune, F. Harieche,
R.M. Hamladji (Algiers, DZ)
P981 KIR gene and genotype frequencies in Russian stem cell donors
E. Khamaganova, Y. Lednev, N. Ovchinina, L. Golovkina (Moscow, RU)
P982 The importance of graft cell composition to outcome after allogeneic stem cell
transplantation
P. Svenberg, O. Ringdén, M. Uzunel (Stockholm, SE)
P983 Donor search for patients at a St.Petersburg medical university bone marrow
transplantation clinic in association with HLA polymorphism
A. Alyanskiy, O. Paina, N. Ivanova, A. Golovacheva, L. Zubarovskaya, B. Afanasyev
(St. Petersburg, RU)
P984 Minority report. Representation of ethnic minority groups at a cord blood bank,
Pavia
P. Bergamaschi, C. Parisi, V. Genovese, E. Beolchini, T. Quaglini, L. Gilardi,
A. Campagnoli, G. Marchese, G. Viarengo, C. Del Fante, A. Marchesi, B. Romano,
C. Perotti, L. Salvaneschi (Pavia, Broni, Voghera, Codogno, Lodi, IT)
P985 Infant or young donors for bone marrow transplant in thalassaemic sibling
recipients: a comparison of graft products
K. Paciaroni, C. Gallucci, C. Alfieri, G. De angelis, A. Isgro, M. Marziali, A. Roveda,
P. Polchi, P. Sodani, J. Gaziev, G. Lucarelli (Rome, IT)
P986 A reassessment of the value of peripheral blood CD34 enumeration prior to
autologous peripheral blood collection
S. Wadiwalla, S. Couban (Halifax, CA)
P987 Influencing factors on stem cell mobilisation and the yield of collection in
paediatric malignancies
C. Landefeld, K. Kentouche, A. Müller, F. Zintl, J. Beck (Jena, DE)
17:30 – Regulatory issues
19:00
P988 First European haematopoietic progenitor cell transplant unit obtaining
re-accreditation of a JACIE quality system: experience and difficulties for
implantation
F. de Arriba, M.L. Lozano, J. Nieto, C. Castilla, J. Márquez, J. Tomás Martínez, J. Rivera,
I. Heras, V. Vicente (Murcia, ES)
P989 Cost of allogeneic haematopoietic stem cell transplantation
R.F. Duarte, B. Patiño, C. Muñoz, M. Arnan, T. Peralta, A. Clopés, J.L. López-Belmonte,
A. Fernández de Sevilla, F.J. Sabater (Barcelona, ES)
125

126
Posters Physicians Tuesday, 31 March 2009
17:30– Cytokines
19:00
P990 Polymorphism in the genes encoding human interleukin-7 receptor-alpha and
outcome after allogeneic haematopoietic cell transplantation with matched
unrelated donor
Z. Shamim, L. Ryder, M. Haagenson, S. Spellman, T. Wang, S. Lee, K. Müller
(Copenhagen, DK; Minneapolis, Milwaukee, Seattle, US)
P991 A prospective randomised multicentre trial of darbepoetin-alfa and I.V. iron
administration after autologous haematopoietic stem cell transplantation
Y. Beguin, J. Maertens, B. De Prijck, R. Schots, P. Frère, C. Bonnet, K. Hafraoui,
E. Willems, G. Vanstraelen, M. Lejeune, K. Theunissen, G. Fillet, F. Baron
(Liege, Leuven, Brussels, BE)
P992 TGFB1 Codon 10 polymorphisms are associated with worst outcome in allogeneic
unrelated donor haematopoietic stem cell transplantation
M. Berro, N. Mayor, L. Cooke, G. Kusminsky, S. Marsh, J.A. Madrigal, B.E. Shaw
(London, UK; Pilar, AR)
P993 A phase II randomised study comparing pegfilgrastim vs. filgrastim after
high-dose chemotherapy and autologous peripheral blood stem cell support
L. Castagna, S. Bramanti, A. Levis, M. Michieli, A. Anastasia, B. Sarina, E. Todisco,
A. Nozza, L. Giordano, A. Santoro (Rozzano, Alessandria, Aviano, IT)
P994 The G-CSF effect in the setting of splenomegaly and extramedullary
haemopoiesis: a mobilisation study in a thalassaemia mouse model as compared
to normal strain
E. Yannaki, N. Psatha, E. Athanasiou, G. Karponi, D. Bougiouklis, V. Constantinou,
M. Demertzi, P. Kaloyannidis, I. Batsis, A. Anagnostopoulos, A. Fassas (Thessaloniki, GR)
P995 The stromal cell-derived factor -1 (SDF-1/CXCL12) gene polymorphism as a
marker of recovery of granulocytes and platelets after transplantation of
haematopoietic stem cells
A. Gieryng, K. Bogunia-Kubik, S. Madej, M. Mordak-Domagala, A. Lange (Wroclaw, PL)
P996 Successfull autologous peripheral blood stem cells collection by a single dose
of pegfilgrastim in combination with chemotherapy in patients with malignant
lymphomas
S. Bassi, S. Steffanoni, P. Antoniotti, A. Babic, A. Alietti, L. Nassi, B. Lucchetti,
S. Sammassimo, M.T. Lionetti, L. Roveda, M. Negri, C. Rabascio, G. Martinelli (Milan, IT)
P997 Timing of G-CSF injection for effective autologous stem cell collection
J.E. Kim, C. Suh, E.K. Kim, B.S. Sohn, I. Park, D.H. Yoon, C. Yoo, G. Jang, D.H. Lee,
S.-W. Kim, J.S. Lee (Seoul, KR)
17:30 – Tolerance and alloreactivity
19:00
P998 HLA-E up-regulation on IFN-g-activated AML blasts impaired CD94/NKG2Adependent
NK cytolysis following haplo-identical haematopoietic stem-cell
transplantation
S. Nguyen, V. Beziat, N. Dhedin, M. Kuentz, M. Uzunov, J. Vernant, P. Debre, V. Vieillard
(Paris, Creteil, FR)
P999 Targeting the programmed death (PD)-1 / PD ligand 1 pathway to induce
peripheral tolerance in allograft recipients
P. Müller, E. Distler, R.G. Meyer, U.F. Hartwig, C. Huber, W. Herr (Mainz, DE)
P1000 Increasing probabilities of kir expression characterize the formation of inhibitory
kir repertoires: evidence against selection of human NK cells
S. Andersson, C. Fauriat, J.A. Malmberg, H.G. Ljunggren, K.J. Malmberg (Stockholm, SE)
P1001 Maintained hyporesponsiveness of NK cells expressing inhibitory KIR for non-self
ligands in HLA-matched sibling stem cell transplantation
A.T. Björklund, M. Schaffer, C. Fauriat, O. Ringdén, M. Remberger, P. Ljungman,
H.G. Ljunggren, K.J. Malmberg (Stockholm, SE)

Posters Physicians Tuesday, 31 March 2009
17:30– Tolerance and alloreactivity (continued)
19:00
P1002 Cord blood banking: the role of NIMA haplotypes on searching for stem cell
compatible donors
C. Capittini, P. Bergamaschi, A.M. Pasi, C. Badulli, I. Sbarsi, F. Garlaschelli, M. Guarene,
A. Marchesi, B. Romano, V. Genovese, M. Martinetti, L. Salvaneschi, M. Cuccia (Pavia, IT)
P1003 The effect of donor KIR and patient HLA genotypes on outcome following
allogeneic haematopoietic stem cell transplantation in a Chinese population
H. Huang, G. Wu, X. Lai, Y. Tan, Y. Luo, F. Zhu (Hangzhou, CN)
P1004 Both naïve and memory lymphocyte subsets participate in alloresponses to HLA
mismatched stimulators – implications for selective depletion of GVHD reactivity
J. Barrett, M. Smith, Z. McIver, N. Hensel, J. Melenhorst (Bethesda, US)
P1005 Management of platelets transfusions in highly immunised beta thalassaemia
children undergoing bone marrow transplantation
S. Napolitano, E. Zino, R. Chiesa, B. Cappelli, R. Crocchiolo, E. Biral, A. Noè, I. Frugnoli,
T. Roccia, C. Evangelio, M. Fossati, A. Polselli, L. Barzizza, S. Rossini, F. Ciceri, P. Ronchi,
M.G. Roncarolo, K. Fleischhauer, S. Marktel (Milan, IT)
P1006 HLA-DR15 and outcome of unrelated donor haematopoietic stem cell
transplantation – An IHWG analysis
M. Stern, A. Gratwohl, M. Malkki, Y. Morishima, S. Spellman, T. Gooley, E. Petersdorf
on behalf of the International Histocompatibility Working Group in Hematopoietic Cell
Transplantation
P1007 Soluble CD30 following allogeneic haematopoietic stem cell transplantation:
an immunologic marker for an immunologic reaction?
K. Hübel, B. Cremer, E. Heuser, M. Hallek, H.P. Hansen (Cologne, DE)
17:30– Data management
19:00
P1008 The effects of incomplete data on survival analysis: a registry perspective
L.K. Wilcox, A. Jiamsakul, P. Lloyd (Darlinghurst, AU)
P1009 Missing items in Promise – Comparing national and megafile data
B. Lindner, H. Greinix on behalf of the Austrian Stem Cell Transplantation Group
P1010 Retrospective survey on methods and indications for blood stem cell
transplantations in one centre over 13 years
P. Mikulasova (Brno, CZ)
P1011 Secondary malignancies after autologous haematopoietic stem cell
transplantation – Data from the Czech transplant centres –
Experiences with EBMT database
K. Benesova, M. Trnkova, K. Doskocilova, B. Vackova, P. Mikulasova, K. Steinerova,
K. Waldmannova, I. Maresova, A. Luks, S. Hrabetova, J. Nepomucka (Prague, Hradec
Králové, Brno, Pilsen, Olomouc, CZ)
P1012 Clues to data-quality management
E.C.M. Miranda, C.V. De Souza, A.C. Vigorito, C. De Souza (Campinas, BR)
P1013 Data management in the HSCT unit of a university, Campinas
E.C.M. Miranda, C.V. De Souza, A.C. Vigorito, C. De Souza (Campinas, BR)
P1014 Allogeneic haematopoietic stem cell transplant in children. Trends and changes
over the last two decades in a single-centre experience
F. Deméocq, E. Rochette, C. Paillard, E. Dore, E. Merlin, A. David, F. Isfan, A. Rey,
C. Piguet, C. Dubray, J. Kanold (Clermont-Ferrand, Limoges, FR)
P1015 Multiple transplants – A descriptive summary of St. Vincent's Hospital Bone
Marrow Transplant Database
A. Jiamsakul, L. Wilcox, P. Lloyd (Sydney, AU)
127

128
Nurses Pre-Meeting Study Day Sunday, 29 March 2009
The focus of the 5 th Annual Study Day for Nurses and Allied Health
Professionals is on "Donor Issues" in the morning and "Infectious Issues"
in the afternoon.
09:00–
12:30
Standard Session
Chair: I. Andersson (Göteborg, SE)
Room H1
N1016 Opening
09:00 E. Aerts (Zurich, CH)
N1017 Basic overview of the significance of HLA matching in HSCT
09:15 J.A. Madrigal (London, UK)
Aims and objectives:
• To understand how HLA typing is evaluated
• To identify the relationship between HSCT graft rejection and GvHD
• To understand the selection pathway of an adequate donor
• To discuss the implications of complete versus partial match in conditioning
regimens and immunosupression and treatment outcomes
10:00 Coffee
Chair: M.I. Rebelo (Lisbon, PT)
N1018 The donor's perspective
10:20 K. Löfgren (Frillesås, SE)
Aims and objectives:
• To be aware of the donor’s feelings and thoughts during this pathway
N1019 Donor work-up, follow-up and ethical issues
10:40 H. Hägglund (Stockholm, SE)
Aims and objectives:
• To be aware of the inclusion criteria in donor programs
• To know the care before during and after the collection procedure
• To discuss the need for follow up of the donors
• To discuss ethical aspects during the donation process
11:30 Workshops on donor issues
• Selection, workup
• Follow-up care
• Ethical issues
Rooms H1/R2/R4
12:30 Lunch

Nurses Pre-Meeting Study Day Sunday, 29 March 2009
13:30–
16:30
Standard Session
Chair: J. Larsen (Stockholm, SE)
Room H1
N1020 Overview of infectious complications
13:30 C. Wennerås (Göteborg, SE)
Aims and objectives:
• Overview of the immune system and its role in the defence against infections
• To identify the risk factors for infection of the HSCT patient
• To identify the most frequent infections during the different phase of the
HSCT process
• To understand the rationale for granulocyte infusion, donor vaccination
N1021 Debate – protective isolation
14:15 A. Mank (Amsterdam, NL); E. Aerts (Zurich, CH)
Aims and objectives:
• To discuss the advantages and disadvantages of nursing patients in
protective isolation
15:00 Coffee
N1022 Nursing care of the patient with infective issues
15:20 M.I. Rebelo (Lisbon, PT)
Aims and objectives:
• Identify the role of the nurse during infectious complications in HSCT trajectory
• To discuss international guidelines for prevention of infection in HSCT recipient
• To recognize the importance of infection control practices in HSCT settings
N1023 Closing
16:15 J. Larsen (Stockholm, SE)
129

130
Nurses Pre-Meeting Study Day Sunday, 29 March 2009
The focus of the advance session will be on evidence based practice,
compliance & patients empowerment and vaccination strategies post HSCT.
13:30–
16:30
Advanced Practice Session
Chair: I. Andersson (Göteborg, SE)
Room R2
N1024 Evidence based practice – Making theory reality
13:30 E. Johansson (Stockholm, SE); J. McLellan (Manchester, UK)
Aim
To develop the participants understanding of evidence-based practice and to
promote the adoption of evidence-based practice.
Learning objectives
By the end of this course, participants should be able to understand how to
• define evidence based practice
• identify problems that need evidence
• ask relevant and focused questions to find evidence
• understand the steps needed to plan and carry out a search of the literature
for the best external evidence
• appraise and interpret evidence
• act on the evidence
15:00 Coffee
N1026 Vaccination strategies
15:20 P. Ljungman (Stockholm, SE)
Aims and objectives:
• To understand the need for vaccination in HSCT patients
• To identify guidelines for the vaccination of patients before and after HSCT
• To discuss new strategies in vaccination
N1027 Closing
16:15 I. Andersson (Göteborg, SE)
Scientific Programme Nurses Group Sunday, 29 March 2009
18:30–
20:00
Opening Session Congress Hall
Please refer to page 33 for details.
20:00 Welcome Reception
Please refer to page 195 for details.

Scientific Programme Nurses Group Monday, 30 March 2009
08:00– Nurses Educational Session 1 Room A7
08:50
Total body irradiation
Chair: E. Wallhult (Göteborg, SE)
N1028 Total body irradiation
M. Adams (London, UK)
Aims and objectives:
• to give an overview of total body irradiation and it’s role in HSCT
• to give examples of TBI and examples of it’s use in practice.
• to discuss the potential complications of TBI
• to explore the management of these complications
• to identify some of the preventative strategies that may be employed now and
in the future
08:00– Nurses Educational Session 2 Room A6
08:50
Chronic myeloid leukaemia
Chair: M. Ni Chonghaile (Dublin, IE)
N1029 Chronic myeloid leukaemia
J. Apperley (London, UK)
Aims and objectives:
• to identify recent developments in diagnosis
• to identify and discuss recent developments on treatment
• to discuss treatment options of both illnesses including indications and the
role of autologous and allogeneic transplantation
• to focus on post transplantation results with early and late complications.
09:00–
10:30
Nurses Opening Session Room E3
A celebration of 25 years of the EBMT Nurses Group
Chairs: E. Aerts (Zurich, CH); M. Ni Chonghaile (Dublin, IE)
N1030 An overview of the achievements & developments of the EBMT Nurses Group
09:00 E. Aerts (Zurich, CH)
N1031 Developments and future of HSCT
09:20 D. Niederwieser (Leipzig, DE)
N1032 EBMT Nurses' group – the first 25 years
09:40 C. Charley (Sheffield, UK)
N1033 Transplant nursing history
10:00 R. Ford (Seattle, US)
10:20 Presentation of Distinguished Merit Award
131

132
Scientific Programme Nurses Group Monday, 30 March 2009
11:00– Nurses Session 1 Room G3
12:20
Donnor issues
Chairs: A. Kisch (Lund, SE); S. Degen (Basel, CH)
N1034 The sibling donor experience: haematopoeitic stem cell donation
11:00 D. Hutt, R. Ovadia, M. Nehari, B. Bielorai, A. Toren, A. Nagler (Tel-Hashomer, IL)
N1035 HLA tissue typing of family donors: respect for privacy and wellness
11:20 G.M.H. Bollen, M.C.E. Schoordijk (Amsterdam, NL)
N1036 Playing with stem cells: meeting the psychological needs of the sibling donor
11:40 I. Cullen, J. Aquan-Assee, N. O'Brian (London, UK)
N1037 The blessings and curses of siblingship – The challenge of relatedness
12:00 between siblings in the context of allogeneic bone marrow transplantation
T. Lanther (Copenhagen, DK)
11:00–
12:20
Nurses Session 2
Symptom management
Chairs: P. Kärvell (Linköping, SE); N. Borras (Barcelona, ES)
Room G4
N1038 View of pain
11:00 G.M.P. Dijkzeul van Schie, A.C. van den Akker, J. Schilstra, M.C.E. Verlaan
(Leiden, NL)
N1039 A randomised placebo-controlled study evaluating the effect of oral zinc
11:20 for the prevention of mucositis in lymphoma patients undergoing high-dose
chemotherapy and autologous stem cell transplantation
A. Skaat, A. Nagler, A. Shimoni, M. Koren-Michowitz (Ramat Gan, IL)
N1040 Adverse events during peripheral haematopoietic progenitor cell collection
11:40 with apheresis: experience in the past two years
P. Andidero, L. Imbalzano, G. Cornelio, G. Cutrupi, G. Placanica, G. Console,
E. Massara, P. Iacopino, M. Martino (Reggio Calabria, IT)
N1041 A mutli-factorial approach is effective in reducing nosocomial infections in
12:00 a leukaemia/stem cell transplant unit
T. Clegg, E. Tholouli, K. Dodgson, M. Murphy, A. Dodgson, K. Ryan, G. Heaton,
G.S. Lucas, J.A. Liu Yin (Manchester, UK)

Scientific Programme Nurses Group Monday, 30 March 2009
12:30– Nurses Satellite Symposium Room G3
13:30
Elucidating the issues in MDS treatment and transplant
S1042
Chairs: L. Arnold (Leeds, UK); J. Larsen (Stockholm, SE)
Welcome and opening remarks
12:30 E. Aerts (Zurich, CH)
S1043 Introduction: what are the issues?
12:35 L. Arnold (Leeds, UK); J. Larsen (Stockholm, SE)
S1044 What are the myelodysplastic syndromes?
12:40 D. Bowen (Leeds, UK)
S1045 Focus on treatment and transplant: decision strategies
12:55 G. Mufti (London, UK)
S1046 The role of the clinical nurse specialist in MDS
13:10 J. Hayden(London, UK)
13:25 Closing remarks
Satellite Symposium organised by MDS Foundation, Inc
Room R2
Complimentary therapies
N1047 Complimentary therapies
J. Stringer (Manchester, UK)
Aims of the Session:
The workshop aims to provide participants with:
• Basic information which will enable them to understand the issues which
must be taken into account when developing a complementary therapy service
within a transplant setting.
• Practical tools, such as examples of information sheets and audit forms
which will allow them to begin to develop services safely and appropriately in
their own areas of work
• First hand knowledge of what is possible
13:40– Nurses Workshop 11 15:10
13:40– Nurses Workshop 2 2
15:10
Sexuality
Room R4
N1048 Sexuality
C. Wendt (Lund, SE); C. Eeltink (Amsterdam, NL)
Aims & Objectives
• To define the problems
• To provide skills to help with defining problems and initiating discussion
• To look at giving information- what information when, boundaries for referral
1 Limited attendance, repeated on Tuesday, 31 March 2009
2 Limited attendance, repeated on Wednesday, 1 April 2009
133

134
Scientific Programme Nurses Group Monday, 30 March 2009
13:40– Nurses Plenary Session 3 Room A6
15:30
Palliative care in paediatrics
Chair: M.I. Rebelo (Lisbon, PT)
N1049 Palliative care in paediatrics
M.J. Pulles (Beek en Donk, NL); Y. Hakansson (Lund, SE)
Aims & Objectives
• To explore the roles of nurses and parents
• To look at the problems encountered & explore strategies for dealing with the
challenges encountered.
13:40– Nurses Plenary Session 4 Room H1
15:30
GvHD – new therapies, nursing care & photopheresis
Chair: A. Mank (Amsterdam, NL)
N1050 GvHD – new therapies, nursing care & photopheresis
R. de Weijer (Utrecht, NL); N. Vreeke (Utrecht, NL); M. Schoordijk (Castricum, NL)
Aims & Objectives
• to give an overview of the prevention and treatment of GVHD
• to identify and discuss new therapies and treatments for GVH
• To discuss the use of photopheresis
• The role of nurses in the management of GVHD
• The multi-disciplinary approach to the management of GVHD
13:40–
15:30
Nurses Plenary Session 5
Quality management
Chair: I. Andersson (Göteborg, SE)
Room G2
N1051 Quality management
N. Som (Bristol, UK)
Aims & Objectives
• To give an overview of quality management and it’s application to HSCT
• To explore and discuss how to implement a quality management plan
• To explore methods for performing audits
13:40–
15:30
Nurses Plenary Session 6
Compliance – whose responsibility?
Chair: E. Wallhult (Göteborg, SE)
Room A2
N1052 Compliance – whose responsibility?
J. Larsen (Stockholm, SE); M. Fliedner (Berne, CH)
Aims & Objectives
• To explore the concept, methodological challenges in measuring non-compliance
• To discuss experiences and interventions that might support patients to live with
the challenges of their chronic disease

Scientific Programme Nurses Group Monday, 30 March 2009
16:00– Nurses Session 3 Room G3
17:20
Survivorship I
Chairs: U. Frödin (Linköping, SE); L. Galgano (Florence, IT)
N1053 Life after discharge from the transplant unit: there isn’t a next step
16:00 B. Quested, T. Rudge, M.E. Purkis (Adelaide, Sydney, AU; Victoria, CA)
N1054 The development of a haematology late effects nurse consultant role with a
16:20 national scope
P. Gates, G. Wheeler, J.F. Seymour, D. Ritchie, N. Goroncy, S. Schembri
(Melbourne, AU)
N1055 Autologous transplantation and disability: an epidemiologic study
16:40 A. Tendas, S. Delogu, T. Dentamaro, L. Cupelli, A. Siniscalchi, P. Niscola,
A. D'apolito, A. Forleo, G. Mazza, A. Polonio, A. Presti, S. Rocci, A. Tangorra,
M. Vigliotti, R. Vigorito, A. Patanè, A.P. Perrotti, P. De Fabritiis (Rome, IT)
N1056 Trendy lifestyle: concerning rules after stem cell transplants
17:00 M. Rademaker on behalf of the Dutch Nurses Group
16:00–
17:20
Nurses Session 4
Patient education
Chairs: S. Zulu (Leiden, NL); K. Tufvander (Göteborg, SE)
Room G4
N1057 A DVD to inform recipients and donors about haematopoietic stem cell
16:00 transplantation
A. Wallart, K. Noe, G. Moreau, J.P. Jouet, I. Yakoub-Agha on behalf of the SFGM-TC
N1058 Development of standardised nursing care plan and information brochure
16:20 for patients at a unit for stem cell transplantation and haematology
A.H. Joergensen, K.R. Angelsen (Oslo, NO)
N1059 Istituto Europeo di Oncologia (IEO) Patient’s and Family Day: an Italian
16:40 experience
L. Orlando, S. Liptrott, A. Babic, A. Agazzi, S. Sammassimo, F. Lupo, A. Maldifassi,
R. Bedolis, P. Arnaboldi, A. Chyla, F. Didier, A. Piredda, G. Martinelli (Milan, IT)
N1060 Improving patients' self-care competence after haematopoietic stem cell
17:00 transplantation, using a modular, nurse-interdisciplinary counselling
programme in addition to standard clinical aftercare:
a prospective randomised study
N. Gittler-Hebestreit, M. Landenberger, H.G. Sayer (Jena, Halle, DE)
135

136
Scientific Programme Nurses Group Monday, 30 March 2009
17:30– Information on National EBMT Room G3
17:40 Nurses Group
Chair: M. Davies (Manchester, UK)
N1060a Participants, who are interested in setting up a national EBMT Nurses Group are
welcome to join the presentation.
17:30– Nurses National Group Meetings
18:30
German Group Room A7
Nordic Forum Room G4
United Kingdom Group Room H1
Middle-European National Group Room G2
Dutch Group Room A2
Swiss Group Room R2
Spanish Group Room R4
17:30– Nurses Poster Presentation (P1110 – P1206)
19:00
(please refer to pages 145 –151 for details)

Scientific Programme Nurses Group Tuesday, 31 March 2009
08:00– Nurses Educational Session 3 Room A7
08:50
Myelodysplastic syndromes
Chair: J. Larsen (Stockholm, SE)
N1061 Myelodysplastic syndromes
M. Markiewicz (Katowice, PL)
Aims and objectives:
• to identify recent developments on diagnosis
• to identify recent developments on treatment
• to discuss treatment options of MDS including allogeneic transplantation
and conditioning regimens
• to focus on post transplantation results with early and late complications
08:00– Nurses Educational Session 4 Room A6
08:50
EU directives
Chair: M. Ni Chonghaile (Dublin, IE)
N1062 An overview of regulation and accreditation of haemopoietic stem cell
transplantation in Europe
D. Pamphilon (Bristol, UK)
Aims and objectives:
• to discuss the background and recent developments with respect to EU
Directives in relation to Haematology & HSCT
• to explain the terminology & implications on practice
• to explore the future developments and potential developments
• to discuss the role of JACIE and national authorities and their impact on
current practice
08:00– Nurses Workshop 11 09:30
Complimentary therapies
Room A2
N1063 Complimentary therapies
J. Stringer (London, UK)
Aims of the Session:
The workshop aims to provide participants with:
• Basic information which will enable them to understand the issues which
must be taken into account when developing a complementary therapy service
within a transplant setting.
• Practical tools, such as examples of information sheets and audit forms
which will allow them to begin to develop services safely and appropriately in
their own areas of work
• First hand knowledge of what is possible
1 repeated session
137

138
Scientific Programme Nurses Group Tuesday, 31 March 2009
09:10– Joint Session Physicians / Nurses Room F4
10:40
Quality of life lessons – into the future
218
Chairs: M. Brune (Göteborg, SE); E. Aerts (Zurich, CH)
Quality of life studies – the nuts and bolts
09:10 A. Kiss (Basel, CH)
219 The impact of genital GvHD on life
09:40 E. Smith-Knutsson (Trollhättan, SE)
220 The impact of long-term follow-up on survivorship
10:10 D. Greenfield (Sheffield, UK)
11:00–
12:20
Nurses Session 5
Paediatric
Chairs: S. Calza (Genoa, IT); S. Twengström-Lord (Lund, SE)
Room G3
N1064 The role of a play therapist on the paediatric day-care and outpatient units
11:00 A.G.M. Neuman-van Eijk, E. Buschman, M.C.W. Timp-van Zoest (Leiden, NL)
N1065 Sibling support
11:20 T. Berisa (Göteborg, SE)
N1066 Quality of life for children and family in isolation
11:40 A. Graca, R. Pires (Lisbon, PT)
N1067 Parental stress and perceived vulnerability five and ten years after
12:00 paediatric SCT
C.M.J. Vrijmoet-Wiersma, M. Egeler, H.M. Koopman, M.A. Grootenhuis
(Leiden, Amsterdam, NL)
11:00–
12:20
Nurses Session 6
Impact of new therapies
Chairs: C. Pino-Molina (Basel, CH); L. Eliasson (Umea, SE)
Room G4
N1068 Nursing staff's attitudes towards medical clowns
11:00 A. Sweed-Nagler, E. Leibowitz, L. Biton, A. Zaken, R. Radiano
(Jerusalem, Tel Aviv, IL)
N1069 High-dose melphalan with stem cell rescue in the ambulatory care setting:
11:20 the process to enable the concept to become a realistic treatment option
A. Nield, C. Charley, C. Dalley, J. Davis, Y. Goddard, M. Salt, J. Snowden,
N. Sprigens, S. Ward (Sheffield, UK)
N1070 Hyperbaric oxygen therapy for post-stem cell transplant haemorrhagic
11:40 cystitis in children and adolescents
R. Baslo, L. Har-Zion, A. Peles-Bortz, Y. Bechor, S. Efrati, D. Ben Meir, I. Yaniv,
J. Stein (Petah-Tikva, Zrifin, IL)
N1071 Haplo-identical stem cell transplantation after non-take allogenic HSCT
12:00 T. Carels, I. Peier (Zurich, CH)

Scientific Programme Nurses Group Tuesday, 31 March 2009
11:00– Nurses Plenary Session Room A7
12:30
More confidence in stem cell mobilisation and collection
Chairs: M. Ni Chonghaile (Dublin, IE); E. Wallhult (Göteborg, SE)
N1072 Physician's perspective
11:00 A.D. Ho (Heidelberg, DE)
N1073 Nurse's perspective
11:30 H. Devine (Columbus, US)
N1074 Feedback on use of Plerixafor
12:00 S. Taylor (Glasgow, UK)
12:10 Interactive part
Aims & objectives
• To understand the stem cell biology behind stem cell mobilisation
• To identify current mobilization strategies - limitations and challenges facing
centres and patients
• To discuss the impact of successful mobilisation
– Clinically
– Emotionally
– Centre efficiency
• To identify different strategies to inform and educate the patient/family
member/donor about the mobilisation procedure
12:30– Nurses Group Annual General Meeting Room G4
13:30
14:00–
15:40
Nurses Session 7
Staff education and development
Room A7
Chairs: A. Söderstrand (Göteborg, SE); M. Rademaker (Amsterdam, NL)
N1075 The route map of learning for nurses in haemato-oncology:
14:00 a haematopoietic progenitor cell transplant nurse competency
evaluation process
L. Ritchie, M. Coughlan, R. De Jesus, C. Kay (Sutton, UK)
N1076 Successful short nurse training project for the implementation of a new
14:20 haematopoietic stem cell transplant programme in Syria
C. Soliman, R. Mouna, S. Agazzi, A. Assanelli, S. Marktel, M.G. Roncarolo,
F. Ciceri, V. Matozzo (Milan, IT; Damascus, SY)
N1077 Haematology nursing knowledge and expertise
14:40 B. Quested (Adelaide, AU)
N1078 The coordinator nurse and laboratory personnel together in the front-line
15:00 of care – A challenge for staff, a benefit for patients?
E. Rom, M. Shpringer (Tel Aviv, IL)
N1079 An evaluation of using E-learning to support haematology nurse education
15:20 K.E. Campbell (Edinburgh, UK)
139

140
Scientific Programme Nurses Group Tuesday, 31 March 2009
14:00– Nurses Session 8 Room G4
15:20
Survivorship II
Chairs: J. Winterling (Stockholm, SE); A. Murst (Stuttgart, DE)
N1080 Promoting psychological and physical health of long-term haematopoietic
14:00 stem cell transplant survivors with a dedicated late-effects clinic
S. Mongta, P. Walker, S. Avery (Melbourne, AU)
N1081 Quality-of-life assessment after haematopoietic stem cell transplant
14:20 M. Kenyon, G. Mufti (London, UK)
N1082 Sexuality intervention in stem cell transplanted patients: is it our duty?
14:40 A. Rand, N. Hanna, I. Abargil, S. Torati (Ramat Gan, IL)
N1083 What nurses can do for female patients with genital graft-versus-host
15:00 disease
A. Wesström, E. Wahlström (Göteborg, SE)
16:00–
17:20
Nurses Session 9
Psychosocial support
Chairs: B. Keinrath (Vienna, AT); C. Charley (Sheffield, UK)
Room G3
N1084 Allogeneic BMT away from home: the experience of Icelandic patients
16:00 T. Saevarsdottir, N. Fridriksdottir, B. Unnarsdottir, S. Reykdal (Reykjavik, IS)
N1085 Nursing aimed at psychiatric stabilisation of the patients proposed for
16:20 haematopoietic stem cell transplantation
I. Iwakiri, N. Nakano, Y. Kamizuru, T. Fukumori, M. Kitahara, A. Utsunomiya
(Kagoshima, JP)
N1086 Who takes care of you? Psychosocial load of haematology/oncology nurses
16:40 A. Vlug, A. Mank (Amsterdam, NL)
N1087 Management of work stress in health care providers at the haematology
17:00 division using Shiatsu (alternative treatment approach)
R. Cohen, A. Mendelson, A. Gorelick (Haifa, IL)

Scientific Programme Nurses Group Tuesday, 31 March 2009
16:00– Nurses Session 10 Room G4
17:20
Management
Chairs: A. Pihlström (Göteborg, SE); S. Liptrott (Milan, IT)
N1088 Development of a preliminary ICF Core Set for patients who have undergone
16:00 allogeneic stem cell transplantation
J. Winterling, E. Johansson (Huddinge, Stockholm, SE)
N1089 Working together with patients: JACIE standards and the benefits of a
16:20 patient satisfaction survey
E. Dannie, A. Kew, K. Nakani, S. Nallamuthu, A.M. Dovernas, A. Nicol, E. Olavarria
(London, UK)
N1090 Building and implementing a new paediatric nurse transplant team within
16:40 an adult BMT unit in a Milan hospital
C. Soliman, S. Marktel, F. Ciceri, M.G. Roncarolo, A.M. Rossetti, V. Matozzo
(Milan, IT)
N1091 The BMT Network NSW, Australia – A unique model for transparent,
17:00 collaborative and patient-focused partnership in BMT units
J.C. Morrow (Sydney, AU)
17:30– Nurses Poster Presentation (P1110 – P1206)
19:00
(please refer to pages 145 –151 for details)
17:30 Nurses Anniversary Reception Foyer Room G4
The Nurses Group would like to invite all nurses to a special Nurses Anniversary
Reception in order to celebrate the ongoing success and development of the
Nurses Group over the last 25 years.
141

142
Scientific Programme Nurses Group Wednesday, 1 April 2009
08:00– Nurses Educational Session 5 Room G3
08:50
Autoimmune diseases in children
Chair: M.I. Rebelo (Lisbon, PT)
N1092 Autoimmune diseases in children
A. Fasth (Göteborg, SE)
Aims and objectives:
• to identify recent developments on diagnosis
• to identify and discuss recent developments on treatment
• to discuss treatment options of both illnesses including indications of
autologous and allogeneic transplantations
• to focus on post transplantation results with early and late complications
08:00– Nurses Educational Session 6 Room G4
08:50
Reduced-intensity transplant
Chair: I. Andersson (Göteborg, SE)
N1093 Reduced-intensity transplant
M. Ni Chonghaile (Dublin, IE)
Aims and objectives:
• to discuss the needs of patients, donors and families undergoing a reduced
intensity transplants
• to discuss the most prominent challenges in RIT nursing
• to discuss indications and conditioning regimens used.
• to focus on post transplantation results with early and late complications
08:00– Nurses Workshop 2 1
09:30
Sexuality
Room J2
N1094 Sexuality
C. Wendt (Lund, SE); C. Eeltink (Amsterdam, NL)
Aims & Objectives
• To define the problems
• To provide skills to help with defining problems and initiating discussion
• To look at giving information- what information when, boundaries for referral
1 repeated session

Scientific Programme Nurses Group Wednesday, 1 April 2009
09:00– Nurses Session 11 Room G3
10:40
Standards of care
Chairs: P. Schnatter (Vienna, AT); E. Johansson (Stockholm, SE)
N1095 Planned discharge starts upon admission
09:00 W.-Y. Hassan, N. Abu-Shkara, N. Porat, R. Radiano (Jerusalem, IL)
N1096 Patient undergoing haematopoietic stem cell transplantation: knowledge
09:20 related to the central venous catheter
L.C. Castanho, S.S. Elias, C.M. Galvão, R.C. de Campos Pere Silveira
(Ribeirão Preto, BR)
N1097 Preventing and treating pressure ulcers in HSCT patients
09:40 G. Hajaj, D. Galitzer, A. Collins, N. Porat, R. Radiano (Jerusalem, IL)
N1098 “Fear” for the low bacterial diet
10:00 K. Bleeker, A. Mank (Amsterdam, NL)
N1099 Is there a place for the Liverpool Care Pathway in the BMT setting?
10:20 C. Evans, L. Cooper, T. Rintala (London, UK)
09:00–
10:20
Nurses Session 12
Multidisciplinary collaboration
Chairs: A. Wesström (Göteborg, SE); M. Ek (Amsterdam, NL)
Room G4
N1100 Development and implementation of nursing audits in Swiss stem cell
09:00 transplantation centres
C. Pino Molina on behalf of the Swiss National Group Stem Cell Care
N1101 That's the way. Patients and nurses' national group cooperation
09:20 M. Ek on behalf of the Dutch nurses group
N1102 Ethics workshop as a tool to help team satisfaction
09:40 C. Pino Molina (Basel, CH)
N1103 Current protective isolation policy within East, Middle and West European
10:00 transplant centres – A pilot survey
E. Bystricka, S. Vokurka, R. Brandejsova, J. Skardova, V. Pavlicova, K. Doskocilova,
I. Hnidkova, D. Brojacova, J. Scudlova, K. Moravcova, E. Murdychova, B. Sedlackova,
B. Nagyova, J. Wintnerova, L. Vylitova, M. Visokaiova, E. Mazur, M. Szwed-Kolinska,
J. Styczynski, M. Legiec, D. Zygadlo, I. Skoda Gorican, R. Ghelase, A. Moicean,
V. Viirsalu, S. Telling, S. Idzan, C. Pfluger, M. Stefanska, B. Keinrath, S. Edl,
C. Charley, C. Pino Molina (Pilsen, Hradec Kralove, Olomouc, Prague, CZ;
Kosice, SK; Katowice, Bydgoszcz, Lublin, Cracow, PL; Ljubljana, SI; Bucharest, RO;
Tartu, EE; Zagreb, HR; Innsbruck, Linz, Vienna, AT; Sheffield, UK; Basel, CH)
143

144
Scientific Programme Nurses Group Wednesday, 1 April 2009
11:00– Nurses Session 13 Room G3
12:00
EBMT NG activity
Chairs: E. Aerts (Zurich, CH); B. Keinrath (Vienna, AT)
N1104 Making progress: an overview of nursing and research activities during
11:00 the past 25 years
C. Eeltink, E. Johansson, S. Liptrott, S. Calza, A. Mank on behalf of the
EBMT NG Research Committee
N1105 A European Survey of Nurse Staffing on HSCT Units
11:20 M. Ni Chonghaile on behalf of the EBMT NG
N1106 The educational resource on graft-versus-host disease produced by the
11:40 EBMT-Nurses Group. Are we getting it right?
S. Liptrott, C. Eeltink, S. Calza, E. Johansson on behalf of the
EBMT NG Research Committee
12:00– Medical update / Awards and closing Room G3
13:00
Chairs: E. Aerts (Zurich, CH); B. Keinrath (Vienna, AT)
N1107 Medical update
12:00 M. Brune (Göteborg, SE)
N1108 Presentation EBMT 2010 in Vienna
12:20 B. Keinrath (Vienna, AT)
N1109 Prizes and closing remarks
12:35 E. Aerts (Zurich, CH)

Posters Nurses Group
Monday, 30 March & Tuesday, 31 March 2009
17:30– Paediatric
19:00
P1110 “The squirrel Colasa tells you what happens”, twenty years later
F.J. Gonzalez, P. Agüeros, M.J. Bárcena, M. Del Campo (Santander, ES)
P1111 I can do needles
P. Askew (Newcastle upon Tyne, UK)
P1113 Mouth care procedure for children undergoing stem cell transplantation –
An every day challenge
P. Kettler, M. Hansen, S. Berthelsen Kaland (Oslo, NO)
P1114 A comparative review of children requiring admission to intensive care unit
following haemopoietic stem cell transplant
S. Weatherby (Manchester, UK)
P1115 Review of paracetamol dosage and hepatotoxicity in paediatric blood and marrow
transplant patients in a single centre
K.V. Montgomery, L. Landzaat, A. Remijn, B. Padhye, E. McCahon, P.J. Shaw (Sydney, AU)
P1116 Patient care in children receiving haploidentical stem cell transplantation after
reduced-intensity conditioning regimens
A. Klaus, C. Schaaf, J. Hardt, S. Roessler, E. Ponstingl, J. Soerensen, A. Jarisch,
T. Klingebiel, P. Bader (Frankfurt, DE)
P1117 The challenges of accessing overseas treatment for the critically ill BMT patient
M. Trnkova, J. Peacock, W. Larmouth, S. Dodd (Newcastle upon Tyne, UK)
P1118 Complex nursing care issues during haematopoietic stem cell transplantation of
a patient with Langerhan's cell histiocytosis: the anticipated and the unexpected
R. Al Mahrizi, J. Goes, B. Mathew, M. Lourdes Macalalad, C. Lagar, S. Wilson,
A. Juanitas, E. Gallardo, J. Thomas, S. Simon, Y. Al Habsi, Z. Al Habsi, C.A. Trampe,
C. Biniza, M. Mathew, D. Mathew, J. Jobi, P.V. Sijimol, V. Recto, S. Jose, J. John,
I. Al Mandhari, N. Al Siyabi, S. Al Yarubi, S. Al Kindi, D. Dennison (Muscat, OM)
P1119 Post bone marrow transplantation in children: what can we learn from central
access venous device infection?
G. Sapir, O. Toren (Jerusalem, IL)
P1120 The rehabilitation requirements of paediatric patients with neurological damage
following haematopoietic stem cell transplantation
J. Reed, K. Towler, R. Wynn (Manchester, UK)
P1121 Quality approach in service of paediatric haematology:
accreditation JACIE1 in 2006 – Assessment of an experience
C. Sozeau, A.S. Rieutord, C. Palasse, D. Roudeix, F. Hemery, E. Labraise, P. Halle,
F. Deméocq (Clermont-Ferrand, FR)
17:30 – Psychosocial support
19:00
P1122 Level of anxiety and depression in patients undergoing peripheral blood stem cell
transplantation
Y. Karacan, S. Kapucu (Ankara, TR)
P1123 Prevalence and severity of post-traumatic stress disorder and its implications for
the quality of life among patients undergoing bone marrow transplantation
R. Cohen , A. Mendelson , M. Sherman (Haifa, IL)
145

146
Posters Nurses Group
Monday, 30 March & Tuesday, 31 March 2009
17:30– Psychosocial support (continued)
19:00
P1124 Understanding emotions through colours
S. Asensio Laseca, J. Abello Lahuerta, I. Cañas Iriarte, C. Conde Ceña, P. Gil Rubio,
I. Lara Marquez, P. Martin Sanchez (Barcelona, ES)
P1125 Allogeneic BMT away from home: the experience of Icelandic family caregivers
who accompany patients
T. Saevarsdottir, N. Fridriksdottir, N. Unnarsdottir, S. Reykdal (Reykjavik, IS)
P1126 Coping strategies of mothers with children suffering from haematology diseases
O. Ivanova, E. Vasilieva, I. Mushchitskaya, E. Semenova, A. Chibizova (St. Petersburg, RU)
P1127 Exposure to death and nurses' attitudes
W.-Y. Hassan (Jerusalem, IL)
P1128 Evaluation of burnout in marrow transplant nurses
Y. Akkus, Y. Karacan, H. Goker, S. Aksu, A. Yanik, G. Gurman, E. Sozer, G. Sucak,
O. Ozcebe (Ankara, TR)
17:30– Aphereses
19:00
P1129 PBSC collection: apheresis procedure and the role of nurses
E. De Marchi, A. Lanti, M. D'Angelosanto, M. Palmato, M. Galceran Bruix,
J. Madathiparambil, N. Bombelli, L. Tiberi, A. Cefali, G. Adorno, G. Isacchi (Rome, IT)
P1130 Granulocyte transfusion in HSCT recipients – Experience from a tertiary care
centre in India
K. Kandhasamy, S. Santhanaselvi, R. Nirmal Shankar (Chennai, IN)
P1131 Is the stem collection instrument a variable in successful peripheral blood stem
cell harvesting?
K.P. Holder, S. Paneesha, I. Novitzky Basso, R. Lovell, D. Milligan (Birmingham, UK)
17:30 – Standards of care
19:00
P1132 Surveillance for healthcare-associated infections among adult
haematology-oncology patients
E. Apostolopoulou, K. Terzis, K. Pissaki, E. Georgoudi, S. Delibasi, M. Pagoni
(Athens, Halkida, GR)
P1133 Care of haematopoietic stem cell transplant patient with suspected invasive
pulmonary aspergillosis
M.C. O'Donovan, C. Morris (Bristol, UK)
P1134 Hickman catheter-associated infections after haematopoietic stem cell
transplantation and their relationship with period elapsing from catheter
implantation to transplantation
M. Ruiz Seixas, M. Vázquez Moncada, R. López López, I. Espigado Tocino, F.J. Márquez
Malaver (Sevilla, ES)
P1135 Central venous catheter in patients undergoing bone marrow transplantation:
ambulatory insertion versus inpatient insertion under general anaesthesia
T. Faibish, A. Mendelson, Z. Poem, I. Kogan, R. Nir, M. Yanko (Haifa, IL)
P1136 Cubital venous catheter as a venous access in stem cell transplant management,
a single-centre experience
S. Kadam, J. Khante, M. Chavan, H. Khan, S. Wilson, N. Kamble, P. Kamble, S. Erande,
A. Divya, M. Nisha, Z. Reena, S. Rajithamol, S. Melinkeri, S. Apte (Pune, IN)

Posters Nurses Group
Monday, 30 March & Tuesday, 31 March 2009
17:30– Standards of care (continued)
19:00
P1137 Comparison of common central venous catheters and those antimicrobial-coated
in patients with allogeneic stem cell transplantation
E. Bystricka, J. Skardova, S. Vokurka, K. Kabatova-Maxova, L. Karasova, J. Cervena,
P. Kibitzova, J. Kostkova, A. Lastovkova, R. Novotna, M. Rerichova, R. Schroderova,
J. Zikova, L. Dolejsova (Pilsen, CZ)
P1138 Nurses' impact on central line infections in the BMT unit at an American
university of Beirut medical centre: infection and prevention
S. Sleiman, A. Ali, N. Abou Fakhr, R. Abou Chahine, J. Jaber, A. Naffaa, R. Nehme
(Beirut, LB)
P1139 Point-of-use water filtration for providing cost-effective protective care in
oncology
Y. Håkansson, K. Andersson, P. Svensson, M. Lindvall (Lund, SE)
P1140 Pall-Aquasafe data: traceability of Pall-Aquasafe filters connected to hospital
points-of-use
E. Awada, N. Cuffel, I. Kriegel (Paris, FR)
P1141 Implications for nursing practice of the source of blood stem cells in autologous
transplantation
A. Ferreira, S. Reis (Coimbra, PT)
P1142 Autologous transplant in cardiac amyloidosis: nursing care
S. Dávila Quintana, M.R. Ortega Carrión, M.R. Muñoz Montaño, I.M. Durán Sánchez,
R.M. Torres Muñoz, J. Jimenez Martinez, V. De la Osa García, M. Aguilar Roman (Seville, ES)
P1143 Nursing care standardisation in clinical pathways/ trajectories in acute myeloid
leukaemia
M. Pallejà Pejoan, N. Claramonte, M. Sanchez, R. Aranda, C. Iglesias, E. Gonzales,
P. Izquierdo (Barcelona, ES)
P1144 The role of dental hygienists in improving hospital-based treatment in HSCT
patients
R. Radiano, M. Aharoni, Y. Carlin, M. Findler, S. Elad (Jerusalem, IL)
P1145 Enteral nutritional support: to audit the effectiveness of percutaneous endoscopic
gastrostomy tube with jejunal extension in patients undergoing allogenic
haematopoietic stem cell transplantation
S. Pattni (Leicester, UK)
17:30 – Survivorship
19:00
P1146 Post-transplant damage: chronic graft-versus-host disease
M.R. Muñoz Montaño, I.M. Durán Sánchez, R.M. Torres Muñoz, J. Jimenez Martinez
(Seville, ES)
P1147 Coordination and follow-up care of patients in MPS I post haematopoietic stem
cell transplant
J. Mercer, S. Jones, H. Church, R. Wynn (Manchester, UK)
P1148 Psychological distress and personal growth in long-term BMT survivors
M.T. Peralta, B. Patiño, C. Ochoa, R.F. Duarte (Barcelona, ES)
P1149 Development of a questionnaire to record specific nutritional problems of
long-term survivors after allogeneic haemopoietic stem cell transplantation
A. Willeke, B. Hildenbrand, A. Dossett, H.H. Bartsch, A. Mumm (Freiburg, DE)
147

148
Posters Nurses Group
Monday, 30 March & Tuesday, 31 March 2009
17:30– Management issue
19:00
P1150 BMT Patient Acuity Tool Project
J.C. Morrow, C. Ahern, D. Collins (Sydney, AU)
P1151 JACIE accreditation process from a paediatric nurse's angle
M. Stenvall (Helsinki, FI)
P1152 Error management on a transplant unit; consequences for nursing staff
P. Kammerer (Basel, CH)
P1153 The ISO 9001:2000 Quality Management System as support in order to obtain
JACIE certification
F. Trenta, M. Mauroni, M. Brunetti, S. Soave, V. Molinari (Rome, IT)
P1154 Integrated clinical record: single document to improve medical assistance
F. Trenta, M. Mauroni, M. Brunetti, V. Molinari, S. Soave (Rome, IT)
P1155 The impact of moving to a new facility and experiencing a JACIE re-inspection
(a quality perspective)
N. Sagoo, N. Montague, D. Buxton, G. Mullowney, R. Barker on behalf of the Yorkshire
Blood and Bone Marrow Transplant Programme
P1156 Lessons in infection control – Managing a parainfluenza outbreak
T. Rintala, L. Bishop, K. Raj, M. Kazmi (London, UK)
P1157 The role of the nurse coordinator in the haematopoietic stem cell
transplantation’s organisation
I. Fournier, A. Havet, I. Vaida (Amiens, FR)
P1158 Stem cell couriers – The Canadian way
M. Ross, S. Mcdiarmid, B. MacDonald, D. Rice (Ottawa, CA)
P1159 A coordinating nurse in a transplant unit
S. Porcheron, S. Castelain, N. Contentin, K. Lee, H. Tilly (Rouen, FR)
P1160 Strong together in the care of haematology
S.J. van der Linden, M.E.B. Grootes, M. Huijser-Mazzucco (Rotterdam, NL)
P1161 Single medical/nursing patient record: one year after implementation
M.G. Deiana, S. Calza, G. Bisaccia, M. Cambiaso, F. Cannavale, P. Castagnoli,
S. Cavalca, E. Cervetto, M. Cotrozzi, M. Francesia Berta, E. Ghibaudo, E. Olcese,
T. Pastorino, R. Pau, A.L. Raiola, A. Toscano (Genoa, IT)
P1162 Changing landscapes in haematopoietic stem cell transplantation for
haematological malignancy
M. Kenyon, G. Mufti (London, UK)
P1163 Outpatient transplants and similar chemotherapy – What do our patients and their
carers think?
P. Statham, R. Sohal, T. Graham, H. Keane, C. Demosthenous (London, UK)
P1164 Telephone clinic follow-up in haematology setting
R. Haynes (London, UK)
P1165 Outpatient transplants – Early hospital admission from the hotel may benefit the
patient in the long run
P. Statham, R. Sohal, T. Graham, H. Keane, C. Demosthenous (London, UK)
P1166 Management of human resources: Italian Group Bone Marrow Transplantation –
Nurses Group (GITMO's NG) – Italian survey 2008
S. Calza, L. Orlando, F. Alberani on behalf of G.I.T.M.O – NG

Posters Nurses Group
Monday, 30 March & Tuesday, 31 March 2009
17:30– Management issue (continued)
19:00
P1167 Nurse-staffing standards within East, Middle and West European transplant
centres: a pilot survey
E. Bystricka, R. Brandejsova, S. Vokurka, J. Skardova, V. Pavlicova, J. Scudlova,
K. Moravcova, E. Murdychova, B. Sedlackova, B. Nagyova, J. Wintnerova, L. Vylitova,
M. Zitkova, V. Koristkova, P. Vrsecka, E. Mazur, M. Szwed-Kolinska, J. Styczynski,
M. Legiec, D. Zygadlo, A. Hellman, M. Skuliber, V. Druzic, M. Visokaiova, E. Vassilieva,
C. Pfluger, B. Keinrath, S. Edl, I.K. Skoda Gorican, R. Ghelase, A. Moicean, C. Charley,
C. Pino Molina, K. Doskocilova, I. Hnidkova, D. Brojacova
(Pilsen, Hradec Kralove, Olomouc, Prague, Brno, CZ; Katowice, Bydgoszcz, Lublin,
Cracow, Gdansk, PL; Zagreb, HR; Kosice, SK; St. Petersburg, RU; Innsbruck, Vienna, AT;
Ljubljana, SI; Bucharest, RO; Sheffield, UK; Basel, CH)
P1168 Are clinical guidelines consistent with clinical practice in regards to re-infusion
of cells?
D. Kennedy, E. Najeme (London, UK)
17:30– Patient education
19:00
P1169 Teaching of patients submitted to haematopoietic stem cell transplantation and
their caregiver: integrative literature review
M. Célere, V.L. Valério, V.D. da Silva Carlucci, R.C. de Campos Pere Silveira
(Ribeirão Preto, BR)
P1170 Investigation on patients’ information about autologous bone marrow procedure
L. Tardieu, K. Lajugie, C. Tisseuil, O. Chicaud, C. Philippon, D. Vigier, P. Turlure,
D. Bordessoule (Limoges, FR)
P1171 Producing a patient information folder in collaboration with a UK charity
E. Davies, C. Nicol (Bristol, UK)
P1172 Acute lymphoblastic leukaemia, a path you can never walk alone!
A.M.G. Kramers, A. van de Loosdrecht (Amsterdam, NL)
P1173 The role of patient education in prevention and early detection of infection
provided in an outpatient setting
S.J. Ladner (Cambridge, UK)
P1174 Family information: discharge contacts and helpful hints
L. Hill, S. Fernandes, L. Young (London, UK)
P1175 The Royal Manchester Children’s Hospital Blood and Marrow Programme Family
Consultation Day
M. Coussons (Manchester, UK)
17:30 – Staff development
19:00
P1176 Development of an evidence-based information brochure for nurses about early
detection and prevention of delirium in haematopoietic stem cell transplant
patients – A practice development project
M. Kirsch, W. Hasemann, E. Dietz, C. Erhardt, C. Arber (Basel, CH)
P1177 Implementation of a nutrition team and their daily work with patients undergoing
an allogeneic stem cell transplantation
K.K.S. Holmberg (Stockholm, SE)
149

150
Posters Nurses Group
Monday, 30 March & Tuesday, 31 March 2009
17:30– Staff development (continued)
19:00
P1178 Haematopoietic stem cell transplantation: the development of an Intranet-based
study guide for nursing staff working within a regional child and adolescent
oncology unit
S. Dodd, J. Guest, A.B. McDonnell (Newcastle upon Tyne, UK)
P1179 Description of competencies for haematology nurses in Sweden
M. Troeng, M. Håkansson, B. Bergström, J. Lundqvist, E. Johansson
on behalf of the Association of Haematology Nurses in Sweden
P1180 Support group for BMT nurses – Triumph over adversity
G. Milner, T. Rintala, J. Hanbury (London, UK)
P1181 Clinical supervision
S. Dodd, K. Wall (Newcastle upon Tyne, UK)
P1182 Preceptorship – was it successful in enabling orientation and learning new skills
on the BMT unit?
J.L. Vise, V.S. Buckley (Bristol, UK)
P1183 Introduction programme for newly recruited nurses
M. Håkansson (Göteborg, SE)
P1184 Human patient simulation – An innovation in haematology nurse education
C. McCaughey, M. Glackin (Belfast, UK)
17:30– Symptom management
19:00
P1185 Predictors of prolonged stay in haematology-oncology department
E. Apostolopoulou, K. Terzis, K. Pissaki, E. Georgoudi, S. Delibasi , M. Pagoni
(Athens, Halkida, GR)
P1186 Mucor: an opportunistic infection in immuno-depressed patients
M.R. Muñoz Montaño, I.M. Durán Sánchez, M. Aguilar Roman, V. De la Osa García,
R.M. Torres Muñoz, J. Jimenez Martinez (Seville, ES)
P1187 Nurse management of carbopenem-resistant Klebsiella pneumoniae outbreak in
the bone marrow transplantation unit of the Rambam Medical Center
D. Shlain, A. Maximova (Haifa, IL)
P1188 Cyclosporine and hyperpilosity
E. Recchia, J.-P. Marie, B. Rio, M. Thevenin (Paris, FR)
P1189 Ongoing prospective clinical trial on primary prevention of cardiac damage
induced by intensive chemotherapy with angiotensin-converting enzyme
inhibitors and beta-blockers: central role of a nurse as coordinator
A. Domenech, M. Rovira, J. Esteve, N. Borràs, A. Ciurana, M. Valverde, X. Bosch
(Barcelona, ES)
P1190 Use of sodium nitroprusside infusion to control hypertension during cord blood
infusion
K. Kandhasamy, R.M. Jessie (Chennai, IN)
P1191 Prevention and therapy of thrombembolic disease in haemato-oncological
patients – Nurse view
M. Visokaiova, J. Bockova (Kosice, SK)
P1192 Complications of central venous catheters
M. van Vliet, C. Potting, N.M.A. Blijlevens, P. Donnelly (Nijmegen, NL)
P1193 Prophylaxis of severe oral mucositis with tramadole and buprenorphine in
patients with lymphoproliferative diseases undergoing high-dose chemotherapy
with autologous haematopoietic progenitor cells rescue: a single centre
experience
L. Russo, N. Meliambro, S. Ipek, T. Gangemi, G. Cusumano, I. Repaci, R. Avenoso,
M. Scirtò, G. Russo, M.G. Monorchio, T. Trimarco, F. Saffioti, G. Ressa, F. Placanica,
T. Poggio, G. Morabito, S. Gallo, D. Princi, G. Messina, P. Iacopino (Reggio Calabria, IT)

Posters Nurses Group
Monday, 30 March & Tuesday, 31 March 2009
17:30– Symptom management (continued)
19:00
P1194 Incidence of oral mucositis and relationship with haematology disease in
348 patients undergoing haematopoietic stem cell transplant in our centre
R. Mendez, L. Casabella (Madrid, ES)
P1195 Effect of Gelclair in patients with erosive oral mucositis after allogeneic stem
cell transplantation
E. Bystricka, J. Skardova, S. Vokurka, K. Kabatova-Maxova, J. Cervena, P. Kibitzova,
J. Kostkova, A. Lastovkova, R. Novotna, M. Rerichova, R. Schroderova, J. Zikova,
L. Dolejsova (Pilsen, CZ)
P1196 Analysis of efficacy of pain treatment in patients undergoing chemotherapy
± bone marrow transplant in single haematological centre
S. Proce, M. Piumatti, B. Castellino, S. Pautassi, A. Ghiglia, A. Cavallo, D. Rapezzi,
D. Mattei, A. Gallamini (Cuneo, IT)
P1197 Survey on the prevalence of pain during the day 8 after HSCT
C. Ferault, L. Vagliano, F. Alberani, A. Errico, L. Galgano, S. Calza
on behalf of the GITMO (Italian Group of Bone Marrow Transplantation)
P1198 Comparison of pain and opioid analgesic requirement between autologous and
allogeneic haematopoietic stem cell transplantation
S. Jeong (Seoul, KR)
P1199 Fatigue before and after stem cell transplantation
Y. Karacan, Y. Akkus, H. Goker, Y. Büyükasik, S. Aksu, I. Haznedaroglu, N. Sayinalp,
O. Ozcebe, A. Yanik, K. Calik, G. Sucak, O. Ilhan (Ankara, TR)
P1200 Chronic graft-versus-host disease: eight years of nursing care
R.M. Torres Muñoz, I.M. Durán Sánchez, M.R. Muñoz Montaño, J. Jimenez Martinez
(Seville, ES)
17:30– Impact of new therapies
19:00
P1201 Palonosetron (Aloxi): a single-centre experience in the prevention of emesis in
patients affected by haematological malignancies
D. Basile, A. Assanelli, C. Soliman, F. Ciceri, V. Matozzo (Milan, IT)
P1202 Nausea scale application in patients with lymphoma receiving high-dose
chemotherapy. Combination of aprepitant with standard antiemetics to prevent
chemoterapy-induced nausea and vomiting
D. Domingues, P. Grades, M. Correia, E. Oliveira (Lisbon, PT)
P1203 Eculizumab (Soliris®): a promising treatment of haemolytic anaemia in
paroxysmal nocturnal haemoglobinuria
I. Hascoët, K. Tabani, V. Nocton, M. Allio, S. Romens, M. Genin, I. Lacheray, S. Simonelli,
G. Socié (Paris, FR)
P1204 Experiences gained from the construction of a national Swedish cord blood bank
B. Waldner (Göteborg, SE)
P1205 Complementary alternative treatments used by patients during stem cell
transplantation in Turkey
Y. Karacan, Y. Akkus, H. Göker, S. Aksu, N. Akdemir, Y. Büyükasik, I. Haznedaroglu,
O. Ozcebe, A. Yanik, C. Akkaya, K. Calik, E. Sozer, O. Ilhan, G. Ozet, G. Sucak (Ankara, TR)
17:30 – Donor issues
19:00
P1206 Haplo-identical stem cell transplantation. A reality in bone marrow transplant unit
M. Ferreira, A. Branco (Lisbon, PT)
151

152
Data Management Group Sunday, 29 March 2009
18:30– Opening Session Congress Hall
20:00
Please refer to page 33 for details.
20:00 Welcome Reception
Please refer to page 195 for details.
Data Management Group Monday, 30 March 2009
Data Management Room J1
ProMISe 2 Training Session
09:00–
12:00
Data entry (Beginners only)
1207 Data entry (Beginners only)
H. Baldomero, K. Kirkland (Basel, CH; London, UK)
13:00–
16:00
Data retrieval Room J1
1208 Data retrieval
C. Ruiz de Elvira (London, UK)

Data Management Group Monday, 30 March 2009
09:00– ProMISe Open Learning Centre Room R9
16:00
During the congress, a small computer room will be open from 09.00 – 16.00
on Monday & Tuesday for users to drop by and ask specific questions regarding
data entry, exports and reports. EBMT/Registry staff will be available at specific
times. (A rota of staff and languages spoken will be displayed at the room entrance
and the EBMTstand).
The learning centre should not be considered as a substitute for the group training
sessions on offer, however through this new initiative we hope to offer additional
support on a more personal level.
As before, group training sessions will take place in the main computer room (J1),
with teaching on Data Entry (beginners only) and Data Retrieval. Sessions are
repeated on Monday & Tuesday to allow more flexibility. Group training places are
limited to a maximum of 30 delegates per session.
09:00–
16:30
Data Management
Educational Sessions
Room J2
1209 Late effects
09:00 A. Tichelli (Basel, CH)
10:15 Coffee
1210 Inborn errors – new trends & experimental approaches
10:30 B. Gaspar (London, UK)
11:30 Coffee
1211 Myeloma
11:40 N. Kröger (Hamburg, DE)
12:30 Lunch
1212 MED-A Form
13:15 V. Chesnel (Paris, FR)
14:45 Coffee
1213 Aplastic anaemia
15:00 J. Passweg (Geneva, CH)
17:00 – Data Managers Reception Foyer Room J2
18:00
You are welcome to come and meet other Data Managers and the EBMT National
registries for a post-session drink outside Room J2.
153

154
Data Management Group Tuesday, 31 March 2009
Data Management Room J1
ProMISe 2 Training Session
09:00–
12:00
Data retrieval
1214 Data retrieval
C. Ruiz de Elvira (London, UK)
13:00–
16:00
Data entry (Beginners only) Room J1
1215 Data entry (Beginners only)
H. Baldomero, K. Kirkland (Basel, CH; London, UK)
09:00– ProMISe Open Learning Centre Room R9
16:00
Please refer to page 153 for further details.
09:00–
16:15
Data Management
Educational Sessions
Room J2
1216 Transplant procedure
09:00 J. Blankart (Hamburg, DE)
10:15 Coffee
1217 CML
10:30 E. Olavarria (London, UK)
11:20 Coffee
1218 Data collection & working methods
11:30 J. Kuipers, H. Bakker (Rotterdam, Leiden, NL)
12:30 Lunch
1219 From study design to publication
13:00 R. Oneto, E. Polge (Genoa, IT; Paris, FR)
14:30 Coffee
1220 Autoimmune diseases
14:45 R. Saccardi (Florence, IT)
17:30 – Data Management Poster Presentation (P1008 – P1015)
19:00
Please refer to pages 127 for details.

List of Chairs
Name Page Name Page Name Page
Abrahamsson J. 71
Aerts E. 50, 77, 131,
138, 144
Andersson I. 128, 130,
134, 142
Apperley J.F. 69
Arat M. 38
Arnold L. 133
Arvidson J. 73
Bacigalupo A. 31, 54
Bakker H. 154
Baldomero H. 152, 154
Baronciani D. 75
Bay J.-O. 47
Bengtsson M. 76
Björkholm M. 27
Blaise D. 42
Blankart J. 154
Borras N. 132
Bosi A. 77
Brand R. 55
Bregni M. 47
Brinch L. 34
Brune M. 30, 33, 36,
50, 77, 138
Calza S. 138
Carreras E. 25, 45
Cavazzana-Calvo M. 74
Chandy M. 41
Charley C. 140
Charron D. 34
Chesnel V. 153
Cornely O. 24
Corradini P. 31
Davies M. 136
de Witte T. 51
Degen S. 132
Dickinson A.M. 30, 60
Dimopoulos M. 26
Dini G. 39
Donnelly P. 58
Eeltink C. 133, 142
Einsele H. 24, 64
Ek M. 143
Eliasson L. 138
Engelhard D. 50
Esteve J. 46
Farge D. 54
Fasth A. 50
Fenaux P. 28
Fibbe W. 70
Fioretos T. 44
Frödin U. 135
Gahrton G. 43
Galgano L. 135
Garderet L. 51
Gaspar B. 48, 153
Giebel S. 40
Gimsing P. 26
Goldmann. J. 54
Gratwohl A. 68
Gribben J. 29
Guglielmi C. 61
Hägglund H. 68
Handgretinger R. 60
Hellström-Lindberg E. 28
Horowitz M. 70
Johansson E. 143
Juliusson G. 56
Kärvell P. 132
Keinrath B. 140, 144
Kimby E. 29, 59
Kirkland K. 152, 154
Kisch A. 132
Klingebiel T. 67
Kodera Y. 70
Koza V. 76
Kröger N. 153
Kuipers J. 154
Kvalheim G. 49
Ladenstein R. 53
Lanza F. 70
Larsen J. 129, 133, 137
Le Blanc K. 50
Lenhoff S. 77
Linkesch W. 44
Liptrott S. 141
Ljungman P. 23, 70, 77
Locasciulli A. 63
Locatelli F. 67
Maertens J. 24
Malmberg K. 74
Mank A. 134
Marr K. 28
Marsh J. 35
Martino R. 31, 64
Marty F. 23
Maschmeyer G. 26
Masszi T. 45
Milpied N. 56
Morris C. 39, 43
Murst A. 140
Nagler A. 49
Ni Chonghaile M. 131, 137, 139
Niederwieser D. 29, 33,
36, 66, 70, 77
Öberg G. 61
Olavarria E. 59, 153
Oneto R. 153
Oudshoorn M. 70
Passweg J. 63, 153
Peters C. 53
Pihkala U. 57
Pihlström A. 141
Pino Molina C. 138
Polge E. 153
Porta F. 48
Powles R. 66
Rademaker M. 139
Rebelo M.I. 128, 134, 142
Ringden O. 34
Rocha V. 46
Rovo A. 55
Rowe J.M. 39
Ruiz de Elvira C. 77, 152, 154
Russell N. 27, 67
Ruutu T. 35, 39
Saccardi R. 54, 154
Scheding S. 25
Schmid C. 49
Schnatter P. 143
Schouten H. 62
Sedlacek P. 57
Sengelöv H. 41, 72
Sierra J. 72
Söderstrand A. 139
Stringer J. 133, 137
Sureda A. 62
Szydlo R. 65
Tichelli A. 38, 153
Toubert A. 37
Tufvander K. 135
Twengström-Lord S. 138
Ullmann A. 58
Urbano-Ispizua A. 42
Velardi A. 24, 37, 70
Veys P. 34
Wahlin A. 40
Wallhult E. 131, 134, 139
Ward K. 71
Weis J. 73
Wendt C. 133, 142
Wesström A. 143
Winiarski J. 75
Winterling J. 140
Yaniv I. 35
Zander A.R. 49
Zulu S. 135
155

156
List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Abadi, U. O423
Abargil, I. N1082
Abbadessa, A. P749
Abbruzzese, L. O261
Abdalla, E. O179, P670
Abdelkefi, A. P575, P863
Abdelsalam, M. P751
Abderrahmani, S. P882
Abdul-Rahman, F P807
Abecasis, M. 318
Abello Lahuerta, J. P1124
Abinun, M. P683, P684,
P694, P695
Abou Chahine, R. P1138
Abou Fakhr, N. P1138
Abrahamsen, I. O402
Abrisqueta, P. P674
Abu-Shkara, N. N1095
Ackermann, O. P687
Adams, J. P677
Adams, M. N1028
Addari, M.C. P559
Ades, L. P587, P938
Adorno, G. P1129
Aerts, E. N1016, N1021,
N1030, S1042, N1109
Afanasyev, B. O297, P510, P564,
P567, P573, P791,
P885, P957, P983
Agay, D. P745
Agazzi, A. N1059
Agazzi, S. N1076
Ager, S. P886
Aglietta, M. O158
Agrawal, S. O277, P872
Agüeros, P. P1110
Aguilar Roman, M. P1142, P1186
Aharoni, M. P1144
Ahern, C. P1150
Ahlborn, R. P569
Ahmed, S. P470, P551,
P880
Ahmed Nacer, R. P882, P980
Ahn, H.S. O146, P639
Aieta, M. P610
Aigner, T. P558
Airaghi, L. O399
Aisa, Y. P486
Aissi-Rothe, L. P904
Ait Ouali, D. P882
Aitken, C. P646
Aiuti, A. 89
Ajmi, N. P863
Akan, H. S14
Akblukak, R. P896
Akdemir, N. P1205
Aker, M. P523, P671, P736,
P786
Akhtar, S. O179, P670,P751
Aki, Z. P663, P682, P768
Akkaya, C. P1205
Akkus, Y. P1128, P1199,
P1205
Aksu, S. P1128, P1199,
P1205
Akyürek, N. P682
Al Habsi, Y. P1118
Al Habsi, Z. P1118
Al Husseini, H. P751
Al Kindi, S. P1118
Al Mahrizi, R. P1118
Al Mandhari, I. P1118
Al Sabty, F. P461
Al Siyabi, N. P1118
Al Yarubi, S. P1118
Al-Abdely, H. P880
Al-Ahmary, A. 201, 202
Al-Ali, H.K. O172, 228
Al-Anazi, K. P880
Al-Dhekri, H. 201
Al-Ghonaium, A. 201
Al-Hersi, A. 202
Al-Jefry, A. 201, 202
Al-Kafaff, A. P940
Al-Mahr, M. 201
Al-Mohareb, F. P470, P880
Al-Mousa, H. 201, 202
Al-Muhsen, S. 201, 202
Al-Nounou, R. P470
Al-Qurashi, F. P470
Al-Rabiah, F. P880
Al-Ramadi, B. P827
Al-Saud, B. 201, 202
Al-Seraihy, A. 201
Al-Sharif, F. P470, P880
Al-Ta'ani, H. P807
Al-Zabin, A. P807
Al-Zahrani, A. O179, P670
Al-Zahrani, H. P470, P880
Alba, F. P531
Albani, M. P837
Alberani, F. P1166, P1197
Albert, M. 198
Albert, M.H. O266,
O267, P685
Alboug, A. 202
Alcántara, J. O419
Alchalby, H. P699
Aldenhoven, M. 197
Aldhekry, H. 202
Aldinucci, A. O164
Alegre, A. O162, P588
Aleinikova, O. P480
Alekseev, S. P510
Ales, M. P679
Alessandrino, E.P. P563, P601,
P933, P977
Alexander, T. P923, P930
Alfieri, C. P819, P823, P874,
P985
Alfred, A. P508
Algarotti, A. P555, P717, P968
Alghonaium, A. 202
Ali, A. P1138
Alietti, A. P996
Alimena, G. P895
Alimoghaddam, K. P478, P590,
P810, P818,
P820, P979
Alizadeh, H. P827
Aljurf, M. 320, P470, P880
Alkhamees, N. 202
Allan, D. O262, P744
Allez, M. 245
Allio, M. P1203
Allione, B. O158, 187
Allouche, H. P863
Almici, C. P483
Alousi, A. P441
Alpár, D. P597
Alseraihy, A. 202
Alsina, M. P434
Altindal, S. P682
Alvisi, C. P563
Alyanskiy, A. P983
Amadori, S. O133
Amigo, M.L. P475
Amorós, A. O175
Amrolia, P. O405, O415
Amtsfeld, G. O147
Anagnostopoulos, A. P549, P565,
Anasetti, C.
P650, P729, P994
P434
Anastasia, A. P861, P993
Andadre de Oliveira, W. O272
Anderson, J. O178
Andersson, B. P441
Andersson, K. P1139
Andersson, P.O. P568
Andersson, S. P1000
Andidero, P. N1040
Andre, M.C. P616
Andree, H. P542, P852, P961
Andreini, A. P605, P754, P940
Andres, M. P790, P811
Andres Moreno, M. P799, P800
Angell, J. P482, P485
Angelsen, K.R. N1058

List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Angelucci, E. P560, P645,
P673, P933
Angrilli, F. P661
Angus, B. P694
Annaloro, C. O399, P878,
P927, P950
Annerén, C. P746
Ansari, A. P932
Ansari, M. P715
Antoniotti, P. P996
Antúnez, C. P702
Aplenc, R. 129
Apostolidis, J. P505, P666
Apostolopoulou, E. P1132, P1185
Apostolou, C. P650
Apperley, J. S43,117, 227, O284,
323, 353, 364, P502,
Apte, S.
P595, P599, P638, N1029
P1136
Aquan-Assee, J. N1036
Aranda, R. P1143
Arat, M. 120, 187, P776, P868
Arber, C. O394, O395, P665,
P833, P1176
Arcese, W. O259, O283, O290,
P495, P974
Ardizzone, S. P927
Argiolu, F. P559
Aricò, M. P806
Arien-Zakay, H. O166
Arima, N. P580
Arkwright, P. 198
Arleo, E. P903, P974
Arnaboldi, P. N1059
Arnan, M. P839, P887, P989
Arnaout, R. 202
Arnold, C. P931
Arnold, L. S1043
Arnold, R. O137, P433, P654,
P688, P923, P930
Arns, C. P843
Arnulf, B. P587
Arpaci, F. P499, P615
Arpinati, M. O142, P442,
P465, P775, P870
Arrais, C. 187, 307
Arranz, R. P963, P964
Arrieta, R. P713
Arrieta Gallastegui, R. O383
Arruga, F. O138, P436, P439
Arslan, O. P776, P868
Artamonov, I. P743
Asadi, M. P590
Asano, S. P484
Asano-Mori, Y. P873
Asenova, S. P629
Asensio Laseca, S. P1124
Askew, P. P1111
Asli, B. P587
Assanelli, A. O141, O171, P481,
P617, N1076, P1201
Astahov, Y. P564
Astolfi, A. O133, O138, P436,
P892
Astrelina, T. P634
Ataergin, S. P499, P615
Atanackovic, D. O157, P896
Athanasiou, E. P994
Athorn, G. O277
Atienza, A. 228, P939
Atkins, H. O262
Atkinson, K. P512
Atsuta, Y. O143
Attal, M. S28, O161
Attolico, I. P607
Auberger, J. P518, P959, P960
Aubourg, P. P696
Audisio, E. P448
Auner, H. O284, P595, P638
Ausoni, G. P725
Avanzini, M. P628, P910
Avenoso, R. P1193
Avent, N. P635
Aversa, F. S23
Avery, S. N1080
Avet-Loiseau, H. O161
Avetisyan, G. P841, P842, P869
Aviv, F. O423
Avivi, I. P884
Avola, G. P453
Awada, E. P1140
Ayala, E. P434
Ayari, S. P447, P487, P543,
P566, P737, P752,
P761, P978
Ayas, M. 201, 202
Ayuk, F. O147, O157, P629,
P699, P766, P897
Ayyildiz, E. P494, P868
Azap, A. P868
Azevedo, W. P828
Azuma, H. O143
Azuma, T. O103
Azzarello, G. P610
Baazizi, M. P882
Babenko, E. P510
Babic, A. P996, N1059
Baccarani, M. O133, O138, O142,
O400, P433, P436, P439,
P442, P454, P465, P775,
P870, P892, P895, P898
Baccoli, R. P524
Bacher, U. O147, O157, 222,
P585, P621, P629,
P699, P766, P897
Bacigalupo, A. O106, 116, 182,
Back, H.J.
185, O256, O259, 315,
316, 317, 319, 320,
343, O384, P835, P918,
P928, P933
O146
Bacon, C. P772
Badbaran, A. O157, P629, P699
Badell, I. P814
Bader, P. O134, 203, O263,
O264, O266, O267,
O425, P691, P777, P796,
P899, P915, P1116
Badiali, M. P559
Badulli, C. P1002
Baeten, E. P780
Baffelli, R. P659
Bagnasco, F. P792
Bahar, B. P478, P810, P818
Bahlis, N.J. P641
Bakanay, S. P776
Bakker, H. 1218
Bakr, M. P470, P880
Balashov, D. P667
Baldomero, H. 1207, 1215
Balduzzi, A. 232, 236, P555
Balère, M. O140, 319, P540
Balint, B. P477
Ball, L.M. P653, P834
Balleisen, S. P437
Ballerini, C. O164, P632
Ballestrero, A. P610
Balotis, C. P505
Balsalobre, P. P562, P658,
P731, P753
Baltadakis, I. P505, P666
Bambi, F. P806
Bandini, G. O142, P442,
P465, P775, P870
Bandmann, O. P688
Bang, S.M. P460, P756
Banovic, T. O428
Bar, I. P488
Barba, P. O175, P853, P953
Barberi, W. P651, P866, P903,
P974
Barborie, A. P694
Barbosa, I.L. P633
Barbouti, A. P549
Barbui, V. P718
Bárcena, M.J. P1110
Barge, D. P683, P684, P695
157

158
List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Bargetzi, M.J. P596
Barker, R. P1155
Barlati, S. P483
Barlogie, B. 121
Baron, F. O387, P944, P954,
P991
Baron, J. P786
Baronciani, D. P560, P645, P673
Baronio, F. P793
Baronti, F. P764
Barra, A. P519, P520
Barraco, F. P450, P606
Barrenetxea, C. O139
Barrett, J. S7, S12, P703,
P1004
Barrois, A. 222
Barros, G.M.N. P926
Barrott, S. P808
Barta, A. P758, P771, P773
Bartelink, I.H. P690, P788
Bartels, K. P896
Barth, A. O263
Bartmann, C. P700
Bartolozzi, B. P443, P871
Bartsch, H.H. P1149
Barzizza, L. P1005
Basak, G.W. P625
Basara, N. O137, O282, P558
Bashtar, M. P820
Basile, D. P1201
Baslo, R. N1070
Bason, C. O377
Bassan, R. P448
Bassi, S. P763, P996
Basso, G. P574
Basso, S. O274, O293
Bastos Oreiro, M. O383
Batai, A. P758, P771, P773
Batinic, D. P469
Batra, G. P794
Batsis, I. P549, P565, P650,
P729, P994
Battegay, M. P833
Battista, M.L. P675, P724, P864
Baudoux, E. O387
Bauer, S. P438
Bauernschmitt, E. P890
Baumann, I. P936
Baumeister, E. P907, P908
Baumert, T. P931
Baurmann, H. P456, P529
Bautista, F. P790
Bautista Sirvent, F.J. P799, P800
Bavaro, P. O290
Bay, J.-O. 190, O385, P894,
P951
Bay, M. P868
Bechor, Y. N1070
Beck, J. O264, O265, O425,
P723, P777, P779,
P857, P987
Bedini, V. P613
Bedolis, R. N1059
Beeken, R. P680
Beelen, D. 0137, 185, 228, O282,
O300, O389, O407,
P438, P734, P637,
P934, P939, P946
Beguin, Y. O387, P944, P954,
P991
Behre, G. O378
Bekassy, A. 120, O281, 315, 320
Beksac, M. 116, 223, P494,
P776
Belhadj, R. P882, P980
Belitser, S.V. P690
Belitzer, S. P780
Bellan, A. P789
Bellesi, S. O149, P553, P593,
P855, P881
Bellesmes, C. P696
Belohradsky, B.H. P685
Belotti, D. P555
Ben Arush, M. P802
Ben Fredj, N. P575
Ben Gaied, O. P863
Ben Meir, D. N1070
Ben Othman, T. P575, P863
Ben Romdhane, N. P863
Ben-Tal, O. O423
Benakli, M. P882, P980
Bence-Bruckler, I. O262
Bencini, S. P443
Bender, K. O406
Bendinelli, M. P837
Bendtzen, K. P826
Benedetti, E. P764, P851
Benedetti, F. P605, P754, P940
Benesova, K. P1011
Benezra, R. O168
Benjamin, R. O381
Bennato, V. P659
Benninghoff, U. P622
Bensoussan, D. P904
Benvenuti, S. P632
Benyamini, N. P884
Benyó, G. P877, P917
Beolchini, E. P984
Berdel, W.E. O154, O287
Bergamaschi, P. P500, P501,
P984, P1002
Berger, M. O106, P521
Berger, P. P528, P862
Berglund, S. P509
Bergonzi, C. P536
Bergsträßer, E. O302, P936
Bergström, B. P1179
Berisa, T. N1065
Bermúdez, A. O139, P662
Bernabeu Esclapez, A. P714
Bernardi, M. O141, O171, P481,
P617, P929, P933
Bernardo, M. O410, O414, P532,
P628, P910, P924
Bernasconi, P. P601, P977
Bernsen, R. P827
Berrie, E. O415
Berro, M. P992
Berry, D.A. O156, 191
Bersträßer, E. O265
Berta, S. P659
Bertaina, A. O414
Bertani, G. P583, P719, P875
Bertheau, P. P514
Berthelsen Kaland, S. P1113
Berti, E. P950
Bertz, H. P432, P534, P738,
P931
Besalduch, J. O162
Bethge, W.A. 222, O266, O282,
O389, P9450,
P946, P952
Beutel, G. O148, O151,
P846, P948
Beyersmann, J. 251
Beziat, V. P998
Biagi, E. P555
Biagioli, T. O164
Bianchetti, A. P483
Bianchi Porro, G. P927
Bianco, P. 217
Biasi, L. P536
Bielorai, B. P496, N1034
Bierings, M. O265, P690,
P782, P788
Bierling, P. P591
Biffi, A. P822
Bika, E. P505
Bilger, K. P951
Billiau, A.D. O429, O430, P618
Binder, M. P770
Binder, T. O147
Biniza, C. P1118
Biondi, A. P555
Biral, E. P816, P822, P909,
P1005
Birchall, C. P490
Bird, P. O415

List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Bisaccia, G. P1161
Biscione, G. P651
Bishop, L. P1156
Bitencourt, M. 318, O412,
P843, P916
Biton, L. N1068
Bittencourt, H. O272, P858,
P919
Bittencourt, M. P644
Bitzioni, A. P729
Bizzetto, R. O283
Bjerkvig, R. 206
Björk, Y. P539
Björkholm, M. S35, S40
Björklund, A.T. P1001
Björkstrand, B. 223, 227
Bladé, J. 122, O162, P592
Blaise, D. O107, O140, O161,
Blanche, S.
O163, 185, 193, O385,
O388, P452, P468,
P528, P540, P711,
P862, P949, P951
P686
Blanes, M. P588
Blankart, J. 1216
Blanquer, M. P702, P712, P714
Blasczyk, R. 185
Blau, I.W. O300
Blazar, B. S26, 90
Bleda, P. P702, P712
Bleeker, K. N1098
Bley, A. P803
Blijlevens, N.M.A. P830, P1192
Blin, N. P447, P543, P566,
P752, P761, P978
Blinova, E. P922
Bloem, A. P780
Blokland, E. O427
Bloom, N. P708
Boccadoro, M. O158, O159,
P838
Bock, O. P699
Bockova, J. P1191
Boeckh, M. S5, 99, 321, P831
Boelens, J.J. 197, O278,
P690, P780, P781,
P782, P788
Bogunia-Kubik, K. O273,
P516, P995
Boher, J. O385, P949
Boissel, N. P938
Bokemeyer, C. P896
Bokhari, S.W. P941
Bolda, F. P659
Bollen, G.M.H. N1035
Bolwell, B.J. P482, P485, P506
Bombelli, N. P1129
Bonetti, S. P793
Bonfim, C. 97, O412, P644,
P656, P812,
P843, P916
Bonifazi, F. 120, O142, O384,
P442, P465, P775,
P870, P895
Bonini, A. P449
Bonini, C. O141, O171, P617,
P710, P929
Bonnet, C. P991
Bonnet, D. 205
Bonnet, E. 323, 324
Bontadini, A. O400, P442,
P465, P775
Boogaerts, M. O286
Boon, L. O430
Booth, C. 198
Borchers, S. P840
Borchert, K. P961
Borckhardt, A. O263, O264
Bordessoule, D. P1170
Bordignon, C. O141, P710
Bordigoni, P. P804,
P904, P951
Borgerding, A. P701
Bories, D. P730
Borisov, V. P922
Borlenghi, E. P448
Borleri, G. P717, P718, P914
Bornhäuser, M. 86, 222, O282,
O285, O389, O390, O424,
P459, P525, P627, P891,
P945, P946, P972
Borràs, N. P1189
Bosch, X. P1189
Bosi, A. 187, 223, O256,
O295, P443, P449, P632,
P659, P871, P933
Botto, B. P645
Bouabdallah, K. O391
Bouabdallah, R. O163, P949
Boudjedir, K. O283, O298, 318
Bougiouklis, D. P994
Boumpas, D. 244
Bourhis, J.H. O107, P540
Bova, I. P511, P604, P630,
P748
Bowen, D. S1044
Bown, N. P683
Boyarshinov, V. P801
Boyer Chammard, A. O385
Braakman, E. O167, O169, P491
Braggio, E. P586
Bramanti, S. P861, P993
Branco, A. P1206
Brand, A. O427, P491, P492,
P975
Brand, R. 228, 229, O286,
P891, P939
Brandejsova, R. N1103, P1167
Brandl, K. O288
Brasca, P. P583, P719
Breccia, M. P895
Bredius, R.G.M. P537, P538,
P690, P788, P928
Bregni, M. O156, 189, 195, 196
Brenner, M.K. O415
Bressolette-Bodin, C. P487
Bresters, D. P653
Brewin, J. O405
Brice, P. O260
Bridger, G. P482, P485, P506
Briere, J. O260
Brinch, L. P455, P466
Brinza, M. P921
Briones, J. O175, P769, P832,
P964
Brissot, E. P543, P566, P752,
P978
Brizio, A. P875
Broccoletti, T. 198
Broeters, D. 120
Brojacova, D. N1103, P1167
Broman, A-K. P539
Bromberg, J. O428
Brookes, C. P955
Brooks, S. P598
Brousse, N. P687
Brown, C. P641
Brown, L. O413, O415
Browne, P. P772, P965
Bruck, F. O387
Brüggemann, M. P740
Brugiatelli, M. P749
Bruinsma, M. O167, O169
Brümmendorf, T. S63, P896
Bruna-Romero, O. P858
Brune, M. O384, P539, P568,
N1107
Brunet, S. O175, P832
Brunetti, M. P1153, P1154
Brunk, A. P616
Bruno, A. P495
Bruno, B. O158, P594, P838,
P851
Bruno, B. O256, P610, P928
Brunori, M. P651
Bruns, I. P437
Brychtova, Y. P546, P958, P969
Bucalossi, A. P530
159

160
List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Bucha, J. O296, P925
Bucher, C. O431
Buchholz, S. P569, P647, P688,
P846, P948
Buckley, V.S. P1182
Budakoglu, B. P499
Budowski, E. P850
Bug, G. P446, P584, P739
Bulabois, C. O107, O391
Bulian, P. O261
Bullens, D.M. O430
Bunjes, D. O170, 184, O259,
P854, P945, P946
Buño, I. P562, P658, P731
Burchert, A. 222
Burdach, S. P777, P796
Burger, J. P596
Burkhardt, R. O172
Burlakova, I. P529
Burlingham, W.J. O427
Burmester, G. P923, P930
Burnett, A. 124
Burniak, A. P859
Burt, R.K. O296, P925
Burthem, J. P677
Burycz, T. P471
Busch, D. P854
Buschman, E. N1064
Busque, L. O104
Busson, M. O397
Buttignol, S. P864
Buxton, D. P1155
Büyükasik, Y. P1199, P1205
Buzyn, A. O107, O161, 184,
Byrne, J.
O255, O258, O391,
P540, P696, P951
O420, P941
Bystricka, E. N1103, P1137,
P1167, P1195
Caballero, D. O106, 120, O139,
O258, P753,
P963, P964
Caballero, T. P839
Cabrespine, A. P894
Cabrespine-Faugeras, A. P951
Cacheux, V. P894
Cafarelli, L. P746
Cahn, J.-Y. O161, P540, P894
Caillat-Zucman, S. P687
Calandra, G. P482, P485, P493,
P506, P507, P589
Caldera, D. P601, P977
Cale, C.M. P685
Calevo, M.G. P643
Calik, K. P1199, P1205
Caliogna, L. P910
Callea, I. P630
Calmels, B. P711
Calore, E. P574
Calugaroiu, C. P921
Calza, S. N1104, N1106,
Cámara, R.
P1161, P1166, P1197
O139
Cambiaso, M. P1161
Camitta, B. 315
Camos, M. O280
Campagnoli, A. P984
Campbell, K.E. N1079
Campilho, F. P633
Campistol, J. P674
Campos, A. P633
Campos, D.J. P656, P812
Camuglia, M.G. P453
Canales, M.A. P713
Canales Albendea, M. O383
Canals, C. O255, O258,
O259
Cañas Iriarte, I. P1124
Candler, K. O178
Candoni, A. P454
Canepa, M. P643
Cangialosi, C. O159
Caniglia, M. P495
Cannas, G. P450, P606
Cannatà, M.C. P630
Cannavale, F. P1161
Cant, A. O411, P683, P684,
P694, P695
Caocci, G. O414, P524, P531,
P532
Capalbo, S. P645, P767
Capaldi, A. P610
Capelli, C. P555, P717, P718
Capello, E. P928
Capittini, C. P1002
Capkova, L. O276
Cappai, L. P531
Cappelli, B. P816, P822,
P909, P1005
Caputo, M. O144
Caracciolo, F. P764, P851
Carcassi, C. P524, P531, P532
Carella, A.M. P449, P476,
P594, P767
Carels, T. N1071
Carles, R. P702
Carlin, Y. P1144
Carluccio, P. O379
Carmagnat, M. O397
Carmona, M. O419, P463, P967
Carnevale Maffè, G. P563
Carnevale-Schianca, F. O158
Carniti, C. O384
Carpenter, P.A. S76
Carrasco, A. O145
Carreras, E. O106, O139, O280,
Carrier, E.
O301, O398, P592, P642,
P674, P757, P953
P625
Carrillo, A. P655
Carrillo Cruz, E. P879
Carrió, A. O280
Carvalhais, A. P633
Carvalho, C. P633
Casanova, L. P515, P1194
Casanova, M. P613
Cascavilla, N. O256, P476, P594,
P645, P767
Caselli, D. P792, P806
Casper, J. O300, P542, P852
Cassinat, B. P894
Cassinotti, A. P927
Castagna, L. O256, P861,
P993
Castagnetti, F. P892, P895
Castagnola, E. P787
Castagnola, M. O149
Castagnoli, P. P1161
Castanho, L.C. N1096
Castel, V. P799, P800
Castelain, S. P1159
Castellanos, G. P712
Castellino, B. P1196
Castermans, E. P944, P954
Castilla, C. P475, P655, P988
Castilla-Llorente, C. P660
Catovsky, D. 225
Catteau, B. P707
Cavagnini, S. P698
Cavalca, S. P1161
Cavallaro, A. P479
Cavallin, M. P724
Cavallo, A. P1196
Cavallo, F. O159
Cavattoni, I.M. P448, P766
Cavazzana-Calvo, M. 197, O411,
P686
Cavenagh, J. P872
Caviglia, I. P787
Cavling Arendrup, M. S36
Cayuela, J.-M. P732
Cazin, I. O380
Ceballos, P. O107
Ceccherini-Nelli, L. P837
Cefali, A. P1129
Cefalo, G. P613
Célere, M. P1169

List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Cellai, I. P632
Cermanova, M. P603
Cerno, M. P675, P864
Cerretti, R. O290, P933
Cervena, J. P1137, P1195
Cervera, R. 244
Cervetto, E. P1161
Cervo, GL P746
Cesaro, S. 329, P574, P789,
P918
Cesbron, A. P978
Cesco-Gaspere, M. O401
Cetin, T. P499
Cetkovsky, P. O276, P461, P467
Cetto, G. O377
Cevreska, L. P473, P762
Chabannon, C. O163, P468,
P711, P949
Chadwick, N. P772
Chae, Y.S. P640,
P681, P865
Chaganti, S. P955, P955
Chakraverty, R. P440
Chalandon, Y. P715
Chalkley, L. 245
Champlin, R. O279, P441
Chan, C. P626
Chancerelle, Y. P745
Chang, M.H. P657
Chapel, A. 340
Chapin, H.H. P825
Charbonnier, A. P468
Charley, C. N1032, N1069,
N1103, P1167
Charlot, C. P450
Charron, D. P732
Charron, M. P519
Chassagne, J. P521
Chatzistamatiou, T. P709
Chaudhri, N. P470, P880
Chaudhry, M.A. P641
Chauvineau, A. P519, P520
Chavan, M. P1136
Chaves, W. O283
Chee, Y.-L. P504
Chehade, H. P715
Chelghoum, Y. P450, P606
Chen, C. P626
Cheong, J.W. P970
Chernykh, E. P922
Chesnel, V. 323, 324, 1212
Chevalier, P. O107
Chevallier, P. P447, P452,
P487, P543, P566,
P737, P752, P761,
P951, P978
Chevret, S. O260, P587
Cheynier, R. P944
Chi, H.S. P937
Chiaretti, S. O133, O138, P439
Chiarvesio, A. P724
Chiba, S. P710
Chibizova, A. P1126
Chicaud, O. P1170
Chiesa, R. P816, P822,
P909, P1005
Chihara, D. P728
Chiu, C.-F. P533
Chiusolo, P. O149, P553, P593,
P725, P855, P881
Cho, B. O146
Choi, I. P623
Choi, J.H. P636
Choma, M. P614, P797, P798
Christensen, I. P826
Christensson, B. P703
Christopeit, M. O378
Chroust, K. P461
Chukhlovin, A. P885
Chung, H. O178
Chung, N.G. O146
Church, H. P1147
Chybicka, A. O265, P689, P797
Chyla, A. N1059
Cibeira, M.T. O162, P592
Ciccocioppo, R. P563, P924
Ciccone, G. O158
Ciceri, F. O141, O171, 229,
O256, 320, O384, P481,
P617, P816, P822, P909,
P929, P1005, N1076,
N1090, P1201
Cicognani, A. P793
Cifarelli, R.A. P607
Cilloni, D. O133, O138, P436,
P439, P454, P898
Cimino, G. O133
Cimminiello, M. P607, P645
Cingarlini, S. O133, O138, P436,
P439, P895
Cinque, R. P679
Cioch, M. P609
Cioni, M. O274, O293
Cirillo, C. P787
Ciurana, A. P1189
Civriz Bozdag, S. P776
Claramonte, N. P1143
Clare, S. 117
Clark, A. P504, P646,
P726, P956
Clark, F. P955
Clark, R. P435
Clarke, M. 245
Clausen, J. P518, P959, P960
Clavel, M. P714
Clavert, A. P752, P761
Clegg, T. N1041
Clement, L. P904
Clerici, D. O171, P481, P617
Clopés, A. P887, P989
Cocorocchio, E. P763
Cohen, A. O177
Cohen, R. N1087, P1123
Cohen, S. O104
Coiteux, V. P707
Cojean, N. P611
Colaci, E. O142, O179, P442,
P465, P670, P775,
P870, P895
Collins, A. N1097
Collins, D. P1150
Collyns, T. P886
Colmenero, I. P515
Colombel, J.-F. 245
Colombo, A. P563, P601, P977
Colturato, I. P828
Colturato, V. O382, P828
Coluccia, P. P613
Combadière, C. P535
Cometa, A. P628, P924
Comi, G. P929
Comoli, P. O274, O293, O414
Conde, E. O258
Conde Ceña, C. P1124
Confer, D.L. 369
Congia, M. P559
Conneally, E. P772, P965
Conradi, R. O173
Console, G. O396, P604,
P645, P721, P748,
P749, N1040
Constantinou, V. P994
Conte, P. P746
Contentin, N. O107, P951, P1159
Cook, A. P529
Cook, G. P435, P490, P664,
P886
Cook, M. P955
Cooke, K.R. 348
Cooke, L. P741, P992
Cooper, L. N1099
Copia, C. P464
Coppoletta, S. P453
Corazza, G. P563, P924
Corbacioglu, S. S19, 239
Cordonnier, C. S39, 213, 323,
324, 325, 328, P433
Cornelio, G. N1040
161

162
List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Cornelissen, J.J. 123, O167,
O169, 183, O278,
O388, P491, P492
Cornely, O. S17, S56, 328
Cornillon, J. P894
Cornish, J. S16, 345
Corradini, P. S81, O157,
222, 223, O256,
O384, P594
Corre, E. O397
Correa-Silva, J. P858
Correia, M. P1202
Cortelazzo, S. P448
Corti, C. O141, O171, P481,
P617, P929
Corti, L. P950
Corti, P. P792
Cosci, E. P530
Coso, D. O163
Cossu, F. P559
Costa, D. O280
Costa, F. P858
Coste-Burel, M. P487
Cotrozzi, M. P1161
Couban, S. 248, P986
Coughlan, M. N1075
Coussons, M. P1175
Cox, C. P635
Craddock, C. P435, P955
Craig, R. O296
Crawley, C. 221
Cremer, B. P1007
Crippa, C. O159
Criscuolo, C. P464
Crocchiolo, R. O171, P816,
P1005
Crocker, M. O145
Cross, N.C.P. P462
Crotta, A. O171, P481, P617
Csalódi, R. P597
Csukly, Z. P758, P771, P773
Cuccia, M. P1002
Cudillo, L. P495
Cuffel, N. P1140
Cullen, I. N1036
Culligan, D. P504
Cullup, H. O102, P512, P513
Cunningham, A. O288
Cupelli, L. P495, P679, N1055
Curti, A. O400, P442, P465
Cusumano, G. P1193
Cuthill, K. P847
Cutini, I. P443
Cutrupi, G. N1040
Cuzzola, M. O396, P582, P604,
P630, P721, P748
Cuzzubbo, D. P787
Cwynarski, K. 229, 306
Czerw, T. 185, P902
Czibere, A. P437
Czuczman, M. S52
Czyz, A P676, P759
D'Addio, A. O400, P449
D'Amico, G. P555
D'Angelosanto, M. P1129
D'Apolito, A. N1055
da Silva Carlucci, V.D. P1169
Dackland, Å. P703
Dagdas, S. P615
Dahl, D. P647
Dahlberg, M. O155
Daikeler, T. O394, O395
Dal Pozzo, S. P632
Dalley, C. P462, P680, N1069
Dallorso, S. P789
Dalva, K. P494
Daly, A. P641
Daly, P. P772
Dammann, E. P647, P846, P948
Dan, E. O400, P775
Danese, S. 245
Dannie, E. N1089
Daolio, P. P613
Dargenio, M. P602
Das-Gupta, E. P941
Dattola, A. O396, P511,
P630, P748
Daturi, R. P500, P501
David, A. P611, P1014
Dávid, M. P597
Davidkin, I. P805
Davidson, J.A. O392, O393,
P544
Davies, E. P1171
Davies, F. P444
Davies, G. O413, O415
Davies, J.M. P504
Davies, M. 117, N1060a
Dávila Quintana, S. P1142
Davis, J. N1069
Day, V. P490
Dazzi, F. O284
de Angelis, C. P735
De Angelis, G. O290, P819,
de Arriba, F.
P823, P874, P985
O162, P988
de Campos Pere Silveira, R.C.
N1096, P1169
de Castro, R. P550
De Fabritiis, P. 187, P679, N1055
de Fontbrune, F.S. O260
De Francesco, R. O144, P645
de Gouw, A.P. P780
De Jesus, R. N1075
de Koning, T. 197
de la Cámara, R. S2, S32, 323,
328, P856
De la Osa García, V. P463, P1142,
P1186
de la Rubia, J. O162, P588
De la Serna, J. P753
de Latour, R.P. O260
de Lavallade, H. P468, P711,
P949
de Lima, M. P441
De Marchi, E. P1129
De Marco, L. O261
De Martiis, D. P698
De Matteis, S. P593, P725
de Mingo Casado, P. P702
de Moerloose, B. O302
De Padua, L. P855
de Pagter, A.P.J. O278, P780,
P781, P782
De Paoli, P. O261
De Paolis, M.R. P602
De Pascale, G. P881
de Paz, R. O162
De Paz Arias, R. O383
De Prijck, B. P991
De Propris, M.S. P903
De Revel, T. P951
De Risi, C. P747
De Risi, L. P871
De Ritis, D. P553, P855
De Rosa, F. P898
De Rosa, L. O159
de Sabata, D. P605, P940
de Saint Basile, G. P686
De Somer, L. O429, O430,
P618
de Souza, C. 230, 316, P586,
P1012, P1013
de Souza, C.V. P1012, P1013
de Souza, M.P. O382, P828
de Vivo, A. P449
de Weijer, R. N1050
de Witte, T. S67, 221, 222,
223, 224, 225, 226,
Dearden, C.
228, 229, 230, O286,
P432, P891, P939
225, P444
Debré, P. P535, P998
Deconinck, E. O107, O140, P951
Decot, V. P904
Dedhin, N. O140, O286
Deeg, J. 254

List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Deiana, M.G. P1161
Del Bono, V. P835
Del Campo, M. P1110
Del Casale, C. O144, P645
Del Fante, C. P500, P501, P984
Del Proposto, G. P495
Del Vecchio, T. P630
Delarue, R. P696
Delaunay, J. P447, P452, P487,
P543, P566, P737,
P752, P761, P978
Delay, M.C. P783
Delcò, C. P715
Delgado, J. O175, O421,
P769, P832
Delia, M. O379, P747
Delibasi, S. P1132, P1185
Delistrati, V. P666
Dell'Agnola, C. O133, O138,
O377, P436,
P439, P895
Dell'Olio, M. P767
Della Porta, M. G. P933
Della Volpe, A. O399, P878,
P927, P950
Delogu, S. P679, N1055
Demartiis, D. P659
DeMattteis, S. P553
Demeckova, E. P461
Deméocq, F. P521, P611, P804,
P1014, P1121
Demertzi, M. P994
Demin, A. P922
Demirer, T. O156, P776
Demosthenous, C. P1163, P1165
Dengler, B. P760
Dengler, J. O282
Denne, C.V. P796
Dennison, D. P1118
Dentamaro, T. P495, P679,
N1055
Depau, C. P560, P673
Derudas, D. P560, P673
Dessaint, J.P. O153
Destro, R. P574
Desveaux, A. P514
Deutsch, V. P743
Devergie, A. O272
Devergie, A. O176, O380,
P550, P938
Devine, H. N1073
Devys, A. P761, P978
Dhedin, N. O107, O161,
O391, P535, P570,
P730, P951, P998
Di Bartolomeo, E. O290
Di Bartolomeo, P. O290, O295,
P433
Di Bella, R. P605, P754, P940
Di Gioia, M. O295
Di Marco, A. P453
Di Marco, E. P787
Di Renzo, N. P602
Díaz, M.A. P515
Díaz de Heredia, C. O411, P814
Diaz-Beya, M. P642
Díaz-Mediavilla, J. O162
Dickinson, A.M. S73, O148,
Didier, F.
P513, P516, P547,
P551, P561, P578
N1059
Diedrich, H. O151, P569,
P840, P846
Dietrich, S. P740
Dietz, E. P1176
Díez, J.L. O139, P963
Díez-Martín, J.L. P562, P658,
P731, P753
Dijkstra, F.S. P962
Dijkzeul van Schie, G.M.P. N1038
Dilloo, D. O134, O425
Dimopoulos, M. S30
Dini, G. O177, 187, 233, 234,
P643, P787, P792
DiPersio, J.F. S46, P482,
P485, P506
Discepoli, G. P607
Dishleva, Z. P634
Distelmeier, L. P437
Distler, E. O291, P825, P999
Dittmann, H. P945, P946
Divya, A. P1136
Dix, C. O271, P911
Dlubek, D. P527, P860
Dmoszynska, A. P609
Dodd, S. P1117, P1178,
P1181
Dodero, A. O384, P594
Dodgson, A. N1041
Dodgson, K. N1041
Doffman, S. O277
Döhler, B. O431
Döhner, H. O170, P854
Dolejsova, L. P1137, P1195
Dolgopolov, I. P801
Dölken, G. O173
Dombret, H. P938
Domenech, A. P1189
Domingues, D. P1202
Dominici, M. P746
Dominietto, A. P835, P928
Don, A. O428
Donaldson, C. P635
Donelli, A. O295
Donnelly, P. S37, 327, P830,
P1192
Donnini, I. O295
Donot, P.E. 357, 359,
360, 362
Donze, O. P551
Doran, Z. 221
Dore, E. P611, P1014
Doria, A. 244
Dörken, B. P654
dos Santos, A.C. O382
Doskocilova, K. P1011, N1103,
P1167
Dossett, A. P1149
Dotti, G. O405
Doubek, M. P546, P727, P958,
P969
Douglas, E.A. P561
Douglas, K.W. P504, P600, P956
Dovernas, A.M. N1089
Doyen, C. 221
Drabko, K. P614, P797, P798
Dragonetti, A. O422
Drake, M. 227
Dray, L. P523, P671, P736,
P850
Dreger, P. 222, 225, 229,
O257, O286, 352,
P740, P891
Drey, L. P966
Drory, V. P743
Drouet, M. P745
Drozdowska, D. P759
Druzic, V. P1167
Duarte, R.F. O139, O259, 313,
O421, P839, P887,
P989, P1148
Dubray, C. P1014
Dubruille, V. P447, P543,
P566, P752,
P761, P978
Duda, D. P860
Dufour, C. 317, 318, 320
Duggan, P. P641
Duggleby, R.C P497
Dulphy, N. P732
Dumont, M.-D. P687
Dumontet, C. P606
Dunn, A. P507
Durán Sánchez, I.M. P1142,
Durante, S.
P1146, P1186, P1200
P892
Duval, M. 318
Duyster, J. P760
163

164
List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Dvorakova, D. P727
Dybedal, I. P455
Dykes, J. S22
Dyla, A. P689
Dytfeld, D. P676, P759
Dziaczkowska, J. P902
Eapen, M. O132, O135,
236, O279
Ebeling, F. 187
Ebell, W. O134, O265
Ebinger, M. O270
Eckert, C. O263
Edel, E. O172
Eder, M. O137, P569, P647,
P846, P948
Eder, S. P581
Edl, S. N1103, P1167
Edoardo, L. P792
Edwards, R. O178
Eeltink, C. N1048, N1094,
N1104, N1106
Efrati, E. P802
Efrati, S. N1070
Egberts, A.C.G. P690, P788
Egeland, T. P455, P466
Egeler, M. P537, P538, P653,
P690, P788, N1067
Egerer, R. P779
Ehlert, C. P571
Ehlert, K. O264
Ehninger, G. 86, O173, 185,
O285, O390, O424,
P433, P459, P525,
P627, P972
Eiermann, T. O147
Einarsdottir, S. P568
Eini, E. P478
Einsele, H. S4, S60, 110, 222,
O271, O300, 323, 324,
325, 328, 332, P608,
P831, P849, P854,
P907, P908, P911
Eisfeld, A.-K. O172
Ek, M. N1101
Ekim, M. P669
El Cheikh, J. O163, O385, P468,
P528, P862, P949
El Weshi, A. P751
El-Ghariani, K. P490
El-Solh, H. 201, 202
Elad, S. P1144
Elarouci, N. 233, 234
Elena, C. P601, P977
Elez, M. P477
Elghazaly, A. P880
Elghazaly, E. P470
Elgue, G. P631
Elhasid, R. P496, P802
Elia, L. O133
Elias, S.S. N1096
Ellis, M. P827
Ellis, S. O277
Elloumi, M. P863
Elmaagacli, A.H. O407, P438,
P451, P637,
P734, P934
Emery, V. S3, P831
Enazi, K. P470
Enevold, C. P826
Engelhardt, M. O258
Eom, Y.W. P636
Erande, S. P1136
Erhardt, C. P1176
Errico, A. P1197
Ersoy, H. P494
Ertem, M. P494, P652, P669
Erttmann, R. O147
Eshaghi, H. P979
Eshel, R. O423
Eskar Sebban, L. O426
Esperou, H. P540
Espigado, I. O139, O419,
P463, P967
Espigado Tocino, I. P879, P1134
Esterni, B. P528, P862
Esteve, J. 186, 187, O280,
Estrina, M.
O281, P592, P1189
P510
Ethell, M. P444
Evangelio, C. P816, P822,
P909, P1005
Evangelista, A. O158
Evans, C. N1099
Eyrich, M. O294, O415, P906
Fabre, M. P687
Facchini, L. P769
Fagioli, F. O106, P785, P792
Fagot, T. O107
Faibish, T. P1135
Falantes, J. P463, P967
Falantes González, J. P879
Falco, P. O159
Falcone, A. O159, P594
Falda, M. 182, P933
Falk, C. P732
Falkenburg, J.H.F. 92, 109, O160,
O292, O404,
O417, P900
Falorio, S. P661
Fallarino, F. 372
Fanali, C. O149
Fanin, R. O158, O256, O384,
P454, P675, P724,
P864, P933
Faraci, M. O177, P643,
P787, P792
Farah, N. P638
Farge, D. 243, 244
Farina, L. O384, P594
Fassas, A. P433, P549, P565,
P650, P729, P994
Fasth, A. N1092
Faucher, C. 328, O385, P452,
P468, P528, P711,
P862, P949, P951
Faul, C. O137, O389, P945,
P946, P952
Fauriat, C. P1000, P1001
Favre, C. P785
Fazio, L. O422
Fedele, R. O396, P582, P604,
P721, P748, P749
Federmann, B. O389, P945,
P946, P952
Fedorenko, D.A. O297, P672
Fegueux, N. O140
Fehse, B. O157, P699
Fenaux, P. S49, P938
Fenk, R. P437
Ferault, C. P1197
Fermand, J.-P. O161, P587
Fernandes, J. O411
Fernandes, S. P1174
Fernandez, A. P475
Fernandez, A.O. 120
Fernandez, H. P434
Fernandez, M. 113
Fernandez, P. P596
Fernández de Larrea, C. P757
Fernandez de Sevilla, A. P753,
P887, P989
Fernández-Avilés, F. O280,
O398, P592, P642,
P674, P757, P953
Fernández-de-Larrea, C. O398
Fernández-Navarro, J. P790,
Ferra, C.
P799, P800, P811
O139, P552,P856, P964
Ferrant, A. 187, O259
Ferrara, F. P464, P767
Ferrara, J. O148
Ferrari, A. O133, O138, P439,
P613, P769
Ferreira, A. P1141
Ferreira, M. P1206
Ferreira, R.B. P633

List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Ferrua, F. P822
Ferwerda, B. P830
Festuccia, M. O158
Feuchtinger, T. O266, O270,
P778, P795
Fevery, S. O430
Fiaccadori, V. P601, P977
Fiaschè, M. P721
Fibbe, W. 338, P628, P975
Fichera, G. O177
Fick, K. P907, P908
Field, T. P434
Fielding, A. P435
Fields, P. P848
Figueiredo-Neves, S. P858
Filardi, N. P607
Filì, C. P536
Fillet, G. O387, P991
Fina, M.P. P775
Findler, M. P1144
Fine, D. P693
Fineman, R. P884
Fingerle-Rowson, G. P893
Finke, J. S72, O155, 228,
230, O286, O300,
P432, P433, P517,
P534, P619, P931,
P738, P939
Finlay, J. 101
Finocchi, A. 198
Fiore, F. P838
Fioredda, F. O177, P643
Fioritoni, F. P661
Fischbacher, D. P901, P905
Fischer, A. O410, O411,
P686, P687, P936
Fischer, G. P581, P919
Fish, D. O104
Fisher, G. P550
Flandrois, G. P761, P978
Fleischhauer, K. O416, P914,
P1005
Flicker, K. O165
Fliedner, M. S66, N1052
Fliedner, T. 118
Fløisand, Y. 228, P455, P466,
P939
Flood, T. P683, P684, P694,
P695
Florio, F. P675
Flückiger, U. P833
Flynn, C. P772, P965
Foà, R. O133, O138, 225,
P439, P651, P866,
P903, P974
Focosi, D. P837, P851
Fogliatto, L. P919
Forcheron, F. P745
Forcina, A. O171
Ford, R. N1033
Forese, P. P602
Forino, C. P659, P698
Forleo, A. N1055
Formankova, R. O276, P784,
P888
Forslöw, U. P720
Forti, S. O399
Fortier, S. O412, P644, P656,
P812, P843, P916
Fortmann, F. 222
Fossati, M. P816, P822,
P909, P1005
Fossati-Bellani, F. P613
Fouillard, L. O107, O140
Fouillard, P. O140
Fournier, I. P1157
Fowler, C.J. P507
Fraboni, D. P819, P824
Franceschetti, M. P914
Francesia Berta, M. P1161
François, S. O107, P951
Frangoul, H. O279
Franke, G.-N. O386, P558
Frassoldati, A. P746
Frassoni, F. O106, P835
Frattini, F. P605, P754, P940
Fredrick, L. P680
Frei, R. P833
Freiberger, P. P585
Freire, A. O419
Frenos, S. P789, P806
Frère, P. O387, P991
Fresno, M. P515
Freudenreich, M. P901
Freund, M. O300, O403, P503,
P542, P556, P620,
P624, P733,
P852, P961
Frey, M. O291
Fridriksdottir, N. N1084, P1125
Friedrich, W. O409, O411, P622
Friedrichs, B. 116
Fries, E. O278
Fritsch, S. P548
Froehlich, E. P742
Frommer, K. P906
Fruehauf, S. P589
Fruehwirth, M. O165, P704
Fruet, F. O400
Frugnoli, I. P816, P822,
P909, P1005
Frusciante, V. P645
Führer, M. O134, O264, O299,
315, 320, P685,
P777, P936
Fujimaki, K. P486
Fujino, M. P649
Fujisawa, S. P648
Fujita, A. P486, P648
Fujiwara, H. O103
Fujiwara, K. O143
Fukuda, T. O136, P678
Fukumori, T. N1085
Fukunaga, A. P580
Fukushima, T. P710
Funes, C. P702
Funke, V. P644, P843, P916
Furlan, I. P796, P936
Furst, A. O107
Furst, S. O140, O161, O385,
P468, P528, P711,
P862, P949
Füssel, M. O390
Gabor, W. P797
Gabriel, I. O284, P502
Gabutti, C. P583, P719, P875
Gadner, H. O134
Gahrton, G. 87, 221, 223, 227
Gaiero, A. O177
Gaipa, G. P555
Galambrun, C. P951
Galceran Bruix, M. P1129
Galenko, L. P573
Galgano, L. P1197
Galieni, P. P449
Galimberti, S. P764
Galitzer, D. N1097
Gallamini, A. O158, P1196
Gallardo, E. P1118
Gallimore, C. O381
Gallo, G. P511
Gallo, S. P1193
Gallucci, C. P823, P824, P874,
P985
Galski, H. O166, P488
Galvão, C.M. N1096
Ganapiev, B. P573
Gandemer, V. O298
Gandola, L. P613
Gangemi, T. P1193
Ganidou, M. P549
Ganser, A. O148, O151, P569,
Gao, D.C.
P647, P840, P846, P948
O168
Garant, R. P447
Garban, F. P951
García de Insausti, C. P712, P714
165

166
List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Garcia Noblejas, A. P856
García Santos, J. M. P702
García-Laraña, J. O162
Garcia-Rodriguez, M.J. P713
Garderet, L. 221, P591
Gardiner, N. P772
Garlaschelli, F. P1002
Garnett, G. P831
Garnier, F. O140
Garofalaki, M. P505
Garreffa, C. O396, P511, P630
Garrigou, P. P745
Garten, C. P972
Gaspar, B. 198, 200, O411,
O413, O415, P543, P566,
P752, P761, P978, 1210
Gastinne, T. P447
Gates, P. N1054
Gattei, V. O261
Gattillo, S. O171, P909
Gatto, F. P582
Gatz, S. P622
Gaudernack, G. O402
Gaudio, F. O379, P645, P747
Gay, F. O159
Gayoso, J. O421, P562, P658,
P731, P753, P963
Gaziev, J. P819, P823, P824,
P874, P985
Gazzola, M. P574
Gedde-Dahl, T. P455, P466
Geddes, M. P641
Gee, A. O279
Geenen, V. P944
Geeraerts, M. P618
Geissler, G. O285
Genadieva Stavrik, S. P473, P762
Genin, M. P1203
Gennery, A. 198, 199, O411,
O413, O415, P683, P684,
P685, P694, P695
Genovese, V. P500, P501,
P984, P1002
Gentile, G. P866
Georgievski, B. P473, P762
Georgoudi, E. P1132, P1185
Gepstein, L. O423
Gerbitz, A. P541
Gerlini, G. P632
Germeroth, L. O403, P854
Germing, U. P437
Geromin, A. P675, P864
Gertow, J. P489, P509, P612,
P912
Gesundheit, B. P523, P671,
P736, P850, P966
Ghadiri, A. P535
Ghaffari, H. P979
Ghashghaie, A. P979
Ghavamzadeh, A. P478, P590,
P810, P818, P820, P979
Ghazarossian, V. O145
Ghelase, R. N1103, P1167
Ghez, D. P696
Ghibaudo, E. P1161
Ghiglia, A. P1196
Ghimenti, M. P837
Ghosh, A. O168, O288
Giaccone, L. O158, P594, P838
Giacobone, E. P500, P501
Giagounidis, A. S51
Giammarco, S. O149, P553, P855
Gianfaldoni, G. P443
Gianni, A. O384
Giannotta, C. P593
Giannoulia, P. P436, P898
Giardelli, A. P909
Giardini, C. P524, P531, P532
Giardino, S. P787
Gibson, B. 131
Giebel, S. 185, O300, P902
Gieryng, A. O273, P995
Gigli, F. O377, P763
Gil, L. P676, P759
Gil Rubio, P. P1124
Gilardi, L. P984
Giles, C. O284, P595
Gilestro, M. O159
Gilevich, A. P920, P922
Gilleece, M. P664, P886
Gillingham, A. P744
Gilmour, K. 198
Giné, E. P592
Giordan, M. P574
Giordano, A.M. O379, P747
Giordano, L. P861, P993
Giorgiani, G. O171, O293,
O414, P924
Giovannini, M. P679
Giraud, C. P519, P520
Girmenia, C. P866
Girschikofsky, M. P770
Gisselbrecht, C. O260
Gittler-Hebestreit, N. N1060
Giudice, V. O142, O400, P442
Giulivi, A. O262, P744
Gjadrov Kuvezdic, K. P469
Glackin, M. P1184
Glass, B. O257, O258, P701
Gluckman, E. O106, O107,
O132, 187, O272, O283,
O298, O301, 318, O411
Gnani, A. P439
Gobbi, M. O106
Goda, V. P758, P771, P773,
P877
Goddard, Y. N1069
Goes, J. P1118
Göhring, G. O265
Goi, K. 318
Goker, H. O388, P1199,
P1205, P1128
Golay, J. P555, P555, P718,
P914
Goldman, J. O284
Goldschmidt, H. 223, P589
Goldstein, G. P496
Goldstone, A. O174, P435
Golmard, J.L. O161
Goloschapov, O. P791
Golovacheva, A. P983
Golovkina, L. P981
Gombert, J.M. P519, P520
Gomes, R.T. O412
Gomez, R. P858
Gomez, S. P497
Gómez Espuch, J. P702
Gómez-Pineda, A. P562, P658
Gonçalo, A.P. P633
Gonzales, E. P1143
Gonzalez, F.J. P1110
González, J. P463, P967
González, J.D. P588
Gonzalez, M. S80
González Campos, J. P879
González-Vicent, M. P515, P814
Gooley, T. O416, P1006
Gopcsa, L. P758, P771, P773
Gorczynska, E. P689, P797, P798
Gordon, W.C. P504
Gorelick, A. N1087
Gorin, N.C. 187, P591
Görlitz, A. O257
Gorodokin, G. O297, P672
Goroncy, N. N1054
Gothot, A. O387, P944
Gotti, E. P718
Goulden, N. O415
Goulmy, E. 94, O427
Gozdzik, J. P798
Gozzini, A. P871
Grabrucker, C. P901, P905
Graca, A. N1066
Gracía-Noblejas, A. O139
Grades, P. P1202
Graef, T. P437
Graeven, U. P637
Gragnani, S. P837

List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Graham, T. P1163, P1165
Gramatzki, M. 222, O300,
P571, P722
Granell, M. O175
Grassi, A. P555, P717, P968
Grassi, V. P659
Grassia, L. P928
Gratwohl, A. 371, O394, O395,
O431, P498, P665,
P833, P891, P1006
Gray, J.J. O381
Greco, G. O144, P645
Greco, M. P476, P767
Greco, R. P929
Greenfield, D. 220
Greil, J. 120, P685
Greinix, H. O148, 223, O268,
P526, P541,
P581, P1009
Grenier, N. P745
Gribben, J. P872
Griffioen, M. O404, O417, P900
Griffiths, M. P955
Grigg, A. 226
Grigoleit, G. P854, P907, P908
Grillo, G. P583, P719, P875
Grimbacher, B. P684
Grisendi, G. P746
Grkovic, L. P469
Gromke, T. P438, P451, P734,
P934
Gronkowska, A. P579
Grootenhuis, M.A. N1067
Grootes, M.E.B. P1160
Grosse-Thie, C. P503, P961
Grothe, W. O378
Gruber, A. 223
Gruenwald, F. P456
Gruhn, B. P723, P779, P857
Grüllich, C. P517
Grund, G. P797
Gualandi, F. O106, O295,
P835, P928
Guarene, M. P1002
Guarini, A. P645, P767, P903
Gudiol, C. P887
Guest, J. P1178
Guggiari, E. O171
Guglielmelli, T. O159
Guidi, S. 120, O256, P443,
P449, P806, P871
Guilhot, F. P519, P520
Guillaume, T. O391, P447, P452,
Guinn, B.
P487, P543, P566, P737,
P752, P761, P978
P598
Guler, T. P499
Gumy-Pause, F. P715
Güngör, T. O134, O408
Günther, A. P571
Gupta, S. P755
Gur, O. O423
Gurman, G. P776, P868, P1128
Gurrado, A. O274, O293
Gustafsson, B. P474
Guyotat, D. O107
Gyung, J.S. P640
Ha, J.O. O146
Haagenson, M. P990
Haas, P. P732
Haas, R. P437
Habermann, I. P627
Haddad, N. P884
Haegele, M. P952
Hafraoui, K. O387, P991
Hägglund, H. P842, N1019
Hahn, A. P647
Hahn, J. P733
Hahn, N. O148, O151, P840
Hajaj, G. N1097
Hajek, R. 221
Håkansson, M. P1179, P1183
Hakansson, Y. N1049, P1139
Hale, G. O415
Halkes, C.J.M. O160
Hallberg, D. P539
Halle, P. P521, P804, P1121
Hallek, M. 225, P893, P1007
Halpenny, M. O262, P744
Halter, J. 119, O394, O395,
O408
Hämäläinen, S. P867
Hamidieh, A.A. P810, P818, P820
Hamladji, R.M. P882, P980
Hammans, S. P693
Han, D.K. O146
Han, K.S. P460, P756
Hanau, G. P643
Hanbury, J. P1180
Handgretinger, R. S74, O134,
Hänel, M.
O263, O266, O267,
O270, 344, O389,
O425, P616, P778,
P795, P906
O285, O390
Hanna, N. N1082
Hannemann, S. P629
Hannon, M. P944, P954
Hansen, H.P. P1007
Hansen, K. P507
Hansen, L. P507
Hansen, M. P1113
Har-Zion, L. N1070
Harada, M. P678
Harada, Y. P710
Hardan, I. P457, P947
Harder, J. O155
Hardt, J. P1116
Harhalakis, N. P505, P666
Harieche, F. P980
Harmata, S. O287
Harousseau, J.L. 221, 229,
O391, P447, P452,
P487, P540, P543,
P566, P737, P752,
P761, P978
Harrold, J.L. P561, P578
Hart, D. O102, P512, P513
Hartwig, U.F. O406, P616, P999
Harvey, H. P683, P684, P695
Hascoët, I. P1203
Hasegawa, Y. P710
Hasemann, W. P1176
Hasenkamp, J. O257, P701
Hasle, H. 128, O302
Hassan, M. O289
Hassan, W.-Y. N1095, P1127
Hassan, Z. O289, P445, P842
Hasselblatt, P. P931
Hasskarl, J. P738
Hassold, N. P911
Hauck, F. P627
Haupt, R. P792
Hauser, H. P557
Haveman, L. P782
Haversath, M. P852
Havet, A. P1157
Hawkey, C.J. 245
Hayden, J. S1046
Hayden, P.J. P600
Hayes-Lattin, B. P507
Hayette, S. P450
Haynes, R. P1164
Hazar, V. P692, P697, P821
Haznedaroglu, I. P1199, P1205
Heath, P. 198
Heaton, G. N1041
Hebia-Fellah, I. P487
Hedstrom, U. P827
Hegenbart, U. 223, P740
Heijnen, I. O394
Heilmann, C. P826
Heilmeier, B. 118
Heim, D. O394, O395,
P665, P833
Heinzelmann, M. 222
Heitger, A. O269
167

168
List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Heizmann, M. P596
Heldal, D. P455, P466
Hellman, A. P1167
Hellström-Lindberg, E. 209, P935
Helström, L. P539
Hemery, F. P1121
Hemmati, P. P654, P688
Hemmerling, J. O406, P616
Henke, E. O168
Hennig, E. O386
Henry, G. P732
Hensel, M. P740
Hensel, N. P1004
Henze, G. O134, O263
Heras, I. O139, P475, P655,
P660, P753, P963,
P964, P988
Herbelin, A. P519
Herbrecht, R. S38
Herling, M. 225, P893
Hermann, S. O154
Hermesz, J. P597
Hernandez Navarro, F. O383
Hernández Palazón, J. P702
Hernandez-Navarro, F. P713
Hérodin, F. P745
Herold, T. P893
Herr, A.-L. O176, 187, O283
Herr, W. O291, O406, P616,
P825, P999
Hertenstein, B. O151
Herzberg, P. P541, P542
Hess, D. P508
Heuft, H. P647
Heuser, E. P1007
Heussel, C.-P. 328
Heussner, P. P541
Hicheri, Y. 325
Hideyuki, K. P486
Hiepe, F. 244, P923, P930
Higgins, E. P772
Hildebrandt, G. P541
Hildebrandt, Y. O157, P585,
P699, P896
Hildenbrand, B. P1149
Hilgendorf, I. P438, P503,
P541, P542, P556,
P852, P961
Hill, G. O428
Hill, K.S. P693
Hill, L. P1174
Hino, M. O136, O418
Hirata, H. P580
Hirsch, H. 98
Hirsch, I. P696
Hissinkmuller, P. P834
Hnidkova, I. N1103, P1167
Ho, A.D. S45, P589, P740,
N1072
Ho, J. O262
Hochhaus, A. 226
Hochsmann, B. 315
Hodson, A. P847, P848
Hoelzer, D. O282
Hofmann, N. A. O165, P704, P742
Holder, K.P. P1131
Hölig, K. 86
Holland, A. O168, O288
Holländer, G. 367
Holler, A. O401
Holler, E. S18, 95, O148,
222, P541, P551,
P733, P777
Holmberg, K.K.S. P1177
Holme, P. P455, P466
Holowiecka-Goral, A. P902
Holowiecki, J. O137, O300, P902
Holroyd, A. O174
Holter, W. O134, O263
Holtick, U. P547
Hong, I.K. P765
Hönig, M. P622
Hoogerbrugge, P. 211
Hopfinger, G. 225
Horal, P. P568
Horky, O. P727, P969
Horowitz, M.M. O132
Horton, R. P497
Horvais, V. P487
Hoshino, T. P486
Hosing, C. P441
Howell, D. O174
Hows, J. 317
Hrabetova, S. P1011
Hrdlickova, A. O276
Huang, H. P976, P1003
Hubacek, P. O276, 330, P888
Hübel, K. P1007
Huber, A.R. P596
Huber, C. O291, O406, P616,
P825, P999
Huebner, D. P493
Huebsch, L. O262
Huh, J. P765, P876
Huijgens, P.C. P962
Huijser-Mazzucco, M. P1160
Humblet-Baron, S. P954
Humpe, A. P722
Hunault-Berger, M. P452
Hungria, V. P586
Hurlock, C. P693
Hussain, F. P880
Hussein, Ayad A P807
Hutt, D. N1034
Huynh, A. O107, O161,
184, P951
Huynh, P. 359, 362
Hwang, T.J. O146, P639
Hyo, R. P486
Iacobazzi, A. P767
Iacobelli, S. 221, 223, 227
Iacobucci, I. O133, O138,
P436, P439, P454,
P892, P898
Iacopino, O. P630
Iacopino, P. O396, P511, P582,
P604, P630, P645,
P721, P748, P749,
N1040, P1193
Iannella, E. P651, P866,
P903, P974
Iavarone, F. O149
Ibatici, A. P835, P918
Ibrahim, K. P470
Ichinohe, T. P836
Ichiyama, S. P836
Idzan, S. N1103
Ifrah, N. P452, P540
Iglesias, C. P1143
Ikinciogullari, A. P494
Ileri, T. P652, P669
Ilhan, O. P494, P776, P868,
P1199, P1205
Illmer, T. O390, P459
Im, H.J. P639
Imbalzano, L. N1040
Imbert-Marcille, B. P487
Indovina, A. P479
Indrac, K. O258, P461
Ine, S. P728
Iniesta, F. P702, P712
Innocenti, I. P725
Inns, H. P886
Inoko, H. O105
Insunza, A. P662
Intermesoli, T. P448
Introna, M. P555, P717, P718,
P914
Inzitari, R. O149
Ionescu, I. O106, O107,
O283, O298, O301
Ionova, T.I. O297, P672
Iori, A.P. P651, P866, P895,
P903, P933, P974
Ipek, S. P1193
Iravani, M. P478, P810, P818
Iriondo, A. O139, P662, P839

List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Irrera, G. O396, P604, P721,
P748, P749
Isacchi, G. P1129
Isernhagen, J. P738
Isernia, P. P977
Isfan, F. P611, P1014
Isgro, A. P819, P823, P824,
P874, P985
Ishigatsubo, Y. P648
Ishige, M. P486
Ishikawa, T. P836
Ito, J.L. S82
Ito, M. P649
Ivanov, R.A. O297
Ivanova, N. P983
Ivanova, O. P1126
Iwakiri, I. N1085
Izquierdo, P. P1143
Izura, V. P702
Izzo, T. P464
Jaber, J. P1138
Jackob, S. P907
Jackson, A. P683
Jackson, G. P516, P578, P932
Jackson, R. P726
Jacobi, R. P781
Jacobs, N. P954
Jacobsen, E.D. P493
Jacobsen, N. 118, P826
Jacque, N. P730
Jäger, E. P899
Jahani, M. P478, P810, P818
Jalali, A. P478
Jalili, M. P810, P818
Jang, G. P997
Jang, J.H. P545, P657
Jang, S. P937
Janin, A. P514
Jankowska-Gan, E. O427
Jansen, K. 324
Jansen-Hoogendijk, A.M. P537,
P538
Janssen, J.J.W.M. P962
Jantunen, E. P867
Jarisch, A. P691, P777, P1116
Jaskula, E. O273, P527,
P859, P860
Jayne, D. 244
Jebavy, L. P603
Jedema, I. O292
Jedlickova, Z. P529
Jeggo, P. P695
Jenq, R. O168, O288
Jeon, M.J. P937
Jeong, S. P1198
Jeong, S.H. P636
Jessie, R.M. P1190
Jeulin, H. P904
Jiamsakul, A. P1008, P1015
Jim, N. O288
Jimenez Martinez, J. P1142,
Jindra, P.
P1146, P1186, P1200
P706
Jindra, P. P458, P461, P973
Jobi, J. P1118
Joergensen, A.H. N1058
Johansen, J. O402
Johansson, E. N1024, N1088,
N1104, N1106,
P1179
John, J. P1118
Johnson, M. O156
Johnson, P.R.E. P504
Jol-van der Zijde, C.M. P537,
P538, P834
Jolles, S. P684
Jones, D.A. P508
Jones, R. P441
Jones, S. P1147
Joo, Y.D. P623
Joosten, A. O427
Jose, S. P1118
Joshi, A. P755
Jost, K. P503, P961
Jouet, J.P. O153, O255, P707,
P951, N1057
Juanitas, A. P1118
Judith, D. P456
Juergens, B. O269
Jun, H.J. P657
Jun, S.E. P815
Jung, C.W. P545, P657
Jung, H.J. O146
Jung, R. P656, P812
Jung, W. P701
Junge, M. P734
Junghanss, C. P503, P541,
P542, P556, P620, P624,
P733, P852, P961
Jungova, A. P461
Jurcek, T. P969
Jürgens, H. P783
Juutilainen, A. P867
Kabatova-Maxova, K. P1137,
P1195
Kabbara, N. O272, P587
Kabickova, E. O276
Kabisch, H. O134, O264, P777,
P803
Kaczmarek, P. P444
Kadam, S. P1136
Kagami, Y. P728
Kagan, O. O423
Kahl, C. P503, P733,
P852, P961
Kai, S. O143
Kaijser, B. P568
Kajiura, D. P649
Kajtár, B. P597
Kakkas, I. P505
Kalhs, P. P581
Kállay, K. P845, P877, P917
Kaloyannidis, P. P549, P565,
P650, P994
Kalwak, K. 198, P685, P689,
P798
Kamal, H. P569
Kamble, N. P1136
Kamble, P. P1136
Kambouris, M. O102, P512
Kami, M. P678
Kamizuru, Y. N1085
Kammerer, P. P1152
Kammoun, L. P570
Kanamori, H. O136, P486, P648
Kanda, J. P836
Kanda, Y. O136, P873
Kandhasamy, K. P1130, P1190
Kaneko, S. P710
Kanfer, E. P502, P595, P638
Kang, H.J. O146, P639
Kang, S.I. P937
Kang, S.Y. P636
Kang, Y.A. P937
Kangarloo, S.B. P641
Kannan, S. P755
Kanold, J. P521, P611,
P804, P1014
Kantele, A. 207
Kantele, J. P805
Kanz, L. O389, P945,
P946, P952
Kapas, B. P771, P773
Kaplan, O. P850
Kapp, M. P907, P908
Kapucu, S. P1122
Karacan, Y. P1122, P1128,
P1199, P1205
Karakantza, M. P577
Karakasis, D. P505, P666
Karanfilski, O. P762
Karas, M. P458, P461,
P668, P706
Karasova, L. P1137
Karasu, G. P697, P821
Karatza, M. P505
169

170
List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Karbach, J. P899
Karimi, A. P590, P820
Karlin, L. P587
Karlsson, H. O152, O289, O405
Karponi, G. P994
Karpouza, A. P565
Kartal, M. O410
Kartashov, A.V. O297
Kashiwase, K. O105
Kashofer, K. O165
Kasliwal, M. P847
Kasparu, H. P557, P770
Kaspers, G. 130
Kasran, A. O430
Kassa, C. P845
Kato, H. P728
Kato, J. P486
Kato, S. O105, O143, P484,
P486, P710
Kaufmann, M. O173, 222, O285
Kawano, Y. P678
Kawase, T. O105
Kay, C. N1075
Käyhty, H. P805
Kazantsev, I. P957
Kazerooni, R. P441
Kazik, M. P692, P821
Kazmi, M. P847, P848,
P932, P1156
Kazýk, M. P697
Keane, H. P1163, P1165
Kearsley, S. O152
Kebriaei, P. P441
Keinrath, B. N1103, N1108,
P1167
Keller, U. P760
Kennedy, D. P1168
Kennel, A. P904
Kentouche, K. P987
Kenyon, M. N1081, P1162
Kertész, A. P845
Keslova, P. O276, P784, P888
Ketels, A. P722
Kettler, P. P1113
Keukens, L. O278, P780
Kew, A. O284, N1089
Khalil, A. P802
Khamaganova, E. P981
Khan, F. O275, O376, P829
Khan, H. P1136
Khan, S.A. P616
Khansari, L. P979
Khante, J. P1136
Kharfan-Dabaja, M. P434
Khatami, F. P478
Khattry, N. P755
Khodabandeh, A. P810, P818
Kiani, A. 86, O285, O424,
P627
Kibitzova, P. P1137, P1195
Kienast, J. O154, O287, O300
Kieslich, M. P691
Kilic, S. P499, P615
Killian, D. P620, P624
Kim, B.K. O150, P460, P554,
P756
Kim, B.S. P460, P756
Kim, C.S. O150
Kim, D.H. P545, P657
Kim, D.Y. P937
Kim, E.K. P997
Kim, H.C. P636
Kim, H.K. O146
Kim, H.S. P809
Kim, I. O150, P460, P554, P756
Kim, J. P626
Kim, J.E. P997
Kim, J.G. P640, P681, P865
Kim, J.S. P756, P970
Kim, J.W. P756
Kim, K. P545, P657
Kim, K.F. P672
Kim, K.H. P657
Kim, S. O418, P765, P876
Kim, S.-W. P678, P997
Kim, S.H. P937
Kim, S.J. P970
Kim, S.J. P657
Kim, S.J. P545, P657
Kim, S.N. P640, P865, P681
Kim, S.W. P765, P876
Kim, S.Y. O146
Kim, T. P654
Kim, W.S. P545, P657, P657
Kimby, E. 225
Kindler, V. P498, P715
King, C. O168
Kircher, B. P518, P960
Kirgner, I. O423
Kirkland, K. P435, 1207, 1215
Kirsanova, N. P480
Kirsch, M. P1176
Kirschner, P. P846
Kiss, A. 218
Kiss, T. O104
Kitahara, M. N1085
Klammer, M. O284
Klamova, H. P467
Klaus, A. P1116
Klein, C. P647
Klein, J.P. O135
Klein-Gonzalez, N. P913
Kleinschmidt, K. P793
Klenner, A.F. O173
Klimko, N. P885
Klingebiel, T. O134, O263,
O264, O267, O425, P691,
P777, P899, P915, P1116
Kloess, S. P915
Kloger, G. P495
Klouz, A. P575
Klyuchnikov, E. O157, P621,
P699, P897
Kmonicek, M. P603
Kneba, M. P740
Kniazhansky, T. P708
Knibbe, C.A.J. P690, P788
Knobler, R. P526
Knop, S. P608, P945
Knuebel, G. P620
Knueppel, A. P620, P624
Kobayashi, T. P486
Kobbe, G. 222, P437
Kobold, S. P896
Kobylka, P. P774
Koch, E. P825
Köchel, C. O271
Kochina, E. P510
Kocmanová, I. P844
Kodera, Y. O105, 370,
O418, P678
Kodo, H. O143
Koehl, U. S25, O267, P915
Koenecke, C. 221, P647
Koenig, J. P557, P770
Koerich, A. P656, P812
Kogan, I. P1135
Koh, Y. P460
Köhler, G. O154
Köhler, W. P688
Kohsaki, M. O143
Koivula, I. P867
Kojima, H. P710
Kojima, S. O299
Kolb, H.J. 118, O148, 204,
P433, P548, P796,
P901, P905
Kolbe, K. O285
Koldehoff, M. O407, P438,
P451, P637
Koliski, A. O412, P916
Kollen, W.J.W. P653
Komarnicki, M. P676, P759
Komarova, L. P567
Kominami, A. P649
Komurcu, S. P499, P615
Kondakci, M. P437
Kondo, E. P913

List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Kondo, T. P836
Kondratenko, I. P685
Konenkova, L. P922
Konkoly-Thege, M. P845
Kontsendorn, J. O148, O151,
P840
Konuk, N. P776
Koo, H.H. O146, P639
Kook, H. O146
Koopman, H.M. N1067
Kordelas, L. O389, P438, P451,
P579, P637, P734, P934
Koren-Michowitz, M. N1039
Koristek, Z. P546, P958
Koristkova, V. P1167
Kornblit, B. P826
Korolkova, O. P920
Korthof, E.T. 315, 317, 320
Kostkova, J. P1137, P1195
Kostorov, V. P573, P957
Kosztolányi, S. P597
Kottaridis, P. P440
Kourakli, A. P577
Kovács, G. P597
Kovacsovics, T. P507
Kowalczyk, J. P614, P797, P798
Koza, V. 187, 229, O258,
O286, P458, P461,
P668, P706, P973
Kozak, T. O286
Kozhevnikov, V. P920, P922
Kozlov, V. P920, P922
Kozlowska, M. P759
Kraft, D. O145, P626
Krahl, R. O172
Kramers, A.M.G. P1172
Kratky, D. P742
Krauter, J. P647, P846, P948
Krawczyk-Kulis, M. P902
Kreisel, W. O155, P931
Kreissl, M. P608
Krejci, M. P546, P727, P958,
P969
Kremens, B. O425, P777
Krempl, L. O269
Kremser, A. P901, P905
Kreyenberg, H. O263, O425,
P777, P899, P915
Kriegel, I. P1140
Krieger, O. P557, P770
Krishna, R. P490
Krishnamurthy, S. O420
Kristensen, J. P827
Kriván, G. P845, P877, P917
Krivoy, N. P802
Kroell, T. P901, P905
Kröger, N. O147, O157, O157,
210, 222, 228, 230,
O301, O391, P585, P621,
P629, P699, P766, P896,
P897, P939, 1211
Krol, L. P888
Król, M. P579
Krons, A. O148
Kruchkova, I. P920, P922
Kruglina, R.V. O297
Kuci, S. P899, P915
Kuentz, M. O161, P540,
P951, P998
Kühl, J.-S. P688
Kuipers, J. 1218
Kuittinen, T. P867
Kulagin, A. O297, P920, P922
Kumar, N. P755
Kumar, S. S27
Kumari, S. O402
Kundt, G. P503, P620,
P733, P852
Kuns, R. O428
Kupesiz, A. P692, P697, P821
Kurbatova, K.A. O297
Kurganova, E. P922
Kurokawa, M. P873
Kurosawa, S. O136
Kurt, P. P692, P821
Kusminsky, G. P992
Kusnierczyk, P. P902
Kuwabara, H. P648
Kuzhan, O. P499, P615
Kuzmina, Z. P526
Kuznetsov, A.N. O297
Kuzushima, K. O103
Kuzyk, A. P516
Kvasnicka, M. 222, P699
Kwon, M. P731
Kwon, S.Y. P809
Kwon, Y.J. P639
Kyrcz-Krzemien, S. P902
Kyriakou, C. O258
La Nasa, G. O295, O414,
P524, P531, P532
Laabidi, S. P863
Labalette, M. O153
Labar, B. P469
Labonte, L. P744
Labopin, M. O106, O137, 181,
182, 183, 184, 185,
187, 249, O281, O283,
323, 324, O388, O411,
P432, P433
Labraise, E. P1121
Labussiere, H. O140
Lachance, S. O104
Lacheray, I. P1203
Ladaique, P. O163, P711, P949
Ladeb, S. P575, P863
Ladenstein, R. 100, 238, P783
Ladner, S.J. P1173
Laercio, M. P919
Lafaurie, M. O380
Lagar, C. P1118
Lahuerta, J.J. O162, P588
Lai, A. P560
Lai, S. P531
Lai, X. P976, P1003
Laird, J. P646
Lajugie, K. P1170
Lakhal, A. P575, P863
Lakhal, M. P575
Lama, B. P898
Lamberta, J. O178
Lambertenghi Deliliers, G. O259,
O399, P878, P927, P950
Lamego, R. P919
Lamparelli, T. P835
Lampertico, P. P878
Landais, P. O411, O415
Landefeld, C. P987
Landenberger, M. N1060
Landmann, E. P857
Landzaat, L. P1115
Lanfranchi, A. P659, P698
Lang, P. O266, O267, O270,
O410, P778, P795
Lange, A. O273, P527, P859,
P860, P995
Lange, C. P629
Lange, J. P527
Lange, S. P620, P624
Lange, T. O386, P558, P945
Lanier, K. P507
Lanino, E. P643, P785,
P787, P918
Lankester, A.C. P537, P538,
P690, P788, P834
Lanther, T. N1037
Lanti, A. P1129
Lanza, F. O295
Lanzer, G. P700, P742
Lapusan, S. O107
Lara Marquez, I. P1124
Larmouth, W. P1117
Larocca, A. O159
Larsen, J. S1043, N1052
Larsen, U. P629
Larsson, K. O300
Lasan Trcic, R. P469
171

172
List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Lass-Flörl, C. P825
Lastovkova, A. P1137, P1195
Laszlo, D. P763
Latagliata, R. P895
Latouche, A. 333
Laughlin, M. O132, O279
Laurenti, L. P593, P725,
P881, P974
Lauria, F. P530
Lavalle, M. P725
Lawitschka, A. O268
Lawlor, E. P965
Lay, A.F. O406
Lazarovici, J. P730
Lazarovici, P. O166
Lazzarino, M. P977
Le, Q.-H. O140, O286, P606
Le Blanc, K. 374, P631,
P703, P842
Le Corroller, A.G. O385
le Coutre, P. P654
Le Gouill, S. O161, O391,
P447, P543, P566,
P752, P761, P978
Leboeuf, C. P514
Lecchi, L. P495
Lechanteur, C. O387
Lecht, S. O166
Leda, M. P614, P798
Ledda, A. P532
Ledderose, G. 118, P548
Lednev, Y. P981
Ledro, S. P605, P940
Lee, C.H. P598
Lee, D.H. P765, P876, P997
Lee, D.S. P460
Lee, H.W. P636, P970
Lee, J.H. P937
Lee, J.H. P937
Lee, J.S. P460, P756, P765,
P876, P997
Lee, K. P1159
Lee, K.H. P937
Lee, K.S. P639, P640,
P681, P865
Lee, M.H. O150, P545
Lee, N.Y. P545
Lee, S. P990
Lee, S.H. O146, P639
Lee, S.J. O135, P640,
P681, P865
Lee, S.M. P623
Lee, S.T. P756
Lee, Y.H. O146
Lee, Y.S. P937
Leenen, P.J.M. O169
Legiec, M. N1103, P1167
Legrand, F. O107
Lehmann, D. 86
Leiblein, S. O386
Leibowitz, E. N1068
Leibundgut, K. 125
Leimer, L. O173
Leis, J. P507
Leitch, E.A. P578
Leite, M. S. P828
Leithäuser, M. P503, P542,
P556, P733,
P852, P961
Lejeune, M. P991
Lellek, H. O147
Lemarie, C. P711, P949
Lemoli, R.M. O400, P449,
P698, P892
Lenaerts, C. O429, O430, P618
Lenehan, H. P677
Lengyel, L. P758, P771, P773
Leo, M. O379
Leon, A. P591
Leone, G. O133, O149,
P553, P593, P725,
P855, P881
Leoni, P. O256, O290
Leotta, S. P453, P645
Lester, T. P694
Leux, C. O391
Leverger, G. P804
Levis, A. O158, O256, P993
Lewis, I. P783
Li, C. P744
Liakopoulou, E. O392, O393,
P435, P544
Liao, Y.-M. P533
Liapis, K. P666
Liebersbach, S. P886
Liebig, T. P913
Liepert, A. P901, P905
Lim, H.J. O146
Lim, J.H. O150
Lim, K.H. P554
Lim, S. P937
Lim, Y.J. O146
Lim, Y.T. O146, P815
Lima, C. P586
Lin, C.-L. P533
Linch, D O174, P705
Lindahl, J. P883
Lindner, B. P959, P1009
Lindvall, M. P1139
Linhartova, E. P784
Linkesch, W. O165, 221, O258,
P700, P704
Linssen, C.F.M. 322
Lionetti, MT P996
Lioznov, M. O157, P585, P621
Liptrott, S. N1059, N1104,
N1106
Liso, V. O379, P645, P747
Lissandre, S. P894
Lisukov, I. O297, P920, P922
Littera, R. P524, P531, P532
Liu, C. O168
Liu, S. O275, P829
Liu, X. O288
Liu, Y. O275, P829
Liu Yin, J.A. N1041
Ljunggren, H.-G. 93, P1000,
P1001
Ljungman, P. S1, S6, 120, 214,
Lloyd, D.
315, 118, 320, 321,
323, 324, 328, P474,
P841, P842, P869,
P1001, N1026
335
Lloyd, P. P1008, P1015
Lo, W.-J. P533
Lobo, A. P932
Locasciulli, A. 315, 317, 320,
Locatelli, F.
323, O384, P716, P918
111, O171, O265,
Lodi, F.
O274, O279, O293, O302,
O410, O414, P524, P531,
P532, P628, P785, P910,
P918, P924, P936
P919
Loeffler, J. P849
Löfgren, K. N1018
Loibl, J. P901, P905
Loiseau, P. P732
Lojko, A. P759
Lojko-Dankowska, A. P676
Lombardini, L. P871
Lonetti, A. O133, O138, P439
Lönnies, H. P703
Lopes, S.M. P633
López, E. P475, P655, P660
Lopez, J. P856
Lopez de la Guia, A. O383
López López, R. P1134
López-Belmonte, J.L. P887, P989
Lopez-Guillermo, A. O258, P757
Lorand-Metze, I. P586
Lorenzi, L. P659
Loseto, G. P645
Losonczy, H. P597
Louie, P. O376
Lourdes Macalalad, M. P1118
Lourie, R. P513

List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Lovas, N. P771, P773
Lovell, R. P955, P1131
Lowenberg, B. O167, O169
Lozano, M.L. P660, P988
Lu, S. O168, O288
Lu, T. O168
Luan, J.J. O255
Luatti, S. P436, P892
Lubenko, A. P490
Lucarelli, B. P651, P866, P974
Lucarelli, G. P819, P823, P824,
P874, P985
Lucas, G. O392, O393, P544,
P677, N1041
Lucas, J. P811
Lucchetti, B. P996
Lueff, S. P771, P773
Luetkens, T. P896
Luinetti, O. P563
Luks, A. P1011
Luksch, R. P613
Luminari, S. P746
Lunardi, C. O377
Lund, K. P726
Lund-Johansen, F. O402
Lundqvist, J. P1179
Luo, Y. P976, P1003
Lupo, F. N1059
Lupo Stanghellini, M.T. O141,
O171, P481,
P617, P929
Luppen, C. P626
Luther, S. P840
Lutz, D. P557, P770
Lutz, P. P611, P804
Luyckx, A. P618
Luznik, L. 91
Lysák, D. P458, P706
Lyu, C.J. P809
Maamar, M. P863
Mac Vittie, T. 337
Maccario, R. O274, O293, P628,
P910, P924
MacDonald, B. P1158
MacDonald, D. P502, P595
MacDonald, K. O428
Macedo, A. P919
Machado, C.M. O382, P828
Machetti, S. P530
Machida, H. P580
Macis, D. P559
Mackinnon, S. O174, 351,
P435, P440
MacMahon, E. P847, P848
Macmullan, D. P955
MacQuaker, G. P646
Madathiparambil, J. P1129
Madden, T. P441
Madej, S. P859, P995
Madene, S. P882
Madero, L. P515
Madrigal, J.A. 112, O420, P497,
P741, P992, N1017
Maertens, J. S13, S54, S57,
187, 230, O255,
328, P891, P991
Magalhães, R. P586, P919
Magarotto, V. O159
Magaud, J.-P. P450
Maggi, F. P837
Maggi, P. O295
Maggio, R. P903
Maghfoor, I. O179, P670, P751
Magro, L. P707
Mahe, B. P447, P543, P566,
P752, P761, P978
Mahendra, P. P955
Maheri, R. P590
Mahlberg, R. O390
Mahmood, S. P508
Mahon, F.-X. S62
Maier, B. P548
Maier, L. P779
Maillard, N. O161, P519,
P520, P696
Maiolino, A. P586
Maisnar, V. P603
Maiwald, S. P525
Majado, M. J. P702, P712
Majolino, I. P716
Malagola, M. P454, P536, P892
Malandruccolo, L. P866, P974
Malášková, L. P844
Malato, S. P481
Malcovati, L. P933
Maldifassi, A. N1059
Malesevic, M. P477
Malkki, M. O416, P1006
Mallard, F. P566
Mallouri, D. P549, P565,
P650,P729
Malmberg, J.A. P1000
Malmberg, K.J. P1000, P1001
Malphettes, M. P587
Maly, J. P603
Manaka, A. P505
Manaka, K. P666
Mancao, C. O405
Mancardi, G.L. 242, O295, P928
Mancini, V. P583, P875
Mancusi, A. P735
Mangione, I. P495
Mank, A. 117, N1021, N1086,
N1098, N1104
Manko, J. P609
Mannelli, F. P443
Manookian, A. P590
Manson, L.M. P504
Manuele, R. O261
Manzano, C. P562
Mapelli, S. P613
Mar, R. P811
Marabelle, A. P611
Marbet, G. P665
Marcatti, M. O141, O171, P617
Marchese, G. P984
Marchesi, A. P500, P501,
P984, P1002
Marcuccio, D. P511, P604,
P630, P748
Marenco, P. P583, P719,
P875, P933
Marengo, A. P838
Maresova, I. P1011
Margall, N. P853
Marie, J.-P. P1188
Marietti, S. P553, P855
Marijt, W.A.F. O160
Marín, A. P967
Marin, D. O284, P502, P638
Marín, P. O398, O421, P592
Marini, M. P483
Marjanovic, S. P477
Markey, K. O428
Markgraf, M. P972
Markiewicz, M. N1061
Markopoulos, K. P563
Markova, M. O276, P467
Marks, D. P435
Marks, R. P432, P534
Marktel, S. P816, P822, P909,
P1005, N1076, N1090
Marmont, A.M. P928
Marmont, F. P448
Marotta, G. P449, P530
Márquez, F.J. P967
Márquez, J. P988
Márquez-Malaver, F.J. P463,
P1134
Marr, K. S53, S55
Marron, G. P726
Marry, E. O140
Marsh, J. 315, 317,
320, P918
Marsh, S. P741, P992
Marshall, S.R. P547
Martin, H. P446, P584, P739
173

174
List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Martin, L. O262
Martín Salces, M. O383
Martin Sanchez, P. P1124
Martin-Antonio, B. O419
Martinelli, G. O133, O138,
Martinetti, M.
O377, O400, P436,
P439, P454, P763,
P892, P895, P898,
P996, N1059
P1002
Martinez, A. P814
Martínez, C. O280, O398,
P552, P592, P642,
P655, P674, P757
Martínez, J. O162
Martínez, S. P702
Martinez, Y. P658
Martino, M. O396, P582,
P604, P610, P721,
P748, P749,
P967, N1040
Martino, M.L. P463
Martino, R. S84, O175, 230,
228, 323, 325, 331,
P753, P832, P853, P939,
P953, P963, P964
Martins, T.C. P828
Márton, G. P917
Martorana, L. P532
Marturano, E. P453
Marty, F. S1, S6, 321
Maruta, A. P648
Marx, M. P854
Mary, J.-Y. 316, P550
Marzano, A. P838
Marziali, M. P819, P823, P824,
P874, P985
Marzollo, R. P698
Maschan, A. P667
Masetti, R. P793
Masnavi, A. P478
Massacesi, L. O164
Massara, E. O396, P582,
P604, P721, P748,
P749, N1040
Massenkeil, G. P654, P923
Massimino, M. P613
Masszi, T. P758, P771, P773
Mastaglio, S. O171, P481, P617
Mastronuzzi, A. O414, P910,
P924
Mateos, M.V. O162
Mateos-Mazón, J.J. O421
Matera, R. P602
Mathew, B. P1118
Mathew, D. P1118
Mathew, M. P1118
Mathieu, C. P904
Matinlauri, I. P867
Matoses, M. P811
Matozzo, V. N1076, N1090,
P1201
Matrai, Z. P771, P773
Matsumoto, K. P486
Matsuura, S. P648
Matsuyama, T. P873
Mattei, D. P1196
Mattes, F. P872
Matteucci, P. O384
Matthes-Martin, S. O265, O266,
O302, O410
Mattsson, J. 341, P445,
Matulova, M.
P489, P509, P612,
P841, P842, P912,
P935, P942
P888
Matyshevskaya, V.N. P672
Mauad, M. O382, P828
Maur, M. P746
Mauro, E. P453
Mauroni, M. P1153, P1154
Maury, S. O107, O140, O255,
319, 320, P918
Maximova, A. P1187
May, J. P635
Mayer, J. S69, P546, P727,
P844, P958, P969
Mayor, N. O420, P741, P992
Mayorova, O. P634
Maziarz, R.T. P482, P485,
P506, P507
Mazur, E. N1103, P1167
Mazza, G. N1055
Mazza, P. P767
Mazza, R. P861
Mazzanti, B. O164, P632
Mazzolari, E. P659, P698
Mazzone, A.M. O379
Mazzucato, M. O261
Mc Dermott, R. P772
McAdams, P. P441
McCahon, E. P1115
McCann, S. 326, P772
McCarty, J. O178, P493
McCaughey, C. P1184
McDiarmid, S. O262, P1158
McDonald, G. 208
McDonnell, A.B. P1178
McIver, Z. P1004
McKeag, N. P693
McLean, S. P965
McLellan, J. N1024
McQuaker, I.G. P504,
P726, P956
McSweeney, P.A. P493
Meazza, C. P613
Meca, J. P702
Mechinaud, F. P452, P687, P737
Medeiros, C. P644, P843, P916
Medeiros, L. O412, P644, P916
Medeot, M. P675, P864
Medinger, M. O395
Meerpohl, J.J. O410
Mehdid, F. P882, P980
Meier, S. P906
Meijer, E. O278, P491
Meineke, V. P745
Mejstrikova, E. O276, P784
Mele, A. O144, P645
Melenhorst, J. P1004
Meliadò, A. P630, P721
Meliambro, N. P1193
Melinkeri, S. P1136
Melnichenko, V.Y. O297, P672
Meloni, G. O133, O258, P974
Mendelson, A. N1087, P1123,
P1135
Mendeni, M. P536
Mendes, C. P633
Mendez, R. P1194
Meneghini, V. P898
Menichetti, F. S34
Mentkevich, G. P801
Menzel, H. P760, P890
Mercante, D. P586
Mercer, J. P1147
Mercurio, S. P453
Merker, K. O294
Merla, E. P476, P594, P767
Merle, M. P901, P905
Merli, M. P601, P977
Merlin, E. P521, P611,
P1014
Mertens, T. P854
Meseguer Olmo, L. P714
Messa, A. O144, P645
Messa, F. O133, O138, P436,
P439, P898
Messina, C. O171, P481, P574,
P617, P792
Messina, G. O396, P604, P721,
P748, P749, P1193
Messina, M. O138, P439
Mestice, A. O379
Metafuni, E. P553, P855
Mettivier, V. P449, P645
Metzger, J. O148, O151
Metzner, B. 229

List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Meyer, R.G. O406, P616,
P999
Meyer-Monard, S. P498, P665
Meyls, I. 198
Mezger, M. P849
Mezlini, A. P863
Mialou, V. 320, P951
Miano, M. 235, P643
Micallef, I.N. P482, P485, P506
Miceli, R. O384
Michallet, M. O140, O107, O161,
221, 225, 226, O286,
O385, P433, P450,
P540, P606, P951
Michalopoulos, E. P709
Michel, D. P854
Michel, G. O298, P804
Michelis, F. P666
Michelutti, A. P724
Michieli, M. O261, P449, P993
Micò, C. P555, P717, P968
Micozzi, A. P866
Mielke, S. S10, S11
Migliavacca, M. O177
Miguel Peres, A. P586
Mijovic, A. P508
MIkala, G. P771, P773
Mikhaylova, A. P564
Mikhaylova, N. P510, P567
Mikulasova, P. P1010, P1011
Mikulska, M. P835
Milanetti, F. O296, P925
Milani, R. P594
Milenkov, V. P762
Milligan, D. 225, O286, P891,
P955, P1131
Milner, G. P1180
Milojkovic, D. O284, P502
Milone, G. 187, 223, O256,
P453, P645
Milpied, N. O107, O161,
182, O255, O301,
O385, O388, O391,
P452, P540
Min, Y.H. P970
Minakovskaya, N. P480
Minev, B. P625
Mininni, I. P651
Minotto, C. P448
Miotti, V. P864
Mir Rasekhian, E. P979
Miracco, C. P530
Miranda, E.C.M. P586, P1012,
P1013
Miranda, L. P858
Mischak, H. O151
Mittal, V. O168
Mitterbauer, M. P581
Miyakoshi, S. P678
Miyamura, K. O418, P649
Miyawaki, S. O136
Mocikova, H. P774
Moffat, D. P726
Mohamed, S. P470, P880
Mohammad, L. P458
Mohr, B. O424, P459
Mohty, M. S78, O107, O140,
181, 183, 247, O385,
O388, O391, P447, P452,
P487, P540, P543,
P566, P737, P752,
P761, P949, P978
Mohyedin, I. P979
Moicean, A. 320, P921,
N1103, P1167
Moiola, L. P929
Moles, M.-P. O391
Molica, S. P749
Molinari, V. P1153, P1154
Moll, G. P631
Moll, S. P715
Mongta, S. N1080
Monma, F. P484, P486
Monorchio, M.G. P1193
Montagna, D. P910
Montague, N. P1155
Montanari, M. O290, P449
Montante, B. P716
Montefusco, V. O159, P594
Monteleone, R. O396, P511, P582
Montero, I. P463, P967
Montes, C. P662, P839
Montgomery, K.V. P1115
Montini, E. P910
Montserrat, E. O280, P674, P757
Montuoro, A. P823, P824, P874
Moon, J.H. P640, P681, P865
Moos, M. P589, P740
Moosmann, P. P596
Morabito, F.C. P721
Morabito, G. P1193
Moraes, D.A. P926
Moraleda, J. M. P702, P712,
P714
Morando, J. O412, P644,
P843, P916
Morante, C. O421
Moravcova, K. N1103, P1167
Morciano, M. O144
Mordak-Domagala, M. O273,
P995
Mordini, N. O158
Moreau, A. P752, P761
Moreau, G. N1057
Moreau, P. S29, O161, 221,
P447, P452, P487,
P543, P566, P737,
P752, P761, P978
Morello, E. P448
Moreno, L. P790
Moreno Martin Retortillo, L. P799,
P800
Moretta, A. P628, P910
Morfini, M. P806
Morgades, M. O139
Morgan, G. S31, P444
Mori, S.I. P678
Mori, T. P486, P873
Morin, A. O277
Morishima, Y. O105, O416,
P678, P728, P1006
Moriuchi, Y. O136
Mormouras, V. P530
Morozova, E. P885
Morra, E. P583, P719, P875
Morreale, G. P787
Morris, C. 221, 223, 224,
227, P1133
Morris, E. O174, O381,
O401, P440
Morrow, J.C. N1091, P1150
Morse, R. P635
Moscato, T. O396, P582, P604,
P748, P749
Moshous, D. O409, P686, P687
Motohashi, K. P486, P648
Motta, B. P927
Motta, M.R. O142, O400, P442,
P465, P870
Mouna, R. N1076
Mousavi, A. P810, P818
Mousavi, S. P478
Mousset, S. P446, P584, P739
Muehlmann, R. P960
Mueller, K. P627
Mueller, S. P608
Mueller-Hilke, B. P556
Mufti, G. S48, S1045,
N1081, P1162
Mulder, A. P492,
Müller, A. P760, P987
Müller, I. O267, O270,
P778, P795
Müller, K. P826, P990
Müller, P. P999
Muller, S. P589
Mullowney, G. P1155
Mumm, A. P1149
175

176
List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Mumm, F. P541
Muñoz, C. P658,
P887, P989
Muñoz Montaño, M.R. P1142,
Munster, D.
P1146, P1186, P1200
O102, P513
Murdychova, E. N1103, P1167
Murphy, G. O168
Murphy, M. N1041
Murru, R. P673
Murtagh, B. O277
Mushchitskaya, I. P791, P1126
Musial, J. P689
Musleh, S. P807
Musolino, C. P749
Musso, M. P610, P645
Musto, P. 223, P464, P767
Muzik, J. P461
Myasnikov, A.A. O297
Na, I.-K. O168, O288
Nabhan, S. 187, 318,
O283, O298
Nachbaur, D. P518, P959, P960
Nademanee, A.P. P482, P485,
P506
Naffaa, A. P1138
Nagafuji, K. O418
Nagasawa, T. P710
Nagatoshi, Y. P678
Nagler, A. S70, O157, O166,
181, 183, 184, 222, 226,
229, O255, O391,O426,
P457, P488, P496, P708,
P743, P947, N1034, N1039
Nagy, Á. P597
Nagy, K. P917
Nagyova, B. N1103, P1167
Nahajevszky, S. P771, P773
Naik, P. O174
Nair, G. P572
Nair, R. P755
Najeme, E. P1168
Najima, Y. P486
Nakahara, F. P873
Nakajima, K. O143
Nakamura, F. P580
Nakamura, N. P486
Nakamura, Y. O136
Nakani, K. N1089
Nakano, N. N1085
Nakauchi, H. P710
Nallamuthu, S. N1089
Nannya, Y. O136, P486
Naor, D. O426
Naparstek, E. O423, P743
Napolitano, S. P822, P909,
P1005
Narayan, S. P677
Narni, F. 223, O259, O384
Nassar, A. P470, P880
Nassi, L. P763, P996
Natale, G. P679
Natalino, F. P651, P903
Nava, S. O152, O289
Navarro, N. P660
Naveed, F. P641
Navratil, M. P546, P958, P969
Navratilova, J. P973
Nawa, Y. O136
Nefussy, B. P743
Negri, M. P763, P996
Nehari, M. N1034
Nehme, R. P1138
Nekolla, E. 118
Nelson, V. P507
Nemoto, N. P710
Nepomucka, J. P1011
Nesi, F. O106
Netea, M.G. P830
Neuburger, S. P654
Neuman-van Eijk, A.G.M. N1064
Neva, A. P483
Neven, B. O411
Newman, J. P693
Nguyen, S. P535, P570, P998
Nguyen Quoc, S. P730
Ni Chonghaile, M. P965, N1093,
N1105
Nicholson, E.K. P956
Nickelsen, M. O257, O258
Nicol, A. N1089
Nicol, C. P1171
Nicolás, F. J. P712
Nicolas-Virelizier, E. P450, P606
Nicolini, F.E. P450, P606
Nicoloso de Faveri, G. P498
Niederwieser, D. S21, S61, S68,
Nield, A.
O172, 221, 222, 223,
226, 227, O286,
323, O386, P558,
P891, P939, N1031
N1069
Niemeyer, C. O264, O265, O299,
Nieto, J.
O302, O410, P777, P936
P475, P660,
P655, P988
Nijmeijer, B.A. P900
Nikiforakis, E. P505, P666
Nikkinen, L. P522
Nikolousis, E. P955
Nilsson, B. P631
Nilsson, O. P539
Nilsson Ekdahl, K. P631
Nir, R. P1135
Nirmal Shankar, R. P1130
Niscola, P. P679, N1055
Nisha, M. P1136
Nobile Orazio, E. P593
Nocton, V. P1203
Noè, A. P816, P822,
P909, P1005
Noe, K. N1057
Noel, S. P520
Noellke, P. O302
Nogai, A. P733
Nola, M. P469
Nomura, F. P649
Nonn, M. P616
Noori, Z. P979
Norbury, G. P694
Norden, J. P561
Norlin, A.-C. P943
Notarangelo, L. P659, P698
Notheis, G. 198, P685
Novara, F. P628
Noviello, M. O171
Novik, A.A. O297, P672
Novitzky Basso, I. P955, P1131
Novotna, R. P1137, P1195
Nowak, I. P902
Nowicki, A. P676, P759
Nozza, A. P993
Nozzoli, C. P443, P871
Nucci, M. P586
Nunes, E. O412, P644, P916
Nuñez, J. P662
Nurgat, Z. P880
O Briain, S. P772
O Mahony, D. P772
O'Brian, N. N1036
O'Donovan, M.C. P1133
O'Dwyer, M.E. P600
O’Meara, A. 197
Oakervee, H. P872
Oakes, R. P664
Obenauf, A. O165, P700
Oberlin, O. P783
Obrtlikova, P. P774
Ochi, T. O103
Ochoa, C. P1148
Ochoa, L. P434
Odenthal, M. P854
Oelke, M. P907
Oelschlägel, U. 86, O285, O424,
P459, P972
Ogawa, A. O143

List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Ogawa, S. O105
Ohara, A. O299
Ohashi, Y. P678
Ohgushi, H. P580
Ojala, P. P522
Okamoto, S. P486, P678, P873
Okas, M. P489, P509,
P612, P912
Oki, Y. P728
Okoshi, Y. O136, P710
Ölander, R.-M. P805
Olavarria, E. S64, 226, O259,
Olcese, E.
O284, 328, P435, P502,
P595, N1089, 1217
P1161
Oldani, E. P448
Oliveira, E. P1202
Oliveira, F. P858
Oliveira, J. P919
Oliveira, L. P586
Oliveira, M. O412, P644, P916
Oliveira-Duarte, G. P586
Olivieri, A. 187, O384, P449,
P594, P607, P645
Olkinuora, H. P805, P813
Olsson, R. P445, P935
Olver, S. O428
Olweus, J. O402
Omar, H. P869
Omedè, P. O158
Oneto, R. O256, 319, 317,
P933, 1219
Onida, F. 221, 245, O259,
O399, P878, P927,
P933, P950
Onodera, M. P710
Ooi, J. P484, P486
Oostdijk, W. P653
Opalka, B. P438
Opelz, G. O431
Opherk, K. O266
Opitz, A. P907, P908
Opitz, C. O287
Or, R. O426, P523, P671,
Orcel, P.
P736, P786, P850, P966
O176
Orchard, K. P598, P693
Ordoñez, A.M. P656, P812
Oren, I. P884
Oriol, A. O162
Oriolo, F. P651
Orlando, L. P763, N1059,
P1166
Ormenese, S. P954
Orofino, M.G. P559
Orrù, N. P532
Orrù, S. P532
Orsatti, A. O399
Orsi, A. P871
Orsitto, E. P851
Ortega Carrión, M.R. P1142
Ortiz, M. O421
Ortuño, F. P475
Oshima, K. P486, P873
Oshima, R. P648
Osipova, E. P634
Osipova, N.E. O297
Osma, M. P475
Ossenkoppele, G. O255
Ostadali, M. P979
Ostrosky-Zeichner, L. S33
Ostuni, A. O144, P645
Otsu, M. P710
Ottaviani, E. O138, P436,
Ottinger, H.
P439, P454, P898
P438, P451, P734
Ottmann, O.G. O281, O282
Oudshoorn, M. 368, P491
Ovadia, R. N1034
Ovchinina, N. P981
Owiti, H. P599
Owoc-Lempach, J. P689,
P797, P798
Ozcakar, Z.B. P669
Ozcan, M. P776
Ozcebe, O. P1128, P1199,
P1205
Özçelik, T. P494
Ozdemir, E. P615
Ozet, A. P499, P615
Ozet, G. P615, P1205
Özkurt, Z. P663, P682, P768
Ozretic, D. P469
Ozsahin, H. P715
Ozturk, B. P499, P615
Ozturk, M. P499, P615
Ozturk, Z. P692, P821
Pabst, T. 221, P596
Pachlopnik Schmid, J. P686
Paciaroni, K. P819, P823,
Padhye, B.
P824, P874, P985
P1115
Pagliara, D. O274
Pagliarino, M. O422
Pagoni, M. P1132, P1185
Paillard, C. P611, P804,
P1014
Paina, O. P983
Pajor, L. P597
Palacios, S. P660
Palandri, F. P892, P895
Palasse, C. P1121
Palazzi, G. P746
Palkova, A. O102, P513
Pallejà Pejoan, M. P1143
Palmato, M. P1129
Palmieri, S. P464
Palomera, L. O162
Palotie, A. P522
Palumbo, A. O158, O159
Palumbo, G. P767
Paluszewska, M. P579
Pamer, E. O288
Pamphilon, D. 126, N1062
Pane, F. O133, O138,
P439, P898
Paneesha, S. P955, P1131
Panitsas, F. P666
Pantaleo, M. P898
Panzer-Gruemeyer, R. O263
Paolini, P. P436
Paolini, S. O133, O138,
Paoloni, F.
O400, P439, P442,
P454, P465, P898
O133
Paolucci, P. P746
Papageorgiou, M. P505
Papalexandri, A. P549
Papassavas, A.C. P709
Papasteriades, C. P505
Papayannidis, C. O133, O138,
P436, P439,
P454, P898
Papineschi, F. O295, P764,
P837, P851
Papusha, L. P667
Parisi, C. P501, P984
Park, B.K. O146, P639
Park, C.J. P937
Park, E. P554
Park, H.J. O146, P639
Park, I. P997
Park, J.A. P639
Park, J.E. O146
Park, J.H. P623
Park, J.S. P636
Park, S. O150, P460,
P554, P756
Park, S.H. P554
Park, S.K. O146, P623
Park, S.S. O146, P815
Parker, A.N. P504, P646,
P726, P956
Parkkali, T. 323
Parma, M. P750
Parody, R. P832, P887, P967
Partanen, J. P522
177

178
List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Parvex, P. P715
Pascutto, C. P933, P977
Pasi, A.M. P1002
Pasic, S. 198
Pasini, A. P793
Pasqua, F. P651
Pasquini, R. P644, P843, P916
Passweg, J. 96, 120, O298,
314, 315, 316, 317,
318, 319, 320,
O412, O431, P498,
P715, P918, 1213
Pastano, R. O377
Pastore, D. O379, P747
Pastorino, T. P1161
Patanè, A. N1055
Patel, B. P435
Patel, H. P794
Patel, K. 356, 358, 361, 363
Patel, M. P470, P880
Patiño, B. P839, P887,
P989,P1148
Patriarca, F. O158, O384,
P675, P724, P864
Pattni, S. P1145
Pau, R. P1161
Paubelle, E. P696
Pauksens, K. 323
Paul, J. O381
Paulussen, M. P783
Pautassi, S. P1196
Pavlicova, V. N1103, P1167
Pavlu, J. O284, P595
Pavone, V. O144, P645
Pawson, D. P490
Pazdzior, D. P689
Peacock, J. P1117
Pearce, R. P435, P664
Peccatori, F. 194, O377
Peccatori, J. O141, O171, P481,
P617, P929
Pedata, M. P464
Pedrazzoli, P. 192, O293, P610
Pedrini, O. P718
Peffault de Latour, R. O272,
Peggs, K.
O298, 316, 320, O380,
O397, P514, P550,
P587, P894, P938
O174, O381, P440
Peggs, K.S. S24
Peier, I. N1071
Peles-Bortz, A. P971, N1070
Peli, A. P536
Pellegrini, C. P775
Pelosini, M. P764, P851
Penack, O. O168, O288
Pennese, E. P602
Peragine, N. P903
Peralta, M.T. P1148
Peralta, T. P887, P989
Perbellini, C. P605
Pérez, E. P475, P655
Perez, L. P434
Pérez Espejo, M. A. P702
Perez-Bercoff, L. P474
Perez-Hurtado, J.M. P814
Perez-Oteiza, J. P963, P964
Pérez-Simón, J.A. 183, P552
Perfetti, P. P750
Perilio, L. O382
Perkins, J. P434
Perotti, C. P500, P501,
P628, P984
Perro, M. O401
Perrone, A. P651
Perrone, M.P. P974
Perrone, T. P747
Perrotti, A.P. P679, N1055
Perry, A. P694
Perseghin, P. P555
Peschel, C. P760, P890
Pescosta, N. O159
Pession, A. P785, P793
Peta, A. P749
Peters, A.M.J. P936
Peters, C. S71, O134, 233,
234, O263, O264, P796
Petersdorf, E. 108, 188,
O416, P1006
Petersen, E. O388
Peto, M. P771, P773
Petrini, M. P764, P837, P851
Petropoulou, A. O176, P938
Pettengel, R. 312
Pettinau, M. P560
Pettit, A. O428
Pezzullo, L. P645
Pfaffendorf, N. P723
Pfeifer, H. O282, P446,
P584
Pfeifer, T. P742
Pfeiffer, M. O270, P778,
P795
Pfistershammer, K. O268
Pfluger, C. N1103, P1167
Philippon, C. P1170
Piazera, F. P644, P843
Pica, G. P601, P977
Picard, C. P687
Picardi, A. P495
Piccaluga, PP. O133, O138,
P436, P439, P454
Piccirillo, N. P593, P725
Piciocchi, A. P974
Pickl, W. O268, P526
Pieri, L. O164
Pieroni, F. P926
Pievani, A. P914
Pignata, C. 198
Piguet, C. P1014
Pihkala-Saarinen, U. P805, P813
Pilatrino, C. 187
Pillon, M. P574
Pilo, F. P560, P673
Pimenov, R. P801
Piñana, J.L. O175, P753, P832,
P853, P953, P964
Pinazzi, M.B. P716
Pineau, M. 328
Pineda, A. P731
Pino Molina, C. N1100, N1102,
N1103, P1167
Pinto, F. 187
Pinto, R. P495
Pinto, V. P835
Pioltelli, P. P750, P933
Piovani, G. P483
Piquet-Gauthier, A. 354
Piras, E. O414, P524,
P531, P532
Piredda, A. N1059
Pires, R. N1066
Piroddi, A. P559
Pirrotta, M.T. P530
Pisacka, M. P784
Pisapia, G. P767
Pissaki, K. P1132, P1185
Pistello, M. P837
Pittiruti, M. P881
Pittrova, H. P973
Piumatti, M. P1196
Piva, L. P613
Pivkova, A. P473, P762
Pizzuti, M. P607
Placanica, G. N1040
Placanica, F. P1193
Planche, L. P487
Plantaz, D. P804
Plantinga, T.S. P830
Platzbecker, U. 86, 228,
Plebani, A.
O285, O390, O424,
P459, P939
198
Plesa, C. P450, P606
Pluta, A. P889
Podda, M P613, P792
Podestà, M. O106
Poem, Z. P1135

List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Poerio, A. P892
Poetschger, U. O134
Poggiaspalla, M. P607
Poggio, T. P1193
Pogliani, E. O384, P448,
P750
Pohlreich, D. P467
Poidomani, M. P453
Poirée, M. P804
Polastri, D. P613
Polchi, P. P819, P823, P824,
P874, P985
Polge, E. 181, 182, 183,
187, 230, 1219
Pollichieni, S. 319
Polonio, A. N1055
Polselli, A. P1005
Ponstingl, E. P1116
Pontari, A. P511, P630
Pool, J. O427
Popat, U. P441
Popova, M. P510
Popp, A.M. P921
Porat, N. N1095, N1097
Porcher, R. O176, O272, O380,
P550, P938
Porcheron, S. P1159
Porkka, K. S65
Porta, F. P659, P698
Porto, L. P691
Porwolik, J. P689
Pospori, C. O401
Possenti, I. P910
Pots, J. O292
Pötschger, U. P783
Potter, M. P435, P444
Potthoff, K. P931
Potting, C. 117, P1192
Poulopoulou, Z. P505
Poulton, K.V. O392, O393,
P544
Powles, R. 336
Praire, A. P606
Pratcorona, M. O280
Prebet, T. P452, P468
Preda, L. P763
Presti, A. N1055
Prestini, K. P536
Prete, A. P785, P792,
P793, P918
Pride, M. 324
Princi, D. O396, P511,
P721, P1193
Proce, S. P1196
Proia, A. P716
Pronkina, N. P922
Psatha, N. P994
Puccetti, A. O377
Pucci, G. P511, P630
Puccini, B. O256
Pugliese, G. P602
Pule, M. O405
Pulles, M.J. N1049
Puoti, M. P536
Purbueva, B. P634
Purkis, M.E. N1053
Purtill, D. O298
Puscariu, T. P921
Pytlik, R. P774
Quaglini, T. P500, P984
Quah, T.-C. P472
Quaresmini, G. P605, P754,
P940
Quarta, G. P645
Quero, A. P586
Querol, S. P497
Quested, B. N1053, N1077
Quick, S. P627
Quinlan, D. P641
Quintana, L. P674
Raaijmakers, S. P538
Rabacchi, G. O422
Rabascio, C. O377, P996
Rabella, N. P832, P853
Rabian, C. O397
Rabitsch, W. P581
Rabusin, M. P785
Racil, Z. P546, P844,
P958
Radaelli, M. P929
Rademaker, M. N1056
Radford, K. P513
Radford Weiss, I. P687
Radiano, R. N1068, N1095,
N1097, P1144
Radke, J. 86, O424
Radocha, J. P603
Radtke, H. P923, P930
Rafaniello, P.R. P763
Raffelt, N. O428
Raffoux, C. P540
Raffoux, E. P938
Rahal, M. P751
Rahemtulla, A. P502, P595,
P600, P638
Rahmoune, N. P882, P980
Raiola, A.L. P1161
Raiola, A.M. O106, P835
Raj, K. P847,
P848, P1156
Rajithamol, S. P1136
Rambaldi, A. 184, O256,
O281, O384, P448,
P555, P717, P718,
P933, P968
Ramella, O. O145
Ramírez, M. P515
Rana, A. O144, P457, P645,
P947, N1082
Randon, F. P605, P754, P940
Rank, A. P548
Rao, K. O415
Rao, U. O288
Raoofi, F. P979
Rapezzi, D. P1196
Räpple, D. P534
Rasheed, W. P470, P880
Rasmusson, I. P631
Rasonyi, R. P771, P773
Ratajczak, P. P514
Raus, N. O140, O161
Ravagnani, F. P613
Raychaudhuri, J. P434
Rebelo, M.I. N1022
Recchia, E. P1188
Rechberger, G. P742
Recto, V. P1118
Reddiconto, G. P602
Reed, J. P1120
Reena, Z. P1136
Refaeli, E. O426
Rego, E. P586
Reibke, R. P548, P901
Reilly, J.T. P462
Reincke, B.S. O425
Reinisch, A. O165, P700,
P704, P742
Reis, S. P1141
Reising, M. O263
Reisner, Y. 215, 373
Reiter, A. P857
Relander, T. O258
Remberger, M. O152, O279,
O289, P445, P935,
Remenyi, P.
P942, P943, P1001
P758, P771,
P773
Remes, K. 229
Remijn, A. P1115
Renaud, M. O107, O140,
O301, P951
Repaci, I. P1193
Repp, R. O300, P571
Rerichova, M. P1137, P1195
Resche-Rigon, M. O260
Resende, R. P858
179

180
List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Resnick, I. O426, P523,
P671, P736, P786,
P850, P966
Ressa, G. P1193
Resta, I. O158, P838
Reti, M. P758, P771, P773
Retter, A P847
Rettinger, E. O425, P915
Reuther, S. P901
Revel-Vilk, S. P786
Rey, A. P1014
Reykdal, S. N1084, P1125
Rezvani, K. O284, P502
Rialland, F. P487
Ribas, P. P588
Ribaud, P. O272, 323, O380,
O397, P550, P938
Ribera, J.M. O139
Ribera Santasusana, J.M. P856
Ricart, E. 245
Ricci, F. O142, P775
Ricci, R. P974
Ricci, V. P837
Ricco, A. O379
Rice, A. O102, P512, P513
Rice, D. P1158
Richardson, D. P598, P693
Richardson, P. S20
Richter, R. P739
Ridder, M. 317
Rieger, M. P740
Rieutord, A.S. P1121
Rigacci, L. O256
Rigolino, C. P582, P630, P721
Rihani, R P807
Rinaldi, C. P864
Ringden, O. O279, O289,
342, P445, P474,
P489, P509, P703,
P842, P982, P1001
Ringhoffer, M. O170, P854
Ringhoffer, S. O170, P854
Rintala, T. N1099, P1156, P1180
Rio, B. O107, O140, O161,
O301, O391, P1188
Ríos, E. P967
Ripamonti, F. P563, P601, P977
Rischewsky, J. 317
Risitano, A. 315, 320
Ristovska, V. P893
Ritchie, D. N1054
Ritchie, L. N1075
Rivera, J. P988
Rizzetto, M. P838
Rizzi, S. O142, O400, P442,
P465, P870
Rizzo, F. P559
Rizzo, M. O159
Robak, T. P889
Robin, M. O140, O176, O260,
O272, O301, O380, O397,
P514, P550, P587,
P894, P938, P951
Robinson, H. P683
Robinson, S. 305, 308,
309, P955
Roccaro, A. P536
Rocchi, J. P837
Rocci, S. N1055
Roccia, T. P816, P822, P909,
P929, P1005
Rocha, V. O106, O107, O132,
O135, O137, O140, 180,
181, 182, 183, 184, 185,
187, 230, 236, O272,
O279, O281, O283, O298,
O301, 318, 346, O380,
O388, O411, P432, P433,
P550, P587, P938
Rochette, E. P1014
Roddie, C. O381
Roddie, P.H. P504
Rodrigues, C. P919
Rodrigues, C.A. O272
Rodrigues, M.C. P926
Rodríguez, M. P967
Rodríguez Lozano, F. J. P712,
P714
Rodríguez-Macías, G. P562,
P658, P731
Roesch, P. P558
Roessig, C. O263, P777
Roessler, S. P1116
Rohde, E. O165, P700,
P704, P742
Rohde, S. P852
Roig, M. P853
Roivainen, M. P805
Rojewski, M. O170, P854
Rokicka, M. P579
Roland, V. P761
Roldán, V. P660
Rom, E. O423, N1078
Romagnoli, P. O164
Romani, L. 365
Romano, B. P500, P501, P984,
P1002
Rome, A. O178
Romens, S. P1203
Roncarolo, M.G. P816, P822,
P909, P1005,
N1076, N1090
Roncevic, P. P469
Ronch, I. P559
Ronchi, P. P1005
Roncon, S. P633
Rondelli, R. P785, P792, P793
Rondoni, M. P454
Roos Weil, D. O161
Roseff, S. O178
Rosen, O. P923
Rosenmayr, A. P581
Rosiñol, L. O162, O398, P592,
P642, P674
Ross, M. P1158
Ross, R.S P438
Rossetti, A.M. N1090
Rossi, F.M. O261
Rossi, G. P448
Rossi, M. P500
Rossignol, A. P519, P520
Rossini, S. O171, P1005
Rosti, G. P892, P895
Rotta, M. O158
Rottmann, M. O173
Rouard, H. P591
Roudeix, D. P1121
Rougemont, A. P715
Roumiantsev, S. P634
Rousseau, R. P611
Roveda, A. P823, P824,
P874, P985
Roveda, L. P996
Rovelli, A. O177, 197, P555
Rovers, J. O104
Rovira, M. O106, O139, O280,
328, O398, P592,
P642, P674, P757,
P953, P1189
Rovó, A. O394, O395
Rowe, J.M. O259, P802, P884
Roy, D.-C. S8, S11, O104
Roy, J. O104
Rozenblum, N. O426
Rozman, M. O280
Rozovski, U. O423
Rubio, M. P696
Rudge, T. N1053
Rufini, V. P725
Ruggeri, A. O298
Ruggeri, G. P940
Ruggeri, L. O400, P735
Ruhm, S. O152
Ruiz, F.J. P702
Ruiz, J. O412, P644,
P843, P916
Ruiz de Elvira, C. 1208, 1214
Ruiz Seixas, M. P879, P1134

List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Rupolo, M. O261
Rush, S. P808
Russell, J. O275, O376, P641
Russell, N. S41, S44, S47,
116, O286, O420,
P435, P891, P941
Russo, D. O133, P436, P454,
P483, P536, P892
Russo, G. P1193
Russo, L. P1193
Russo Rossi, A. O379
Rutgeerts, O. O429, O430,
P618
Rutten, C.E O417
Ruutu, T. 116, 0137, 224,
228, O281, O286,
O300, P939
Ryan, K. N1041
Ryder, L. P990
Rykavicin, O.A. O297
Ryoo, H.M. P623
Ryu, J.S. P765
Ryu, K.H. O146
Ryu, S.G. P937
Saarela, J. P522
Sabater, F.J. P887, P989
Sabloff, M. O262
Sabo, E. P884
Sabri, E. O262
Saccardi, R. O164, 240, 242,
244, 246, O295,
P632, P871, 1220
Sacchi, N. O106
Sadraee, M. P979
Saevarsdottir, T. N1084, P1125
Sáez, V. P702
Saffioti, F. P1193
Saglio, G. O133, P439
Sagoo, N. P1155
Saidani, K. P882
Sainati, L. O302
Saito, A. M. P678
Saito, T. P836
Saji, H. O105
Sakai, R. P486, P648
Sakamaki, H. P486, P678, P710
Sakellari, I. P549, P565,
P650, P729
Salah, V. P715
Salar, A. P769
Saleh, A.J.M. P470, P880
Saliagopoulou, C. P709
Salmi, F. P436, P439
Salmon, A. P904
Salooja, N. 118, P638
Saloum, R. P650
Salt, M. N1069
Salvadè, A. P555
Salvaneschi, L. P500, P501,
P984, P1002
Salvi, A. P968
Samarasinghe, S. O405
Samey, B. 181, 182,
O281, P433
Sammassimo, S. P996, N1059
Sampol, A. P552, P963
Samuel, S. P523, P671, P850
San Miguel, J. O162, P963, P964
Sanahuja, M. P811
Sanchez, F. P832
Sanchez, M. P1143
Sánchez Salinas, A. P702
Sánchez-Blanco, J. P655
Sanchez-Gonzalez, B. P769
Sanchez-Guijo, F.M. O106
Sánchez-Ortega, I. P839, P887
Sánchez-Valdepeñas, C. P515
Sanders, E.A.M. O278, P781
Sanders, J. 318
Sanderson, J. P932
Sanft, J. P723
Sanna, M.A. P559
Sano, F. O136
Santarone, S. O290, P433,
P434, P661
Santhanaselvi, S. P1130
Santoro, A. P861, P993
Santoro, G. P483
Santosuosso, M. P632
Santucci, S. P898
Sanz, G. S77, O139, O283,
O298, O301
Sanz, J. O139
Sanz, M.A. O139, P588
Sapir, G. P1119
Saporiti, G. P950
Saracco, P. O422
Sarhan, M P807
Sarina, B. P861, P993
Sasazuki, T. O105
Sato, A. P484, P486
Sato, H. O143
Sauer, M. O266, P647
Saulquin, B. P543, P566, P752,
P761, P978
Sauter, B. P456
Sauvageau, G. O104
Savignano, C. P864
Savoie, M.L. P641
Savoldo, B. O405
Sawinski, K. P759
Sayer, H.G. N1060
Sayili, A. P652
Sayinalp, N. P1199
Sbarsi, I. P1002
Scalzulli, P. P767
Scaradavou, A. O132
Scaramozzino, P. P511, P630
Scaramucci, L. P679
Schaaf, C. P1116
Schäfer Eckart, K. O173, 187,
O285
Schäfer-Eckhart, K. O282
Schäfers, M. O154
Schaffer, M. P1001
Schafhausen, P. P896
Schaich, M. O173, O390
Schallmoser, K. O165, P700,
P704, P742
Schanz, U. O408, P572
Scheible, M. O266
Scheid, C. P547
Scheike, T.S. 333
Scheinberg, D. O168
Schembri, S. N1054
Scherer, F. O408
Schetelig, J. 86, 225, 230,
O285, O390, P891
Schiano de Collela, J.M. O163
Schiavo, R. O293, P610
Schieder, H. P766
Schiffer, E. O151
Schilbach, K. P906
Schiling, G. O157
Schilstra, J. N1038
Schlegel, P.G. O294, O415
Schlegelberger, B. O265
Schleuning, M. O148, 226,
P456, P529
Schlösser, V. O287
Schmelz, R. P525
Schmetzer, H. P901, P905
Schmid, C. 181, 182, 231,
P901, P905
Schmitt, A. O403, P854
Schmitt, M. O403, P854
Schmitt, T. O406
Schmitt-Graeff, A. O155
Schmitz, M. 86
Schmitz, N. S79, 116, O257,
O258, O259
Schmugge, M. O265, O410
Schneck, J.P. P907
Schneider, G. O425
Schneider, S. P930
Schneider, U. P930
Schnittger, S. P796
181

182
List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Schnitzler, M. O300
Schnürer, E. O291
Schober, O. O154
Schoenenberger, A. P596
Scholten, M. 224, 226, 229
Schoordijk, M. N1050
Schoordijk, M.C.E. N1035
Schots, R. P991
Schouten, H. S42, O255, 311
Schrappe, M. O134
Schrauder, A. O134, O263,
P571, P777
Schrezenmeier, H. 315, 316, 320
Schroderova, R. P1137, P1195
Schroeder, S. O172
Schrum, J. O147, P803
Schub, N. P571
Schubert, J. 222, O257
Schubert, M.S. O173
Schubert, S. P722
Schuld, P. 226
Schulenburg, A. P581
Schulte, C. P451, P934
Schulz, A. O263, O264, O409,
O410, P622
Schumacher, P. P518
Schumacher, R. P659
Schumm, M. O270, P795
Schuster, F. O266, P901
Schütte, V. O378
Schutten, M. O278
Schütz, C. P622
Schuurman, R. O278, P781, P782
Schwaeble, J. P584
Schwarz, K. P622, P689
Schwarz, S. O157
Schwerdtfeger, R. O173, 222,
228, O282, O285,
Schwinger, W.
O389, P446, P456,
P529, P939, P946
O267
Scimè, R. O256, O384, P479
Scirtò, M. P1193
Scollo, C. P750
Scoppettuolo, G. P881
Scott, F.M. P504
Screnci, M. P866, P974
Scuderi, F. P787
Scudlova, J. N1103, P1167
Searle, E. P794
Secondino, S. O293, P610
Sedlacek, P. 232, O265, O276,
P784, P888
Sedlackova, B. N1103, P1167
Sedzimirska, M. P527
Seedhouse, C. O420
Segatti, A. P902
Seger, R. O408
Seggewiss, R. O271, P608, P911
Seidl, C. P739
Seifried, E. P739, P854
Sekora, A. P620, P624
Semenova, E. P791, P885,
P957, P1126
Sengelöv, H. O137, 182
Sentyakova, T. P922
Seo, E.J. P937
Seo, J.J. O146, P639
Seo, S.K. P623
Seol, M. P937
Sergeevicheva, V. P920, P922
Serrano, D. O139, P562, P658,
P731, P753, P856
Serve, H. P446, P584, P739
Serventi-Seiwerth, R. P469
Seto, M. P728
Setubal, D. O412, P644,
P843, P916
Severino, A. P716
Seymour, J.F. N1054
Seystahl, K. P911
Shah, M. P755
Shaheen, H. 202
Shamanski, S.V. O297
Shamim, Z. P990
Shamshiri, A.R. P590, P820
Shapira, M. O426, P523,
P671, P736, P786,
P850, P966
Sharon-Richman, J. P502
Shaughnessy, P.J. P493
Shaw, B.E. O416, O420, P435,
P444, P741, P992
Shaw, P.J. P1115
Shem-Tov, N. P457, P947
Shen, Y. P513
Shenton, G. P886
Shepherd, P.C.A. P504
Sherman, M. P1123
Shevchenko, Y.L. O297
Shibayama, H. O136
Shimabukuro-Vornhagen, A. P913
Shimoni, A. O157, O391,
O426, P457, P496,
P947, N1039
Shin, H.Y. O146, P639
Shiryaev, S. P957
Shlain, D. P1187
Shlomchik, W. 347
Shouls, S. 355
Shpall, E. P441
Shpringer, M. N1078
Shriki, N. P971
Sibilla, S. O144, P645
Sibon, D. O260
Sica, S. O149, P553, P593,
P725, P855, P881
Siegel, S. P801
Siegert, W. O285
Siegloch, K. 310
Siena, S. O293, O293
Sierra, J. O139, O175, P769,
P832, P853, P953
Siitonen, S. P805
Sijimol, P.V. P1118
Silling, G. O154
Silva, L. O398
Silva, R. P843
Silver, R. 226
Silverman, L. S50
Simione, A.J. P828
Simões, B.P. P926
Simon, R. P917
Simon, S. P1118
Simone, M. P823
Simone, M.D. P819, P874
Simonelli, S. P1203
Simonetti, F. P851
Simoni, A. 184
Simpson, M. 245
Sinai, A. P971
Sinfield, L. O102, P512
Singer, M. O174
Siniscalchi, A. P679, N1055
Sinkó, J. P845, P877
Sintnicolaas, K. P491
Sipos, A. P758, P771, P773
Sirohi, B. 334
Sirvent, A. O107, O140,
O283, O301
Sizikov, A. P922
Sizikova, S. P920, P922
Skaat, A. N1039
Skardova, J. N1103, P1137,
P1167, P1195
Skarznska, M. P689
Skert, C. P536
Skoda Gorican, I. N1103, P1167
Skorobogatova, E. P634, P667
Skuletic, V. P477
Skuliber, M. P1167
Skvortsova, Y. P667
Slaper, I. 127
Slatter, M. O413, P683, P684,
P694, P695
Sleiman, S. P1138
Smias, C. P565, P650
Smith, M. P1004

List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Smith, O. O168, O288
Smith-Knutsson, E. 219, P539
Snarski, E. P579
Snowden, J. P462, P490,
Soave, S.
P508, P680, P688,
P932, N1069
P1153, P1154
Sobh, M. O140, O286,
P450, P606
Socié, G. 116, 118, 120, O161,
O176, 187, O258, O260,
O272, O281, O298, 315,
316, 317, 318, 320, 349,
O380, O388, O397, P514,
P540, P550, P587, P732,
P894, P918, P938, P1203
Sodani, P. P817, P819, P823,
P824, P874, P985
Soerensen, J. O264, P691,
P1116
Sohal, R. P1163, P1165
Sohn, B.S. P765, P876, P997
Sohn, S.K. P545, P640,
P681, P865
Sokolowski, P. P688
Solano, C. O139, P552, P588,
P856, P963
Solaz, N. P652
Soler, C. P591
Soliman, C. P909, N1076,
N1090, P1201
Solomon, S. P493
Som, N. 357, 358, 360,
363, N1051
Somers, J.A.E. P491, P492
Song, J.A. P554
Sood, N. P664
Sorà, F. P593, P725, P881
Soracco, M. P835
Sorasio, R. O158, P594, P838
Soresina, A. 198
Sorio, M. P605, P754, P940
Sormani, M. O295
Sorour, Y. P462, P808
Soudy, H. O179, P670
Soulier, J. O161
Sousa, T. P633
Soutar, R.L. P504
Souza, M.O. O382
Soverini, S. O133, O138,
P439, P892, P898
Sozeau, C. P1121
Sozer, E. P1128, P1205
Spadaro, A. P453
Spagnoli, A. P495
Spalding, K. 216
Span, L.F.R. 322
Spartà, V. O274, P910
Specchia, G. O256, O379,
P645, P747
Speicher, M. O165
Spellman, S. O416, P990, P1006
Sperotto, A. P675, P724, P864
Speth, F. P622
Spina, A. P747
Spina, F. P594
Spina, M. O261
Spiniello, E. O396, P511, P582,
P604, P630, P748
Spinnewijn, L. 228, P939
Sprangers, B. O429
Spreafico, F. P613
Sprigens, N. N1069
Spyridonidis, A. 182, P577, P619
Stadler, M. O282, P569,
P647, P688, P840,
P846, P945, P948
Stadtmauer, E.A. P482, P485,
P506
Stalika, E. P729
Stamatovic, D. P477
Stancheva, N. P791, P885, P957
Stanzani, M. O142, P442, P465,
P775, P870
Starita, A. P764
Starrenburg, C.W.J. O160
Starý, J. O265, O302, P784
Stasche, T. P896
Statham, P. P1163, P1165
Stauss, H. O401
Stavropoulos-Giokas, C. P709
Steckel, N. P451. P734, P934
Stefanska, M. N1103
Steffan, A. O261
Steffanoni, S. P996
Steffen, H. P608
Stein, J. P802, P971, N1070
Steinberger, P. O268
Steinerová, K. 228, P458, P668,
P706, P939, P973, P1011
Stelitano, C. P749
Stelljes, M. O154, 222, O282,
O287, O300, O389, P946
Stenvall, M. P1151
Stepansky, P. P736, P786
Stern, M. O395, O431, P665,
P735, P833, P1006
Sternieri, R. P746
Stevanovic, S. P900
Stevens, C. O132
Stewart, D. O376, P641
Stiff, P.J. P482, P485, P506
Stocco, V. P978
Stojanoski, Z. P473, P762
Stoltz, J.F. P904
Stölzel, F. O390
Stone, R. 117
Stoppa, A.M. O163, P949
Storb, R. O158
Storek, J. O275, O376,
P641, P829
Storlazzi, CT. O133, O138
Stowasser, N. 118
Straathof, K.C. O405, O415
Stracieri, A.B.P.L. P926
Strahm, B. O263, O265,
Strano, A.
O302, O410, O425,
P777, P796, P936
P453
Streetly, M. P847, P848
Stringer, J. N1047, N1063
Strobbe, L. 228
Stronen, E. O402
Stroud, M. P693
Strunk, D. O165, P700, P704,
P715, P742
Studt, J. O395, P665
Stuebig, T. P456
Stuhler, G. O266, O300,
O389, P908
Stumpf, A.N. O404
Stüssi, G. O408, P572
Styczynski, J. 233, N1103,
P1167
Styrenius, M. P539
Suarez, F. P696
Suaris, T. O277
Subbotina, N. P801
Sucak, G. P663, P682, P768,
P1128, P1199, P1205
Suemori, K. O103
Suh, C. P765, P876, P997
Suh, D. O168
Suh, J.S. P640, P681, P865
Sullivan, D. P434
Sumazaki, R. P710
Sundberg, B. P631
Sundfeldt, K. P539
Sundin, M. P703
Sung, K.W. O146, P639
Sunol, R. O175
Surace, R. P630
Sureda, A. O162, O175, 229,
Sutton, L.
O255, O258, O259, 303,
304, 305, 350, P753,
P769, P832, P953
P570, P730
Suttorp, M. P627
183

184
List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Suyani, E. P682
Suzukawa, K. P710
Suzuki, R. O418
Svenberg, P. P982
Svensson, P. P1139
Svoboda, T. P458, P706
Sweed-Nagler, A. N1068
Sy, S. O275, O376, P829
Sykora, K.-W. O134, O264,
P647
Symeonidis, A. P577
Sysoeva, T.S. P672
Szalontay, C. P597
Szislo, T. P890
Szmigielska-Kaplon, A. P889
Szomor, Á. P597
Szwed-Kolinska, M. N1103,
P1167
Szydlo, R. O284, P435, P502
Tabani, K. P1203
Tábori, J. P597
Tabrizi, R. O107, O140, 183,
O385, P951
Tagliaferri, E. P878, P927, P950
Taguchi, J. O136
Tahinopoulou, B. P729
Taioli, S. P775
Taji, H. P728
Takach, S. O262, P486
Takahashi, S. P484, P486
Takahashi, T. P873
Takanashi, M. O143
Takaue, Y. P678
Takeuchi, J. O136
Talbi, A. P882
Tamouza, R. P732
Tan, P.-L. P472
Tan, S.M. P907
Tan, T.-D. P576
Tan, Y. P976, P1003
Tanaka, H. O143, P486
Tanaka, M. P486
Tanaka, P. P586
Tangorra, A. N1055
Taniguchi, S. P678
Tanosaki, R. P678
Tarabar, O. P477
Tardieu, L. P1170
Tarella, C. O384
Tarnani, M. P593
Tarnowska, A. O273, P860
Tasic, O. P477
Taskinen, M. 252, P813
Tassara, M. P481
Taube, R. P456
Tauro, S. P955
Tavela, M. O272
Tavor, S. O423
Taylor, N. P680
Taylor, P. S75
Taylor, S. N1074
Tazzari, P. O142, P775
Tchirkov, A. P611
Tecchio, C. P605, P754, P940
Tedeschi, R. O261
Tedone, N. O286
Telli, S. O274
Telling, S. N1103
Teltschik, H. O267, O270,
P778, P795
Tendas, A. P679, N1055
Terakura, S. P678
Terenziani, M. P613
Terol, M.J. O162
Terragna, C. P892
Terranova, P. P787
Terriou, L. O153, P707
Terruzzi, E. P448, P750
Terwey, T. P654, P688
Terzis, K. P1132, P1185
Testi, A.M. P974
Testoni, N. O133, O138, P436,
P439, P892, P898
Testori, A. O296, P925
Teupser, D. O172
Tezcan Karasu, G. P692
Thaler, D. O165, P704
Thalheimer, M. O173
Thall, P. P441
Themeli, M. P619
Theorin, N. 183, O258, O388
Theunissen, K. P991
Theurich, S. O378
Theuser, C. O390
Thevenin, M. P1188
Thiakos, A. P709
Thiant, S. O153
Thiebault, A. O161
Thieblemont, C. O260
Thiede, C. 86, O285, O390,
Thiel, A.
O424, P459, P525
P923, P930
Thiel, E. 375, P733
Thiele, J. 222
Thiele, R. P907, P908
Tholouli, E. P677, N1041
Thomas, J. P1118
Thomas, X. P450, P606
Thompson, N. P932
Thomson, K O174, O255,
O381, P440
Thrasher, A. 88
Tiberi, L. P1129
Tichelli, A. 115, 116, 118, 120,
253, 315, 316, 317, 320,
O394, O395, P498, 1209
Tigaud, I. P450
Tilly, H. P1159
Timp-van Zoest, M.C.W. N1064
Tiniakou, M. P577
Tintori, V. P806
Tirella, S. P563
Tirelli, U. O261
Tischer, J. 118, P548
Tisseuil, C. P1170
Tjønnfjord, G. O402, P455,
P466
Tobiasson, M. P935
Todisco, E. P861, P993
Todoric Zivanovic, B. P477
Toffoletti, E. P724, P864
Tojo, A. P484
Toki, N. P486
Tol, M. P494
Tolar, J. 339
Tomas, J.F. P753, P963,
P964
Tomás Martínez, J. P988
Tomaszewska, A. P579
Tomiska, M. P546, P958
Tomiyama, J. O136
Tonerini, M. P851
Tonn, T. P854
Toor, A. O178
Topaly, J. P589
Topcuoglu, P. P776
Toporskj, J. O267
Toraldo, F. P530
Torati, S. N1082
Torbagyi, E. P758, P771, P773
Torelli, G.F. P651, P866, P895,
P903, P974
Toren, A. P496, N1034
Toren, O. P1119
Torjeman, L. P575, P863
Torosian, T. P579
Torrebadell, M. O280
Torrent, M. P814
Torres del Rio, S. P702
Torres Muñoz, R.M. P1142,
Toscano, A.
P1146, P1186, P1200
P1161
Tóth, Á. P877, P917
Toubert, A. O397, P732
Touvard, L. P745
Towler, K. P1120
Townsend, W. O174
Tozzi, M. P530
Trampe, C.A. P1118
Travaini, L. P763

List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Treleaven, J. P444
Tremmel, A. P758, P771,
P773
Trenschel, R. O300, P438, P451,
P734, P934
Trenta, F. P1153, P1154
Trestman, S. O423
Treves, A. P708
Triantafyllou, E. P577
Tridello, G. P574, P789
Trifonov, S.I. P672
Trimarco, T. P1193
Tringali, S. P479
Trneny, M. P774
Trnkova, M. P1011, P1117
Troeger, C. P498
Troeng, M. P1179
Troncy, J. P450, P606
Trujillo, P. O419
Trümper, L. O257, P701
Tsakiris, D. O395, P665
Tsimperis, S. P650
Tsirigotis, P. P966
Tsitsikas, D.A. O277, P872
Tsuchida, M. P710
Tsukada, N. P484, P486
Tukic, L. P477
Tulpakov, A. P667
Turin, I. P910
Turlure, P. P452, P1170
Turner, B. O102, P512, P561
Turpeinen, H. P522
Turrini, M. P583, P719, P875
Tyndall, A. 243, O394, O395
Tzouvara, E. P577
Ubeda, C. O288
Ubezio, G. O106
Uccelli, A. P928
Uchida, N. O136
Uchiyama, T. P836
Uderzo, C. O177
Ueda, R. P678
Uehara, T. P486
Ueno, N. O156
Ugarte-Torres, A. O275, P829
Uharek, L. 222, O282, O300,
P733, P945, P946
Uhlich, F. P896
Uhlin, M. P489, P509,
P612, P912
Ullmann, A. 323, P825
Ulloa-Montoya, F. P618
Unal Ince, E. P652, P669
Unnarsdottir, B. N1084
Unnarsdottir, N. P1125
Urbani, E. O400
Urbani, S. P632
Urbano-Ispizua, A. O419, P463,
P879, P967
Urbanowska, E. P579
Usai, S. O142, P442, P465,
P775, P870, P895
Usardi, P. O399, P878, P927,
P950
Usnarska-Zubkiewicz, L. P471
Ussowicz, M. P689
Usui, N. P678
Usuki, K. O136, P873
Utsunomiya, A. N1085
Uygun, V. P692, P697, P821
Uysal, A. P776
Uysal, Z. P652, P669
Uyttebroeck, A. O255
Uzunel, M. O152, P703, P982
Uzunov, M. O107, P535, P570,
P730, P998
V. Stackelberg, A. O134, O263
Vacca, A. O414, P524,
P531, P532
Vaccaro, A. P660
Vaccher, E. O261
Vackova, B. P774, P1011
Vadikolia, C. P729
Vagia, M. P505, P666
Vagliano, L. P1197
Vago, L. P914
Vaida, I. P1157
Vainio, O. P805
Valacca, A. P602
Valcárcel, D. O139, O175,
Valent, P.
P552, P769, P832,
P853, P953
S58
Valério, V.L. P1169
Valizadeh, N. P820
Valkova, V. O276, P467
Valle, V. P651, P866, P895,
P903, P974
Vallet Regi, M. P714
Valli, M. P924
Valtolina, V. O171
Valverde, M. P1189
van Baarle, D. O278, P781
van Bergen, C.A.M. O404
van Biezen, A. 224, 225, 226,
227, 228, 229, 230,
O286, P891, P939
van de Loosdrecht, A. P1172
van de Meent, M. O292
van den Akker, A.C. N1038
van den Berg, H. P783
Van den Brink, M. O168, O288
van den Heuvel-Eibrink, M. O302,
P936
van der Bom, J.G. P653
Van der Burg, M. P689
van der Linden, S.J. P1160
van der Meijden, E.D O404, O417
van der Velden, W.J.F.M. P830
van Dijk, N.M. 322
van Gelder, M. P891
van Gils, I.C.M. P653
van Halteren, A.G.S. O427
van Hensbergen, Y. P492
van Heuvel-Eibrink, M. O265
van Kampen, R. O255
van Laar, J. 243, 244
van Lint, M.T. 118, O177,
P835, P928, P933
van Luxemburg-Heijs, S.A.P O417
van Mook, W.N.K.A. 322
van Os, M. 222
van Rhee, F. P493
Van Schie, M.L.J. P900
van Soest, P.L. O169
van Tol, M.J.D. P537, P538
van Vliet, M. P1192
van Walraven, A.M. P975
van Weel, M. 118
Vanazzi, A. P763
Vanbellinghen, J. F. O387, P954
Vandenberghe, E. P772, P965
Vandenberghe, P. O430
Vannier, J.P P804
Vanstraelen, G. P991
Varaldo, R. O106
Varet, B. P696
Varraso, A. P645
Vasilieva, E. P1126, P1167
Vasilieva, Y. P791, P885, P957
Vasiliou, S. P505
Vasquez, M.L. P964
Vavilov, V. P791
Vaz, C.P. P633
Vázquez, L. P839,
P856, P963
Vázquez Moncada, M. P1134
Veith, E. O269
Velardi, A. S9, S12, 114,
O400, P735
Veltroni, M. P806
Venard, V. P904
Venigova, P. P973
Verardi, R. P483
Verdeguer, A. P790, P799,
P800, P811
Verdonck, L. 187, O286
Verfaillie, C. P618
Vergine, C. P602
185

186
List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Verlaan, M.C.E. N1038
Vernant, J.P. O255, P535, P540,
P570, P730, P998
Veronesi, E. P746
Vértesi, G. P917
Vertone, D. P607
Vettenranta, K. P805, P813
Vey, N. P452, P468, P949
Veyrat-Masson, R. P521
Veys, P. 197, O411, O413, O415
Vezzoli, P. P950
Vianelli, N. P870
Viarengo, G. P500, P501, P984
Vicente, V. P475, P655, P660,
P988
Viehweg, M. P542
Vieillard, V. P998
Viganò, M. P878
Vigier, D. P1170
Vigliotti, M. N1055
Vignetti, M. O133
Vigorito, A.C. P1012, P1013
Vigorito, R. N1055
Vigouroux, S. O161, P452
Viirsalu, V. N1103
Vilar, F.J. P794
Villa, A. O409
Villa, J. P839
Villano, S. 321
Villaverde, R. P702
Vinnicombe, S. O277
Visani, G. S59, P454
Viscoli, C. S15, P835
Vise, J.L. P1182
Visokaiova, M. N1103,
P1167, P1191
Visotchin, I. P801
Visser, O. P962
Vitale, A. O133, O138,
P439, P974
Vitek, A. P467
Vitolo, U. P645
Vivancos Moreau, L. P702
Vlug, A. N1086
Vogel, W. O389, P945,
P946, P952
Voisine, C. O401
Vokurka, S. P458, P668,
N1103, P1137,
P1167, P1195
Volin, L. 182, 184, 223, 225,
230, O300, P522, P891
Volke, S. P857
Voltarelli, J.C. P926
von Bergwelt-Baildon, M. P547,
P913
von Bonin, M. O424, P459
von dem Borne, P.A. O160
von Harsdorf, S. P541, P854,
P945, P946
von Luettichau, I. P796
von Willebrand, E. P805
Vora, A. P808
Vorlicek, J. P546, P958
Voskuyl, A. 244
Voss, B. P915
Vossen, A.C.T.M. P834
Vreeke, N. N1050
Vrijmoet-Wiersma, C.M.J. N1067
Vrsecka, P. P1167
Vylitova, L. N1103, P1167
Wachowiak, J. P614, P797, P798
Wadiwalla, S. P986
Waer, M. O429, O430, P618
Waesch, R. P534
Wagner, E.M. O291, O406
Wagner, H. P857
Wagner, J.E. O132
Wagner, N. P893
Wahlström, E. N1083
Wajant, H. P907
Wakama, T. P823
Wälchli, S. O402
Waldmannova, K. P1011
Waldner, B. P1204
Walker, P. N1080
Walker, U. 244
Walker, V. P693
Wall, D. O411
Wall, K. P1181
Wallart, A. N1057
Waller, M. O392
Wandt, H. O173, 222, O258
Wang, L. P528, P862
Wang, T. P990
Wang, X. O403
Wang, X.N. P547, P551
Ward, K. O255, 330, O381
Ward, S. N1069
Wassmann, B. O282, P446
Wassmuth, R. P525
Watanabe, M. O136
Watanabe, N. P486
Waterhouse, M. P619
Watson, L. P941
Watts, M.J. P705
Wauben, B. 356, 361
Wawer, A. P796
Weatherby, S. P1114
Weber, G. O425, P899, P915
Weber, T. O378
Wehler, D. O406
Weigl, R. P526
Weinberg, K.L. 366
Weinbergerová, B. P844
Weintraub, M. P786
Weissinger, E.M. O148, O151,
P840
Weissman, I. P626
Wels, W. P899
Weltermann, A. P557, P770
Wendel, F. P608
Wendelin, K. O173
Wendt, C. N1048, N1094
Wennerås, C. N1020
Wermke, M. P525
Wernli, M. P596
Wesström, A. N1083
Wexler, S. P635
Wheeler, G. N1054
Whelan, J. P783
Wickenhauser, C. P913
Widmer, A.F. P833
Wiela-Hojenska, A. P471
Wiersum-Osselton, J. P975
Wierzbowska, A. P889
Wiesneth, M. O170, P854
Wiktor-Jedrzejczak, W. 225, P579
Wilcox, L. P1008, P1015
Wilks, M. O277
Willasch, A. O263, O425,
P899,P915
Willeke, A. P1149
Willems, E. O387, P944,
P954, P991
Willems, L. O380
Willemze, R. O160, 230,
O292, 316, O404,
O417, P900
Williams, J. P808
Wils, E.J. O167
Wilson, J. O102, P513
Wilson, S. P1118, P1136
Wilson, Y. O428
Windebank, K. P694
Winiarski, J. P842
Winterling, J. N1088
Winterová, J. P844
Wintnerova, J. N1103, P1167
Winzler, C. P574
Wischhusen, J. P911
Witz, F. P951
Wochnik, A. O170
Woellner, C. P684
Woesmann, W. P857
Wojcik, B. P614, P798
Wojcik, D. O265, O302, P689

List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Wojnar, J. P902
Wolf, D. P850
Wolff, D. P541, P542, P556,
P733, P852
Wolff, I. P723
Wölfl, M. O294
Wolschke, C. P766
Wolska, A. P889
Won, H.J. P623
Won, S.C. P809
Worel, N. P526, P581
Worth, L. P441
Wozniok, I. P849
Wraith, J. E. 197, 212
Wright, G. O401
Wright, J. P508, P680
Wu, G. P976, P1003
Wulf, G. 222, O257, O258,
P701, P945
Wynn, R. 197, P794,
P1120, P1147
Xavier, S. P858
Xerry, J. O381
Xu, J. P635
Xu-Bayford, J. O413
Xue, S. O401
Yagci, M. P663, P768
Yaghmaian, H. P979
Yakoub-Agha, I. O107, O153,
O161, 182, O391,
P540, P707, N1057
Yakouben, K. 323
Yakovleva, M. P634
Yakushiji, K. O136
Yalcinkaya, F. P669
Yamaguchi, T. O136, P486
Yamamoto, K. P728
Yamamoto, W. P648
Yamashita, K. P836
Yamashita, T. O136, P678
Yamazaki, R. P486
Yañez, L. P662, P839
Yang, L. O262, P744
Yang, M. P641
Yanik, A. P1128, P1199, P1205
Yaniv, I. 234, 237,
P971, N1070
Yanko, M. P1135
Yannaki, E. P549, P565,
P650, P994
Yano, S. O136, P678
Yasukawa, M. O103
Yasukawa, S. P625
Yatsiv, I. P786
Yegin, Z.A. P663, P682, P768
Yeh, S.-P. P533
Yeoh, A. P472
Yerushalmi, R. O426, P457,
P496, P947
Yesilipek, A. P692, P697, P821
Yi, H.G. O150
Yi, S.Y. P657
Yilmaz, A. P868
Yin, J.A.L. O392, O393,
P544, P677
Yip-Fa, A. P519, P520
Yokota, A. P486
Yokoyama, T. P649
Yoo, C. P997
Yoo, E.S.Y. O146
Yoo, K.H. O146, P639
Yoon, D.H. P876, P997
Yoon, S.S. O150, P460,
P554, P756
Yoshimi, A. O299, P936
Young, L. P1174
Young, N. P886
Young, N.S. 315
Ystiugov, A. P634
Yun, S.C. P937
Zabelina, T. O147, O157,
222, P766
Zacarias, N. P641
Zaccheddu, F. P560
Zach, O. P557
Zaffaroni, N. P628
Zago, M. O272
Zaidi, S. P470
Zaidman, I. P802
Zaja, F. P724
Zak, P. P461, P603
Zaken, A. N1068
Zalcberg, I. P586
Zalyalov, Y. P573
Zamagni, C. P610
Zambelli, A. P610
Zanazzo, G. A. P789
Zander, A. 120, O137, O147,
O157, 222, O300,
P585, P621, P629,
P699, P766,
P803, P897
Zanet, E. O261
Zanis-Neto, J. O412, P644,
P656, P812,
P843, P916
Zanotti, C. P968
Zanussi, S. O261
Zaoutis, T. S83
Zaucha-Prazmo, A. P614, P798
Zavrelova, A. P603
Zecca, M. O265, O293,
O302, O414
Zeis, M. O285
Zerbinati, R.M. O382
Zerweck, A. P534, P738
Zeschke, S. O157
Zhang, M.J. 250
Zhou, F. O275, P829
Zhu, F. P976, P1003
Ziebermayr, R. P770
Ziegler, C. P517
Zielinski, C. P581
Ziemer, S. P930
Ziemsen, T. P972
Zikova, J. P1137, P1195
Zimmermann, M. O134
Zinchenko, A. P573
Zinno, F. P495
Zino, E. O416, P1005
Zintl, F. P723,
P779, P987
Zinzani, P. P775
Zisser, B. P971
Zitkova, M. P1167
Zizkova, H. P784
Zorbas, I. P729
Zoumbos, N. P577
Zubarovskaya, L. P510, P791,
P957, P983
Zubarovskaya, N. P791, P885
Zucchetti, E. P583, P719
Zuckerman, T. P884
Zuffa, E. P449
Zwaveling, J. P690, P788
Zweegman, S. P962
Zygadlo, D. N1103, P1167
187

188
Instructions for Speakers and Authors
Speakers’ Centre / Audiovisual Equipment
The Speakers’ Centre is located at the Göteborg Convention Centre on Level 2 (Room G1).
All lecture rooms will be equipped with a computer and a data projector (beamer)
for PowerPoint presentations. PowerPoint presentations must be handed in via CD-ROM,
USB compatible memory stick, or via the own laptop at the Speakers’ Centre at least
one hour before the beginning of the session. Speakers will have the opportunity to
check their presentations on PCs available in the Speakers’ Centre.
Poster Sessions for Physicians
Dates of poster Poster No Time of poster Poster Poster
sessions presentation Mounting Removal
Monday, 30 March 2009 P432–P722 17.30–19.00 08.00–09.00 19.00–19.30
Tuesday, 31 March 2009 P723–P1015 17.30–19.00 08.00–09.00 19.00–19.30
Authors are kindly asked to be present at their posters during their respective
Poster Session and the times shown above.
It is essential that all authors mount and remove their posters at the above
mentioned times to enable the poster boards to be used for the following session.
Poster Sessions Nurses Group
The posters of the Nurses Group (P1110 – P1206) will be on display during the whole
EBMT 2009 congress, Monday – Wednesday. (Contrary to the posters of the physicians
there will be no change of posters for the Nurses Group).
Authors of the Nurses Group will have the opportunity to discuss their poster with the
participants during the following poster session times:
Dates of poster Poster No Time of poster Poster Poster
sessions presentation Mounting Removal
Monday, 30 March 2009 P1110–P1206 17.30 h–19.00 h Monday, Wednesday,
Tuesday, 31 March 2009 P1110–P1206 17.30 h–19.00 h 30 March 2009 1 April 2009
08.00–09.00 11.00–13.00
Authors are kindly asked to be present during both poster session times shown above.
Location of Posters
The posters for Physicians and Nurses are located at the Göteborg Convention Centre in
Hall B (Level 1).
Poster Measurements for Physicians and Nurses
HORIZONTAL PRESENTATION height: 120 cm (47,244 inches)
width: 190 cm (74,803 inches)
Publication of Abstracts
All accepted abstracts are published in the Supplement of the Bone Marrow Transplantation
Journal as well as on a CD-ROM. Both items are available during the congress and are
included in the registration fee.
As of 13 March 2009, accepted abstracts can also be viewed on the congress
homepage www.congrex.ch/ebmt2009, link: Scientific Programme

CME Accreditation at EBMT 2009
As a participant of EBMT 2009 you are eligible to receive Continuing Medical Education
(CME) credit points from the European Hematology Association (EHA).
European haematologists are highly motivated to provide proof that they are updating their
knowledge and skills through participation in CME activities.
The European Hematology Association CME System is being implemented as a service to
European haematologists in response to this need. The System facilitates identification and
registration in CME activities which have been submitted to a peer-review accreditation
process and respond to pre-established quality standards.
CME accreditation is a permanent feature of EBMT annual meetings.
Physicians attending EBMT 2009 are eligible to receive 1 EHA-CME credit point for every
hour of accredited scientific programme.
EHA-CME points will be awarded for the following sessions.
• Educational sessions • Plenary sessions
• Workshop sessions • Joint sessions
• Controversy sessions • Presidential symposium
• Oral sessions • Working Party sessions
How to claim your EHA-CME points
The electronic EHA-CME system is fully automated and you may claim your credits online.
You may create your account, claim your credits, and print your EHA-CME certificate online
at www.ehaweb.org (select ‘CME’).
Steps to claim your EHA-CME Credit Points
Step 1 Visit www.ehaweb.org and select the CME link on the left side of the page.
Step 2 From the CME home page, select the Claim Credits tab at the top.
– If you are an account holder: you may login on this page.
– If you do not have an account yet, you may create an account by using the
link register here on this page.
Step 3 Click on Select Meeting in the left-hand menu or the button next below your
personal overview.
Step 4 Select your meeting from the list
Step 5 Enter your personal login code (provided with your registration documentation).
Click Verify to continue.
Step 6 Answer the general questions regarding the meeting.
Step 7 Click next at the bottom of the page to continue to Claim Credits › Select Sessions.
Step 8 Evaluate the sessions that you have attended from 1 to 10. (10 is the highest score).
Step 9 Click next at the bottom of the page to view your personal account.
The system will automatically save your information after you have left the page.
Step 10 To print your EHA-CME certificate please use the print-button on the far right side
of the table.
Your personal login code will be provided with your registration documentation.
You will have three months after the closure of the meeting to claim your
EHA-CME Credit Points.
Further information on the European Hematology Association CME system is available at
cme@ehaweb.org and www.ehaweb.org
189

YOU’VE ONLY JUST
ARRIVED & ALREADY
WE’RE THINKING OF
YOUR NEXT TRIP
As the official airline network for the 35th
Annual Meeting of the European Group for
Blood and Marrow Transplantation, we’d like
to thank you for choosing the Star Alliance
network and hope that all goes really well for
you here today.
Whilst you concentrate on the day’s events, we
hope you’ll consider us the next time you need
to attend a conference.
With over 18,100 flights a day to 975 airports
across 162 countries, our 24 member airlines
will extend a wide choice of flights to any future
conference you’re planning to attend. And no
matter which of those airline’s frequent flyer
programmes you belong to, you can earn and
redeem miles across all of them.
So the next time you want to concentrate all
your energies on your conference,we hope
you’ll decide to leave the travel arrangements
to us.
www.staralliance.com
Information correct as at 07/2008

Registration Information
Registration fee
Congress Registration
All documents including registration
packets (congress wallet, personal name
badge, abstract book, vouchers) will be
handed out to the registered participants
during the following hours:
Saturday 28 March 2009: 17.00–19.00
Sunday 29 March 2009: 08.00–19.00
Monday 30 March 2009: 07.30–18.00
Tuesday 31 March 2009: 07.30–18.00
Wednesday 1 April 2009: 07.30–15.00
Payment
All fees for the congress registration and social
events should be paid in EURO (€) to the
EBMT 2009 Organising Secretariat – clearly
stating the participant‘s name and address
• by bank transfer (free of charge) to
– Beneficiary: EBMT 2009 c/o Congrex
Switzerland Ltd.
– UBS AG, Kloten / Switzerland,
EURO Account No. 278-821.000.64 N
(EBMT 2009, c/o Congrex
Switzerland Ltd.)
– IBAN Code: CH150027827882100064N
– BIC: UBSWCHZH80A
• by credit card (Visa, Mastercard,
American Express)
• by bank cheque
Until As from As from
8 January 9 January to 27 February 2009
2009 26 February 2009
Physicians EBMT-Member € 320.– € 395.– € 450.–
Non-member € 410.– € 480.– € 530.–
Nurses Group
Data Management Group
Quality Managers
EBMT-Member € 230.– € 290.– € 340.–
Non-member € 290.– € 360.– € 410.–
Student* € 100.– € 125.– € 150.–
Accompanying person € 25.– € 25.– € 25.–
* Students must be one of the authors of an accepted abstract and must provide proof of undergraduate
student status. A written certification by the head of the programme is required and must be sent to
Congrex Switzerland Ltd. (Fax +41 61 686 77 88).
The fee for active participants includes unlimited access to all sessions, the welcome reception, industry
exhibition, one copy of the final programme and one copy of the abstract book.
The fee for accompanying persons includes the welcome reception and access to the exhibition.
Please note: Although included in the registration fee, some sessions and the welcome reception require
separate registration (see registration form).
Responsibility
The participant acknowledges that he/she
has no right to lodge damage claims
against the organisers should the holding of
the congress be hindered or prevented by
unexpected political or economic events or
generally by force majeure, or should the
non-appearance of speakers or other
reasons necessitate programme changes.
With registration, the participant accepts
this proviso.
Confirmation
Upon receipt of the correct registration fee,
each participant will receive a confirmation
of registration. Please bring this confirmation
to the registration desk at the congress
centre as proof of your registration.
Cancellation / Refund Policy
Refund of registration fees, less 25%
administrative charges, can be applied for
in writing until 11 February 2009 to the
Organising Secretariat in Basel, Switzerland.
After this date no refund will be possible.
For any change of names a fee of € 30.–
will be charged.
191

192
General Information (in alphabetical order)
Abstracts
All accepted abstracts are published in a
Supplement of the Bone Marrow Transplantation
Journal available during the congress.
One complimentary copy is included in the
full registration fee.
Address of venue and Organising
Secretariat during and after the
EBMT 2009
For detailed information please refer to
page 21.
Airline
Save up to 20% discount with the Star
Alliance Network
The Star Alliance Member Airlines have
been appointed as the Official Airline
Network for the EBMT 2009. Participating
airlines for this event are ANA, Air Canada,
Air China, Asiana Airlines, Austrian Airlines,
LOT Polish Airlines, Lufthansa, SWISS
International Air Lines, Scandinavian
Airlines, South African Airways, Spanair,
TAP Portugal, Turkish Airlines, United,
Adria Airways, Croatia Airlines and Blue1.
www.staralliance.com/conventionsplus
Badges
Access to all scientific events is only possible
with your personal badge which you will
receive at the registration desk in Göteborg.
Please always wear your badge! Lost badges
will only be replaced with proof of your
original registration.
Climate
In March, the average temperature in
Göteborg is 3 – 5°C. Warm clothes are
necessary.
Currency
All official meeting prices are indicated in
Euro (€). The currency in Sweden is the
Swedish Krona (SEK) (1 €= 11.00 SEK as
per February 2009).
All major credit cards are accepted in most
hotels, restaurants and shops.
EBMT Society Booth
Throughout the meeting, EBMT and JACIE
staff will be available at the EBMT booth
to answer any questions you may have
concerning the EBMT Society or JACIE
accreditation programme.
Elections are being held for the position
of EBMT President Elect and re-elections of
the Chairpersons of the Chronic Leukaemias
and Late Effects Working Parties.
The Principal Investigator or representative
of your centre is encouraged to
visit the booth to vote. The EBMT booth
(No. 501) is located within the Exhibition
area in Hall B (Level 1).
Voting will take place from 12.00 on
Sunday, 29 March to 17.00 on
Tuesday, 31 March 2009.
Candidates profiles can be found in the
March edition of the e-EBMT News,
circulated to EBMT members at beginning
of March. Copies of the profiles are
available for consultation at the EBMT
booth. Election results will be presented
at the General Assembly meeting from
08.00 – 09.00 on Wednesday morning,
1 April 2009.
Exhibition
The EBMT 2009 exhibition presenting the
latest technical equipment and pharmaceutical
products will take place in Hall B
of the Göteborg Convention Centre.
Exhibiton Dates and Times
Sunday 29 March 2009: 10.00–18.30
Monday 30 March 2009: 08.30–17.00
Tuesday 31 March 2009: 08.30–17.00
Wednesday 1 April 2009: 08.30–13.00

General Information (in alphabetical order)
Final Programme
The final programme is also available on
the Internet www.congrex.ch/ebmt2009
Hotel Accommodation
Congrex Travel Ltd., the official EBMT Travel
agency is present with a desk in the
registration area during the meeting. For
assistance on-site, please contact the counter
“Hotel Accommodation” at the secretariat
located at the Göteborg Convention Centre
(Level 1).
Contact on-site:
Tel. +46 31 708 82 53
Fax +46 31 708 82 54
Insurance
The meeting organisers cannot accept
liability for personal injuries sustained, or for
loss or damage of property belonging to
meeting participants or their accompanying
persons, either during, or as a result of the
meeting. Please check the validity of your
own insurance.
Internet corner
Several internet terminals are located in
the exhibition area and are available to all
congress participants during the opening
hours of the exhibition. The internet corner
is being sponsored by Bristol-Myers Squibb.
Language
The congress language is English.
Simultaneous translation (English / Swedish)
will be provided for the Patient & Family Day.
Local Information
The local agency SKD Euroconf AB is
present during the meeting. For assistance
on-site please contact the counter “Local
information” at the secretariat located at the
Göteborg Convention Centre (Level 1).
For detailed contact information please
refer to page 21.
Contact on-site:
Tel. +46 31 708 82 55
Lunches
On Monday – Wednesday, a lunch buffet
will be served in the exhibition area of the
congress venue.
Registration
For detailed information please refer to
page 191.
Restaurants
One of the many reasons to visit Göteborg
and the West of Sweden is definitely
the food. Göteborg is known for its fine,
locally produced ingredients and top-notch
restaurant life. Four restaurants in Göteborg
have been acknowledged with a star in
the Michelin Guide.
Since the Convention Centre is located in
central Göteborg, most restaurants in
different price ranges and categories are
within walking distance from the venue and
the hotels. Restaurants are generally open
from 12.30 –14.30 for lunch; and then in
the evening from 19.30–22.00.
For more information please contact the
“Local information” desk located at the
Secretariat.
193

194
General Information (in alphabetical order)
Shopping in Göteborg
Göteborg is a lively city for shopping where
you can find just about anything within an
easy walk of the centre. There’s no shortage
of interesting shops right in the heart
of the city, and if you feel like exploring –
or taking a short tram ride – then Järntorget,
Linnéstaden, Haga old town, Vasastaden and
the main boulevard, Avenyn, all offer great
shopping too. Big brand names jostle for
space with small specialist shops. Trendy,
traditional, cool, essential, exclusive or
inexpensive – you’ll find them all. NK and
Nordstan are the two most well-known
indoor shopping malls in the centre, where
you can find all you need.
Speakers’ Centre
The Speakers’ Centre is located on Level 2
(Room G1).
All speakers will be asked to hand in their
PowerPoint presentations prior to their
lecture at the SSC.
Tipping
Tipping is generally not required in Sweden,
since service charges are included in the
taxi, hotel and restaurant rates. However,
at restaurants tipping of around 10% is
appreciated if the guest is satisfied with the
service and food.
Transport in Göteborg
Please refer to “Travelling to the Göteborg
Convention Centre” (pages 197/198) for
more details.
Venue
The EBMT 2009 meeting takes place at
the Göteborg Convention Centre (GCC).
The GCC is situated centrally in the heart
of the city’s concentrated event area.
The Göteborg Convention Centre, together
with the Swedish Exhibition Centre, was
built in the early 1970s. In 1984 the towershaped
Hotel Gothia was built and in 1992
the Congress Hall was added. Today, the
convention centre offers many wellequipped
conference rooms including a
modern congress hall.
The Göteborg Convention Centre together
with the Hotel Gothia Towers – Göteborg’s
tallest hotel – is just the perfect size for the
EBMT 2009 meeting.
Göteborg Convention Centre
Mässans gata 20
402 26 Göteborg / Sweden
www.gcc.se
World Wide Web
The complete EBMT 2009 Final Programme
including the abstracts is also available on
the EBMT 2009 website
www.congrex.ch/ebmt2009.

Social Events
Sunday, 29 March 2009, 20.00
Welcome Reception
After the Opening Session, participants,
accompanying persons and exhibitors are
invited to attend the Welcome Reception,
which will be held in the Göteborg
Convention Centre. The reception is partially
hosted by the City of Göteborg and the
Västra Götaland region.
Free admission
Monday, 30 March 2009, 19.30
Concert in the Stenhammar Hall
The traditional EBMT concert will take place
in the Stenhammar Hall, which is housed in
the famous Göteborg Concert Hall where
the Swedish National Orchestra has grown
from a small regional ensemble into a
fully-fledged symphony orchestra. The Hvila
string quartet – a selection of musicians
from the main orchestra, accompanied
by the pianist Sara Sjödal-Callersten, will
perform an inspiring concert including
typical Nordic music from the 19th and
20th centuries.
Price: €30.– per person
The Stenhammar Hall is situated in the
Gothenburg Concert Hall by “Götaplasen”
at the top end of Avenyn (the main street
of Gothenburg). The Stenhammar Hall
can be reached within a 10 minute walk
from the Convention Centre and is in
close proximity to the city’s main hotels.
For more information on how to get there
and for public transport options, please
ask at the “Local Information” desk at
the Secretariat, located in the Göteborg
Convention Centre at the main entrance
on the ground floor.
Tuesday, 31 March 2009, 20.00
EBMT Party at Kajskjul 8
”Kajskjul 8” is situated on the quay, close to
the Gothenburg Opera – 20 minutes walk
from the Convention Centre – in a genuine
harbour environment, offering charm and
ambience. The oldest part of Kajskjul 8 was
built in the late 19 th century and served as
a warehouse for storing spices. In 1994
the building was carefully renovated into a
restaurant, preserving the traditional
exterior.
Following an apéritif, the resident chef and
the Amanda Ensemble (www.amanda.nu),
a popular and inventive local choir, will
together create an amazing vocal and
culinary fusion. The Valdemar band will
round-off the evening with its wide repertoire,
ranging from rock’n’roll to waltz and quickstep.
Certainly, an unforgettable night!
Price per person:
€90.– (Physicians)
€65.– (Nurses and
Data Management Group)
Transfer buses
19.30 Various transfer buses for Kajskjul
8 will leave from different keypoints and
hotels. Bus schedules are available at the
“Secretariat” and “Local information”
counter on-site.
Make your own way to Kajskjul
By public transport:
From the Congress Center
(Korsvägen stop C):
Bus: No 50 Stop Rosenlund
From the Central Station
(Centralstationen stop D):
Bus: No 60 Stop Rosenlund
By foot:
From the central station, Kajskjul 8 can
be reached within a 10 minute walk.
195

196
Daily Tours and Post-Congress Tour
Sunday, 29 March 2009, 13.30–17.00
City Tour of Göteborg
Meeting Point: Göteborg Convention
Centre – Entrance No 5,
10 minutes before departure.
Price: €30.– per person
Tour includes: local guide, coffee, entrance
fees where required.
Monday, 30 March 2009, 09.30–11.30
Guided Tour of the Fürstenberg
Gallery at the Museum of Arts
Meeting Point: Main entrance, Göteborg
Museum of Art, Götaplatsen / Avenyn,
10 minutes before departure.
Delegates are advised to make their own
way to the museum (5–10 minutes walking
distance from the Göteborg Convention
Centre and most central hotels) where a
guide will gather the group for the tour.
For public transportation please contact the
“Local information” desk on-site.
Price: €27.– per person
Tour includes: local guide, coffee, entrance
fees where required.
Göteborg Art Museum
Tuesday, 31 March 2009, 13.30–16.30
Gunnebo House and Gardens –
Guided tour and Afternoon Tea
Meeting Point: Göteborg Convention
Centre – Entrance No 5,
10 minutes before departure.
Price: €55.– per person
Tour includes: local guide, afternoon tea,
entrance fees where required.
Thursday & Friday, 2 & 3 April 2009,
07.30–20.00
Post Congress Tour –
2 day tour of Öland and Smaland,
the Kingdom of Crystal
Meeting Point: Leaving from the Göteborg
Convention Centre and Central Station,
10 minutes before departure.
Please note that the return time is approximate
due to the traffic.
Price: €335.– per person
Tour includes: bus transfer, local guide,
dinner on first day (beverages at own
expense), accommodation incl. breakfast,
all entrance fees, guided tour of Kosta
Museum and opportunity to shop at the
Factory outlet, guided tour of parts of Öland
including famous landmarks.
Additional tickets for the daily tours will be sold on-site at the “Local Information” desk.
On-site requests for tours are welcome but can not be guaranteed. Tours are based on a
minimum of 30 participants. The organisers reserve the right to cancel any tour if there
are less than 30 persons registered, in which case the ticket fee will be reimbursed in full.
Otherwise tickets for tours are non-refundable.
For more information on the tours and / or directions to the various meeting
points, please contact the “Local Information” desk located at the secretariat
at the Göteborg Convention Centre (ground floor).

Travelling to Göteborg Convention Centre
Göteborg Convention Centre
Göteborg Convention Centre is located in
the city centre with walking distance to
most hotels and shopping areas.
For tourist information, please look at the
official visiting guide: www.goteborg.com
Airport bus to/from Landvetter
airport
We recommend using the bus from the
airport to the Göteborg Convention Centre.
During day time the bus leaves every
15 minutes and takes 20 minutes to its first
stop (Korsvägen), which is in front of the
Convention Centre. For timetable please
visit www.flygbussarna.com.
Price per person: SEK 80 (€8.–) one way
and SEK 150 (€15.–) for return ticket (can
be purchased online). Credit card or SEK is
accepted on board.
Airport bus to/from Göteborg
city airport (serves Ryanair,
Wizz Air and Air Berlin)
The timetable for airport coaches from City
Airport correspond with Ryanair Wizz Air
and Air Berlin. They leave the airport for
Nils Ericson Terminal when all passengers
are on board. If flight arrival times change,
the bus schedule is adapted accordingly.
In the event of a flight cancellation, there
will be no bus connection. For timetables
please visit www.flygbussarna.com.
The journey takes approx. 30 minutes to
the Central station (stop Nils Ericssonsterminalen).
Price per person: SEK 60 (€6.50) one way
and SEK 110 (€11.70) for return ticket.
Credit card or SEK is accepted on board.
Taxis
We recommend Taxi Göteborg, VIP-taxi or
Taxi Kurir. All taxi companies have fixed
prices, approx. SEK 400 (€43.–) to/from
the airports and City Centre. We encourage
delegates to agree the fare with the driver
before embarking on their journey.
Taxi Göteborg: Tel. +46 31 65 00 00
Taxi Kurir: Tel. +46 31 771 86 00
VIP Taxi: Tel. +46 31 27 86 00
Arriving by Car
Leave the E6 highway at the Mässan/
Scandinavium/Liseberg sign.
Nearest parking: Focus multistorey car
park, adjacent to complex.
Arriving by Train
From Central Station (Drottningtorget), take
tram no 2 or 4 to Korsvägen, opposite the
Hotel Gothia Towers / Göteborg Convention
Centre. From Brunnsparken (next to the
Central Station), take tram no 5.
A single journey within Göteborg costs
approx. SEK 25 (€2.70).
Public Transport in Göteborg
Västtrafik is responsible for the public
transportation system within Göteborg and
surrounding areas. A network of trams,
buses and ferries makes travel around the
city very easy. For more information on
routes and timetables see
www.vasttrafik.se.
A one-way ticket costs approx. SEK 25
(€2.70) depending on the purchase
method.
Another option is the “Göteborgspasset” a
1- or 2-day card for SEK 225 (€24.–) or
SEK 310 (€33.–) which entitles to free
transportation and includes entrance fees to
museums etc.
For more information and to buy the
“Göteborgpasset” please visit the “Local
information” desk.
197

198
Travelling to Göteborg Convention Centre
How to purchase a ticket
There are different procedures to purchase tickets for all types of public transport in Göteborg.
– Prepaid card: a prepaid discount card of
SEK 100 (€9.50) can be purchased at
most kiosks. This is the cheapest option
if you are planning to travel frequently
during the congress, as the card is valid
for approx. 5–6 single journeys. For an
adult you need 2 coupons which you have
to validate at the ticket machine onboard.
There is also the option of a 1-day or
3-day card for approx. SEK 65 (€6.90) or
SEK 130 (€13.90).
– Ticket station next to the Göteborg
Convention Centre: The closest place
near the GCC to buy tickets is:
the Pressbyran shop at the tram
station Korsvägen.
Trams: a common mode of public transport in Göteborg
– Trams/Buses: on the trams there is a
ticket machine onboard which only
accept coins. The driver does not accept
cash payment.
– Buses: on the buses only prepaid tickets
can be used.
– SMS ticket (can only be used with a
Swedish Mobile phone account!):
Instructions on how you send is posted
on the tram stop.
Costs: approx. SEK 20 (€2.20)
per one-way ticket.

List of Exhibitors
481 AirInSpace,
Montigny-le-Bretonneux / FR
211 Amgen (Europe) GmbH, Zug / CH
425 Biosafe, Eysins / CH
353 Biotest AG, Dreieich / DE
411 Caridian BCT, Brussels / BE
421 Celgene International
605 CellGenix Technologie Transfer GmbH,
Freiburg / DE
511 Cephalon Europe, Maisons-Alfort / FR
571 Chart Biomedical Ltd., Bracknell / UK
231 Chugai sanofi-aventis, Gentilly / FR
538 Consarctic, Schoellkrippen / DE
601 Exem Consulting SA, Gordola / CH
201 Fresenius Biotech GmbH,
Gräfelfing / DE
537 GE Healthcare, Little Chalfont / UK
321 Genzyme Transplant Oncology, Europe
311 Gilead
223 Hospira
453 ICCBBA, Redlands, CA / USA
643 Macopharma / FR
233 Medac, Wedel / DE
603 Med Tech Solutions GmbH, Fürth / DE
521 Miltenyi Biotec GmbH,
Bergisch Gladbach / DE
221 MSD, Whitehouse Station, NJ / USA
423 Mundipharma International,
Cambridge / UK
451 Nature Publishing Group, London
443 Novartis Oncology, Origgio / IT
539 Orphan Europe, Paris / FR
461 Osiris Therapeutics, Inc.,
Columbia, MD / USA
471 Pall Medical, Portsmouth / UK
441 Pfizer, Paris / FR
431 Pierre Fabre Medicament,
Boulogne / FR
455 Saladax Biomedical, Basel / CH
401 Schering-Plough, Kenilworth / USA
457 Stemcell Technologies, European Office
459 Stemsoft Software Inc.,
Vancouver, BC / CA
611 Swedish Orphan International,
Stockholm / SE
351 Therakos, Ascot / UK
301 ThermoGenesis Corp.,
Rancho Cordova, CA / USA
641 Vidacare Corporation,
San Antonio, TX / USA
531 World Courier
Book Display
523 Wisepress Online Bookshop,
London / UK
Non Profit Organisations
501 EBMT – European Group for Blood
and Marrow Transplantaion,
Barcelona / ES
613 ASBMT, Arlington Heights, IL / USA
533 EBMT 2010, Vienna / AT
617 ESH (European School of Haematology),
Paris / FR
619 Eurocet, Rome / IT
615 International NetCord Foundation,
Arlington Heights, IL / USA
525 MDS Foundation,
Crosswicks NJ / USA
621 Myeloma Euronet & Lymphoma
Coalition, Berlin DE & Aylesbury / UK
535 National Cord Blood Program,
New York / USA
199

200
Exhibition Floor Plan
Ground Floor
Lunch &
Coffee Breaks
Entrance
To Registration & Secretariat
Relax
Area
211
201
233
231
223
221
351 353
@-Corner
321
311
301
Entrance Entrance
471 481
451
441 443
431
423
421
411
401
457 459
453 455
461
425

525 527
521
511
501
571
537 538 539
531 535
533
523
Entrance
Eat
&
Go
641
643
601 603 605 611 613 615 617 619 621
To Lecture Halls
(upper floor)
To Lecture Halls
(upper floor)
Poster Exhibition
Physicians & Nurses
Poster Sessions Physicians
Monday, 30 March 2009:
P432 – P722
Tuesday, 31 March 2009:
P723 – P1015
Poster Sessions Nurses Group
Monday, 30 March 2009:
P1110 – P1206
Tuesday, 31 March 2009:
P1110 – P1206
201

202
The Swedish Exhibition Centre
Entrance No. 8,
Congress Hall
Footbridge to the Swedish
Exhibition Centre
Congress Hall
K
E
Press Centre
Halls A–K
H
D
Entrance No. 2, Expo Hall
J
C
Car Park
G
B
Airport Bus,
City Trams,
Buses
F
Shopping Centre
A
Taxi Stand
Entrance No. 4, Hotel
Goods Reception,
Mässans Gata 6
Entrance No. 5,
Göteborg Convention Centre,
Main Entrance EBMT 2009

Floor Plans of the Göteborg Convention Centre
Level 2
Entrance No. 8
Congress Hall
Congress Hall
Level 1
Entrance No. 8
Congress Hall
E1
E2
Stage
Estrad
Restaurant &
Function Room
Level 3
R32
R33
R31
Main Entrance
EBMT 2009
Congress Lobby
Bryggan
R35
R34
R36
Reception
Café
E E3 D
H
Level 3
Cloakroom
Registration / Secretariat
Reception R21
R26
R22
R25
R23 R24
R38
R37
R31
R32
R33
R38
R37
R36
R35
R34
Reception
Hotel reception
H2
H1
Service Center
Hotel
lobby
Entrance No. 4
Hotel Gothia Towers
Incontro
Bar &
Restaurant
Eden
Restaurant
Lecture Halls: Halls A, E, F, G, H, J, Congress Hall Meeting rooms: Rooms R
J
J2
J1
R2
Welcome Reception
R3
G1
R4
R9 R10
G2 G3
R6
R5
Entrance No. 4
Hotel Gothia Towers
R11 R12
Press Centre
Reception
R21
Reception R26
R22
R25
R23 R24
Speakers’ Centre
G4
to Level 2
Lecture Halls
A2
Hall B
C
Industrial Poster
A
Exhibition Exhibition
(see pages 198+199)
A7
G
F
F1
F4
Expo Hall
Expohallen
Entrance No. 2 Expo Hall
A5
A6
Entrance No. 1
Entrance No. 2 Expo Hall
to Level 2
Lecture Halls
Entrance No. 1
203

204
Göteborg City Map and List of Hotels
List of Hotels
1
2
3
4
5
6
7
8
9
Elite Plaza
Avalon
Clarion Collection Odin
Elite Park Avenue
First G
Best Western Hotel Göteborg
Gothia Towers
Liseberg Heden
Quality Panorama
10 Radisson SAS Scandinavia
11 Rica City
12 Riverton
13 Scandic Crown
14 Scandic Europa
15 Scandic Opalen
16 Scandic Rubinen
17 Lorensberg
18 Onyxen
19 Poseidon
20 Royal
21 Spar Gårda
22 Spar Majorna
23 Vasa
A
B
Göteborg Convention Centre –
Congress Venue & Welcome Reception
“Koncerthuset”–Göteborg Concert Hall –
Concert
22
Copyright: Stadsbyggnadskontoret
12
6

1
23
14
2
19
5
10
20
16
4
13
3
B
8
11
17
15
18
A
9
7
21
205

206
Notes

Spectra Spec ctra Optia APHERESIS AP PHERESIS
SY SYSTEM STEM
The Spectra Optia ®
The
Spectr
a Optia
Apheresis
SSystem
ystem
nnow
o w iincludes
ncludes
the
aability
bilit
tto
o pperform
erform
mmononuclear
ononuclear
cell
( (MNC) MNC)
ccollection
oll
e ection
iin
n EEurope.
urope.
T TThis
h i is
brings b br
i ings
t tthe
h he
vvalue
a l lue
oof
f
eefficiency,
ff ficiency,
p ppurity
urity
aand
nd
cconsistency
onsisten
tto
o ccell
ell
ccollections,
ollections,
bbenefiting
enefiting
ppatients,
atients,
cclinicians
linicians
aand
nd
llaboratory
aboratory
p pprocesses.
rocesses.
Join
us
aat
t booth b booth
# #411 411
tto
o llearn
earn
more m o ore
aabout
bout
tthe
he
rrelease
elease
oof
f the t h he
SSpectra
pectra
OOptia
ptia
MMNC
NC
protocol. prot
o ocol.
www.caridianbct.com
www. caridianb
c ct.
com
Come see
how we have elevated
the gold standard in
therapeutic apheresis…

Committed
to developing and
delivering innovative therapies
Dedicated
to improving the lives
of cancer patients worldwide
Celgene International Sàrl
Route de Perreux 1
2017 Boudry
Switzerland
+41 32 729 8500
www.celgene.com
© 2009 Celgene